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Abstract
Hypertension is defined as a chronic state of elevated blood pressure, and results in a
significantly increased risk of developing diseases such as; coronary heart disease, kidney
damage and stroke. Essential hypertension is a multifactorial and polygenic condition
that remains asymptomatic until much of the damage has already been done, resulting
in many going undiagnosed (1 in 3) until the health impact has become severe. Globally,
hypertension is responsible for 9.4 million deaths every year. Therefore, in order to
improve upon the diagnostic assessment of the disease, this current study made use
of the Spontaneously Hypertensive Rat (SHR) as a polygenic model of elevated blood
pressure. Using an optimised next generation sequencing approach to guide biomarker
discovery, transcripts predicted to be significantly regulated between the SHR and
its normotensive control were selected as candidate biomarkers of hypertension. The
interferon-induced protein with tetratricopeptide repeats 1 (Ifit1) saw a robust elevation
in the blood of SHRs at both juvenile and adult ages. This, coupled with its key
integretive role in innate immunity, lead to Ifit1 being selected for further validation
through a series of environmentally induced forms of elevating blood pressure. Ifit1
performed well as a biomarker of the SHR strain, against a host of normotensive controls.
As such, Ifit1 was selected for additional characterisation in the blood through Flow
Cytometry as well as assessment in a key integrative region of the brain tasked with
cardiovascular control.
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for warmly welcoming me several times into their laboratory. Olivera’s patience and
knowledge have given me a firm foundation of surgical techniques in assessing physiology.
I would like to dedicate this work to my family, for their encouragement and support.
They have always been a great source of strength for me and I will always admire them
for this.
A special thank you goes to Dr Michael Greenwood and Dr Mingkwan Greenwood for
their advice over the years. Not only have they supported my work at the experimental
level, but they have always guided my research and provided a daily sounding board
for ideas.
Despite their best efforts to distract and therefore derail my career, I would like to
thank Ben Gillard, Dr Ben Flynn, George Horn, Dr Matt Birnie, Audrys Pauza, and
Dr Paul Bishop. Their humour and ability to lift my spirits have seen me through the
many stressful moments of the past four years.
Finally, I would like to extend a big thank you to the Murphy Group as a whole, in
addition to many members of the Lightman Group. From experimental advice to coffee





1.1 Hypertension . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.1.1 A Rise in Blood Pressure . . . . . . . . . . . . . . . . . . . . . . 1
1.1.2 The Hypertensive Pandemic - A Global Burden . . . . . . . . . 4
1.1.3 A Genetic Basis for Hypertension . . . . . . . . . . . . . . . . . 5
1.1.4 The Brain’s Role in Hypertension . . . . . . . . . . . . . . . . . 6
1.2 Animal Models in Hypertension . . . . . . . . . . . . . . . . . . . . . . 9
1.2.1 Surgical Models of Hypertension . . . . . . . . . . . . . . . . . . 9
1.2.2 Genetic Models of Hypertension . . . . . . . . . . . . . . . . . . 9
1.2.3 Reconciliation of the Genome-Environment Interface . . . . . . 10
1.3 The Hunt for Biomarkers . . . . . . . . . . . . . . . . . . . . . . . . . . 12
1.4 Transcriptomics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
1.4.1 Evolution of Nucleotide Sequencing . . . . . . . . . . . . . . . . 13
1.4.2 Next Generation Sequencing . . . . . . . . . . . . . . . . . . . . 14
1.5 Bioinformatics Challenges . . . . . . . . . . . . . . . . . . . . . . . . . 15
1.5.1 Quality Control . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
1.5.2 Trimming . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
1.5.3 Read Alignment . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
1.5.4 Transcript Quantification and Normalisation . . . . . . . . . . . 21
1.5.5 Differential Gene Expression . . . . . . . . . . . . . . . . . . . . 22
1.6 Statement of Intent and Aims . . . . . . . . . . . . . . . . . . . . . . . 24
2 Candidate Selection Using RNAseq 25
2.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
2.2 Aims . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
2.3 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
2.3.1 Animals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
2.3.2 Sample Preparation . . . . . . . . . . . . . . . . . . . . . . . . . 27
2.3.3 Blood RNA Extraction . . . . . . . . . . . . . . . . . . . . . . . 28
2.3.4 RNA Quality Control & cDNA Synthesis . . . . . . . . . . . . . 29
2.3.5 RNA Sequencing . . . . . . . . . . . . . . . . . . . . . . . . . . 30
2.3.6 Quality Control and Adapter Trimming . . . . . . . . . . . . . . 30
2.3.7 Alignment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
2.3.8 Normalisation of Reads . . . . . . . . . . . . . . . . . . . . . . . 31
2.3.9 Differential Gene Expression Predictions . . . . . . . . . . . . . 32
V
Contents
2.3.10 Candidate Selection . . . . . . . . . . . . . . . . . . . . . . . . . 32
2.3.11 Oligonucleotide Primers . . . . . . . . . . . . . . . . . . . . . . 33
2.3.12 Primer Validation . . . . . . . . . . . . . . . . . . . . . . . . . . 34
2.3.13 qPCR of Target Genes . . . . . . . . . . . . . . . . . . . . . . . 39
2.4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
2.4.1 RNAseq Dataset . . . . . . . . . . . . . . . . . . . . . . . . . . 40
2.4.2 qPCR Data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
2.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
2.5.1 RNAseq Data . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
2.5.2 qPCR Data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
2.5.3 Comparison of RNAseq and qPCR output . . . . . . . . . . . . 56
2.5.4 Concluding remarks . . . . . . . . . . . . . . . . . . . . . . . . . 59
3 Optimisation of High-Throughput approach 60
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
3.1.1 Building upon previous findings . . . . . . . . . . . . . . . . . . 60
3.1.2 In Silico Optimisation . . . . . . . . . . . . . . . . . . . . . . . 60
3.1.3 Repetition of RNAseq Dataset . . . . . . . . . . . . . . . . . . . 61
3.1.4 Microarray vs RNAseq . . . . . . . . . . . . . . . . . . . . . . . 64
3.2 Aims . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
3.3 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
3.3.1 In Silico Optimisation . . . . . . . . . . . . . . . . . . . . . . . 65
3.3.2 Tissue Preparation . . . . . . . . . . . . . . . . . . . . . . . . . 66
3.3.3 N=6 RNAseq . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
3.3.4 Microarray . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
3.4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73
3.4.1 In Silico Optimisation . . . . . . . . . . . . . . . . . . . . . . . 73
3.4.2 RNAseq . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
3.4.3 Microarray . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89
3.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94
3.5.1 In Silico Optimisation . . . . . . . . . . . . . . . . . . . . . . . 94
3.5.2 RNAseq . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98
3.5.3 MicroArray . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
3.5.4 RNAseq vs MicroArray . . . . . . . . . . . . . . . . . . . . . . . 103
3.5.5 Concluding remarks . . . . . . . . . . . . . . . . . . . . . . . . . 105
4 Validation of Candidate Selection in WKY and SHR Strains 106
4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106
4.1.1 Genetically Isolated Animal Cohort . . . . . . . . . . . . . . . . 106
4.1.2 Spectral Analysis & Baroreceptor Sensitivity . . . . . . . . . . . 107
4.2 Aims . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
4.3 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
4.3.1 Animals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
4.3.2 Surgical Procedure . . . . . . . . . . . . . . . . . . . . . . . . . 111
4.3.3 Direct Blood Pressure Measurement . . . . . . . . . . . . . . . . 111
4.3.4 Spectral Analysis & Baroreceptor Sensitivity . . . . . . . . . . . 112
Page VI
Contents
4.3.5 Linear Regression Modeling . . . . . . . . . . . . . . . . . . . . 113
4.3.6 New qPCR Reference Gene Selection . . . . . . . . . . . . . . . 113
4.4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114
4.4.1 Validation of Findings in a New Cohort of Animals . . . . . . . 114
4.4.2 Physiological metrics . . . . . . . . . . . . . . . . . . . . . . . . 118
4.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 128
4.5.1 Methods of Obtaining Blood Pressure Readings . . . . . . . . . 128
4.5.2 Physiological Metrics of the SHR . . . . . . . . . . . . . . . . . 128
4.5.3 Oaz1 as a reference gene . . . . . . . . . . . . . . . . . . . . . . 131
4.5.4 Genetic spread of the SHR and WKY rats . . . . . . . . . . . . 132
4.5.5 Concluding remarks . . . . . . . . . . . . . . . . . . . . . . . . . 133
5 Widening the Search - Additional models of hypertension 135
5.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 135
5.2 Aims . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 137
5.3 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . 138
5.3.1 Multi-strain Blood Analysis . . . . . . . . . . . . . . . . . . . . 138
5.3.2 Sprague Dawley Dehydration . . . . . . . . . . . . . . . . . . . 139
5.3.3 BHR Restrained Vs Control (4wks & 12wks) . . . . . . . . . . . 139
5.4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 140
5.4.1 Multi-strain Blood Analysis . . . . . . . . . . . . . . . . . . . . 140
5.4.2 Sprague Dawley Dehydration . . . . . . . . . . . . . . . . . . . 141
5.4.3 BHR Restrained Vs Control (4wks & 12wks) . . . . . . . . . . . 141
5.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 143
5.5.1 Multi-Strain Analysis . . . . . . . . . . . . . . . . . . . . . . . . 143
5.5.2 Sprague Dawley Dehydration . . . . . . . . . . . . . . . . . . . 147
5.5.3 BHR Restraint . . . . . . . . . . . . . . . . . . . . . . . . . . . 148
5.5.4 Concluding remarks . . . . . . . . . . . . . . . . . . . . . . . . . 149
6 Characterisation of Ifit1 150
6.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150
6.1.1 Coupling Expression to Cardiovascular Centres of the Brain . . 154
6.1.2 fluorescence-activated cell sorting (FACS) . . . . . . . . . . . . 155
6.2 Aims . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 157
6.3 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . 157
6.3.1 Tissue Collection - PVN Isolation . . . . . . . . . . . . . . . . . 157
6.3.2 RNA Extraction . . . . . . . . . . . . . . . . . . . . . . . . . . 159
6.3.3 cDNA Synthesis . . . . . . . . . . . . . . . . . . . . . . . . . . . 160
6.3.4 Quantitative PCR Analysis . . . . . . . . . . . . . . . . . . . . 160
6.3.5 9-Colour Panel Antibody Validation . . . . . . . . . . . . . . . . 160
6.3.6 Fluorescence-activated cell sorting . . . . . . . . . . . . . . . . . 175
6.3.7 FACS Analysis on Permeabilised Cells . . . . . . . . . . . . . . 181
6.4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 185
6.4.1 Ifit1 Expression in the PVN . . . . . . . . . . . . . . . . . . . . 185
6.4.2 FACS Analysis to Isolate Cell Types . . . . . . . . . . . . . . . 185
6.4.3 FACS Analysis on Permeabilised Cells . . . . . . . . . . . . . . 189
Page VII
Contents
6.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 189
6.5.1 Ifit1 Role in Hypertension . . . . . . . . . . . . . . . . . . . . . 189
6.5.2 Ifit1 in the paraventricular nucleus (PVN) . . . . . . . . . . . . 191
6.5.3 FACS Analysis to Isolate Cell Types . . . . . . . . . . . . . . . 194
6.5.4 FACS Analysis on Permeabilised Cells . . . . . . . . . . . . . . 198
6.5.5 In Silico Characterisation of Ifit1 . . . . . . . . . . . . . . . . . 199
7 Reflections & Future Directions 203
7.0.1 Furthering the validation of Ifit1 . . . . . . . . . . . . . . . . . . 203
7.0.2 The Aetiology of Hypertension . . . . . . . . . . . . . . . . . . 204
7.0.3 Translating the findings to a human cohort . . . . . . . . . . . . 205
7.0.4 Concluding remarks . . . . . . . . . . . . . . . . . . . . . . . . . 206
A Chapter 1 207
B Chapter 3 210




1.1 An illustration from an experiment in Harvey’s De Motu Cordis . . . . 2
1.2 The Platt-Pickering debate over the qualitative or quantitative nature of
hypertension . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
1.3 Schematic overview of central nervous system regulation of BP . . . . . 8
1.4 Example Pipeline for RNAseq Experiment . . . . . . . . . . . . . . . . 16
1.5 Equation for calculating Phred Score . . . . . . . . . . . . . . . . . . . 18
1.6 Phasing Phenomenon observed within Illumina’s Sequencing by Synthesis
technology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
2.1 Representative plot of a post-PCR melt curve . . . . . . . . . . . . . . 36
2.2 Equation of linear regression for Primer validation . . . . . . . . . . . . 37
2.3 Equation to calculate Primer Efficiency . . . . . . . . . . . . . . . . . . 37
2.4 Example Standard Curve . . . . . . . . . . . . . . . . . . . . . . . . . . 38
2.5 qPCR plate layout for WKY vs SHR Comparison . . . . . . . . . . . . 39
2.6 RNAseq Quality Control metrics . . . . . . . . . . . . . . . . . . . . . 41
2.6 RNAseq Quality Control metrics, continued. . . . . . . . . . . . . . . . 42
2.7 Tophat Alignment rates for N=3 Dataset . . . . . . . . . . . . . . . . . 43
2.8 Principal Component Analysis - Raw vs EdgeR Normalised . . . . . . . 45
2.9 Molecular Function Gene Ontology analysis of EdgeR Significant Tran-
scripts in the Blood . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
2.10 qPCR Relative Expression of Putative Reference genes in Blood . . . . 50
2.11 qPCR Relative Expression of Blood Biomarkers . . . . . . . . . . . . . 53
2.11 qPCR Relative Expression of Blood Biomarkers. Cont. . . . . . . . . . 54
3.1 Overview of TruSeq Stranded mRNA Preparation protocol . . . . . . . 69
3.2 n=3 Area Under the Curve (AUC) . . . . . . . . . . . . . . . . . . . . 73
3.3 n=3 ROC Curves . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
3.4 n=3 False Discovery Curves . . . . . . . . . . . . . . . . . . . . . . . . 75
3.5 n=3 False Discovery Rate . . . . . . . . . . . . . . . . . . . . . . . . . 75
3.6 n=3 Number of Significant Calls . . . . . . . . . . . . . . . . . . . . . . 76
3.7 n=3 Spearman Correlation Coefficient . . . . . . . . . . . . . . . . . . 77
3.8 n=3 Matthew’s Correlation Coefficient . . . . . . . . . . . . . . . . . . 77
3.9 DESeq2 Comparison of Replicates - Area Under the Curve (AUC) . . . 78
3.10 DESeq2 Comparison of Replicates - False Discovery Rate . . . . . . . . 79
3.11 DESeq2 Comparison of Replicates - Number of Significant calls . . . . 79
3.12 DESeq2 Comparison of Replicates - Matthew’s Correlation Coefficient . 80
IX
List of Figures
3.13 RNAseq Quality Control Metrics . . . . . . . . . . . . . . . . . . . . . 82
3.13 RNAseq Quality Control Metrics. Continued. . . . . . . . . . . . . . . 83
3.14 Mapping levels between n=3 and n=6 RNAseq experiments0 . . . . . . 84
3.15 PCA Plot featuring Previous n=3 RNAseq and current n=6 RNAseq
experiments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
3.16 DESeq2 Generated Log2 Fold Changes between n=3 and n=6 RNAseq
Datasets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86
3.17 UpsetR Generated comparison of DESeq2 significant genes (P-Value<0.05)
between n=3 and n=6 RNAseq . . . . . . . . . . . . . . . . . . . . . . 88
3.18 Quality control generated Pseudo-images of Microarray Gene Chips . . 89
3.19 Global Histogram of Microarray Intensities . . . . . . . . . . . . . . . . 90
3.20 Boxplots of log2(PMij) intensities for both pre- and post RMA normalisation 90
3.21 Principal Component Analysis for both pre- and post RMA normalisation 92
3.22 Scatter and Volcano plots of Microarray results . . . . . . . . . . . . . 94
3.23 Equation for calculating the Matthew’s correlation coefficient (MCC).
The MCC serves to produce a metric that integrates all of the logical
outcomes from the RNAseq predictions. . . . . . . . . . . . . . . . . . . 96
3.24 Illustration of Illumina’s Patterned Flow Cell Technology . . . . . . . . 100
4.1 Representative plot of blood pressure spectra . . . . . . . . . . . . . . . 109
4.2 Equation for calculating the Coefficient of Variance . . . . . . . . . . . 114
4.3 qPCR Blood Expression of Putative reference genes and the novel Oaz1
reference gene across Wistar Kyoto (WKY) and spontaneously hyperten-
sive rat (SHR) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115
4.4 Rescaled plot of Oaz1 expression in Blood . . . . . . . . . . . . . . . . 116
4.5 qPCR blood expression of Ifit1 across a geographically distinct cohort of
Wistar Kyoto (WKY) and spontaneously hypertensive rat (SHR) animals117
4.6 Physiological data in SHR and WKY strains at both juvenile and adult
ages. Statistics are presented as unpaired Student’s T-Test P-values,
between strains at any given age (P-value<0.05, *; P-value<0.01, **;
P-value<0.001, ***). . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119
4.7 Spectral Analysis for WKY versus SHR comparison . . . . . . . . . . . 120
4.8 Baroreceptor Sensitivity (mmHg−1) and Set Point (mmHg−1) for WKY
versus SHR comparison . . . . . . . . . . . . . . . . . . . . . . . . . . . 121
4.9 Linear Regression Analysis of Physiological MAP against Ifit1 blood
expression . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123
4.10 Linear Regression Analysis of Physiological BPM against Ifit1 blood
expression . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 124
4.11 Linear Regression Analysis of Physiological BRS against Ifit1 blood
expression . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 125
4.12 Linear Regression Analysis of Physiological Baroreceptor Set Point
against Ifit1 blood expression . . . . . . . . . . . . . . . . . . . . . . . 126
4.13 Linear Regression Analysis of Spectral Analysis Data against Ifit1 blood
expression . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127
5.1 Multistrain Analysis of Ifit1 blood expression . . . . . . . . . . . . . . . 140
Page X
List of Figures
5.2 Environmentally induced hypertension in SD rats by dehydration . . . 142
5.3 Restraint stress paradigm of induced hypertension . . . . . . . . . . . . 143
5.4 Phylogenetic Tree of 28 Rat Strains . . . . . . . . . . . . . . . . . . . . 145
6.1 Structural differences in Ifit family proteins . . . . . . . . . . . . . . . . 151
6.2 Phylogeny of Ifit family proteins . . . . . . . . . . . . . . . . . . . . . . 152
6.3 Representative gating strategy for 9-Colour FACS Analysis . . . . . . . 158
6.4 Coronal section of Rat Brain illustrating atlas coordinates and Toluidine
Blue stain of the Paraventricular Nucleus (PVN). Here is a coronal section
of the rat brain at Bregma -1.8mm showing the location of PVN lateral
to the third ventrical. The PVN has been enlarged in the left side of the
image to illustrate both a Toluidine Blue stain of the region (Right), and
a depiction of how the nuclei are separated (Left; dorsal parvocellular
subdivision (DP), magnocellular division (MN), medial parvocellular
subdivision (MP), periventricular parvocellular subdividion (P), ventral
parvocellular subdivision (VP).) . . . . . . . . . . . . . . . . . . . . . . 159
6.5 PCR Product of size matching that of Ifit1. Viewed on 1% Agarose Gel 163
6.6 Semi-quantitative assessment of PCR inserts and vector . . . . . . . . . 165
6.7 Equation for calculating Ligation Molar Ratio . . . . . . . . . . . . . . 165
6.8 BamHI & XhoI Digest on Plasmid Construct . . . . . . . . . . . . . . . 168
6.9 Antibody test on various cell lysates . . . . . . . . . . . . . . . . . . . 173
6.10 Antibody test on transfected HEK293T cells . . . . . . . . . . . . . . . 174
6.11 Calculations for Cell Abundance and Viability . . . . . . . . . . . . . . 178
6.12 Equation to calculate the Stain Index for Fluorescently conjugated Anti-
bodies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 179
6.13 FACS Validation of Anti-Ifit1 Dilutions (1:800 & 1:400) . . . . . . . . . 182
6.13 FACS Validation of Anti-Ifit1 Dilutions (1:200 & 1:100) . . . . . . . . . 183
6.13 FACS Validation of Anti-Ifit1 Dilutions (1:50) . . . . . . . . . . . . . . 184
6.14 qPCR Relative Expression of Ifit1 in the PVN . . . . . . . . . . . . . . 186
6.15 Differences in leukocyte populations across WKY and SHR strains . . . 187
6.16 fluorescence-activated cell sorting (FACS) output of BV605 Positive cells
(Stained with anti-Ifit1 antibodies) . . . . . . . . . . . . . . . . . . . . 190
C.1 fluorescence-activated cell sorting (FACS) gating strategy used to isolate
Ifit1 expressing cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 222
Page XI
List of Tables
1.1 Table of Phred Scores against Base Miscalls . . . . . . . . . . . . . . . 18
2.1 Table of reagents required for cDNA synthesis Master Mix . . . . . . . 29
2.2 Description of the core modeling strategies of DGE analysis methods for
RNAseq. Adapted from Khang, T. F., & Lau, C. Y. (2015)1 . . . . . . 31
2.3 Amended qPCR Primer Design Parameters . . . . . . . . . . . . . . . . 33
2.4 qPCR Primer Sequences for Primer Validation . . . . . . . . . . . . . . 35
2.5 Table of reagents for qPCR Master Mix . . . . . . . . . . . . . . . . . . 35
2.6 Original RNAseq Output of Finally selected Candidate Transcripts . . 47
2.7 Additional information on candidate transcripts . . . . . . . . . . . . . 48
2.8 Comparison of RNAseq output with qPCR validation on candidate
biomarkers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
2.9 false discovery rate (FDR) of RNAseq differential gene expression (DGE)
tests. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
3.1 List of key arguments to generateSyntheticdata command. . . . . . . . 66
3.2 Comparison of RNAseq Output with qPCR Validation on Candidate
Biomarkers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87
3.3 Comparison of Microarray Output with qPCR Validation on Candidate
Biomarkers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93
4.1 RNAseq Generated Coefficient of Variance for selecting new reference
genes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114
6.1 RNAseq generated counts for Ifit1 expression in cardiovascular centres
of the brain . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 155
6.2 Primers for PCA amplification of Ifit1 Gene . . . . . . . . . . . . . . . 161
6.3 Reaction master mix for Phusion DNA PCR . . . . . . . . . . . . . . . 162
6.4 PCR Amplification Protocol . . . . . . . . . . . . . . . . . . . . . . . . 162
6.5 PCR Digestion Mastermix . . . . . . . . . . . . . . . . . . . . . . . . . 164
6.6 Ligation Mastermix for T4 DNA Ligase . . . . . . . . . . . . . . . . . . 166
6.7 Spectrophotometry output for Isolated Ifit1 constructs . . . . . . . . . 167
6.8 Digestion Mastermix for confirming insert in plasmid construct . . . . . 169
6.9 Sanger Sequencing of Plasmid Primer Sequences . . . . . . . . . . . . . 169
6.10 Reagents used for Western Blot analysis of Ifit1 protein expression . . . 172
XII
List of Tables
6.11 Panel design for FACS isolation of various Leukocyte populations in rat
whole blood . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 176
6.12 Optimisation of Antibody Dilutions via the calculation of a Stain Index
for each . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 180
6.13 Statistical Comparison of Leukocyte Populations in WKY and SHR blood188
6.14 Location of single nucleotide polymorphisms in SHR Ifit1 transcripts, as
compared against the RN6 reference genome . . . . . . . . . . . . . . . 200
A.1 Post-Trimming Alignment Rates for n=3 RNAseq Dataset . . . . . . . 207
A.2 Original RNAseq Output of WKY vs SHR 4 weeks blood comparison . 208
A.3 Original RNAseq Output of WKY vs SHR 4 weeks blood comparison Cont.209
B.1 DESeq2 generated output for n=6 differential gene expression analysis
of WKY juvenile blood vs SHR juvenile blood at 4 weeks of age . . . . 211
B.2 DESeq2 generated output for n=6 differential gene expression analysis
of WKY juvenile blood vs SHR juvenile blood at 4 weeks of age. Cont. 212
B.3 Microarray generated output for n=6 differential gene expression analysis
of WKY juvenile blood vs SHR juvenile blood at 4 weeks of age . . . . 213
B.4 Microarray generated output for n=6 differential gene expression analysis





ACI August & Copenhagen inbred.
ANOVA analysis of variance.
ANS autonomic nervous system.
ASPA Home Office animals (scientific procedures) act 1986.
BALF broncho-alveolar lavage fluid.
BBDP biobreeding diabetes prone.
BHR borderline hypertensive rat.
BN Brown norway.
BP blood pressure.
BPM beats per minute.
BRS baroreceptor sensitivity.
BSA bovine serum albumin.
CI confidence interval.
CNS central nervous system.
CV coefficient of variance.
DBP diastolic blood pressure.
DESeq differential gene expression analysis based on the negative binomial distribution.





DP dorsal parvocellular subdivision.
EdgeR empirical analysis of digital gene expression data in R.
EDTA ethylenediaminetetraacetic acid.
ELISA Enzyme-Linked Immunosorbent Assay.
eQTL expressed quantitative trait-loci.
EtOH ethanol.
F344 Fischer 344.
FACS fluorescence-activated cell sorting.
FDR false discovery rate.
FFT fast fourier transformation.
FHH Fawn hooded high blood pressure.
FHL Fawn hooded low blood pressure.
FPKM fragments per kilobase of exon model per million reads.
GC guanine-cytosine.
GK Goto-Kakizaki.
GTF gene transfer format.
GWAS genome wide Association study.
HF high frequency.
Ifit1 interferon-induced protein with tetratricopeptide repeats 1.
ISG interferon stimulated gene.
ISRE interferon stimulated response elements.








LL Lyon low blood pressure.
LN Lyon normotensive.
LPS lipopolysaccharide.
MAP mean arterial pressure.
MCC Matthew’s correlation coefficient.
MDS multidimensional scaling analysis.
MHS Milan hypertensive strain.
MIQE minimum information for publication of quantitative real-time PCR experi-
ments.
mmHg millimetres of mercury.
MMP maximum mappable prefix.
MN magnocellular division.
MNS Milan normotensive strain.
MP medial parvocellular subdivision.
mRNA messenger ribonucleic acid.
NIL neurintermediate lobe.
NOS nitric oxide synthase.
NTS nucleus tractus solitarii.
P periventricular parvocellular subdividion.
PAMP pathogen associated molecular pattern.
PBS phosphate buffered saline.
PCA principal component analysis.
PCR polymerase chain reaction.
PI pulse interval.





QUOD quality in organ donation.
RAAS renin-angiotensin-aldosterone-system.
RMA robust multiarray averaging.
RNA ribonucleic acid.
RPKM reads per kilobase of exon model per million reads.
rRNA ribosomal ribonucleic acid.
RVLM rostral ventrolateral medulla.
SBH Sabra hypertension prone.
SBN Sabra normotensive.
SBP systolic blood pressure.
SBS sequencing by synthesis.
SD Sprague-Dawley.
SEM standard error of the mean.
SHR spontaneously hypertensive rat.
SNP single nucleotide polymorphism.
SNS sympathetic nervous system.




STAR spliced transcripts alignment to a reference.
STDev standard deviation.
TAC transcriptome analysis console.




TMM trimmed mean of the M-values.
TPM transcripts per million.
VLF very low frequency.
VP ventral parvocellular subdivision.
WAG Wistar albino Glaxo.






1.1.1 A Rise in Blood Pressure
In 1628, the English physician William Harvey published a pioneering description of
the functionality of the heart and blood. In his seminal Exercitatio Anatomica de Motu
Cordis et Sanguinis in Animalibus (Anatomical Account of the Motion of the Heart
and Blood in Animals), Harvey was the first to observe the properties of the blood,
and its integrated systemic circulation around the body by the heart. In doing so, he
gave rise to the modern history of cardiovascular research and mankind’s understanding
of its importance (Figure 1.1). Prior to his work, blood was thought to be separated
between venous and arterial systems that were quite separate, and the heart simply
considered an internal regulator of heat. Over 100 years later, Stephen Hales took
Harvey’s work and further propelled the field with his first quantitative measurements
of blood pressure.2 Using finely produced glass columns inserted into the arteries of
animal subjects, Hales could note the height to which the column of blood rose; giving
rise to a comparative metric of blood pressure.
Historically, the disease of hypertension was described as a “fullness disease”,
resulting from an excess of blood in a sufferer’s vessels. Early Persian medical texts
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Figure 1.1: A drawing taken from Harvey’s Exercitatio Anatomica de Motu Cordis et
Sanguinis in Animalibus depicting an experiment on valves in the venous circulatory system.
described the symptoms as including; headaches, general redness, being warm to the
touch, distension of the skin, vascular rupture, and even hemorrhagic stroke.3 A natural
treatment option therefore took the form of blood-letting or the application of leeches
to balance the perceived overabundance of blood present.4
It was not until the late 19th/ early 20th century that hypertension gained true
clinical importance, catalysed by the invention of the cuff-based sphygmomanometer by
Scipione Riva-Rocci in 1896.5 This novel device was expanded upon shortly after by
Russian surgeon Nikolai Korotkov. Korotkov improved upon Riva-Rocci’s approach
through the use of a stethoscope to listen to a series of audible sounds when the arteries
were auscultated alongside the deflating arm cuff of the sphygmomanometer. Korotkov
noted these sounds as being indicative of changes in blood pressure when the heart
muscles were contracted (Systole) and relaxed (Diastole), allowing for physicians to
discern between the two in a clinical setting.6 Armed with the knowledge of these
new diagnostic “Korotkov sounds”, as they become known, physicians could begin to
pick apart the complex relationship between blood pressure and health; and in 1913,
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Theodore Janeway became the first person to describe how individuals with an increased
blood pressure were statistically more likely to die earlier than those with a lower blood
pressure.7
Today, hypertension is clinically classed with the single diagnostic criteria of chroni-
cally elevated blood pressure (BP). However, in reality hypertension presents a multifac-
torial disease state with a significant impact on a range of physiological processes. BP
is a normally distributed quantitative trait across the general population, with normal
arterial BP (normotensive) falling within the range of 100 – 140mmHg at systole and
60 – 90mmHg at diastole. The disease of hypertension becomes diagnosed when blood
pressure is measured above the upper end of the normal distribution over multiple time
points. †
Current European guidelines define hypertension when measurements are consistently
over 140/90mmHg systolic and diastolic respectively, whereas the latest American
guidelines have moved this threshold down to over 130/80mmHg.8,9 This new definition
of hypertension within the American guidelines is based largely on the results derived
from large meta-analyses such as SPRINT (Systolic Blood Pressure Intervention Trial).10
In contrast to this, the european guidelines are based on population attributable risk
statistics. However, both guidelines suggest a therapeutic end goal of a BP under
130/80mmHg. In 2003, an additional designation of “Pre-hypertension” was termed for
individuals with a systolic blood pressure (SBP) between 120-139mmHg and a diastolic
blood pressure (DBP) of between 80-89mmHg in order to catch those at risk of further
elevations of BP.11 This additional designation allows for prophylactic measures to be
put in place in order to slow or stop the rise in BP before it leads to a higher risk of
cardiovascular disease; either through clinical, or lifestyle intervention. In reality, these
classifications provide an arbitrary series of thresholds against a normally distributed
†These multiple measurements are essential in ensuring elevated BP is a chronic symptom and not
one resultant of a patient’s anxiety at a clinical visit; a phenomenon known as “White coat syndrome”.
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range of BP within the population. As such, they only serve as a guide that may
well be subject to change, as their primary purpose is to identify those at risk of the
disease states associated with hypertension. Thereby enabling healthcare professionals
to intervene accordingly.
As BP begins to rise, so too do the risk factors associated. Elevated blood pressure
significantly increases one’s susceptibility towards; stroke, ischemic heart disease, and
peripheral vascular disease.12–14 Additional associated diseases include; aortic aneurysms,
diffuse aetherosclerosis, atrial fibrillation, pulmonary embolism, and chronic kidney
disease.15,16 These diseases are not limited to the heart and kidneys, as hypertension is
also a serious risk factor for retinopathy, and even generalised cognitive impairment and
dementia.17,18 It is therefore not surprising that hypertension is classed as the most
important preventable risk factor for premature death in the world.19
1.1.2 The Hypertensive Pandemic - A Global Burden
Globally, hypertension is responsible for approximately 9.4 million deaths every year and
causes around 45% of heart disease related deaths and 51% of deaths due to stroke.20
In 2008, around 40% of adults over 25 years old were diagnosed with hypertension, a
significant rise from 600 million in 1980 to approximately 1 billion. This increasing
prevalence has been attributed to an ever-aging population in addition to increased
behavioural risk factors, such as poor diet or sedentary lifestyle.21 The world health
organisation (WHO) estimates that this number will continue rising to 1.5 billion
by 2020.22 As of 2001, sub-optimal blood pressure was estimated to cost healthcare
providers $370 billion per year globally; a number that represents about 10% of the
world’s overall healthcare expenditure.23
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1.1.3 A Genetic Basis for Hypertension
For a long time it was unknown whether the genetic basis for BP was a quantitative
trait, or a dichotomous disease state. These perspectives gave rise to the famous
Platt-Pickering debate during the 1950’s, a discussion on the unimodal or bimodal
distributions of BP in the general population. Platt regarded hypertension as a distinct
condition, showing a bimodal distribution within the population.24 Whereas Pickering
saw BP as a continuous distribution, with some reaching the clinically set threshold levels
of hypertension (Figure 1.225). Platt determined that hypertension was a manifestation
of simple Mendelian disease inheritance, grounded in a single genetic mutation that
gives rise to the hypertensive phenotype. As the debate continued well into the
1960’s, Pickering’s quantitative model gained little support. It was not until increasing
epidemiological evidence suggested the link between elevated BP and cardiovascular
disease that this changed. The ability of a range of pharmaceutically distinct anti-
hypertensive drugs to reduce BP, and therefore cardiovascular disease, all strengthened
Pickering’s normally distributed model. Furthermore, genome wide Association study
(GWAS) cemented this within the scientific community, as they showed the importance
of considering the polygenic association of genes with hypertension26–28 †.
Today hypertension diagnoses are split into those where a discernible cause is
known (Inessential or Secondary Hypertension), and those whereby the specific cause
of hypertension can not be identified (Essential or Primary Hypertension). Secondary
hypertension only makes up a small proportion of hypertensive cases, at between 5-
10%.11,31,32 It can be caused by a wide variety of conditions, including; renal disease,
endocrine disorders, and side effects from pharmaceuticals. Due to the tangible nature
of the disease, therapeutic measures can be put in place to target the cause of the
disorder and effectively manage BP back to physiological levels.
The vast majority of hypertensive cases however (90-95%), have no known cause to
†It should be noted, that Platt’s model cannot be entirely disregarded as there exist rare familial
forms of hypertension with a Mendelian root, and therefore inherited as single-gene disorders.29
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Figure 1.2: The Platt-Pickering debate over the qualitative or quantitative nature of
hypertension. Platt considered hypertension to be a distinct condition, and therefore one
resulting of Mendelian genetics. Whereas, Pickering saw blood pressure (BP) as a continuum
amongst the general population, with hypertension arising in those at the extreme end of the
distribution. He therefore concluded there to be a polygenic aetiology to the disease. Image
adapted from Padmanabhan et al. 201230
their chronically elevated BP. This grouping of individuals are clinically known as those
with Primary Hypertension. Primary hypertension accounts for the highest proportion
of cardiovascular disease and is considered to be polygenic in nature.33
BP regulation is a complex physiological process, governed by an intricate network
of interacting pathways that culminate in changes to cardiac output or peripheral
resistance. For these reasons, dissecting the genetic underpinnings of the hypertensive
phenotype presents a unique set of challenges. Previous studies have demonstrated the
genetic contribution towards BP management. Based on familial studies, specifically
those focusing on monozygotic and dizygotic twins, it is estimated to have a heritability
rate of between 31-68%.34,35 It is for these cumulative reasons that isolating the precise
genetic cause towards hypertension has proven so difficult.
1.1.4 The Brain’s Role in Hypertension
The mechanisms by which humans regulate mean arterial BP are not completely
understood. While they can be broadly grouped into distinct regulatory systems, in
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reality they are interrelated. One key regulatory system is that of the renin-angiotensin-
aldosterone-system (RAAS) which centres on production of angiotensin II, a potent
endogenous vasoconstrictor.36 Over the last few decades significant progress has been
made to develop a series of treatments for hypertension, many focusing on modulation
of the RAAS. However, around 40% of hypertensive patients remain unresponsive
to pharmaceuticals of these classes.37 This coupled with the established associations
between an elevated sympathetic nervous system (SNS) and hypertension implicate the
neurogenic basis of the disease. One key system at play is that of the baroreceptor reflex.
Briefly, the baroreceptor reflex involves afferent projections from arterial baroreceptors
to central nervous system (CNS) pathways (Figure 1.3). These in turn, effect their
inhibitory or excitatory processes on sympathetic outflow, ultimately culminating in
alterations to heart rate and cardiac output, in addition to influencing the long term
activity of the RAAS.38 The baroreceptor reflex is primarily tasked with short term BP
fluctuations, responding to tissue’s metabolic demand throughout a day. However, it is
thought that chronic hypertension arises when alterations to the baseline of this reflex
are modified, effectively resetting the homeostatic set-point of BP to an elevated mean
arterial pressure.
For these reasons, the search for blood-born biomarkers has been supplemented
by looking toward an additional CNS region of the hypothalamus involved in this
pathway; the paraventricular nucleus (PVN). The PVN is located lateral to the third
ventricle and can be further differentiated into eight distinct groups of nuclei in rats
consisting of either large magnocellular or smaller parvocellular neurons.40 These
parvocellular projections directly influence sympathetic tone via the rostalventrolateral
medulla (RVLM) and the intermediolateral cell column.41 The magnocellular neurons
are tasked with the production of oxytocin and vasopressin, the latter being key for
osmoregulation via secretion from the pituitary. Moreover, the PVN is also involved
in several other physiological functions, including; response to biological stressors and
























Figure 1.3: Schematic overview of the central nervous system (CNS) control of sympathetic
outflow and ultimate regulation of BP. central nervous system (CNS) outflow is the result of
integrated actions from a collection of CNS regions, including several centres of the cortex, lower
centers of the hypothalamus, circumventricular organs (Area Postrema, AP; Periventricular
Anteroventral Third Ventricle, AV3V), and basal ganglia (especially the Locus ceruleus). The
critical integrator site for these regions is the nucleus tractussolitaries (NTS), situated within
the medulla oblongata. This site receives inhibitory signals from baroreflexes (pressure and
volume signals) and stimulatory signals from muscular and renal chemoreceptors (metabolic
signals). The ultimate determiner of sympathetic nervous system (SNS) outflow is the rostal
ventrolateral medulla (RVLM), which receives tonic inhibition from the adjacent NTS. The
circumventricular organs, such as the AP and AV3V, are devoid of the blood brain barrier and
therefore are of particular interest for their role in sensing hormonal and metabolic signals
from the blood. The complex integrated signalling taking place centrally ultimately results
in the RVLM sending signals via the spinal cord and sympathetic ganglia to regulate stroke
volume (SV), heart rate (HR), and systemic vascular resistance (SVR). Image adapted from
Chopra et al., 201139
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when studying the neurogenic basis of hypertension.
1.2 Animal Models in Hypertension
When trying to elucidate the aetiology, and any biomarkers that should precede the onset
of hypertension, animal models can prove invaluable. There exist several animal models
of hypertension, each with their own aetiology and resulting disease characteristics.
Therefore, a great level of care is required when selecting one to study that best reflects
essential hypertension in humans.
1.2.1 Surgical Models of Hypertension
One commonly used model in hypertension research is that of the two-kidney one-
clip (2K1C). The model requires surgically constricting one renal artery in the rat,
leading to a chronically reduced renal perfusion with the contralateral kidney remaining
unmodified. The model is characterised by an early and rapid rise in plasma renin
in response to the reduced renal artery pressure followed by a resulting increase in
circulating angiotensin II (ang II).44 The 2K1C/1K1C models are considered robust
models of hypertension. However both require invasive surgery to induce a hypertensive
state putting a high degree of stress on the animal, and arguably not mimicking the
aetiology of human hypertension.
1.2.2 Genetic Models of Hypertension
One of the most widely used rat models of hypertension is that of the spontaneously
hypertensive rat (SHR). Originally developed in the 1960’s by Okakamoto and Aoki,
the strain was obtained by inbreeding Wistar rats that exhibited the highest BP. After
only a few generations the result was a strain of rat that spontaneously begins to
develop increased BP at around 5-6 weeks of age until plateauing at a systolic BP of
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180-200mmHg. This is in contrast to the accepted normal blood pressure of between
80-100mmHg.45 The importance of this strain resides in its onset of hypertension
without the need for pharmacological, surgical or dietary intervention (contrary to
models such as the Two-Kidney One-Clip or Dahl Salt-Sensitive rats).
For this reason, the SHR presents a model very distinct from the others; one that
mimics the polygenic aspect of human hypertension. Furthermore, as with any accurate
model of a disease state, fully hypertensive adult SHRs develop many of the hallmarks
of end-organ damage associated with hypertension in humans. These include; cardiac
failure (approx. 60% of SHRs develop heart failure after 18 months of age), cardiac
hypertrophy (approx. 30% increase in size), and proteinuria from renal dysfunction.46–48
The SHR also exhibits impaired endothelium dependent relaxation, a feature of human
hypertension that is commonly exhibited and portends the cardiovascular risk that
often occurs when left untreated.49 Further support for using the SHR as a proxy to
human hypertension is given by its responsiveness of many of the pharmaceutical classes
that are used on humans. For example; renin-angiotensin-aldosterone-system (RAAS)
inhibitors, calcium antagonists, and vasodilators.50–52 However, SHRs are less responsive
to diuretics and endothelin antagonists, and the data on the effect of beta-blockers has
proven unequivocal.50,52,53 The spontaneous nature of SHR hypertension coupled with
its polygenic aetiology make it an ideal candidate to study the genetic basis of human
hypertension. At 4 weeks old (juvenile), SHRs present a prehypertensive age, and
therefore an age of interest when trying to assess key differences in their transcriptome
that could predict their inevitable rise in BP.
1.2.3 Reconciliation of the Genome-Environment Interface
Unlike monogenic diseases, complex polygenic disease states are much more likely to be
a function of the environment. Hypertension is no different in this respect, as multiple
modifiable risk factors towards the disease have been identified. It is therefore important
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to consider the interactions between a genetically predisposed individual, and the lifestyle
factors that may contribute to a hypertensive phenotype. One such modifiable risk
factor in the development of hypertension is salt intake.54 While the specific guidelines
towards recommended salt intake have varied in light of contradicting studies, there is
a clear relationship between a high salt diet and elevated blood pressure.55
With this is mind the Dahl salt-sensitive rats represent another commonly used
model of hypertension. In the 1950’s, Meneely et al. began to study the effects of a high
salt diet on the BP of rats. The team noted a linear relationship between the percentage
of NaCl (between 0 and 10%) within the diet and the average BP measured within a
cohort of Sprague-Dawley (SD). They further noted the marked degree of variation
between individuals in their BP response to salt.56 Then in the 1960’s, Dr. Lewis
Dahl built upon the observations of Meneely et al. by studying the effects of chronic
excess of salt in rat models.57 Dahl took advantage of the observation that rats had a
differential response to salt. Being mindful of the data suggesting genetic influences
on blood pressure in humans, he set about selectively breeding rats either susceptible
(Dahl-Salt Sensitive) or resistant (Dahl-Salt Resistant) towards the hypertensive effects
of a high salt diet (8% NaCl). Dahl et al. managed to clearly separate these lines after
only three generations of breeding. The blood pressure of Dahl-Salt Resistant animals
were effectively similar between those fed a control diet or a high salt diet. However
the Dahl-Salt Sensitive animals develop severe and fatal hypertension under a high salt
diet.58,59
Although the organ damage endpoints are comparable to many other models of
hypertension, with cardiac hypertrophy (approx. 32%) and eventual cardiac failure (4-5
months of age) robustly observed, the model requires a dietary intervention before these
become apparent.46 The Dahl Salt-Sensitive and resistant animals constitute a hugely
important model of studying blood pressure regulation, as they present an opportunity
for reconciling the genome-environment interface in the aetiology of hypertension.
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1.3 The Hunt for Biomarkers
Often referred to as a “silent killer”, hypertension is asymptomatic in its early stages.
This results in many patients remaining undiagnosed (1 in 3) until the impact becomes
severe and possibly fatal, highlighting the need for improved diagnostics.60 Should
elevated BP remain unmanaged, it becomes a serious risk factor for the diseases
outlined prior. In order to effectively manage hypertension, the need to intervene before
associated risk factors develop is paramount. For that reason, it is important to identify
a series of biological markers, or biomarkers, that precede the onset of the disease.
These characteristic changes can be at any level of biology, provided they serve as an
objective metric for the progression of the disease accurately and reproducibly. Another
crucial consideration of a clinically relevant biomarker is its accessibility. Blood offers
an accessible tissue that can be obtained through relatively non-invasive means. Here
the search for prognostic biomarkers is centred on the biological level of the blood
transcriptome. This is due to the ability of RNA to reflect the biological state of the
individual in a highly dynamic manner; being able to integrate both the genetic and
epigenetic mechanisms at play in the aetiology of the disease. Indeed many studies are
looking towards transcript expression in offering a robust biomarker for a disease state
due to their early and more accurate predictive properties.61–63
1.4 Transcriptomics
The transcriptome is the total sum of transcripts and their respective quantities within
a cell. These can include all of the mRNAs, small RNAs and non-coding RNAs a cell
is actively expressing. Focusing the search on the transcriptome allows for a dynamic
metric of gene expression, allowing a reconciliation between an organism’s genetic




1.4.1 Evolution of Nucleotide Sequencing
In 2003, the complete mapping of the human genome gave rise to a new era in genetic
analysis. The project sought to sequence a representative version of each human
chromosome (approximately 3 billion bases in total).
The base resolution of libraries was resolved via a process based on Sanger Sequencing.
From its conception in 1977, Frederick Sanger’s eponymous sequencing technique was
a ground breaking development in the ability to unravel the genetic code of life.64
The central development in the technique was the use of specific chain-terminating
inhibitors of deoxynucleotide Triphosphates (dNTPs) to prevent the elongation of
oligonucleotides. DNA templates that were to be sequenced were combined with DNA
polymerase, free deoxynucleotide bases (dATP, dCTP, dGTP, and dTTP), and separated
out into 4 separate incubations, each with sparse mixture of one radioisotope labeled
dideoxynucleotide base (ddATP, ddCTP, ddGTP, and ddTTP). Following a heating
step to denature the template DNA, a cooling step allows the DNA primer to anneal.
DNA polymerase could then synthesise a complementary DNA strand one base at
a time. These bases are randomly incorporated until a dideoxynucleotide base was
utilised, terminating the DNA elongation. The resulting mixture was one of newly
synthesised DNA strands, each differing in length by a single nucleotide and all labeled
at their 3’ end with a radioisotope. In order to read the sequences researchers could
separate the new DNA strands based on size through electrophoresis as each strand
differed by a single DNA molecule. By running all strands through an electrophoresis
gel, the resulting pattern of labeling on radiation sensitive film could be read one base
at a time, taking note of which original incubation it belonged to to therefore to resolve
the base for that read.65
The whole process was painstakingly slow, and to this day remains the world’s
largest collaborative biological project taking a total of 13 years to reach completion.
This huge undertaking relied on a massively parallel and admirably driven workforce
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consisting of 20 institutions that spanned 6 nations.66 As a result, the whole process
cost an estimated $2.7 billion to yield the first draft sequence.65
1.4.2 Next Generation Sequencing
Today an individual’s genome can be resolved in as little as a day. This huge reduction
in time is due to a coevolution of massively parallel sequencing technology, and an
exponential development in the computational power required to process it. Further-
more, these rapid advances have resulted in a marked reduction in associated costs.
The downward trend in the price to sequence the human genome has far surpassed
Moore’s law, a metric used to assess technological improvements as computational power
advances. These advancements have been termed as “Next-Generation Sequencing
(NGS)”. They expand upon the procedural concepts outlined by Sanger Sequencing
and translate them to a massively-parallel approach. While many variations of NGS
technology exist, one of the main approaches employs the sequencing by synthesis (SBS)
method.
The procedure begins with the random fragmentation of genomic DNA, or cDNA,
to produce a pool (Library) of uniformly sized fragments. A series of adapters are
ligated to each end of the fragments, as well as unique stretches of oligonucleotides
for later identification of the original sample from which the fragments were derived
(“Barcoding”). Each library is mixed and washed over a flow cell where a lawn of bound
oligonucleotides bind the complementary adapters that flank the sample fragment. At
this point cluster generation is required to yield clusters of similar fragments such that
their cumulative signal is sufficient to be detected by the sequencer. This can take
place within the sequencer machine (as an onboard cluster module), or on an external
machine (such as the cBot, Illumina, Inc. - San Diego, CA, USA). This is achieved
via a process known as “Bridge Amplification”, and begins with the opposite end of a
ligated fragment bending over and “bridging” to another complementary oligo bound
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to the flow cell lawn. Through repeated denaturation and extension cycles (similar
to a polymerase chain reaction (PCR)), fragments are locally amplified from single
molecules into millions of unique, clonal clusters along the flow cell. At this point the
SBS process can take place.
SBS technology classically uses four fluorescently labeled nucleotides to sequence
millions of clusters bound to the flow cell in parallel †. During each of the sequencing
cycles, a single complementary deoxynucleotide triphosphate (dNTP) binds to the
oligonucleotide chain, and reversibly terminates strand elongation. After dNTP incor-
poration the bound fluorophore is excited and detected through laser imaging to resolve
the specific base that was incorporated within that cluster. The reversible terminator
dNTP can then be enzymatically cleaved ready for the next cycle of incorporation.
By the very nature of NGS, huge amounts of data are produced from any given
experiment. Depending on the organism being studied, genomes can vary in size from
the smallest non-viral genome at 160Kb, to the largest known at 670GB. The complexity
of the transcriptome represents its own challenge with regions of the genome being
expressed more than once; giving rise to an additional dimension of data to interpret.
The ability to deal with this scale of “Big Data” in an acceptable length of time
is incredibly computationally demanding. To maintain a feasible time frame for any
given project, focus needs to be given to optimising mathematical approaches to best
optimise available computational power.
1.5 Bioinformatics Challenges
The chaining of processes required to take the raw .Fastq sequencing files to a final
biologically interpretable output is referred to as a “Pipeline” (Figure 1.4). Currently,
†Illumina’s NextSeq Series introduced the concept of 2-channel SBS technology, with only two
flourophores required. Here only two images are needed to resolve each base, contrary to the classical 4
images employed before. This is achieved by using a red and green wavelength filter to identify colours
as red (C), green (T), a combination (yellow, A) or no colour, given (G). This concept has radically
sped up sequencing runs but has raised concerns about accuracy.
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there are no “gold standards” in optimal pipelines for differential expression. Different
laboratories favour different pipelines depending on the organism being studied, their




























Figure 1.4: Example Pipeline for RNAseq Experiment. Here each step is shown from raw
demultiplexed reads to final biologically interpretable output files. Some examples of software
programs are shown for each step. Also displayed are the common file types associated with




Bioinformatic quality control (QC) of outputted NGS reads is equally as essential as the
QC steps taken at the library preparation stage. These QC checks should be employed
pertinently at several stages along the bioinformatic analysis. The very first step in
any RNAseq pipeline is the QC analysis of the raw reads to assess; sequence quality,
guanine-cytosine (GC) content, overrepresentation of particular subsequences (k-mers,
where k equals the length of the sequence in bases), duplicated reads and the presence
of the adapters used during the library preparation stage. Each of these metrics can be
indicative of a potential error that may have confounding effects on the final results.
To this end, FastQC provides a comprehensive software package for Illumina-generated
reads to produce graphical plots of the above analyses.67
While the technology used for the Human Genome Project has since become out-
dated for experiments requiring a high-throughput approach, its legacy has given rise
to a series of novel assessments that remain in use today. The most common metric
for base calling accuracy is the Phred Quality score. The Phred score was originally
developed as an algorithmic approach towards resolving Sanger sequencing reads, taking
into account the peak resolution and shape of the detected fluorophore signal. While
these attributes no longer exist in next-generation sequencing technologies, the process
of generating Phred scores has remained largely the same. Using different sets of
parameters, relevant to the specific sequencing chemistry being used, accuracies are
correlated against a large lookup data set of known accuracies (Figure 1.5).
The resulting Q-Score is one that represents the probability of an incorrect base
call after any given number of bases resolved (Table 1.1). Lower Q-scores can increase
levels of false positive variant calling, resulting in inaccurate conclusions or higher costs
due to additional validation experiments. Today, the “gold standard” of sequencing
experiments is a Q-score of 30 (Q30), which translates to a probability of 1 potential
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Q = log10 p
Where; Q = Phred Quality Score
p = Probability of an incorrect base
Figure 1.5: Equation for calculating Phred Score. Here probabilities (p) are retrieved from
pre-calculated lookup tables of known accuracies.
miscall in 1,000 bases.
Phred scores have proven to be incredibly consistent throughout a series of different





Accuracy of base call
10 1 in 10 90%
20 1 in 100 99%
30 1 in 1,000 99.9%
40 1 in 10,000 99.99%
Table 1.1: Table of example Phred scores and their accompanying base calling accuracies.
1.5.2 Trimming
It is essential to remove the adapters added to each fragment during the library
preparation stage. A trimming software package (e.g. Trimmomatic or BBDuk) can be
used to trim low quality bases, trim adapter sequences, or simply discard poor quality
reads. All of which will improve mappability to a reference genome. However, it must
be noted that the more aggressive the trimming approach, the greater loss of potentially
important information contained within the reads. For this reason, a balance needs to
be struck in order to get the most from the sequencing experiment.
Furthermore due to a phenomenon known as “Phasing”, read quality classically falls
towards the 3’ end of reads.69 This occurs when the nucleotide blocker, employed during
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each sequencing by synthesis chemistry cycle, fails to be removed after signal detection.
During the next cycle of chemistry, a nucleotide is prevented from binding the template
DNA fragment, and the old nucleotide is once again detected. The fluorescent signal
of the old nucleotide most probably differs from the signal produced around it from
homologous template strands and is therefore not a synchronous signal. For the rest
of the sequencing procedure the result will be one cycle behind the detection signal
of the other strands of that homologous cluster, polluting the signal detected by the
sequencer’s camera and preventing a high confidence base call for that particular cluster.
This phenomenon occurs with a relatively low probability. However over time this
can accumulate and begin to pollute the detected light signal more and more. This is
especially true with increasing read lengths. Sequence quality plots can quickly identify
if this quality becomes too low across the read allowing the bioinformatician to make
the decision whether to remove these low-quality bases (Figure 1.6).
1.5.3 Read Alignment
Once reads have been filtered or trimmed for optimum quality, they can be aligned
to either a reference genome or transcriptome. Either present a series of pro’s and
con’s to be assessed on an experiment by experiment basis. An important metric for
read alignment success is simply the percentage of reads successfully mapped to the
reference genome/transcriptome. Depending on how stringent the aligner algorithm,
this can provide an overall indicator of the sequencing accuracy, and whether or not
any contaminating DNA is present. As an example, an expected rate of between 70
and 90% of RNAseq reads should map to the human genome with some of those reads
mapping to several identical regions within the reference (known as “Multi-Mapping
Reads”).70 It would be expected that a lower level of total reads map when mapping
to the transcriptome, as unannoted regions will be lost. As a consequence more reads
become defined as multi-mapping due to the number of reads falling onto shared exons
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Figure 1.6: Phasing Phenomenon observed within Illumina’s Sequencing by Synthesis
technology (Illumina, Inc. - San Diego, CA, USA). Phasing occurs when a blocker nucleotide
is not removed during one of the chemistry cycles of the experiment (Above, Image taken from
ECSeq Bioinformatics69). Downstream signal is therefore asynchronous within the homologous
cluster, and leads to a decreasing confidence in accurate base calling, as represented by a
reduction in Phred score (Below, BoxWhisker type plot generated by FASTQC (v0.11.7)67).
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from the same genes. For these reasons, priority has been given to mapping reads to
the reference genome rather than the transcriptome.
Additional parameters that need to be considered are the uniformity of reads across
exons, as reads that primarily accumulate at the 3’ end of poly(A) selected samples
may be indicative of low quality starting RNA.
1.5.4 Transcript Quantification and Normalisation
Most analyses of RNAseq data require an estimation of the number of genes expressed,
usually for later differential gene expression (DGE) analysis. The most basic approach to
quantifying expression levels is to simply aggregate the number of raw counts of mapped
reads, through programs such as FeatureCounts, or HTSeq-count.71,72 This process
makes use of a gene transfer format (GTF) file, containing genomic coordinates for
genes and their exons, to quantify the number of reads that fall within these boundaries.
However, these “raw” read counts are not sufficient for comparing the expression of
transcripts between samples, as they are greatly affected by a series of confounding
factors inherent in both library preparation and RNAsequencing. These include factors
such as; sequencing depth, transcript length, and inherent biases in RNAseq technlogy.
Therefore, read normalisation is essential before read counts can be used downstream
with any confidence.
The process of read normalisation is one that has presented the greatest variety in
approaches. In order to convert raw read counts into a measure of relative abundance
that can be biologically interpreted, normalisation is an essential step. It is this crucial
nature that has led normalisation to gain so much research interest. As so many factors
can lead to a potentially confounding effect on the final output, there is no single
normalisation strategy that appears to adequately deal with all of these factors.
One of the early methods to address these confounders was to perform a within-
sample normalisation, by dividing the raw count by the number of kilobases in its exon
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model, and again by the total number of reads generated the sequencing experiment.
The resulting measure was called the reads per kilobase of exon model per million reads
(RPKM).73 The RPKM, and its derivatives such as the analogous fragments per kilobase
of exon model per million reads (FPKM), were for a long time the most frequently
reported gene expression values for RNAseq †. The need to correct for gene length
is only necessary for correctly assessing gene expression levels within the sample as
compared with other genes. However, it it not necessary when comparing any changes
to transcript expression within the same gene across samples as they will be subject to
the same bias of longer genes accumulating more reads. For this reason, the additional
transcripts per million (TPM) normalisation method is often also used.74
1.5.5 Differential Gene Expression
The key to differential gene expression (DGE) analysis is the comparison of gene
expression across samples. A significant problem with the above methods is that they
normalise away the sequencing depth of the experiments which can differ between the
samples. The above methods rely on normalising total counts under the assumption
of a homogeneous transcript distribution. They can therefore perform poorly should
any sample contain a heterogeneous distribution of transcripts, as highly expressed
transcripts can skew the distribution of counts.74–76 All of the newer DGE analysis
suites utilised here offer their own forms of normalisation, and all ignore features that
are either highly expressed or highly variable when calculating normalisation factors.
The following DGE analysis software suites aim to successfully deal with differing library
composition.
†With single-ended reads, both RPKM and FPKM are equivalent. As paired-end experiments
generate two reads that correspond to a single fragment, the latter of the two was created as a way of
preventing doubly counted reads per transcript.
Page 22
Chapter 1. Introduction
empirical analysis of digital gene expression data in R (EdgeR)
One of the more popular DGE analysis suites is EdgeR, from Robinson et al.77 EdgeR
utilises the trimmed mean of the M-values (TMM) approach towards normalisation,
whereby a single sample is selected as a reference. It selects this sample by creating
a library size scale for each gene for each sample, and calculating the average 75th
quantile across all samples. The sample with the 75th quantile closest to the average
value becomes the reference sample for downstream fold change calculations. Geometric
means of fold changes (biased genes) and absolute expression levels (highly or lowly
expressed) are calculated from this raw count before being trimmed twice by thresholds
defined by these values. In other words, the most “extreme” genes are removed before
calculating the weighted scaling factors for each individual gene.
differential gene expression analysis based on the negative binomial distri-
bution (DESeq) & DESeq2
Both DESeq and DESeq2 take the approach of finding a ratio of each raw read count
to the geometric mean of all read counts for that specific gene, across all samples. Here
the denominator becomes the pseudo-reference sample by which all samples are scaled
by. As in EdgeR, by using the geometric mean extreme outliers have less impact in the
resulting scaling factors.78,79
A series of independent studies have shown the choice of DGE analysis approach
to have the potential to markedly affect the outcome of the data, and that no specific
package used is likely to yield favourable results for all experiments.80–82 For this reason,
a great deal of care is employed for selecting an apropriate DGE analysis approach for
this body of work.
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1.6 Statement of Intent and Aims
It is therefore the aim of this body of work to use next-generation sequencing to profile
the transcriptome of a genetic model of human hypertension. By identifying biomarkers
of the disease, it may be possible to develop a prognostic test for identifying those at
risk and to further treat the individual prior to the onset of the disease, mitigating
the organ damage that may otherwise have occured. Using this undirected approach
may allow for the detection of novel transcript biomarkers that have previously not
been implicated in hypertension. It further seeks to do so in peripheral blood, a tissue
easily accessible in a clinical setting. Once a robust biomarker is revealed, efforts will
be directed towards further characterising its potential involvement in the disease in
the hope of revealing novel mechanistic insights into the aetiology of hypertension.
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Candidate Selection Using RNAseq
2.1 Introduction
In order to begin the search for potential biomarkers of hypertension, RNAsequencing
can provide a key overview of transcriptomic changes between normotensive and
hypertensive rat strains. This high-throughput approach allows a comparison to be
made between the WKY and SHR transcripts; profiling their respective abundances
and enabling a highlighting of any significant differences between the two. Furthermore,
sequencing the transcriptomes of these animals at an age prior to hypertension (within
the SHR) will identify transcripts that show the potential to prognostically differentiate
between animals that will later develop hypertension and those that will not.
One of the key challenges with primary research involving animal models is how
translatable these models are to human biology. This is indeed the main test in taking
biological insights gained from the laboratory to the clinic. It is therefore pertinent to
conduct a literature review of potential genetic traits that have already been identified
within a human population. Only a handful of studies have covered the genetic traits
associated with blood pressure, although these lacked replication or were based on
limited sample sizes.83–86 However, one group in particular curated six independent
studies and conducted an association assessment to produce a meta-analysis of gene
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expression signatures of blood pressure and hypertension.87 The study made use of
patients who were not receiving any anti-hypertensive treatments in order to avoid the
possibility of transcriptomic profiles representing pharmaceutical intervention. This
allowed the analysis of patterns in the data that were reflective of inherent genetic
predispositions. From the 7,017 participants, differentially expressed BP genes were
identified from the largest cohort which were cross referenced with the other cohorts
to produce a final list of genes implicated in regulating blood pressure. The study
continued to perform a meta-analysis of all participants for BP associated genes. This
was followed by a GWAS and integrating expressed quantitative trait-loci (eQTL) data
in order to differentiate transcriptomic changes from BP from putative causal pathways
involved in BP regulation. These final lists enabled a directed approach to be taken
with a previously obtained RNAseq output dataset and give rise to the possibility of
any downstream biomarkers being translated to a human cohort.
In this chapter the initial approach towards assessing differentially expressed tran-
scripts between a normotensive and hypertensive rat model is outlined, making use of a
high-throughput RNAseq analysis approach.
2.2 Aims
Using a previously sequenced n=3 generated dataset, the following will be performed;
• A full QC assessment of previously generated RNAseq raw reads
• Pipeline designed for RNAseq to produce list of differentially expressed genes
• Gene ontology of resulting data
• Candidate selection based on the output data
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• Validation using the newly extracted RNA
• Assessment of the false discovery rate
2.3 Materials and Methods
2.3.1 Animals
All animal work complied with the Home Office animals (scientific procedures) act
1986 (ASPA). spontaneously hypertensive rat (SHR) and their age matched Wistar
Kyoto (WKY) controls were supplied at either the prehypertensive 3 weeks of age, or
the fully hypertensive 12 weeks of age (n=3/group for RNAseq cohort, n=12/group
for qPCR validation cohort; Harlan UK Ltd. - Loughborough, UK). Animals were
houses in Plexiglas cages in groups of 3 per cage. Each rat had access to food and water
ad libitum and were supplied with cardboard tubing for cage enrichment. They were
maintained in these conditions and checked daily for signs of poor health for 7 days to
allow them to habituate to their new environment and being handled. This minimised
any potentially confounding effects on our data by way of elevated stress or ill-health.
2.3.2 Sample Preparation
Rats were sacrificed via guillotine, and whole blood was collected from the decapitated
rat via a funnel into a potassium ethylenediaminetetraacetic acid (EDTA) tube (BD
Biosciences - Franklin Lakes, N.J., U.S.A) to prevent coagulation. The body was gently
massaged to prevent internal coagulation. Each blood sample had ∼ 600µl of RNAlater
Solution (Ambion Inc. - Austin, Texas, USA) added and was then stored at -20°C.
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2.3.3 Blood RNA Extraction
All RNA extraction took place on wet ice and in an RNAse free environment, ensured
by good laboratory practice in addition to liberal cleaning of equipment and work spaces
with RNAaseZap (Ambion Inc. - Austin, Texas, USA).
Blood samples were initially thawed on wet ice after having been stored at -80°C.
The RiboPure Blood Kit (Ambion Inc. - Austin, Texas, USA) was used to extract
total blood RNA. All centrifugation steps were conducted at ∼ 16,000 x g at room
temperature as per the RiboPure Blood Kit protocol. As samples were stored in
RNAlater Solution they were first centrifuged for 1 minute. The supernatants was
removed and 800µl Lysis Solution and 50µl Sodium Acetate Solution was added to
the pellets. After vigorously vortexing to lyse the blood cells, 500µl of Acid-Phenol:
Chloroform was added to each sample for the phase separation step. Samples were
left for 5 minutes at room temperature before centrifuging for 1 minute to separate
the aqueous and organic phases. The upper (aqueous) phase containing the RNA was
aspirated to a new tube. 600µl 95-100% ethanol (EtOH) was added to each, and samples
were vortexed briefly to ensure mixing. Samples were then passed through a filter
cartridge housed in a 2ml tube 700µl at a time. 700µl of Wash Solution 1 was added
and washed through the column by centrifuging for 5-10 seconds. Again, flow-through
was discarded before 2 x 700µl washes with Wash Solution 2/3 were conducted as
centrifugations of 5-10 seconds each. Flow-through was discarded and samples were
centrifuged again for 1 minute to remove residual fluid from within the filter. Finally,
to elute the RNA the spin cartridges were transferred to a new RNAse free tube and
50µl of Elution Solution (at 75°C) was added to the centre of the filter. Samples were
left for 20 seconds before centrifuging for 20-30 seconds to elute RNA. This step was
repeated resulting in 100µl of RNA containing water.
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2.3.4 RNA Quality Control & cDNA Synthesis
Ensuring samples were constantly placed in wet ice, extracted RNA was assessed for
purity and quantity via spectrophotometry (NanoDrop 2000c, ThermoScientific). Once
output values were collated samples that presented poor 260:230 and 260:280 ratios were
omitted. The finally selected samples were then used for cDNA conversion. The cDNA
synthesis kit requires an RNA input volume of 12µl. Since a dilution of samples to a
normalised concentration requires fewer potentially damaging steps than a concentrat-
ing of samples, samples were normalised to that of the smallest sample concentration
multiplied by 12. Samples could then be diluted to this value by adding RNAse free
Millipore H20 up to a total volume of 12µl. This resulted in all samples having the same
final concentration prior to cDNA synthesis. cDNA conversion was conducted using the
Quantitect RT kit (Qiagen - Hilden, Germany). Normalised samples were incubated
with 2µl of genomic DNA wipe-out reagent at 42°C for 2 minutes before returning to
wet ice in order to digest unwanted genomic DNA. An Reverse Transcription (RT)
mastermix sufficient for all samples (+10%) was then prepared (Table 2.1). 6µl of this
mastermix was added to each of the normalised samples before incubation at 42°C for
45 minutes. After, the incubation samples were immediately placed in a water bath set
at 95°C for 3mins in order to stop the conversion and denature all of the previously
active enzymes. Samples were then rapidly returned to wet ice ready for qPCR analysis.
Reagent Volume Per 12µl Sample of RNA
Reverse Transcriptase 1µl
RT Buffer (5x) 4µl
RT Primer Mix 1µl
Total Volume 6µl
Table 2.1: Table of reagents required for cDNA synthesis Master Mix
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2.3.5 RNA Sequencing
For RNA-sequencing, RNA samples were sent to a private sequencing service for addi-
tional quality control, library preparation, and sequencing (SourceBioscience Limited -
Nottingham, U.K.). Amplified cDNA libraries were prepared from isolated RNA samples
previously obtained within the laboratory from 3 animals per strain and sequenced using
the Illumina HiSeq 2500 Sequencer (Illumina, Inc. - San Diego, CA, USA). Total RNA
samples were enriched by hybridisation to bead-bound rRNA probes using Ribo Zero Kit
to obtain rRNA- depleted samples. This was followed by the construction of Illumina
libraries using ScriptSeq v2 (Illumina, Inc. - San Diego, CA, USA) that applies unique
barcode adapters. The libraries were assessed for their quality using a Qubit dsDNA
High Sensitivity DNA Kit and Agilent 2100 Bioanalyzer (Agilent Technologies, CA,
USA; Agilent High Sensitivity DNA Kit). This followed with further enrichment and
amplification of the libraries by qPCR using KAPA Biosystems Library Quantification
Kit, before all samples were normalised to 2 nM. Equal volumes of individual libraries
were pooled and run on a MiSeq using MiSeq Reagent Kit v2 (Illumina, Inc. - San
Diego, CA, USA) to validate the library clustering efficiency. The libraries were then
re-pooled based on the MiSeq demultiplexing results and sequenced on a HiSeq 2500
sequencing platform (Illumina, Inc. - San Diego, CA, USA) and cBot with Ver 3 flow
cells and sequencing reagents. Library reads of greater than 30 to 35 million were
generated for each individual library. The data were then processed using Real-Time
Analysis (RTA) and CASAVA thus providing four sets of compressed FASTQ files per
library. FASTQ files were concatenated across lanes to yield two files per sample (Reads
1 and 2 of a paired end sequencing run).
2.3.6 Quality Control and Adapter Trimming
All raw reads were pre-processed for quality assessment using the FastQC package.67
This measures a series of metrics and provided their output in graphical form, allowing
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a bioinformatician to assess the need for adapter removal, quality trimming and size
selection before pushing forward with the pipeline. A Phred30 quality cutoff was
adopted (99.9% base call accuracy).
2.3.7 Alignment
RNAseq alignment and data analysis were all performed in-house using a high-performance
computer; “Hydra”. This pipeline made use of bash and python scripting to accept
RNAseq post-trimmed data as input, before ultimately producing output tables of
differentially expressed transcripts. Paired-end (2x100bp) raw input data was initially
aligned with Tophat to the sixth iteration of the Rattus norvegicus reference genome
(Rn6).88 HTseq was used to generate read counts using the ENSEMBL Rnor 6.0.97
annotation for reference.72
2.3.8 Normalisation of Reads
Here, raw read counts were supplied as input to the pipeline and each statistical DGE
calling software suite applied is own normalisation strategy to deal with library size,
transcript length, or detection of counts to transcripts (Table 2.2).
Method Description Reference
EdgeR Negative binomial count distribution; Robinson, McCarthy
genewise dispersion parameter estimation & Smyth (2010)77
via conditional maximum likelihood;
empirical Bayes shrinkage of dispersion parameter;
exact test for p-value computation
DESeq Negative binomial count distribution; Anders & Huber
local regression modeling of mean and variance parameters (2010)78
DESeq2 Negative binomial count distribution; generalized linear model; Love, Huber
shrinkage estimation of dispersion parameter and fold change & Anders (2014)79
Table 2.2: Description of the core modeling strategies of DGE analysis methods for RNAseq.
Adapted from Khang, T. F., & Lau, C. Y. (2015)1
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2.3.9 Differential Gene Expression Predictions
Due to the huge number of available packages for calling differential expression, this
pipeline initially made use of several statistical methods from the R Bioconductor suite:
DESeq, DESeq2, and EdgeR. Each of these methods allows for the prediction DGE
with high confidence, and to utilise the predictions with low p-values in downstream
validation. As such, the resulting dataset produced contained all of these prediction
approaches to enable an assessment of the differences between them.
2.3.10 Candidate Selection
Primary Candidate List
Over 12,000 transcript elements were flagged up from this comparison, including;
pseudogenes, miRNAs and rRNAs, in addition to protein coding transcripts. Using
datasets for both blood samples, reads were initially ranked based on EdgeR. The
selection of EdgeR to rank by fold change was an arbitrary one, and based on it being
established in the literature and of a lower stringency to the other statistical tests.
This resulted in a greater list to use for downstream filtering. Unidentified transcripts
without a putative role/classification were then discarded, as well as reads identified as
non-protein coding so focus could be given to characterised mRNA transcripts. Once
these parameters were established, an arbitrary selection of genes whose reads were
observed to be most significantly modulated between the WKY and SHR strains gave a
preliminary candidate list for validation (Table A.2).
Final Candidate List
From the primary candidate list, 12 transcripts were selected. Half of these were genes
that were selected based on EdgeR P-values <0.05 (with the exception of Cat, which
had an EdgeR P-value of 0.08 and was included in order to test the accuracy of the
DGE software). The remaining 6 transcripts that made up the final candidate list, were
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transcripts that were implicated in Huan et al.’s 2015 Metaanalysis of hypertensive
signature genes and similarly detected within the RN6 WKY vs SHR dataset, regardless
of whether or not they were significant or not between the two strains. This resulted in
a final list of 12 transcripts that could be used to both validate the RNAseq predicted
fold changes observed, and identify potential biomarkers that could discern between
the hypertensive strain and its control (Table 2.7).
2.3.11 Oligonucleotide Primers
Once targets were selected, nucleotide sequences of genes of interest were obtained
from the NCBI GenBank database. The output FASTA format sequences could be
transferred to the NCBI Primer design tool online.89 Of the options available only; PCR
Product Size, Primer Melting Temperatures (Tm), and Organism were altered (Table
2.3). This was in order to yield primers that were more specific to their intended targets,
by allowing for a smaller PCR product size and a more narrow range of temperature for
primer melting. All other parameters were kept at default settings. Final primers were
selected to be complimentary to exonic regions in order to detect both heteronuclear
and mature RNA transcripts. Each primer was ran on a single plate to look for relative
changes in detection.
Parameter Default Setting Amended Setting




Min; 57.0, Opt; 60.0, Max;
63.0, Max Tm Difference; 3
Min; 58.0, Opt; 59.0, Max;
60.0, Max Tm Difference; 2
Organism Homo sapiens Rattus novegicus (taxid:
10116)
Table 2.3: Amended qPCR Primer Design Parameters. Here, the core settings amended
include; the expected product size, the primer melting temperature (Tm), and the organism
for which the primers are being designed against.
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2.3.12 Primer Validation
For conducting any of the RT-qPCR plates, 2µl of cDNA converted from the blood
RNA extraction was pipetted out (in duplicate) into a 0.1mL 96-well Reaction Plate
(Applied Biosystems, Life Technologies™ - USA) placed on wet ice. A master mix was
prepared containing the; forward and reverse primers for the region of interest and the
SYBR Green Master mix buffer (Roche - Basel, Switzerland) containing; SYBR Green
dye, DNA Polymerase, dNTPs and a salt buffer (Table 2.4). This was made up to a
total reaction volume of 13µl per well with RNAse free H20 (Table 2.5). Also included
were a No Template Control (NTC), which included all of the aspects of the reaction
mixture outlined above except for the 2µl sample template, and a Millipore H20 only;
both in duplicate. These enabled an assessment as to whether any contamination in
the reaction mixture or water would yield any confounding fluorescence that would
influence the final CT reads.
Plates were centrifuged in a desktop centrifuge (PerfectSpin Plate Centrifuge; VWR
PeqLab, UK to collect the reaction mix at the base of each well and remove any bubbles
that could otherwise optically interfere with the instrument. The plates were then loaded
into the StepOne RealTime PCR System (Applied Biosystems, Life Technologies™ -
USA). Settings were kept consistent for all qPCR experiments performed, with total
reaction volume amended to 13µl, and a run of 40 cycles. The threshold for calculating
CT values was set automatically but checked visually to confirm it was bisecting the
exponential phase of the detection curve. A melt curve was performed on each plate
after the extension phase of the final qPCR cycle. StepOne RealTime PCR System
software automatically rendered a graph displaying changes in fluorescence reporter
(∆-R) against increasing temperature (∆°C). This enabled the confirmation that no
signals were produced due to artefacts such as primer dimerization (Figure 2.1). Once
both the CT and Melt curve graphs were checked, raw CT values were exported for
further use in Microsoft Excel.
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Table 2.4: qPCR Primer Sequences used for Primer Validation. Primers were designed using
the NCBI Primer design tool online with settings amended to those seen in Table 2.3.89
Reagent Volume Per Reaction
SYBR Green Master mix buffer 6µl
Forward Primer (100ng/µl) 0.048µl
Reverse Primer (100ng/µl) 0.048µl
RNAse Free H20 4.904µl
Sample cDNA 2µl
Table 2.5: Table of reagents required for qPCR Master Mix
Page 35
Chapter 2. Candidate Selection Using RNAseq
Figure 2.1: Representative plot of a post-PCR melt curve as generated by StepOne RealTime
PCR Software (Applied Biosystems, Life Technologies™ - USA). Plot shows the levels of
fluorescence against changing temperature to ensure primers show a uniform melting point
that would not yield false positive detections.
Once raw CT values were in Excel technical replicates were first assessed for variation.
The Grubb’s, or Extreme Studentized Deviate (E.S.D.) test, on GraphPad’s Outlier
Calculator was used to assess whether or not a replicate was an outlier within a treatment
group.90 The test calculates a specific Z-score for each sample and predicts an outlier
if the sample’s Z-score is over a threshold specific to the N of the samples supplied.
Technical replicates that satisfied this criteria were averaged to produce an average CT
value per biological replicate.
In order to confirm the qPCR primers adhere a linear and predictable increase in
fluorescence, proportional to increases in target cDNA, every primer was first subjected
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to a calibration run. This was conducted using a pool of all sample’s cDNA in order
to cover the dynamic range of gene expression for all of the following experiments. A
series dilution was made using this pooled cDNA and RNAse free Millipore H20 to the
following dilutions; Neat, 1:2, 1:5, 1:10, 1:20, and 1:50. 2µl of each dilution was used in
duplicate to produce a series of average CT values per dilution.
The following formula was then used to assess primer efficiency and plot this on a
standard curve (Figure 2.2, Figure 2.4) at a range of dilutions used;
y = kx + d
Where; y = Average CT for a given dilution
k = Line of best fit, using ”Least Squares” method
d = y intercept at Loge(1)
Figure 2.2: Equation to represent the linear regression of logn[cDNA] versus Primer CT
Value.
From this, a PCR efficiency metric was calculated using the equation depicted in Figure
2.3. PCR primers were deemed to be acceptably efficient if this value was between
80-120%. As there were several candidate genes selected for further validation, any
genes whose primers failed to show efficiencies within this range were dropped from
future analysis. This enabled focus to be given to only the genes with the ability to
detect with a higher level of confidence.
E = (10(−
1
Slope) − 1)× 100
Where; E = Primer Efficiency (%)
Slope = Slope coefficient, as denoted by k in equation 2.2
Figure 2.3: Equation to calculate Primer efficiency from linear regression calculated from
equation 2.2 (%).
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Glrx5 - Standard Curve CT versus Ln[cDNA]
Y = -1.387*X + 30.91
R2 = 0.8937
Figure 2.4: Example Standard Curve for assessing primer efficiency (Glrx5). Detection
values are plotted against the natural log transformed range of cDNA template dilutions.
From the resulting regression analysis, the calculation of the slope was input into the formula
outlined below.
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2.3.13 qPCR of Target Genes
PCR plates were conducted via the above methodology once primers were deemed to be
suitably efficient. An initial plate was ran with β-Actin as the reference gene for blood
on all WKY and SHR samples, both juveniles and adults. Afterward, each primer was
ran using the same template layout (Figure 2.5) for ease of comparison later on.
Figure 2.5: qPCR Layout for WKY vs SHR comparisons at both Juvenile and Adult ages
Here, the 2−∆∆CT method of normalisation was used as per Livak et al, 2001.91
Firstly, absolute CT values for the appropriate tissue reference gene were selected from
the CT values for the gene of interest to produce a ∆CT value. Following this calculation,
the mean ∆CT was subtracted from each of the individual sample values giving a ∆∆CT
value per sample. Finally the negative exponent was taken of these values to produce
a relative gene expression fold change (2−∆∆CT ). This resulted in a series of values
normalised against the selected housekeeping gene, that could be compared relatively
against other values on the same plate.
Following a Shapiro-Wilk test for normality, statistics were calculated by conducting
an unpaired two-tailed Student’s T-test analyses via the GraphPad Prism statistical
software package. Genes whose expression did not pass the Shapiro-Wilk test for
normality were compared betweem strains using a Mann-Whitney test for significance
(Ankrd35, Dusp1, Myadm, and Zcchc9). A confidence interval of 95% (0.05) was
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QC Of RNAseq Data
FastQC output of reads, both pre- and post adapter trimming, showed consistently
high mean Phred quality scores across the entire read length (Mean Phred<30, Figure
2.6). Furthermore, per base N content also showed a pass as the mean count for all
positions across the reads was below the <5% cutoff threshold. The metric for per
sequence quality scores also shows a pass for both pre- and post trimmed reads as the
most frequently observed mean quality is the Phred cutoff of >27. The analysis of
GC content was conducted to assess potential levels of contamination by assessing the
distribution of GC bases across the reads. Here it flagged a failure across all samples as
it did not follow the pattern of a normal distribution as expected. The software issues
a failure flag if the sum of the deviations from the normal distribution represents more
than 30% of the reads. When assessing for over-represented sequences, all of the reads
fail the FastQC analysis as each of the read files were found to contain sequences that
represent more than 1% of the total reads.
Alignment to a Reference Genome
Tophat produced alignment rates were relatively low for each sample with high levels of
discordant or unaligned reads reported (Figure 2.7). On average, 67% of reads were
aligned to the reference genome, of which an average of 0.5% were multiple alignments.
Furthermore, of the aligned and singly-mapped reads, an average of only 31% were
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Untrimmed Trimmed
Figure 2.6: RNAseq Quality Control Metrics, as generated by the FastQC package.67 Here,
Quality control metrics are displayed both before and after adapter trimming.
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Untrimmed Trimmed
Figure 2.6: RNAseq Quality Control Metrics, as generated by the FastQC package.67 Here,
Quality control metrics are displayed both before and after adapter trimming.
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concordantly mapped. Interestingly, the SHR samples had a higher rate of; Total Read
Alignment, Multiple Alignments, and Concordantly aligned reads, as compared with
the WKY samples (Table A.1).
Figure 2.7: Plot of Tophat generated alignment rates (Millions of reads) for the n=3 dataset.
Here, the total reads are split into; Aligned, Multimapped, Discordantly Mapped, and Not
Aligned.
Generation of Gene Counts
Aligned reads were annotated using the Rn6 Rattus norvegicus genome to produce a
count of transcripts for each animal. Running a Principal Component Analysis (PCA)
on the samples before and after EdgeR normalisation reveals inherent biases within
the data (Figure 2.8). Raw reads reveal a distinct pattern on both PC axis, with
two out of three SHR samples forming an isolated cluster on the right hand side of
the graph. This separation represents the greatest source of variation (PC1=57.15%).
The second PC for the raw reads effectively stratifies between the experimental groups.
Post-normalisation, PC1 now appears to resolve the two experimental groups across the
X-axis (PC1=77.89%). The PC2 variation no longer isolates samples effectively, and is
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now likely representative of biological variation between samples. Here, the necessity
for normalisation to prevent RNAseq induced biases from altering our downstream
biological interpretation becomes apparent.
Differential Expression
Final predictions for differential expression were curated and the first two pages of “hits”,
ranked by EdgeR P-Value smallest to highest, are listed in Table A.2. To summarise,
12,564 transcript elements were detected by the RNAseq run, with transcript counts
up to 629,055 (Hba-a3, WKY DESeq Generated average count). Adopting a P-Value
threshold of <0.05, DESeq predicted 354 transcripts to be significantly regulated
between the strains. EdgeR provided a less stringent prediction of 1,821 significantly
regulated transcripts and DESeq2 reported 691 transcripts.
Gene ontology analysis of all EdgeR transcripts that had P-Values <0.05 showed
the majority of significantly regulated genes to belong to the Hydrolase, Transferase
and Oxidoreductase activity GO terms (Figure 2.9).
The finally selected genes are outlined in Table 2.7.
2.4.2 qPCR Data
Validation of Reference Genes for Normalisation
Analysis of putative reference genes in blood revealed a series of significant changes
between the strains at both age groups. It should be noted that as there is no reference
gene with which to normalise these data, all expression levels are left as unnormalised
CT values, meaning a lower CT value denotes a higher abundance. Furthermore as
these are CT values, each amplification cycle represents an exponential increase in
abundance. Therefore a difference of 1 cycle translates to a doubling or halving of
transcript abundance.
β-Actin showed a significant increase in abundance in the SHR within both age
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WKY vs SHR Juvenile − Normalised reads PCA
Figure 2.8: Principal Component Analysis (PCA) of n=3 counts. PCA was conducted on
both raw (Top) and EdgeR normalised (Bottom) counts. Both PCA outputs reveal a clear
separation between the strains.
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Figure 2.9: Molecular Function Gene Ontology analysis of EdgeR Significant (P-Value<0.05)




























ENSRNOG00000013538 Capza1 85.87 81.55 0.95 1.00 1.00 1.00 0.95 0.92
ENSRNOG00000019050 Ifit1 296.53 2324.18 7.84 1.30E-45 8.26 1.33E-25 7.47 1.70E-47
ENSRNOG00000025108 Ankrd35 0.60 91.29 151.25 2.16E-14 121.41 4.42E-23 20.44 3.09E-14
ENSRNOG00000001242 Gstt3 0.00 132.70 NA 1.60E-22 1464.58 2.78E-28 31.94 2.74E-18
ENSRNOG00000008364 Cat 11696.90 7572.97 0.65 0.09 0.68 0.01 0.65 1.16E-04








ENSRNOG00000053450 Myadm 43.34 31.92 0.74 1.00 0.77 0.27 0.75 0.51
ENSRNOG00000003977 Dusp1 41.59 35.33 0.85 1.00 0.88 0.69 0.86 0.79
ENSRNOG00000004206 Glrx5 4888.10 2072.04 0.42 8.59E-08 0.45 7.55E-07 0.43 7.80E-12
ENSRNOG00000021106 Gramd1a 48.59 75.08 1.55 1.00 1.60 0.03 1.48 0.23
ENSRNOG00000020938 Ppp1r15a 594.23 834.08 1.40 0.47 1.47 0.01 1.39 0.01
ENSRNOG00000013631 Slc31a2 5.54 2.16 0.39 1.00 0.42 0.39 0.65 NA
Table 2.6: Original RNAseq Output of Finally selected Candidate Transcripts. DESeq generated average counts are displayed for each
gene, along side fold changes and P-Value predictions from each differential expression analysis software. N.B. For DESeq2, the log2 Fold
Change values have been converted to the comparable fold change values. Furthermore, the “NA” P-Values issued by DESeq2 are returned
due to a single sample with an extreme outlier (as detected by Cook’s distance). Genes are separated on the y-axis to show genes selected





























ENSRNOG00000013538 Capza1 capping actin protein of muscle
Z-line subunit alpha 1
Predicted to have actin filament binding activity. Predicted to be involved in actin cytoskele-
ton organization; barbed-end actin filament capping; and cell junction assembly.
ENSRNOG00000019050 Ifit1 Interferon-induced protein
with tetratricopeptide repeats
Predicted to be involved in cellular response to cytokine stimulus; defense response to virus;
and response to bacterium. Orthologous to several human genes including IFIT1B (interferon
induced protein with tetratricopeptide repeats 1B).
ENSRNOG00000025108 Ankrd35 Ankyrin Repeat Domain 35 Orthologous to human ANKRD35 (ankyrin repeat domain 35)
ENSRNOG00000001242 Gstt3 Glutathione S-transferase
theta-3
Predicted to have glutathione transferase activity. Predicted to be involved in glutathione
metabolic process.
ENSRNOG00000008364 Cat Catalase Exhibits catalase activity. Involved in several processes, including hydrogen peroxide
catabolic process; response to ozone; and response to vitamin. Localizes to several cellu-
lar components, including the Golgi apparatus; mitochondrial intermembrane space; and
peroxisome. Used to study bacterial pneumonia; brain ischemia; cholestasis; colitis; and
lung disease. Biomarker of several diseases, including artery disease (multiple); auditory sys-
tem disease (multiple); end stage renal failure; eye disease (multiple); and neurodegenerative
disease (multiple). Human ortholog(s) of this gene implicated in several diseases, including
acatalasia; eye disease (multiple); lung disease (multiple); osteonecrosis; and pseudoxanthoma
elasticum. Orthologous to human CAT (catalase).
ENSRNOG00000051682 Zcchc9 Zinc Finger CCHC-Type Con-
taining 9
Predicted to have nucleic acid binding activity and zinc ion binding activity. Predicted to
be involved in negative regulation of phosphatase activity. Orthologous to human ZCCHC9








ENSRNOG00000053450 Myadm Myeloid Associated Differentia-
tion Marker
Predicted to be involved in several processes, including negative regulation of heterotypic
cell-cell adhesion; negative regulation of macromolecule metabolic process; and negative reg-
ulation of protein kinase C signaling. Orthologous to human MYADM (myeloid associated
differentiation marker).
ENSRNOG00000003977 Dusp1 Dual Specificity Phosphatase 1 Exhibits growth factor binding activity and protein tyrosine/threonine phosphatase activity.
Involved in several processes, including negative regulation of nitrogen compound metabolic
process; regulation of apoptotic process; and response to testosterone. Localizes to the
nucleus. Used to study Huntington’s disease. Biomarker of several diseases, including anti-
basement membrane glomerulonephritis; brain disease (multiple); hypertension; pancreatitis;
and portal hypertension. Human ortholog(s) of this gene implicated in breast cancer. Or-
thologous to human DUSP1 (dual specificity phosphatase 1).
ENSRNOG00000004206 Glrx5 Glutaredoxin 5 Predicted to have several functions, including 2 iron, 2 sulfur cluster binding activity; electron
transfer activity; and protein disulfide oxidoreductase activity. Predicted to be involved in
protein lipoylation. Localizes to the dendrite; neuronal cell body; and nucleus. Human
ortholog(s) of this gene implicated in autosomal recessive pyridoxine-refractory sideroblastic
anemia 3. Orthologous to human GLRX5 (glutaredoxin 5).
ENSRNOG00000021106 Gramd1a GRAM Domain Containing 1A Predicted to have cholesterol binding activity and cholesterol transfer activity. Predicted to
be involved in cellular response to cholesterol. Orthologous to human GRAMD1A (GRAM
domain containing 1A).
ENSRNOG00000020938 Ppp1r15a Protein Phosphatase 1 Regula-
tory Subunit 15A
Exhibits protein phosphatase 1 binding activity. Involved in several processes, including cellu-
lar response to nutrient levels; cellular response to organonitrogen compound; and regulation
of cellular protein metabolic process. Localizes to the cytosol. Biomarker of brain ischemia
and transient cerebral ischemia. Orthologous to human PPP1R15A (protein phosphatase 1
regulatory subunit 15A).
ENSRNOG00000013631 Slc31a2 Solute Carrier Family 31 Mem-
ber 2
Predicted to have copper ion transmembrane transporter activity. Predicted to be involved
in cellular copper ion homeostasis and regulation of copper ion transmembrane transport.
Orthologous to human SLC31A2 (solute carrier family 31 member 2).
Table 2.7: Additional information on candidate transcripts. Displayed here are the ensembl gene ID accession numbers alongside their
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groups, at around 1 fold difference which approximately translates to a doubling in
transcript abundance (Figure 2.10; juvenile WKY vs SHR, -0.79 fold, P-Value=0.032;
adult WKY vs SHR, -1.01 fold, P-Value=0.038).
A similar, but more significant difference was observed for GAPDH as SHR blood
again saw an increase in its expression as compared with WKY blood (Figure 2.10;
juvenile WKY vs SHR, -0.94 fold, P-Value=0.022; adult WKY vs SHR, -0.98 fold,
P-Value=0.023).
RPL19 showed the greatest change in abundance between the strains, at both
ages. This was in the same direction as the other putative reference genes tested, but
saw a greater magnitude of change (Figure 2.10; juvenile WKY vs SHR, -1.04 fold,
P-Value=0.008; adult WKY vs SHR, -0.84 fold, P-Value<0.0001).
Producing the Geometric Mean, by use of the BestKeeper software suite, did little to
normalise the data towards consistent CT values across the groups. The CT values still
saw a significant decrease when comparing SHR to WKY (Figure 2.10; juvenile WKY
vs SHR, -0.92 fold, P-Value=0.013; adult WKY vs SHR, -0.907 fold, P-Value=0.0045).
Biomarker Candidates
qPCR analysis on my selected transcripts revealed a series of changes taking place
within the whole blood. Expression of Capza1 in the whole blood showed now significant
differences between the strains at either age group (Figure 2.11a; juvenile WKY vs SHR,
+0.1 fold, P-Value=0.60; adult WKY vs SHR, -0.1 fold, P-Value=0.55). Furthermore
there was a much greater spread within the juvenile animals than in the adult animals,
of either strain.
Expression levels of MYADM showed a significantly increased level in the SHR
juvenile as compared with the WKY. However this difference was not reflected in the
adult cohort (Figure 2.11a; juvenile WKY vs SHR, +0.36 fold, P-Value=0.04; adult
WKY vs SHR, +0.12 fold, P-Value=0.11).
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Geometric Mean - Whole Blood
**
*
Figure 2.10: qPCR ∆CT values for putative reference genes; β-Actin, Glyceraldehyde
3-phosphate dehydrogenase (GAPDH), and 60S Ribosomal Protein L19 (RPL19). Statistics
are presented as unpaired Student’s T-Test P-values, between strains at any given age
(P-value<0.05, *; P-value<0.01, **; P-value<0.001, ***).
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DUSP1 expression saw a significant decrease across the juvenile comparison. However
this was not replicated within the adult comparison. The control WKY juvenile group
showed a much greater level of variation between each animal compared with the other
groups whose expression levels were more stable (Figure 2.11a; juvenile WKY vs SHR,
-0.75 fold, P-Value=0.0051; adult WKY vs SHR, -0.001 fold, P-Value=0.88).
Transcript levels of Glrx5 were elevated in the juvenile cohort as compared with the
adult cohort, however no significance existed between the strains at either age group
(Figure 2.11a; juvenile WKY vs SHR, +0.01 fold, P-Value=0.96; adult WKY vs SHR,
+0.01 fold, P-Value=0.71).
Gramd1a showed a significant increase in transcript abundance in the juvenile SHR
compared with the juvenile WKY. This change was not observed across the strains in
the adult comparison (Figure 2.11a; juvenile WKY vs SHR, +0.61 fold, P-Value=0.003;
adult WKY vs SHR, +0.02 fold, P-Value=0.90).
Neither age group showed a significant change in expression levels for Ppp1r15a in
the blood (Figure 2.11a; juvenile WKY vs SHR, +0.1 fold, P-Value=0.64; adult WKY
vs SHR, -0.01 fold, P-Value=0.83).
Ifit1 saw an incredibly significant and robust elevation in transcript abundance in
the SHR as compared with the WKY. This was consistent in both the juvenile and
adult age groups. However the increase was much more pronounced within the juvenile
cohort (Figure 2.11b; juvenile WKY vs SHR, +68.2 fold, P-Value<0.0001; adult WKY
vs SHR, +8.31 fold, P-Value<0.0001).
qPCR showed Ankrd35 levels to be significantly regulated between the strains,
with SHR blood showing much higher levels of the transcript as compared with their
age-matched controls. This increase in abundance was greater in magnitude within
the juvenile cohorts, however was more tightly grouped within the adult comparison
(Figure 2.11b; juvenile WKY vs SHR, +3.31 fold, P-Value=0.0005; adult WKY vs
SHR, +0.544 fold, P-Value=0.0002).
SLC31A2 expression in the blood was not significantly different between either age
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group comparison. A slight increase in spread was observed within the SHR juvenile
sample as compared with the WKY juvenile group (Figure 2.11b; juvenile WKY vs
SHR, -0.13 fold, P-Value=0.44; adult WKY vs SHR, -0.05 fold, P-Value=0.29).
Expression of Gstt3 in whole blood showed a robust and significant elevation in the
SHR vs the WKY in both age groups. Furthermore all groups showed a tight clustering
of expression levels with the exception of the WKY juvenile group, where expression
of Gstt3 appeared to greatly vary (Figure 2.11b; juvenile WKY vs SHR, +43.4 fold,
P-Value<0.0001; adult WKY vs SHR, +14.8 fold, P-Value<0.0001).
Levels of Cat remained relatively unchanged, with no significance reported from the
unpaired Student’s T-Test. Variation was much greater within the juvenile animals as
compared with the adult animals, reaching an almost significant increase in the juvenile
SHR cohort (Figure 2.11b; juvenile WKY vs SHR, +0.68 fold, P-Value=0.09; adult
WKY vs SHR, +0.03 fold, P-Value=0.57).
Zcchc9 showed a robust increase in the SHR vs the WKY across both age groups.
This increase was much greater in magnitude in the juvenile comparison, compared with
the adult comparison (Figure 2.11b; juvenile WKY vs SHR, +5.89 fold, P-Value<0.0001;
adult WKY vs SHR, +0.47 fold, P-Value<0.0001).
2.5 Discussion
2.5.1 RNAseq Data
Potential issues to QC Output
The first step following an RNAseq experiment, is to assess the quality of the resulting
reads. From this QC step many of the raw .fastq read files flagged up as failing the
various QC metrics FastQC assesses. While mean quality scores appeared consistently
high (Phred Score>30) across the entire reads and per sequence, as well as the all
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Figure 2.11: Relative mRNA expression of Candidate Biomarkers in the whole blood of
Wistar Kyoto (WKY) and Spontaneously Hypertensive Rats (SHR) at both 4- and 12 weeks
of age. Here, expression is presented as 2−∆∆CT , normalised to relative expression of β-Actin,
using the WKY as the control group for each normalisation. Statistics are presented as
unpaired Student’s T-Test P-values, between strains at any given age (P-value<0.05, *;
P-value<0.01, **; P-value<0.001, ***).
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Figure 2.11: Relative mRNA expression of Candidate Biomarkers in the whole blood of
Wistar Kyoto (WKY) and Spontaneously Hypertensive Rats (SHR) at both 4- and 12 weeks
of age. Here, expression is presented as 2−∆∆CT , normalised to relative expression of β-Actin,
using the WKY as the control group for each normalisation. Statistics are presented as
unpaired Student’s T-Test P-values, between strains at any given age (P-value<0.05, *;
P-value<0.01, **; P-value<0.001, ***).
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reads having a low percentage N-count, the GC Content flagged up as a fail across all
samples. Warnings to this module indicate a problem with the library itself and may
have been resultant of either a specific contaminant (adapter dimers for example) or a
contamination with a different species.93 Many of the potential issues that arose are
dealt with by trimming adapters that are left on from the indexing stage of the library
preparation. However, the trimming of reads failed to improve upon the GC content.
2.5.2 qPCR Data
Having selected a series of potential biomarker candidates, qPCR provided a different
experimental approach to validate both their biological validity in another cohort of
animals, in addition to the RNAseq generated dataset itself.
One of the problems faced in any validation study is that of identifying a suitable
housekeeping gene for the comparison. Quantitative RNA data are relative to both
the total quantity and constituent transcripts contained within the extracted RNA.
Therefore the reference genes used for standardization are of critical importance, and
any analysis of the validity of qPCR data must consider the relevance of the genes
selected for their ability to successfully normalise any discrepancies in the input RNA.
Initially RPL19 was investigated to normalise gene expression against. This was
due to its previous usage as a reference gene by the laboratory within brain tissues
and therefore primers were readily available.94 qPCR analysis of blood tissue showed
significantly increased levels of RPL19 in the SHR compared with the WKY across
both age groups. For this reason a suitable housekeeping gene that remained stable
between the strains in blood tissue needed to be identified. Multiple studies have
investigated the stability of reference genes in different tissues, but very few have done
so in blood. It was for this reason that the putative reference genes; β-Actin and
GAPDH were investigated. Both were significantly modulated across the strains and
were therefore not suitable to normalise against. The Bestkeeper software produced
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by Pfaffl et al (2004) allowed the coordination of all of the reference genes analysed to
give a standardised geometric mean to compare the candidate genes against.95 This
approach resulted in a set of housekeeper values that were still significantly modulated
in blood tissue across strains for both age groups. Moreover, the P-values obtained
between the strains were more significant than those obtained for β-Actin alone, and so
β-Actin was selected as the reference gene due to its comparably low significance. While
this may not impact on the analysis of profoundly modulated gene expression, such as
that observed for ifit1, it is of crucial importance to conclude with any confidence that
the modulation is resultant of the experimental variable and not merely an inherent
difference across the experimental groups. Further efforts must be made in order to
identify a stable housekeeper for future validation steps. This could be achieved by
using more putative housekeeping genes to produce a more stable geometric mean. An
alternative strategy could be to consult the RNAseq data to investigate the genes that
were not significantly modulated between the strains. Once properly validated, this
could provide a stable housekeeping gene to normalise against in future studies.
2.5.3 Comparison of RNAseq and qPCR output
False Discovery Rate
When comparing the RNAseq changes in gene expression with the qPCR analysis,
multiple disparities were observed in either the fold change or level of significance (Table
2.8, Table 2.9). Many of the changes statistically significant in the RNAseq data were
not as significant in the qPCR findings and vice versa. There are many reasons why
this could be the case, all of which should be considered when interpreting these results.
A potential source of variation may have arose from the method by which the
libraries were prepared. Here libraries were depleted of rRNA by use of the Ribosomal
Depletion method. A comparison of this method against a Poly(A) selection method





















DESeq EdgeR DESeq2 qPCR
Gene Name WKY.Avg SHR.Avg FC P-Value FC P-Value FC P-Value FC P-Value
Capza1 85.87 81.55 0.95 1.00 1.00 1.00 0.95 0.92 1.1 0.60
Ifit1 296.53 2324.18 7.84 1.30E-45 8.26 1.33E-25 7.47 1.70E-47 63.51 <0.0001
Ankrd35 0.60 91.29 151.25 2.16E-14 121.41 4.42E-23 20.44 3.09E-14 3.68 0.0005
Gstt3 0.00 132.70 NA 1.60E-22 1464.58 2.78E-28 31.94 2.74E-18 28.47 <0.0001
Cat 11696.90 7572.97 0.65 0.09 0.68 0.01 0.65 1.16E-04 1.6 0.09
Zcchc9 2.11 37.30 17.71 5.25E-04 17.93 5.67E-11 7.06 NA 6.67 <0.0001
Myadm 43.34 31.92 0.74 1.00 0.77 0.27 0.75 0.51 1.35 0.04
Dusp1 41.59 35.33 0.85 1.00 0.88 0.69 0.86 0.79 0.34 0.0051
Glrx5 4888.10 2072.04 0.42 8.59E-08 0.45 7.55E-07 0.43 7.80E-12 1.01 0.96
Gramd1a 48.59 75.08 1.55 1.00 1.60 0.03 1.48 0.23 1.58 0.003
Ppp1r15a 594.23 834.08 1.40 0.47 1.47 0.01 1.39 0.01 1.09 0.64
Slc31a2 5.54 2.16 0.39 1.00 0.42 0.39 0.65 NA 0.96 0.44
Table 2.8: Comparison of RNAseq output with qPCR validation on candidate biomarkers. N.B. For DESeq2, the log2 fold Change values
have been converted to the comparable fold change values. Furthermore, the “NA” P-Values issued by DESeq2 are returned due to a single
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Table 2.9: false discovery rate (FDR) of RNAseq differential gene expression (DGE) tests,
as calculated by False Positives (DGE P-Value<0.05 ∧ qPCR P-Value<0.05) / True Positives
(qPCR P-Value<0.05).
percentage reads aligning to intronic regions.96 The study finds that 220% more reads
would have to be sequenced in order to achieve the same level of exonic coverage when
using rRNA depleted libraries as compared with Poly(A) selected libraries. As the focus
of this study was primarily expression of mature transcripts, a Poly(A) selection method
of library preparation may optimise the detection of reads aligning to exonic regions;
utilising a greater percentage of the available read depth and ultimately improving
upon the accuracy of resulting DGE calling.
One of the causes of disparity between the RNAseq output and the qPCR validation
may find its roots in the poor QC output from the RNAseq reads, in particular the GC
content. FastQC raised a failure flag across all reads for this metric and indicated the
source of the error to be either adapter dimer contamination or a contamination from
another species. Due to the width of the peaks across the distribution it suggests the
latter is the case.93
It should also be noted that these discrepancies may well be due to true biological
differences between the samples and not a reflection of any bias inherent to the experi-
mental method used to measure transcript expression. While these are both inbred rat
strains, there will still exist a level of biological noise at these given sample numbers.
It therefore becomes a question of replicates necessary to get the most out of the
differential expression analysis. Experiments with a low number of replicates will often
have poor statistical power to be able to resolve differentially expressed genes correctly
and furthermore cannot account for natural biological noise.97,98 With this in mind an
experimenter could simply increase the number of replicates to improve upon statistical
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power and to ultimately improve upon correctly identifying differentially expressed
transcripts. However the relatively high cost of RNAseq, coupled the drive for primary
researchers to reduce the number of animals used, make this approach prohibitive. For
this reason it seems pertinent to tease out the precise relationship between accurately
resolving differentially expressed genes and the replicate number required to do so. A
few studies have sought to answer this question. Two of which took publicly available
RNAseq data from 21 clones of two separative strains of mouse.80,99,100 Soneson &
Delorenzi (2013) compared various DGE tools and measured for a level of concordance
between the tools’ outputs in order to assess their suitability. They concluded none of
the 11 DGE tools they assessed performed acceptably with fewer than 3 replicates.80
Burden et al use the metric of FDR to rank five DGE tools, concluding that at least
six replicates are required per condition to achieve a low FDR.100
A study in 2016 was the first of its kind to use a much greater dataset of 48 biological
replicates across 2 conditions in order to answer this question and provide guidelines for
future RNAseq experiments.101The study continues to suggest that for future RNAseq
experiments, at least 6 replicates per group should be considered with an optimum
of 12 replicates per condition where identifying the majority of all DGE is required.
Furthermore, they state that for experiments with <12 replicates per condition; EdgeR
or DESeq2 is to be used. This is in accordance with studies that provide a much lower
level of replication
2.5.4 Concluding remarks
Here 3 biological replicates per strain are relied upon for the RNAseq analysis, which is
confirmed by the qPCR validation to be greatly underpowered for detecting a series of
robust differentially expressed transcripts. Further optimisation is therefore required in






3.1.1 Building upon previous findings
Given the high false discovery rate observed for the n=3 dataset, it is pertinent to
revisit the standard practice for any given RNAseq experiment. As an RNAseq pipeline
presents a long string of individual manipulation events, both pre- and post sequencing,
there exist many variables that could potentially lead to confounding results. The
vastly different pipelines and methods of library preparation do not lead to directly
comparable datasets. Instead, here the focus is given to the main potential sources of
error, in the hopes of optimising each step in the approach for future experiments.
3.1.2 In Silico Optimisation
Over the last few years, increasing numbers of novel differential expression methods
have been produced, each assuming a different statistical spread to best represent the
relationship between raw RNAseq counts and actual abundance of genes.
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A key issue with assessing the different normalisation strategies is the need to
validate each test’s predicted expression changes using other technologies in order to
account for the presence of False Discovery Rates. Classically this is done by selecting
a cross-section of transcript candidates and performing qPCR to assess how accurate
the predicted fold changes are when compared to the biologically observed fold changes
qPCR shows. While this is the best way to validate the large datasets NGS produce,
it is time consuming and can always be improved upon by including more and more
validation candidates.
One of the ways in which a pipeline can be optimised is via the inclusion of
synthetically generated sequencing data. With a standardised dataset, the number of
differentially expressed genes can be set, and furthermore compared with the number
genes predicted to be differentially expressed by each statistical method. Here the R
studio program CompcodeR is used, which enables the synthesis of a dataset to the
specifications set out by the user.102 The program makes use of the data generation
method outlined in Soneson and Delorenzi (2013).80
3.1.3 Repetition of RNAseq Dataset
Using the literature, and findings from the In Silico optimisation, a repeat of the
previous RNAseq experiment was conducted. Based on these results, alterations were
made to the number of replicates, library preparation, and the analysis pipeline itself.
All of which will be inspected to see how each alteration can serve to optimise the
approach, and lead to results more consistent with the qPCR data obtained from a
greater number of replicates in the previous chapter.
Library Preparation
One of the first major decisions to be made during an RNAseq experiment, is the
way in which the library of transcripts will be made. ribosomal ribonucleic acid
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(rRNA) is by far the most highly abundant constituent of the total transcriptome, for
any animal or human tissue, comprising 80-90% of the total RNA.103 Therefore, the
transcripts of interest must be isolated in order to get the most from the finite number
of reads each RNAseq experiment is capable of. With this in mind, two main options
exist to isolate mRNA transcripts; Poly(A) selection, and rRNA depletion. Poly(A)
selection involves the selection of polyadenylated RNA (including mRNA transcripts)
using oligo(dT) primers to bind to the polyadenylated tails. rRNA depletion takes
an alternative approach to removing the highly abundant rRNA transcripts. Using
magnetic beads with rRNA complimentary sequences, rRNAs hybridize to the beads
and can be subsequently removed from the total RNA sample by isolating the magnetic
beads that now contain them. Each of these approaches has a series of unique advantages
and disadvantages, with many studies discussing these at great length.104–107
Where input is limited, or potentially degraded, rRNA depletion manages to leave
fragmented transcripts in the sample library. This is due to the potential lack of
polyadenylated tail, preventing these fragments from being enriched by use of the
Oligo(dT) selection process.104,105,107 As the input for this series of experiments is high
in abundance, and low in degradation, this does not present a problem that needs
overcoming.
With such high quality input tissue, the key consideration for this library preparation
is how to maximise the number counts generated via RNAseq, and specifically for those
types of transcripts that are the focal point of this study. As touched upon briefly in sec-
tion 2.5.3, Poly(A) selection presents the best way in which to maximise the sequencing
depth as the focus here is on the protein-coding fraction of the transcriptome.96,104,106
The previous n=3 dataset was obtained through rRNA depletion (Section 2.3.5).
Here the new RNAseq experiment makes use of the Poly(A) selection method of library
preparation in an attempt to see if this can resolve the high levels of duplicated reads
observed in the n=3 dataset, allowing more reads to be used for transcripts of interest.
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Number of replicates
Building upon the In Silico optimisation, and the literature review conducted in section
2.5.3, the new RNAseq experiment will make use of an optimised number of replicates
in order to minimise the false discovery rate.
Analysis Pipeline
Once samples are resolved by the RNA sequencer, the resulting reads need to mapped to
a reference genome in order to identify precisely which genes these original transcripts
were produced from. For this reason, the ability to align as many reads as possible
to the reference, and to do so accurately, has the potential to translate to significant
changes in the ultimate DGE analysis.
The advent of RNAseq technology gave rise to a new challenge when trying align
reads to a reference genome, as new software had to take into account alternative
splicing. A new generation of splice-aware software was therefore created, with several
advances over the earlier BLAST-like alignment tool (BLAT).108,109 In 2009, Tophat
was released as part of this new generation, and made use of a two-step approach to
read alignment. Firstly, reads were assessed to discover exon junctions, before using
this information as part of the final alignment to the reference genome.88 This, and
similar tools, set the standard in read alignment algorithms for a long time and was
therefore a key step in the previous pipeline employed for the n=3 dataset. However,
year on year additional programs are released, with each purporting to be capable of;
greater alignment rate, higher alignment accuracy, or faster alignment compute speeds.
All of which are valuable attributes to any RNAseq experiment.
As with the DGE prediction software, several groups have sought to compare
these approaches with both biologically and in silico generated datasets. A paper
in 2013, compared 26 mapping protocols based on 11 programs and found major
differences between these methods based on a series of performance benchmarks.110 The
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benchmarks used included; total alignment yield, exon junction discovery, suitability of
alignments for transcript reconstruction, mismatch and gap placement, and basewise
accuracy. These tests were conducted on paired-end RNAseq reads from a human
leukemia cell line (K562), mouse brain lysates (C57BL/6NJ), as well as two simulated
human transcriptomes.111–113 From the biologically derived samples (i.e. the K562,
and CB57BL/6NJ), both were Poly(A) selected libraries. From their comparison, the
spliced transcripts alignment to a reference (STAR) software performed the best across
a host of the performance metrics tested, most notably the highest level of primary
alignments devoid of mismatches, and the highest accuracy in splice-detection.70 Based
on the findings of this paper, and others, STAR was selected as a new splice-aware
aligner to compare against the previous Tophat alignment software.114,115
3.1.4 Microarray vs RNAseq
While RNAseq presents the most current and thorough way to perform a high-throughput
analysis of the transcriptome, microarrays have continued in their popularity over the
last few years due to their reliability and relatively low cost. This is especially true when
studying a well characterised model organism with a well defined genetic annotation, such
as the Rattus norvegicus, as microarray chips can yield an enormously comprehensive
snapshot of the transcriptomic profile of an animal. Here the focus is on transcripts that
are significantly modulated between the two experimental strains being studied. With
this in mind, microarray presents an approach that is more than capable of shining light
on these differences, and can furthermore act as an independent technology by which
to validate the RNAseq based approach used here. Therefore, a comparison between an
RNAseq and Microarray output would provide a key foundation in pushing forward
with biomarker discovery.
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3.2 Aims
Building upon the n=3 dataset, priority is given to assessing potential sources of the
high false discovery rate, and optimising the approach for subsequent studies. This will
be achieved via the following;
• An In Silico assessment of the optimum number of replicates
• An In Silico assessment of the optimum statistical software suite for calling differ-
ential gene expression
• Performing a microarray of differential gene expression
• A repeat of the RNAseq experiment, with an adjusted library preparation method
and number of replicates
• A comparison of microarray output with RNAseq output
3.3 Materials and Methods
3.3.1 In Silico Optimisation
Comparison of Methods (n=3 )
Using the CompcodeR program in an RStudio environment, a series of synthetically
generated RNAseq datasets were produced. The generateSyntheticdata command in-
cludes many different arguments to best replicate the type of data the finally adopted
differential expression method is to be used on. The below table (Table 3.1) includes
the settings used for the base comparison of methods (n=3; reads = 1x107; 12,500
total genes; 10% differentially expressed). These parameters were set to be comparable
to the previous RNAseq data the laboratory had processed. The initial CompcodeR
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comparison therefore acted as a benchmark test of methods, before alterations to
parameters were made for further optimisation of our pipeline. This run was performed
via the runComparisonGUI command, and repeated 10 times with all parameters left
as default (0.05 for all settings). CompcodeR then runs a comparison of methods based
on these 10 replicates.
Argument Amended Setting Description
n.vars 12500 Initial number of genes to be generated
in the simulated data set.
Samples.per.cond 3 Number of samples in each condition (n).
n.diffexp 1250 Number of genes simulated to be differentially
expressed between the included conditions.
seqdepth 1.00E+07 Total number of mapped reads.
Fraction.upregulated 0.5 Fraction of differentially expressed
genes that are upregulated
Between.group.diffdisp FALSE Sets whether or not levels of dispersion
are different between conditions
Filter.threshold.total 1 Threshold for total of any given gene
across all replicates.
Table 3.1: List of key arguments to generateSyntheticdata command. Here are the specific
parameters used for generation of the dataset used for the Comparison of Methods (section
3.3.1). For the Comparison of Replicates (section 3.3.1), the Samples.per.cond parameter
was adjusted for the generation of each dataset to be used.
Comparison of Replicates
Once a comparison was made for a synthetic dataset with 3 replicates per group, a
comparison of varying n values was made by maintaining all parameters as above, but
altering the sample.per.cond argument. In order to narrow the optimisation, DESeq2
was selected for comparing the number of replicates due to its performance in the n=3
comparison against other DGE software.
3.3.2 Tissue Preparation
Animals were sacrificed, had blood extracted and RNA isolated as outlined in Chapter 2
materials and methods. As blood tissue is primarily comprised of haemoglobin containing
erythrocytes for the transportation of oxygen, the blood transcriptome comprises
approximately 80-90% globin mRNA. Evidence also shows an abundance of globin gene
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transcripts originating from erythrocyte progenitor cells, as globin RNA has been seen to
comprise >70% of the transcriptome of adult human reticulocytes.116 Samples therefore
required depleting of these transcripts in order to prevent downstream techniques from
only detecting the overly abundant globin.117 This was achieved by subjecting the
RNA samples to a GLOBINClearTM Protocol.118 Samples were initially assessed for
RNA concentration using the Nanodrop 2000c (ThermoFisher) and normalised with
RNAse-free water for RNA reactions between 1-10µg and input volumes of ≤14µl before
running through the GLOBINclear procedure. This made use of biotinylated oligos,
complementary to globin mRNA, to hybridize to the globin transcripts. Streptadvidin
magnetic beads were then added to bind with the now biotinylated globin transcripts,
and a magnetic microcentrifuge rig captured and isolated the bound complexes. This
allowed for globin-free total RNA supernatant to be decanted, leaving the vast majority
of the globin mRNA behind.
The final RNA samples were sent to a private sequencing service for further analysis
including library preparation, microarray and RNAseq assessment (SourceBioscience
Limited - Nottingham, U.K.).
3.3.3 N=6 RNAseq
For RNA-sequencing, libraries were built using the TruSeq Stranded mRNA kits
(Illumina, Inc. - San Diego, CA, U.S.A.; Figure 3.1). In a similar approach to the
globin depletion protocol outlined above, polyadenylated mRNA was first isolated by
use of binding complimentary oligo(dT)s bound to magnetic beads. This was contrary
to the previously obtained RNAseq dataset (n=3) which made use of rRNA depletion
rather than mRNA selection. The magnetic beads were then magnetically isolated from
the RNA pool, along with the bound polyadenylated mRNA transcripts. The remaining
mRNA was then cleaned, fragmented, and primed ready for cDNA synthesis (Step
1; Figure 3.1). Using random nucleotide primers, the first cDNA strand is initially
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synthesised before actinomycin is used to prevent second strand synthesis (Step 2;
Figure 3.1). After this, the RNA template is degraded to ensure only the second strand
is used for next cDNA synthesis. Here Deoxyuridine Triphosphate (dUTP) nucleotides
are used in place of Deoxythymidine Triphospgate (dTTP) nucleotides, in order to allow
for a differentiation between the first and second strands of cDNA later on (Step 3;
Figure 3.1). The newly synthesised double stranded cDNA is next prepared for adapter
ligation via an additional adenylation at the 3’ end of each strand (Step 4; Figure 3.1).
This enables the cDNA to hybridize with the thymine overhang on the 3’ end of the
adapters. Adapters are ligated onto the cDNA fragment and dUTPs are enzymatically
removed from the fragments (Step 5; Figure 3.1). Following enzymatic removal of
the dUTPs, fragments are PCR amplified to produce a resultant library that can be
validated quantitatively via qPCR (Step 6/7; Figure 3.1). Additional quality control
takes place using a 2100 Bioanalyzer (Agilent Technologies) to assess fragment size
and to ensure primer dimerisation has not occurred (Step 8; Figure 3.1). This quality
control step is also employed at various stages along the sample preparation to ensure
RNA integrity is maintained. Unlike spectrophotometric methods of RNA analysis
electrophoresis methods measure the sizes of RNA fragments, enabling information to
be gleaned as to how degraded the transcripts are at any given step. Since each sample
was ligated to an adapter containing a specific nucleotide sequence, libraries could then
be pooled for running on the flow cell (Step 9/10; Figure 3.1).
Once libraries are washed over the flow cell cDNA fragments hybridise, via their
adapters, to complimentary olignucleotides bound on to the flow cell. At this point,
cluster generation will occur via bridge amplification to yield isolated clusters born from
the same original fragment. After clustering, libraries were loaded onto an Illumina
HiSeq 4000 flow cell (Illumina, Inc. - San Diego, CA, USA) and ran to obtain a final
count of around 52 million paired-end reads per sample at 2 x 75bp read length.
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Figure 3.1: Overview of TruSeq Stranded mRNA Preparation protocol. Image adapted from
www.abmgood.com
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3.3.4 Microarray
For microarray analysis of the whole blood transcriptome, the current market leader for
producing assay chips is ThermoFisher Scientific. When studying expression profiles
within the rat, ThermoFisher offers two options as part of their ClariomTM range. The
Clariom DTM Rat 1.0 Assay was selected over the Clariom STM due to its ability to
perform a comprehensive and detailed analysis of both coding and noncoding genes, in
addition to exons and splice variants. This greater level of resolution comes at a greater
financial cost, however it does futureproof the data for a more comprehensive analysis
if required.
In order to prepare for microarray analysis, the GeneChipTM Whole Transcript
Pico protocol was followed (ThermoFisher Scientific,119). Isolated and purified RNA
was initially incubated with a reverse transcriptase and PCR primers containing a T7
promoter. This constituted the first-strand cDNA synthesis step, and primes the 5’ of
the transcripts for further manipulation downstream. Next, a 3’ adapter is added to the
single-strand cDNA, and used as a template for double-stranded cDNA synthesis in a pre-
in vitro transcription (IVT) amplification reaction. The reaction makes use of a DNA
polymerase and RNase H to degrade the RNA and synthesise a single-stranded cDNA
containing a 3’ adapter. The resulting single-stranded cDNA could then be converted to
double-stranded cDNA, enabling it to act as a template for in vitro transcription. This
was achieved through Taq DNA polymerase and a set of Adapter-specific primers to
simultaneously synthesise and pre-amplify the double-stranded cDNA. Once the double-
stranded cDNA had been sufficiently amplified, anti-sense RNA, or complimentary
RNA (cRNA), could be synthesised and further amplified via an in vitro transcription
using the double-stranded cDNA as a template and the T7 RNA polymerase. This
approach towards RNA preparation is derived from the Eberwine or RT-IVT method,
outlined by Van Gelder et al., 1990.120 The samples were next purified of any enzymes,
inorganic phosphates, salts and unutilised nucleotides, using purification beads. This
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was in order to prepare the cRNA samples for the second-cycle single-stranded cDNA
synthesis.
At that point, a spectrophotometry quality control checkpoint was carried out
to assess purity and quantity of the cRNA samples and to normalise libraries ready
for continuing. From the normalised libraries of cRNA, a sense-strand cDNA was
synthesised through reverse transcription and second-cycle primers. The resulting
sense-strand cDNA incorporates dUTP at a maintained ratio to the incorporated
dTTP, preparing the cDNA for later fragmentation. RNase H was next used to
hydrolyse the cRNA template, leaving the single-stranded cDNA. Following hydrolysis,
another purification step was carried out on the second-cycle single-stranded cDNA
and, after a second spectrophotometry quality control checkpoint, the samples were
ready for cDNA fragmentation and labeling. The purified, sense-strand cDNA was next
biochemically fragmented by a combination of Uracil-DNA Glycosylase (UDG) and
Apurinic/ayrimidinic Endonuclease 1 (APE1), utilising the unnatural dUTP residues
introduced earlier in the protocol, to break the DNA strand. The resulting fragments
were next labeled by terminal deoxynucleotidyl transferase (TdT) using ThermoFisher’s
propriety DNA labeling reagent that is covalently linked with biotin. Samples were
then loaded onto the GeneChip for hybridisation via the conjugated biotin molecules.
The GeneChip was put through a series of wash and staining steps before being scanned
ready for image anaylsis.
Once the raw output data was returned from the sequencing company, it was be
put through a series of stringent quality control steps. All further analysis was carried
out on a desktop computer, making use of the R environment to run Oligo and Affy
packages to process the raw .cel files.121,122 The first step in quality control assessment,
is the generation of chip pseudo-images to shed light on potential inconsistencies on
individual arrays (Figure 3.18). A further quality control is to plot the distribution
of the log base 2 intensities (Log2(PMij) for array i and probe j) of the perfect match
probes, in order to compare probe intensity behaviour across the different arrays (Figure
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3.19). The shape and distributions of the intensities should all be relatively consistent
across the different arrays, with any discrepancy indicating a potential source of error
that requires additional normalisation. Box plots show the same differences in probe
intensities across chips, however allow for a clearer the overall distribution than in the
histograms; especially when assessing the effects of normalisation.
There are several sources of potentially confounding noise in microarray experiments.
There may be inconsistencies with the quantity of RNA used for hybridisation, subtle
differences in hybridisation conditions, imperfections on the chip array surface, or an
imperfect synthesis of the probes themselves. Any of these sources of noise may lead to
the observation of differences between the arrays that are not reflective of biological
variability, and therefore need to be removed in order to make accurate conclusions
about the data. In order to normalise both within and across each chip, the Robust
Multiarray Averaging (RMA) method was used.
The Robust Multiarray Averaging (RMA) method of normalisation makes use of only
the Perfect Match (PM) probes, and performs a series of steps. Initially, a background
correction is performed in order to correct for spatial variation within each individual
array. This is achieved by calculating a background-corrected intensity for each PM
probe to ensure all background corrected intensities are positive. It then makes a Log2
transformation of the background corrected intensities to improve the distribution of
the data in both up- and down-regulated directions. The Log2 transformed data then
undergoes a Quantile normalisation in order to correct for sources of noise across the
arrays. This makes the expression data comparable between the arrays.
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3.4 Results
3.4.1 In Silico Optimisation
Comparison of Methods (n=3 )
Once the software was run, a series of investigative plots were drawn in order to compare
how accurate the various statistical tests were for that given synthetic dataset. These
plots are displayed below as representative plots of 1 replicate out of 10.
In Figure 3.2 a numerical representation of Receiver Operating Characteristics
(ROC) curve is shown. Total area under the curve (AUC) tends towards a value of
1 as the test is better at detecting truly positive genes ahead of truly negative genes.
This plot shows the total performance of each test, however indiscriminately towards
alterations in true positive stringency. When the total plot is taken into account, EdgeR
GLM marginally performs the best at a score of 0.82. This is closely followed by
DESeq2 and DESeq GLM at 0.81.
Figure 3.2: Area Under the Curve (AUC)
Figure 3.3 shows a summary of ability of a test to rank truly positive genes (y-axis)
ahead of truly negative genes (x-axis). A good test procedure maximises the area under
the curve and tends towards the upper left of the plot. Here all tests perform similarly
under these conditions. As the true positive rate is low (i.e. threshold for significance is
more stringent) DESeq2 and Voom-Limma appear to show the lowest levels of false
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positive calling. As the true positive rate increases, however, EdgeR and NOISeq TMM
appear to best mitigate false positive calling.
Figure 3.3: ROC Curves
Figure 3.4 represents a visual depiction of the number of false discoveries reported
(y-axis) against a list of genes ranked for significance via their respective statistical
test (x-axis). Hence, at any given position on the number of selected genes, the y-axis
represents the number of truly non-differentially expressed genes that are ranked above
that position. A good statistical test places few true negatives amongst the top-ranked
genes, and therefore is shown by a curve tending to the bottom right of the plot with a
slow rise on the y-axis. Here both DESeq2 and Voom-Limma perform the best, with
the least number of false discoveries amongst their top ranked genes up until 1250
genes; where all tests appear similar in their inability to exclude false negatives.
Further to the above, Figure 3.5 is a representation of False discovery rate (FDR).
This figure indicates the number of inaccurately called false positives amongst the genes
predicted to be differentially expressed at an adjusted p-value threshold of 0.05 (dashed
line). A good test should see the observed FDR close or below the imposed adjusted
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Figure 3.4: False Discovery Curves
p-value threshold. Voom-Limma appears to perform below the adjusted value threshold
of 0.05, with all others greatly over this threshold.
Figure 3.5: False Discovery Rate
The total number of significant genes called with the adjusted p-value threshold of
0.05 is plotted in Figure 3.6. This is compared with the originally set number of genes
to be significantly different between the two conditions when synthesising the dataset
(10% of total; 1250 Genes). The plot therefore is a measure of stringency alone.
In Figure 3.7, a comparison between the scores each differential expression method
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Figure 3.6: Number of Significant calls
give to each gene. The Spearman’s correlation between scores returns a value between
-1 and 1, with a high positive value of correlation coefficient indicating both methods
similarly ranked genes. These comparisons are plotted as a heat map (index displayed).
It appears that Voom-Limma shows the greatest difference between all of the other
tests. Perhaps to be expected, EdgeR GLM and EdgeR exact show similar correlation.
The Matthew’s Correlation Coefficient is a measure of performance summary by
combining the number of observed; true positives, true negatives, false positives, and
false negatives into a single metric (Figure 3.8). The coefficient is ranked from -1 to 1,
with a value of 1 corresponding to a perfect classification and -1 corresponding to a
completely inaccurate classification with regards to the true labels. Furthermore, on
this scale a value of 0 corresponds with a random assignment of label. Here DESeq2
far outperforms the other tests in its ability to accurately reconcile all classification
labels. Both Voom-Limma and the original iterations of DESeq performed the worst,
with scores of around 0.23.
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Figure 3.7: Spearman correlation between scores
Figure 3.8: Matthew’s Correlation Coefficient
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Comparison of replicate number - DESeq2
Based on the above metrics, DESeq2 was selected for further optimisation to see how it
best performs given a variety of replicates. A similar series of plots to the comparison
of DGE methods can be seen here.
Figure 3.9 shows the AUC, based on the ROC curve outlined above. Here the AUC
metric appears similarly strong across all of the number of replicates tested, with an
n=6/7 showing the strongest AUC.
Figure 3.9: Area Under the Curve (AUC)
The false discovery rate between the samples with different replicates shows a pre-
dictable pattern, as increasing numbers of replicates lead to a significant reduction in
FDR (Figure 3.10). This appears consistent, however the reduction in FDR between
n=5 and n=6 is greater than the previous reductions. Furthermore, an interesting
increase in FDR occurs between n=6 and n=7, showing n=6 to outperform n=7 within
DESeq2.
Figure 3.11 shows a steady and consistent increase in the number of significantly
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Figure 3.10: False Discovery Rate
regulated genes called as the number of replicates is increased. The in silico generated
dataset contained a predetermined number of 1,250 significantly regulated genes. With
this in mind, the closest prediction was for the n=7 dataset at approximately 800
significant calls.
Figure 3.11: Number of Significant calls
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When these data are collated by use of the Matthew’s Correlation Coefficient, an
interesting result appears (Figure 3.12). Contrary to expectation, an increase in
replicate number does not equate to an overall better performance of the analysis. Here
the n=6 dataset marginally outperforms the n=7 dataset. It should be noted that this
result is based purely on a single in silico generated dataset, with predetermined effect
size, analysed with DESeq2 only.
Figure 3.12: Matthew’s Correlation Coefficient
Moving forward, it therefore appears that n=6 should provide a significant improve-
ment in output for RNAseq experiments, whilst still ensuring the cost of the experiment
does not become prohibitive.
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3.4.2 RNAseq
RNAseq n=3 vs n=6
As with the pipeline utilised for the n=3 dataset, the initial QC output was scrutinised
to ensure there were no potential errors with the raw fastq files. Here fastqc data are
displayed for both the n=3 and n=6 datasets, in order to make an initial comparison
between the output of the RNAseq experiments (Figure 3.13).
Ignoring the different read lengths between the two RNAseq outputs, the reads
generated as part of the n=6 dataset are consistently much higher than those of the
n=3 dataset (Figure 3.13). Furthermore, the levels of Phred score reduction across the
read appear much less severe within the n=6 dataset.
This is further reflected within the Per Sequence Quality Scores, with the newer
n=6 dataset showing a much higher number of reads with a phred score approaching
40 (Figure 3.13).
The number of N calls per base are consistently low between both datasets, however
those of the n=6 dataset are only just visible as advancing over the x-axis across the
read (Figure 3.13). The same cannot be said about the n=3 dataset, where the per
base N content can be discerned from the x-axis. Regardless, this only ever accounts
for a maximum of well below 1% of the reads, and so is unlikely to affect the alignment
to the reference genome and eventual differential expression calling for genes that are
abundantly present in the samples.
The per sequence GC content sees the greatest level of improvement between the
datasets (Figure 3.13). The distribution for the n=6 experiment is much more consistent
and even, with the fastqc issuing a warning on reads rather than a failure (as denoted
by the orange colour of the distributions, rather than the red). This is due to the sum
of the deviations from the normal distribution representing more that 15% of the reads.
While this is not optimum, it does present a significant improvement over the n=3
experiment where the sum of deviations from the normal distribution being >30%.
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The percentage of total sequences showing an over representation is markedly differ-
ent between the two experiments (Figure 3.13). This is occurring despite comprehensive
adapter trimming having taken place on both experimental outputs.
N=3 N=6
Figure 3.13: RNAseq Quality Control Metrics, as generated by the FastQC package.67
Here Quality control metrics are displayed for both the n=3 and n=6 datasets, after adapter
trimming has occured.
When the percentage of uniquely mapped reads are plotted for both Tophat and
STAR, a series of distinct patterns become apparent (Figure 3.14). Most notably, the
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N=3 N=6
Figure 3.13: RNAseq Quality Control Metrics, as generated by the FastQC package.67
Here Quality control metrics are displayed for both the n=3 and n=6 datasets, after adapter
trimming has occured.
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percentage of aligned reads for either alignment strategy are much greater for the new
RNAseq experiment. When comparing alignment strategy within RNAseq experiments,
a clear separation between Tophat and STAR is observed in the n=6 experiment. Within
the new cohort of samples, the average number of concordantly mapped reads increases




























































Figure 3.14: Levels of Concordantly mapped reads of both n=3 and n=6 run - Comparison
between Tophat and STAR aligners
The PCA generated, as part of the DESeq2 package, shows the first two principal
components to account for the majority of the variation observed between all four
groups (Figure 3.15). The greatest level of variance observed (PC1; 82% Variance)
clearly resolves between the old and new sequencing experiments. The second largest
variance (PC2; 11% Variance), resolves between the WKY and SHR strains, regardless
of the batch from which they originate. Furthermore, each individual group shows an
incredibly tight clustering, showing the majority of the variance is accounted for by
either strain or batch.
Figure 3.16 shows a scatter plot of DESeq2 predicted Log2 fold changes of all
genes with a multiple test corrected P-Value <0.05. A linear regression analysis shows
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Figure 3.15: principal component analysis (PCA) Plot featuring Previous n=3 RNAseq and
current n=6 RNAseq experiments. Sample colours are grouped by experiment and strain.
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the correlation between the Log2 Fold changes of both datasets with the correspond-
ing; slope coefficient, R2, and 95% Confidence interval (CI) values displayed. A high
level of concordance appears between the values of each dataset, with the n=3 dataset












DESeq2 Sig Log2Fold Change Comparison
0.9239 to 0.9468
0.8767R2 = 
95% CI = 
0.9328 ± 0.01649Slope = 
Figure 3.16: Scatter Graph representation of DESeq2 significant (P-Value<0.05) Log2 Fold
Changes across n=3 and n=6 RNAseq experiments
The total output for the new n=6 DGE analysis is displayed in Table B.2 of the
appendix. Table 3.2 represents a curated version, displaying only the original candidate
genes along side their associated qPCR validation values.
Figure 3.17 shows an UpsetR generated plot of DESeq2 significant (P-Value <0.05)
genes for both the n=3 and n=6 datasets. Each dataset is split into positively (i.e.
upregulated in the SHR as compared with the WKY) and negatively (i.e. downregulated
in the SHR) regulated genes. These total set sizes are displayed on the bottom left
x-axis. Intersections of conserved genes are then displayed by use of individual nodes
along the main x-axis, with the number of genes common to the highlighted nodes
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Chapter 3. Optimisation of High-Throughput approach
displayed along the y-axis (as denoted by the “Intersection Size”). Highlighted in orange
and blue are the shared nodes for downregulated and upregulated in both n=3 and
n=6 datasets respectively. The greatest level of overlap in DESeq2 significant genes, is
within the downregulated genes (321 conserved genes) compared with the upregulated























   
0200400600800
Set Size
Upregulated Genes Downregulated Genes
Figure 3.17: UpsetR Generated comparison of DESeq2 significant genes (P-Value<0.05)
between n=3 and n=6 RNAseq experiments; separated by direction of change. Total set sizes
are displayed in the bottom left x-axis, and sets being compared are designated by highlighted
nodes across the main x-axis. The number of genes individual to a set, or conserved across
multiple are denoted by the nodes highlighted and the corresponding “Intersection Size” on
the y-axis.
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3.4.3 Microarray
Quality Control
The R-generated pseudo-images showed a consistent patterning of intensities across
all arrays, except for WKY5 which showed a circular artefact of increased intensity
(Figure 3.18). The uniform nature of the artefact suggested it was an error with the
manufacture of the chip itself. For this reason, this microarray sample was repeated,
with the repeated array showing no such artefact.
Figure 3.18: Quality control generated Pseudo-images of Microarray Gene Chips of sample
WKY4 (left) and WKY5 (right). Here a clear artefact can be seen in the WKY5 sample in
the shape of a ring around the chip. The artefact appears to be a defect within the gene
chip, and one that was possibly the result of a loading or manufacture error. This sample was
subsequently re-ran before inclusion in the experiment.
Once the array for WKY5 was rerun, a histogram representation of Log intensities
across each array was produced (Figure 3.19). Here each sample shows a consis-
tent distribution. This was therefore not indicative of any sample requiring an over
normalisation or to be omitted all together.
The boxplots of the log2(PMij) intensities and the RMA normalised log2(PMij)
intensities reveal an uneven distribution between each of the samples (Figure 3.20).
This is most notable for sample SJ1 and WJ5, whose interquartile range appear trun-
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Figure 3.19: Histogram showing the Log intensities across the chip for all arrays. Here a
uniform distribution of intensities across can be seen across all chips. Therefore, this QC
metric does not highlight any causes for concern at this stage of the QC pipeline.
cated compared with the other samples. These intersample differences in log2(PMij)
intensities are no longer perceivable after RMA normalisation. The global distributions
therefore all appear comparable.
Figure 3.20: Boxplots of log2(PMij) intensities for both pre- and post RMA normalisation.
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A PCA was conducted to better assess for any overarching dimensions of noise
apparent in the data, and to see whether or not they align with the experimental design
(Figure 3.21). The PCA of the raw intensities shows the first principal component (i.e.
the greatest dimension of variability; x-axis), to account for 67.4% of the total variation.
Across this axis, the individual samples are resolved, leading to the conclusion that
the greatest source of variation in the raw intensities is due to biological variability.
This pattern can be observed regardless of the strain to which the samples belong. The
second principal component (y-axis) accounts for 8.65% of the variation, and shows a
clear resolution between the two strains across this axis.
This pattern is relatively conserved after RMA normalisation, however there is no
longer a clear separation between the strains across the second principal component
(y-axis; 4.83%). This dimension of variability has been normalised against, whereas
the first principal component now accounts for a greater percentage of the global noise
(x-axis; 74.48%). Across this axis, samples are separating based on biological or technical
noise.
Differential Expression Analysis
From Thermofisher’s Transcriptome Analysis Console (TAC, ThermoFisher Scientific)
generated DGE table, a total of 68,011 transcript elements were detected. Of this
total, 832 reached a multiple test corrected (FDR) P-Value<0.05. This total list of
transcript elements comprised of 24,753 transcripts designated as “Coding”, of which
442 reached a FDR P-Value<0.05 (Table B.3) of the appendix. A curated form of the
final DGE output from Thermofisher’s transcriptome analysis console (TAC) software
for candidate genes is displayed in Table 3.3.
In Figure 3.22, the entire detected transcriptome is displayed in scatter and volcano
plots. Each punctum denotes an individual transcript, with puncta highlighted in red
as being significantly upregulated, and those highlighted in green significantly downreg-
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WKY vs SHR Juvenile − RMA Normalised PCA
Figure 3.21: Principal Component Analysis for both pre- and post RMA normalisation. The
greatest source of noise (PC1) appears to resolve the biological replicates, regardless of strain
(Raw, 67.4%; RMA Normalised, 74.48%). The second principal component (PC2) separates
the strains. The raw PCA shows a robust separation across the strain, which appears to be
normalised for in the RMA normalised PCA (Raw, 8.65%; RMA Normalised, 4.83%).
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Chapter 3. Optimisation of High-Throughput approach
ulated. Also highlighted here in the red circle, is the Ifit1 transcript; one of the most
significantly upregulated genes in the n=3 RNAseq dataset that was validated through
qPCR analysis. The scatter plot shows a greater level of genes to be upregulated in
the SHR than downregulated. The volcano plot illustrates the greater level of these
upregulated transcripts in reaching P-Value significance.
Figure 3.22: Scatter and Volcano plots of Microarray results
3.5 Discussion
3.5.1 In Silico Optimisation
Comparison of Methods
In an attempt to build upon the previously obtained n=3 RNAseq dataset, and mitigate
the high FDR observed, an In Silico generated dataset was created. Using the n=3
dataset as a foundation, the parameters of the in silico dataset were set in order to best
emulate the results of the biologically generated dataset. Unlike a biologically derived
RNAseq output, the precise expression values of each gene are predetermined, allowing
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for a precise correlation to be drawn between the actual and predicted DGE.
With this in mind, CompcodeR was able to produce a series of performance bench-
marks for each of the statistical DGE tools. With 3 replicates, and averaged over 10
randomly generated datasets (whilst still maintaining the same parameters outlined in
Table 3.1), the majority of the tests appeared consistent in their overall performance.
The main benchmarks that saw a separation in the tool’s performance were; the number
of significant calls, the false discovery rate, and the Matthew’s Correlation Coefficient.
The FDR not only varied greatly between the various DGE tools tested, but within
the replicated datasets assessed. Some of the tools showed a great spread in the FDR
report, such as NOISeq, and DESeq. By far the best performing tool was limma-voom
with TMM normalisation. However, this was due to the hugely stringent nature of
its analysis as it predicted the lowest number significantly regulated genes by a large
margin.
There was a great disparity in the number of genes predicted to be significantly
regulated by the various DGE tools. Interestingly, DESeq2 was markedly more stringent
then EdgeR in the n=3 (Section 2.4.1; DESeq2 P-Value<0.05, 691 transcripts; EdgeR
P-Value<0.05, 1,821 transcripts). However, here DESeq2 consistently predicted the
greatest number of significantly regulated genes, with this number being closest to the
true number of regulated genes.
In an attempt to curate these findings, and integrate them into an overall performance
benchmark, a MCC was conducted. The MCC takes into account both the true and false
positives and negatives, and provides a metric that is generally regarded as balanced
(Figure 3.23). The produced coefficient ranges from -1 to 1, with a score of 1 denoting
a completely correct binary classifier. Here DESeq2 performs markedly better, with a
series of MCC scores between 0.45 and 0.5.
It should be noted that each iteration of a synthetic dataset will subtly change based
on the random algorithms employed in the generateSyntheticdata command. This will
therefore subtly influence the various comparisons drawn above. Whilst the attempt was
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MCC =
(TP × TN)− (FP × FN)
[(TP + FP )× (FN + TN)× (FP + TN)× (TP + FN)]
1
2
Where; TP = True Positives
TN = True Negatives
FP = False Positives
FN = False Negatives
Figure 3.23: Equation for calculating the Matthew’s correlation coefficient (MCC). The
MCC serves to produce a metric that integrates all of the logical outcomes from the RNAseq
predictions.
made to mitigate this by running several synthetic datasets through this comparative
software, each run in trialing this software has been sufficient to reliably rank each test
on any given metric such that its position remains uninfluenced. For that reason, a
single generated dataset can suffice in allowing the assessment of these tests as there is
less concern with the absolute values they gain, rather how they perform against each
other.
What is clear from these comparisons, is just how varied each strategy is in its
strengths and weaknesses. No one test appears to outperform the rest across all
benchmarks. However, it does appear that DESeq2 best resolves the relationship
between false and true calls towards significantly regulated genes. For this reason,
further optimisation made use of the DESeq2 DGE prediction software.
Comparison of replicate number - DESeq2
Based on the subtle performance differences across the DGE statistical approaches,
coupled with the literature, DESeq2 was selected to further optimise the number of
replicates required.
From the CompcodeR datasets, increasing the number of replicates resulted in a
consistently increasing number of significantly regulated gene predictions. This follows
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an expected pattern as an increase in replicates gives rise to a more accurate estimation
of the sample distribution. This in turn leads to a greater statistical sensitivity in
detecting truly regulated genes.
The key issue with the n=3 dataset was the high FDR. Interestingly, based on
the simulated data 6 replicates leads to the lowest FDR by DESeq2. Moreover, this
observation was strong enough to lead to a consistent result within the MCC benchmark
as n=6 outperforms the n=7 based on MCC, contrary to expectation.
For the comparison of replicate numbers, a single replicate was generated for
each DESeq2 analysis. The compcodeR generateSyntheticdata command works by
modeling gene counts from a Negative Binomial distribution, using mean and dispersion
parameters obtained from previously obtained RNAseq gene expression data.80 A
random variable is generated to represent the gene counts for this model, in conjunction
with the key parameters outlined in Table 3.1. It is this random variable that will lead
to interexperimental noise in gene expression counts between generateSyntheticdata
generated data, much in the same way biological noise affects expression distributions.
It is likely this noise is the cause for any discrepancies observed within the comparisons,
including the counterintuitive increase in FDR in the n=7 In Silico dataset. This could
be mitigated by replicating the replicates, and generating a larger series of datasets to
be cycled through for any given replicate number to be tested.
Furthermore, it should be noted that there may be gains in performance between
the different DGE statistical approaches, as the number of replicates is increased. Here
only DESeq2 was benchmarked with different numbers of replicates. For this reason,
a more comprehensive assessment could be ran to iteratively compare all of the DGE
approaches available, with several permutations of replicates.
It would be possible to run this In Silico, however this has previously been performed
with experimentally generated RNAseq data, as outlined in section 2.5.3. Here the
focus was given to an In Silico generated dataset, with selected parameters to best
mirror the results observed in the original n=3 dataset as no other biological proxy was
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available.
Furthermore, running the analysis with additional replicates greater than 7 may
shed light on the optimum number of replicates to accurately call this particular number
of regulated genes, however given the increasing cost of additional replicates, this trade
off may not be required for the generation of a candidate list of biomarkers.
For these reasons, and the findings of the high throughput studies mentioned in
section 2.5.3, 6 replicates per group were selected for use in a repeat of the WKY and
SHR blood transcriptome comparison.
3.5.2 RNAseq
n=3 vs n=6 Datasets
The fastqc output for both the n=3 and n=6 RNAseq experiments presented a series of
metrics by which a comparison could be drawn between the raw fastq files of each. It
is the first step after sequencing, and already shows a series of interesting differences
between the experiments.
The first, and arguably most important metric of raw fastq files, was the quality of
base calling from the sequencer itself. In other words, the accuracy of each base call
as measured by the Phred score. Comparing across the different RNAseq experiments
reveals an interesting difference between the consistency of average Phred scores across
each read. The n=3 reads show a steady fall in Phred score across the read, whereas
those from the n=6 experiment are consistently high. This observation could be resultant
of two factors; the sequencing technology used, and the length of the reads generated.
The first potential cause of this difference, is the length of reads being used. The
n=3 experiment used 2x100bp reads, whereas the n=6 dataset used much shorter
2x75bp reads. Due to the phenomenon of phasing, outlined in section 1.5.2 of the
introduction, average read quality will always tend to decrease as the reads get longer.
Therefore longer reads, such as those generated in the n=3 dataset, are much more
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susceptible to this reduction in base calling accuracy. Of course the shorter read length
comes with the caveat of reduced information. This is a concern when this additional
information is required for a per base resolution required for focusing on single nucleotide
polymorphism (SNPs). Here this loss of resolution is acceptable as the focus is given
to whole transcripts whose expression is modified between the model organisms being
studied.
Year on year, subtle improvements are being made to all next-generation sequencing
platforms. Most notably with Illumina’s sequencing by synthesis technology, improve-
ments to the sequencing chemistry and the methods of detection are constantly resulting
in increasing accuracy to base calls. Here the n=3 dataset was generated with the
HiSeq2500 (Illumina, Inc. - San Diego, CA, USA), a platform that was released in 2012.
The n=6 experiment was conducted on the HiSeq4000; a platform released 3 years later
in 2015. This difference in time translates to a great increase in base call accuracy.
One of the most notable improvements to Illumina’s approach is the transition from
standard flow cells to “Patterned” flow cells, as used in the HiSeq4000 (Figure 3.24).
Patterned flow cells contain billions of nanowells at fixed locations across both surfaces
of the flow cell. This structured organisation leads to an even spacing of sequencing
clusters across the the cell, enabling a clearer detection of bases from each cluster and
mitigating the previous need to map cluster sites. This results in higher Phred Q-Scores
and a quicker run time.123
One of the main differences between the n=3 and n=6 RNAseq experiments with
regards to QC output, was the greatly differing GC content per sequence. FastQC
issued a complete failure for the n=3 reads due to the sum of the deviations being
>30%. This was not the case for the n=6 experiment, where only a warning was issued
(based on the FastQC threshold of >15%). The main reasoning behind this could be
the improved approach towards good laboratory practice. This way potential bacterial
contaminants with differing GC contents could be successfully avoided.
Another large discrepancy between the experiments was the difference in overrepre-
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Figure 3.24: Illustration of Illumina’s Patterned Flow Cell Technology. Each flow cell
contained billions of nanowells, each forcing clustering to follow an ordered spacing. This
translates to improved confidence in base calling due to the lack of overlapping signals being
produced.
sented sequences. This appears to be resultant of the method in which the libraries
were prepared. The n=3 experiment made use of ribosomal RNA depletion, whereas
the n=6 used poly(A) selection. This seemingly subtle difference in obtaining mRNA
transcripts translates to a significant difference in the output of libraries for sequencing.
Following a nBLAST of the sequences flagged as being overrepresented, the majority of
those observed in the n=3 dataset were found to be rRNA or mtRNA in nature. This
is due to the method of rRNA depletion’s inability to efficiently remove all rRNA from
the sample before sequencing. As with any molecular protocol there will never be a
100% recovery or depletion of a molecular target, meaning several rRNA transcripts
will remain in the library for sequencing.
This problem is mitigated by the Poly(A) selection method, as even a suboptimal
recovery of the total poly-adenylated mRNA population will still be relatively devoid
of rRNA. This way, the finite amount of RNAseq reads per flow cell can be utilised
for identifying protein-coding genes. Of course this prevents the discovery of novel
non-coding transcripts that are increasingly found to have a profound regulatory role in
biology.124 However, here the focus is on protein coding transcripts, and so the Poly(A)
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selection method presents the best option for moving forward.
The decision was made to optimise the step of read alignment, in order to tease
out the greatest level of information regarding gene expression from the data. Here
the previous pipeline for the n=3 dataset made use of the Tophat read alignment
algorithm. The newer spliced transcripts alignment to a reference (STAR) algorithm
was selected to compare Tophat against. When assessing the alignment rates between
Tophat and STAR, the Original and New experiments must be taken in isolation as
different experimental approaches, including the differing library preparations, will
translate to differences in reads produced and ultimately how they are aligned. Taking
the new n=6 dataset in isolation, a clear separation in concordant alignment rates is
observed between Tophat and STAR. The writers of the STAR algorithm claim a higher
level of sensitivity, while maintaining a low false-positive rate, due to the way in which
STAR processes reads.70
As part of its approach, STAR can be split into two distinct phases of alignment;
seed searching, and clustering/stitching/scoring. The initial phase involves taking each
read and searching for the longest sequence that it can match in one or more locations
on the reference genome. The longest perfect match becomes known as the maximum
mappable prefix (MMP). The aspects of the reads that can be mapped separately are
referred to as “seeds”, so the first maximum mappable prefix (MMP) becomes seed1.
STAR then searches for the remainder of the read to find the next MMP which it
terms seed2. Each MMP search is conducted in both forward and reverse directions,
facilitating a better ability to find anchors for reads the contain errors towards their
ends, improving mapping sensitivity for higher sequencing error rate conditions.
The second part of STAR’s approach takes all of the generated seeds and stitches
them together by grouping all seeds that are not multimapping, terming them ’anchor’
seeds. These are used for producing the final alignments. The algorithm importantly
clusters seeds from the mates of paired-end RNAseq reads, using each paired-end read
as a single sequence. This allows for a possible genomic gap, or an overlap between the
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inner ends of the paired-end mates. It is this principled usage of paired-end data that
leads to a further increased sensitivity towards read alignment.
A detailed comparison, conducted in 2017 by Costa-Silva et al., took two human
RNAseq datasets and ran them through a permutation of DGE pipelines. As part of
this study, six methods of mapping reads were used, including Tophat and STAR. Based
on a series of benchmarks, including total number of significant calls and concordance
with qRT-PCR data, the group concluded that the method by which the reads were
initially aligned did little to impact on the final analysis.125
However, it seems unlikely that such a large difference between the concordantly
mapped pairs, observed here between Tophat and STAR, would not translate to
important differences in eventual DGE results. As the paper does not declare the
mapping rates for each of the sequence aligners used, it is not possible to see whether
any discrepancies in alignment rate are apparent or indeed whether they are comparable
to those observed here. Due to the higher levels of concordantly aligned reads STAR
presents the best way in which to proceed for an optimised RNAseq pipeline.
The differences observed within the QC metrics previously discussed are all methods
of assessing the suitability of the raw reads for eventual differential expression analysis.
Therefore, regardless of whether they pass or fail these metrics, robustly regulated genes
may still ultimately surface to be predicted as significantly regulated.
A good way in which to further probe the data, and assess for levels of noise
arising from differing expression values, is to conduct a principal component analysis
(PCA). Here an interesting series of observations can be made. The first observation, is
that of the first principal component which appears to best resolve between the n=3
and n=6 datasets. This means that the global noise, irrespective of source, is due to
batch effects observed between the two experiments. While from the same biological
strains at comparable ages, these samples have been subjected to completely different
library preparations and processing pipelines. Therefore, it is not surprising that batch
effects represent a greater source of variability than the differences between the strains
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themselves.
3.5.3 MicroArray
For this experiment, RMA was used to normalise the data at the beginning of the
pipeline. It is possible to use other methods of microarray normalisation, such as
the Gene-Chip RMA (GCRMA). GCRMA is an expansion on RMA, with the only
difference being the internal correcting for non-specific binding to the probes, contrary
to the RMA approach which does not factor in the issue of non-specific binding. It
does this by using the probe sequence information to estimate a ratio of probe affinity
to non-specific binding. During a series of pilot experiments, the developers of the
algorithm determined the contributions of each nucleotide on each position of the probes,
making use of artificial DNAs that mismatched at specific positions.126 As there was
no specific binding within this experiment, the only intensities measured were those
resulting from mismatching. This enabled the team to estimate the affinities of each of
the probes. GCRMA can either use this experiment as a reference, or compute new
probe affinities based on the negative control probes of the specific array used.
Here the RMA approach was sufficient to produce a normalised dataset for use
in differential gene expression analysis. All QC output observed was based on this
approach, with RMA appearing to adequately normalise the global data expression
ranges. A repeated analysis could be ran using the GCRMA approach to account for
the non-specific binding, however this comparison is beyond the scope of this thesis,
and the lower level of normalisation (RMA) has already demonstrated the microarray
approach to be suitable for differential expression analysis in this context.
3.5.4 RNAseq vs MicroArray
Interestingly, the microarray dataset presented no false positives, and so had a FDR of
0%. While this is a large reduction in FDR from the n=6 RNAseq dataset, microarray
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as a technology is still prohibitive for downstream analysis. The slightly higher FDR
observed in the DESeq2 analysed n=6 RNAseq data (0.28%), is an acceptable trade-off
when considering the additional benefits RNAseq offer. Through the very nature of
RNAseq’s sequencing by synthesis, one of the key advantages of RNAseq is its ability to
differentiate the expression abundances of individual isoforms of transcripts. Moreover,
if a library is sequenced with a sufficient read depth, discrepancies in reads at the base
resolution can aid in single nucleotide polymorphism (SNP) discovery. Furthermore,
and providing the use of a well annotated reference genome such as here with the
Rattus norvegicus, interpretation of read counts is intuitively simple compared to the
intensities given by microarray chips.125 These additional advantages allow RNAseq
technology to take this research from biomarker discovery to biomarker characterisation.
For this reason, RNAseq will be used as the foundation of biomarker discovery moving
forward.
It is worth noting that here 12 genes were selected for validation of the RNAseq
and Microarray datasets. This number represents a modest fraction of total genes to
validate such high-throughput methods as RNAseq and Microarray. In order to gain
additional confidence in each dataset’s FDR, and by extension their validity as a whole,
additional candidates must be validated with qPCR technology. Individual transcript
qPCR analysis is time consuming, as primers must be designed and validated before
using to assess individual transcript expression across replicates.
A commercially available qPCR plate array would allow for a much greater number
of transcripts to be analysed in a high-throughput manner. Furthermore, each of the
primers are previously optimised and need to meet the stringent performance standards
that follow the minimum information for publication of quantitative real-time PCR
experiments (MIQE) guidelines.125 These plates do come at a much greater cost,
however this approach would greatly reduce the time taken to validate high-throughput
transcriptome analyses, and provide a series of expression metrics from an entirely
separate technology. The completely different experimental pipeline, and the high-
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throughput approach, could provide a standard workflow to be conducted side by side
with RNAseq/Microarray analysis, ultimately leading to a final sequencing dataset with
a much greater level of confidence. At the time of writing, Thermofisher® offer 842
TaqMan® Gene expression assays for Rat alone (86 when applying the search term of
“blood”). With this specific project in mind, the TaqMan® Array Rat Hypertension
96-well plate (Array ID; RAWCWC9) would be an ideal starting point for blood specific
expression assay.
3.5.5 Concluding remarks
This chapter has allowed for a much greater understanding the potential pitfalls of high-
throughput data, and has indeed been successful in mitigating many of these. Through
a variety of changes to the RNAseq pipeline, including; a new library preparation
method, additional replicates, and a modified analysis pipeline, a much more established
foundation can be lay for biomarker discovery. Here and regardless of the technology used,
the Ifit1 transcript saw the most robust increase in the blood of the pre-hypertensive
SHR compared with the normotensive WKY. This increase was further validated
through qPCR in section 2.4.2. Due to this huge increase, focus will be given to




Validation of Candidate Selection in
WKY and SHR Strains
4.1 Introduction
In this chapter, experiments have been designed to build upon previous findings by
validating Ifit1 expression in a new cohort of animals from an isolated breeding colony.
Furthermore, by using the optimised RNAseq dataset efforts can be made to identify
and validate a novel reference gene for qPCR analysis. The expression profiles observed
in this new cohort can then be linked to physiological changes taking place within the
hypertensive rat strain to gain a direct correlation between physiological metrics and
expression data.
4.1.1 Genetically Isolated Animal Cohort
The previous identification and validation of Ifit1 was conducted in a cohort of animals
bred by a specific supplier, situated within the U.K. (Envigo). However, a notable level
of behavioural and genetic differences have been observed within both the WKY and
SHR strains, with differences often being attributable to the vendors and breeders from
106
Chapter 4. Validation of Candidate Selection in WKY and SHR Strains
which they originate.127 As an extension of assessing Ifit1, and its ability to discern
between a normotensive and hypertensive rat, the following experiments were conducted
in animals from a geographically isolated breeding population at the Multidisciplinary
Center for Biological Research (UNICAMP - São Paulo, Brazil) that also display a
similar health status to the U.K. population previously studied.128 This was in order to
discern whether these robust changes were common to other substrains and not simply
a quirk of the substrains previously tested.
4.1.2 Spectral Analysis & Baroreceptor Sensitivity
With technological and mathematical advances, it has become possible for blood pressure
readings to reveal more than simply systolic, diastolic blood pressure or heart beats per
minute. Mean arterial pressure is a culmination of mainly; cardiac output and systemic
vascular resistance.
In the early 1970’s, Sayers et al. measured the power spectrum of heart rates to
elucidate their frequency content. The team showed that as well as the previously
observed relationship between heart rate fluctuations and respiratory cycle, there are
additional periodic fluctuations in heart rate that occur at lower frequencies.129,130
Further work has shown that low-frequency peaks in heart rate fluctuations are related
to cyclic fluctuations in peripheral vasomotor tone, whereas mid-frequency peaks are
related to the frequency response of the baroreceptor reflex.131
A decade later, Akselrod et al. observed a link between drugs that autonomically
modulate the heart, and fast frequency oscillations in the heart rate spectrum, suggesting
the technique could be useful in the quantification of heart rate control via the autonomic
nervous system (ANS).132
In humans and rats, three distinct frequency domains have been noted; Very
Low Frequency (VLF; 0.0195 - 0.25Hz), Low Frequency (LF; 0.27-0.74Hz), and High
Frequency (HF; 0.75 - 5Hz).133 Each of these components reflect a distinct aspect of
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physiological control of blood pressure.
The VLF component of blood pressure contains the majority of the signal spectra,
and has been found to be reflective of multiple mechanisms of blood pressure regulation
such as; myogenic tone, physical activity, temperature regulation, and efferent sympa-
thetic outflow. Furthermore, various circulating or local vasoactive factors including
Nitric Oxide, and Vasopressin have been found to alter the VLF spectra observed.134–136
The LF oscillations of SBP, DBP, and the LF/HF ratio of HR are all recognised
markers of sympathetic drive towards blood vessels and the sympatho-vagal balance
within the heart, respectively.137–139 Furthermore, the LF component can become
especially predominant during cardiovascular stress, indicating a heightened sympathetic
outflow and greater baroreflex response.134
HF components represent a more minor constituent of the total spectrum. For
blood pressure, they reflect the respiratory effects on the large thoracic vessels. Within
the heart rate spectrum, the HF domain constitutes the greatest power of the whole
spectrum, and arises as a result of vagal-mediated regulation of heart rates due to
respiration (e.g. Respiratory Sinus Arrhythmia).133,134
Spectral analysis therefore serves to decompose these complex constituents of BP
and heart rate readings, and display them as a function of frequency (Figure 4.1).
The central methodology of spectral analysis can be reduced to either non-parametric
(Fast Fourier Transformation) or parametric (Auto-regressive modelling), however these
mostly provide similar outcomes.133 Here focus will be given to the LF component of
blood pressure signalling, in an attempt to assess the sympathetic drive associated with
biomarker expression.
The baroreceptor reflex is an important regulator of the cardiovascular system. It
functions to maintain arterial pressure within physiological levels through negative feed-
back, in order to maintain a homeostatic set point. Through baroreceptors in the aortic
arch and carotid sinuses, detections of high blood pressure trigger afferent pathways
towards the NTS. These signals ultimately culminate in modulating sympathetic and
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Figure 4.1: Representative plot of blood pressure spectra illustrating the three distinct
frequency domains observed following a Fast Fourier Transformation of blood pressure signal;
Very Low Frequency (VLF; 0.0195 - 0.25Hz), Low Frequency (LF; 0.27-0.74Hz), and High
Frequency (HF; 0.75 - 5Hz).
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parasympathetic outflow, resulting in continuous alterations to stroke volume, heart
rate, and systemic vascular resistance.39
Many cardiovascular diseases have been associated with alterations towards barore-
ceptor sensitivity, for example; chronic heart failure, myocardial infarction, and obstruc-
tive sleep apnea.140–142 Within the study of hypertension, baroreceptor regulation has
been shown to “reset” towards an elevated blood pressure set point and to function
with a reduced sensitivity towards hypertension.143
Here spectral analysis and baroreceptor sensitivity analysis are employed in order to
resolve additional information on the cause of hypertension in the SHR. Furthermore, to
use these to see whether Ifit1 can be used as a correlative measure of spectral analysis
or baroreceptor derived metrics of cardiovascular disease.
4.2 Aims
To link transcript expression data at juvenile and adult ages with physiological mea-
surements of blood pressure by;
• Establishing an experimental design to gather direct blood pressure measurements
from alive animals.
• To make use of spectral analysis methods in order to tease out subtle differences
in neurological control in blood pressure across the different ages.
• To link these metrics back to transcript expression data to see whether their
expression reflects physiological changes taking place.
• To make use of the previously obtained RNAseq data to select a novel reference
gene for further qPCR normalisation.
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4.3 Materials and Methods
4.3.1 Animals
All subsequent experiments were conducted by myself. All animals used for the
following procedures were sourced from the Multidisciplinary Center for Biological
Research (UNICAMP - São Paulo, Brazil). Their usage adhered to the Guide for the
Care and Use of Laboratory Animals from the National Academy of Sciences, published
by the National Institute of Health (Copyright © 1996 by the National Academy of
Sciences) and was ethically approved by the Committee of Ethics in Animal Research
from Ribeirão Preto Medical School, University of São Paulo, SP, Brazil. All animals
were housed individually with ad libitum access to food and water, and were maintained
on a 12 hour light-dark cycle at a maintained temperature of 21°C.
4.3.2 Surgical Procedure
Rats were initially anesthetized with a mixture of ketamine (50mg/kg, I.P.; União
Qúımica Farmacêutica Nacional S/A, Embu-Guaçu, SP, Brazil) and Xylazine (10mg/kg,
I.P.; Hertape Calier Saúde animal S/A, Juatuba, MG, Brazil), and implanted with
a polyethylene catheter (PE-50 attached to PE-10, Becton Dickinson, Sparks, MD,
U.S.A.) into the left femoral artery. The catheters were tunneled via the subcutaneous
space and through an incision in the interscapular region of the animals’ nape.
4.3.3 Direct Blood Pressure Measurement
After 48 hours recovery from the surgical procedures, the arterial lines from the animals
were connected to a pressure transducer (MlT844, ADInstruments - Bella Vista, NSW,
Australia) attached to a Bridge Amplifier (FE221, ADInstruments - Bella Vista, NSW,
Australia). Animals were housed individually and allowed to freely roam their cages
as arterial pressure was continuously sampled at a rate of 2kHz for 30 minutes in an
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IBM/PC through an analogic to digital interface (Power Lab 4/40, ADInstruments -
Bella Vista, NSW, Australia).
Using a three-way valve within the measurement apparatus, a bisecting section of
tubing attached to a pump and pressure meter was used to make measurements at
various defined pressures to calibrate the resulting mV signal range detected by the
amplifier. These values were then used to calibrate the signals for each rat, enabling a
conversion to be made from detected mV to an interpretable mmHg. From this, an
average MAP, SBP, DBP and BPM could be drawn from stable regions of signal.
4.3.4 Spectral Analysis & Baroreceptor Sensitivity
Prior to spectral analysis, BP and HR signals were re-sampled at 20Hz and processed
with a nine-point Hanning window filter and linear trend removal as detailed by
Japundžic-Žigon et al.144 Using a fast fourier transformation (FFT), spectra could
be obtained across 15 overlapping 2048-point time series. This corresponded to 410
seconds (approximately 7 minutes) of sampling time for SBP, DBP, and HR. The power
spectrum for BP (mmHg2) and HR (BPM2) was calculated for 30 FFT segments
across the whole spectrum (0.0195-3Hz) and for the following frequency ranges; High
Frequency (HF, 0.8-3Hz), Low Frequency (LF, 0.195-0.8Hz), and Very Low Frequency
(VLF, 0.0195-0.195Hz). BP and HR spectra were then expressed in normalised units in
order to assess spectral frequency distribution. The oscillation of LF signal for SBP,
DBP, and LF/HF HR are established biomarkers of sympathetic regulation of vascular
tone and sympathovagal balance to the heart, respectively.138,139
Here the Spontaneous Baroreceptor Reflex by the sequence method was employed
to scan the signal for consecutively increasing/decreasing SBP samples, followed by a
series of increasing/decreasing pulse interval (PI) samples that were delayed by 3 - 5
beats with respect to SBP. A threshold of sequence length was set to 4 beats.143 Using
in-house developed software (BP Complete), baroreceptor sensitivity (in ms mmHg−1)
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was asssessed as a mean linear regression coefficient (PI = BRS x SBP + Constant;
where fitting of the regression model is conducted using the “sum of least squares”
method). Baroreceptor set point for SBP (in mmHg) was calculated as the median value
of all SBP-PI sequence points, as defined in Bajić et al.145 Comparison of baroreceptor
sensitivity and set point between the strains at either age was conducted as an unpaired
Student’s T-Test.
4.3.5 Linear Regression Modeling
All qPCR work was conducted in the University of Bristol, U.K. on blood samples
shipped from the University of São Paulo and was conducted as previously outlined.
Linear regression modeling was conducted on raw Ifit1 CT levels against various physio-
logical metrics measured here using GraphPad Prism (Version 7.0, La Jolla California
USA,146). The software iteratively calculated the values of slope and intercept of several
overlaid linear lines of best fit, in order to produce a regression model that minimises
the sum of squares of the vertical distances of the points from the line.
4.3.6 New qPCR Reference Gene Selection
In order to normalise the final abundance measurements from the 2−∆∆CT technique,
as outlined in section 2.3.13, it is essential to identify a suitable reference gene. A
literature review revealed very little in the way of suitable blood-based reference genes
so as well as the putative reference genes commonly used in other tissue types (β-actin,
GAPDH, RPL19), a new reference gene was essential for determining an accurate
2−∆∆CT comparison of transcript expression levels.
Since there was a wealth of high throughput sequencing data available, it was
pertinent to check which transcripts were most stable between the two strains in the
RNAseq data. To achieve this, a coefficient of variance (CV) was calculated for each
gene across all of the normalised counts for each sample (Figure 4.2).
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Coefficient of V ariance(CV%) =
Standard Deviation
Mean
Figure 4.2: Equation for calculating the Coefficient of Variance across all reads of any given
gene
Genes were then ranked according to the lowest CV to give a final list of genes
that show the lowest amount of variation across all of the samples from both strains
(Table. 4.1). Also displayed are some of the common reference genes employed by the
laboratory for various tissue types.









Table 4.1: RNAseq Generated coefficient of variance (CV) as calculated via the equation
outlined in the equation in Figure 4.2 from the n=6 cohort RNAseq experiment. Calculated
CV values were then ranked from smallest to largest. Here Oaz1 (Ornithine decarboxylase
antizyme 1) is highlighted as the reference gene selected for further validation. Also featured
are the corresponding CV values for common putative reference genes.
4.4 Results
4.4.1 Validation of Findings in a New Cohort of Animals
qPCR Validation of Novel Reference Genes
Despite normalisation of total input RNA concentration during the cDNA synthesis
stage of sample preparation, a clear difference in expression levels exist across either
the strains or age groups for both GAPDH and β-Actin (Figure 4.3). β-Actin saw the
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Figure 4.3: qPCR Blood Expression of Putative reference genes and the novel Oaz1 reference
gene across Wistar Kyoto (WKY) and spontaneously hypertensive rat (SHR). Expression is
displayed here as 2−∆CT normalised values for GAPDH, β-Actin, and the novel Oaz1 reference
gene, in addition to the standard error of the mean (SEM) for juvenile and adult strains.
Statistical analysis made use of two-way analysis of variance (ANOVA) with Tukey’s multiple
test correction. (P-Value <0.05, *; <0.01, **; <0.001, ***).
greatest level of change across the age groups, and across the comparison of Wistar
Kyoto (WKY) versus spontaneously hypertensive rat (SHR) at the adult age group
(Figure 4.3; juvenile WKY vs SHR, -0.85 fold, P-Value=0.32; adult WKY vs SHR,
-3.87 fold, P-Value<0.0001; WKY juvenile vs adult, -3.2 fold, P-Value<0.0001).
The expression levels of GAPDH were much greater in the adult cohort as compared
with the juveniles. However, there was no significant difference between the two strains
at any given age. Furthermore, the juvenile cohort showed a much tighter spread of
expression values, as compared with the spread observed within the adults (Figure 4.3;
juvenile WKY vs SHR, +0.59 fold, P-Value=0.83; adult WKY vs SHR, +0.58 fold,
P-Value=0.89; WKY juvenile vs adult, +2.79 fold, P-Value=0.001).
The levels of expresion observed for the Oaz1 appear much more stable across the
experimental groups after a two-way ANOVA (Figure 4.3). Amending the scale for the
Oaz1 expression plot shows the levels of variation between the groups (Figure 4.4). There
appears a lower level of expression within hypertensive or aged animals, however this is
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Figure 4.4: Rescaled qPCR Blood Expression of Oaz1 reference gene across Wistar Kyoto
(WKY) and spontaneously hypertensive rat (SHR). Expression is displayed here as 2−∆CT
normalised values for Oaz1 reference, in addition to the standard error of the mean (SEM)
for juvenile and adult strains. Statistical analysis made use of two-way analysis of variance
(ANOVA) with Tukey’s multiple test correction. (P-Value <0.05, *; <0.01, **; <0.001, ***).
Page 116
Chapter 4. Validation of Candidate Selection in WKY and SHR Strains
not significant in the juvenile or adult cohorts, as a high level of intra-group variation
exists (Figure 4.4; juvenile WKY vs SHR, -0.22 fold, P-Value=0.35; adult WKY vs
SHR, -0.32 fold, P-Value=0.15; WKY juvenile vs adult, -0.35 fold, P-Value=0.12).









































































Figure 4.5: qPCR blood expression of Ifit1 across new cohort of Wistar Kyoto (WKY) and
spontaneously hypertensive rat (SHR) animals sourced from Multidisciplinary Center for
Biological Research (UNICAMP - São Paulo, Brazil). Here expression is displayed as both
Oaz1 normalised 2−∆∆CT values and raw (unnormalised) Ifit1 2−∆CT values. Statistics are
presented as Two-way ANOVA P-values, between strains at any given age (P-value<0.05, *;
P-value<0.01, **; P-value<0.001, ***).
qPCR analysis of the Ifit1 expression showed a similar, and hugely robust, profile
of change as within other animal cohorts sourced from other suppliers (Figure 4.5).
Here the strain differences were much more severe at both ages. This observation was
further exagerated when normalised to the newly identified Oaz1 reference gene than
when not normalised at all. Regardless of normalisation strategy, the differences in
Page 117
Chapter 4. Validation of Candidate Selection in WKY and SHR Strains
Ifit1 blood expression are compelling within the Brazilian cohort of animals (Figure
4.5; juvenile WKY vs SHR, -0.22 fold, P-Value=0.35; adult WKY vs SHR, -0.32 fold,
P-Value=0.15; WKY juvenile vs adult, -0.35 fold, P-Value=0.12).
4.4.2 Physiological metrics
Blood Pressure
Direct physiological measurements revealed a series of novel and expected patterns across
the experimental groups (Figure 4.6). A clear and statistically significant difference in
MAP exists between the adult WKY and SHR animals, as to be expected from this
well established comparison (P<0.0001 ). The comparison between the juvenile WKY
and SHR animals showed the SHR to have a significantly elevated blood pressure as
compared with their normotensive and age-matched WKY controls (P<0.0001 ).
Spectral Analysis
Here spectral analysis revealed a significant increase in the LF domain of the BP
spectra within the SHR animals compared with their normotensive controls in the
adult cohort. This profile was consistent between SBP and DBP (Figure 4.7, SBP,
juvenile WKY vs SHR, P=0.25 ; adult WKY vs SHR P<0.0001, DBP, juvenile WKY
vs SHR, P=0.08 ; adult WKY vs SHR, P<0.0001 ). Furthermore, a significant increase
is observed within the LF/HF ratio of the HR for the adult cohort only, pointed to an
increased sympathetic output to the heart (Figure 4.7, juvenile WKY vs SHR, P=0.85 ;
adult WKY vs SHR P=0.002 ).
Baroreceptor Sensitivity
Results from the analysis of the baroreceptor set point showed a clear increase in the
SHR versus the WKY across both ages tested (Figure 4.8). Data points were clustered
tightly and therefore resulted in a robustly significant P-Value from the Student’s T-Test
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Figure 4.6: Physiological data in SHR and WKY strains at both juvenile and adult ages.
Statistics are presented as unpaired Student’s T-Test P-values, between strains at any given
age (P-value<0.05, *; P-value<0.01, **; P-value<0.001, ***).
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Figure 4.7: Spectral Analysis for WKY versus SHR comparison. Statistics are presented
as unpaired Student’s T-Test P-values, between strains at any given age (P-value<0.05, *;
P-value<0.01, **; P-value<0.001, ***).
Page 120
Chapter 4. Validation of Candidate Selection in WKY and SHR Strains
analysis (juvenile WKY vs SHR, P<0.0001 ; adult WKY vs SHR P<0.0001 ). Analysis
of baroreceptor sensitivity saw a similarly robust difference, with SHR animals seeing a
significantly reduced baroreceptor sensitivity compared to the WKY animals (Figure
4.8). This was consistent across both ages (juvenile WKY vs SHR, P=0.0003 ; adult













































Figure 4.8: Baroreceptor Sensitivity (mmHg−1) and Set Point (mmHg−1) for WKY versus
SHR comparison. Statistics are presented as unpaired Student’s T-Test P-values, between
strains at any given age (P-value<0.05, *; P-value<0.01, **; P-value<0.001, ***).
Correlation with Ifit1 expression levels
In order to deduce whether Ifit1 expression levels could be used as a direct measurement
of blood pressure, linear regression modelling was employed using the Oaz1 normalised
2−∆∆CT values. Global regression modelling revealed little correlation between Ifit1
expression and MAP, with a low R2 value and relatively neutral slope coefficient (Figure
4.9). Due to the distinct groupings being observed on the scatter graph, this analysis
was repeated on subsets of the data, taken for either WKY, SHR, juvenile or adult.
The SHR subset saw by far the greatest R2 value, denoting the best “Goodness of
Fit” for the regression model (Figure 4.9; SHR, R2 = 0.77, Slope = -0.16 (95% CI ±
0.02); WKY, R2 = 0.03, Slope = -10.42 (95% CI ± 21.46)). However, as the juvenile
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SHR animals had the highest expression of Ifit1 and lower MAP than the adult SHRs,
this slope followed a negative coefficient of -0.16.
When the strains were separated based on age groups, a positive regression model
was observed in both sets. However, both the R2 and slope coefficients were relatively
modest for these subsets (Figure 4.9; All adult, R2 = 0.57, Slope = 1.32 (95% CI ±
0.38); All juvenile, R2 = 0.21, Slope = 0.08 (95% CI ± 0.04)).
The linear regression analysis of Ifit1 blood expression against beats per minute
(BPM) for all samples showed a stronger positive correlation. While the slope coefficient
was modest, its accompanying R2 value indicated a greater “Goodness of Fit” (Figure
4.10; R2 = 0.57, Slope = 0.31 (95% CI ± 0.05)).
Splitting this regression between the WKY and SHR strains, the SHR again saw
a much stronger R2 value for its positive correlation (Figure 4.10; SHR, R2 = 0.57,
Slope = 0.26 (95% CI ± 0.06); WKY, R2 = 0.02, Slope = -18.13 (95% CI ± 48.91))
Again, samples were further split into juvenile and adult subsets to assess whether
Ifit1 saw a greater correlation within a specific age group. The resulting regression
results were broadly comparable in terms of their R2 values, however the adult cohort
saw a subtle increase in the slope coefficient of the regression model (Figure 4.10; All
adult, R2 = 0.53, Slope = 1.67 (95% CI ± 0.52); All juvenile, R2 = 0.60, Slope = 0.24
(95% CI ± 0.05)).
Baroreceptor sensitivity was plotted against blood expression of the transcript.
Making use of all datapoints, from both ages and strains, regression modelling revealed
little relationship between the two metrics (Figure 4.11; R2 = 0.04, Slope = -0.005
(95% CI ± 0.004); SHR, R2 = 0.09, Slope = 0.003 (95% CI ± 0.003); WKY, R2 =
0.0007, Slope = 0.19 (95% CI ± 2.71); All adult, R2 = 0.36, Slope = -0.04 (95% CI
± 0.02); All juvenile, R2 = 0.24, Slope = -0.01 (95% CI ± 0.006)). All of the various
subsets taken saw a low level of “Goodness of Fit”, aside from the adult subsection
which had the highest R2 value of 0.36.
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Figure 4.9: Linear Regression Analysis of Physiological mean arterial pressure (MAP), as
millimetres of mercury (mmHg), against Oaz1 normalised Ifit1 blood expression 2−∆∆CT
values. For the regression model, displayed here are the slope coefficient of the regression line
and the R2 correlation coefficient. Also highlighted in grey is the 95% confidence interval (CI)
range for the model. Note the rescaled x-axis for the WKY plot.
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Figure 4.10: Linear Regression Analysis of Physiological beats per minute (BPM) against
Oaz1 normalised Ifit1 blood expression 2−∆∆CT values. For the regression model, displayed
here are the slope coefficient of the regression line and the R2 correlation coefficient. Also
highlighted in grey is the 95% confidence interval (CI) range for the model. Note the rescaled
x-axis for the WKY plot.
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Figure 4.11: Linear Regression Analysis of Physiological baroreceptor sensitivity (BRS),
as ms mmHg−1, against Oaz1 normalised Ifit1 blood expression 2−∆∆CT values. For the
regression model, displayed here are the slope coefficient of the regression line and the R2
correlation coefficient. Also highlighted in grey is the 95% confidence interval (CI) range for
the model. Note the rescaled x-axis for the WKY plot.
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Linear regression modeling of Ifit1 against the Baroreceptor Set Point revealed little
correlation when considering all animals of both ages, aside from the adult cohort
(Figure 4.12; R2 = 0.004, Slope = -0.02 (95% CI ± 0.07); SHR, R2 = 0.69, Slope =
-0.24 (95% CI ± 0.04); WKY, R2 = 0.01, Slope = 4.04 (95% CI ± 13.14); All adult, R2
= 0.64, Slope = 2.72 (95% CI ± 0.72); All juvenile, R2 = 0.16, Slope = 0.09 (95% CI ±
0.06)).
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Figure 4.12: Linear Regression Analysis of Physiological Baroreceptor Set Point, as
mmHg−1, against Oaz1 normalised Ifit1 blood expression 2−∆∆CT values. For the regression
model, displayed here are the slope coefficient of the regression line and the R2 correlation
coefficient. Also highlighted in grey is the 95% confidence interval (CI) range for the model.
Note the rescaled x-axis for the WKY plot.
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Metrics for spectral analysis of sympathetic activity saw very little correlation with
Ifit1 expression in the blood. (Figure 4.13; SBP LF R2 = 0.004, Slope = 0.003 (95%
CI ± 0.008); DBP LF, R2 = 0.02, Slope = 0.003 (95% CI ± 0.004); HRLF/HF , R2 =
0.007, Slope = -0.0001 (95% CI ± 0.0004)).





































0.00264 ± 0.007984Slope = 
R2 = 0.004534









































-0.0001551 ± 0.0003888Slope = 
R2 = 0.006583










































0.002964 ± 0.004153Slope = 
R2 = 0.01997
Figure 4.13: Linear Regression Analysis of Spectral Analysis Data, against Oaz1 normalised
Ifit1 blood expression 2−∆∆CT values. Here Systolic blood pressure (SBP) and Diastolic blood
pressure (DBP) Low Frequency spectra are used (LF; 0.27-0.74Hz, mmHg2). Also displayed
is the linear regression for heart rate (HR) ratio of LF to High Frequency (HF; 0.75 - 5Hz,
HRLF/HF ). For the regression model, displayed here are the slope coefficient of the regression
line and the R2 correlation coefficient. Also highlighted in grey is the 95% confidence interval
(CI) range for the model. Note the rescaled x-axis for the WKY plot.
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4.5 Discussion
4.5.1 Methods of Obtaining Blood Pressure Readings
There exist three main methods of assessing blood pressure in a rat; radio telemetry, intra-
arterial catheters, and tail cuff plethysmography. Each present their own advantages
and disadvantages that must be considered for any experiment. Both radio telemetry
and intra-arterial catheters are invasive methods of obtaining real time blood pressure
readings, with intra-arterial yielding the most precise values.147 The non-invasive tail
cuff method requires animals to be handled and restrained for the period of measurement
which may lead to falsely elevated blood pressure readings, as demonstrated in both
mouse and rat studies.148,149 Indeed, restraint stress has been used extensively as a
method of inducing acute increases in blood pressure.137 Therefore, and further to
the additional precision, invasive blood pressure measurements are best suited for
obtaining stabilised blood pressure readings, by mitigating the stress responses seen in
the conscious rat.
4.5.2 Physiological Metrics of the SHR
Direct blood pressure measurements in juvenile animals revealed an interesting significant
increase in MAP in the SHR compared with the WKY. This is contrary to the previous
assumption that the 4-week old age presented a pre-hypertensive time point in the SHR.
During the literature review conducted prior to the experiments outlined in section
2.4.2, multiple development profiles of when hypertension began were reported, ranging
from 5-weeks to 7-weeks.150,151 No papers could be found that directly measured blood
pressure profiles across age specifically within the São Paulo cohort of SHR.
Analysis of the baroreceptor reflex showed a pattern consistant with the literature,
for both baroreceptor set point and sensitivity. Multiple studies have noted the elevated
set point within the SHR model of hypertension, and further observed a similar pattern
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in humans exhibiting chronically elevated blood pressure.137,152The same is true with
baroreceptor set point, with many using these key physiological metrics as a way of
highlighting the suitability of the SHR model for human hypertension.153,154 The
observation that baroreceptor set point was higher in the SHR, and sensitivity was
blunted amongst these hypertension animals, was therefore expected in this cohort of
animals and well supported from the literature.
What is less clear from the literature, is the age at which these changes appear
to occur in the SHR model. Here the juvenile cohort were 4 weeks old at the time
of analysis. Considering the significant changes in blood pressure for these juvenile
animals, it is not surprising that alterations are taking place to the baroreceptor response.
However, changes in baroreceptor function have previously only been noted in animals
as young as 8 weeks of age.139,155,156
This study made use of Spectral analysis derived LF spectra, in order to assess the
sympathetic modulation of blood pressure regulation. For both the adult SHRs, SBP
and DBP LF spectra were higher than in their age-matched controls. The observations
that these metrics are significantly elevated in the SHR strain are well documented in
the literature, as multiple studies have characterised the elevated sympathetic outflow
in this model of hypertension.39,132 Again, there does appear to be a disparity between
the literature and these findings in terms of age. While sympathetic activation is
known to precede the onset of hypertension, a rise in sympathetic outflow has only
been noted in animals as young as 6 weeks.157 Here physiological data shows the onset
of hypertension as young as 4 weeks old and so an accompanying rise in sympathetic
outflow is to be expected. However, a significant modulation towards sympathetic
outflow was not observed in these animals through this analysis. For this reason it may
be pertinent to attempt more direct sympathetic measurements rather than inferring
from spectral readings.158 With direct measurements we can validate spectral results
as well as ascertain whether the juvenile SHR rats truly display elevated sympathetic
activity or or not.
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For these reasons, it may be necessary to take SHR animals at a younger age and
compare them with age matched WKYs in order to truly study biomarker expression
during the development of the disease. Currently, juvenile animals are obtained at
3-weeks of age and habituated on site for a week to ensure no confounding experimental
effects due to elevated stress of shipment. This presents several potential problems
however, notably the availability of animals younger than 3-weeks of age as suppliers
do not recommend weaning prior to this age. Indeed, several studies have found
direct effects of weaning on long-term physiological phenotypes.159 These maternal
deprivations can have prolonged effects on stress hormones critical in blood pressure
regulation.160,161 The disparities observed for age of onset of hypertension, and indeed
the other physiological hallmarks that accompany it, may well be down to the genetic
variation in the SHR strain, as explored later in section 4.5.4.
Correlation with Ifit1 expression levels
In an attempt to delve deeper into the possible suitability of Ifit1 expression as a metric
of physiology, linear regression modelling was employed. Various metrics pertinent to
blood pressure were assessed; mean arterial pressure, beats per minute, baroreceptor set
point, and baroreceptor sensitivity. Regression modelling revealed a mixture of results.
One of the key reasons for the poor correlations between Ifit1 and the metric being
assess, is the robust rise in Ifit1 levels in the juvenile animals. While the direct blood
pressure measurements have shown the juvenile SHRs to have elevated blood pressure as
compared with their age-matched controls, their blood pressure is not as fully developed
as within the adult SHRs. This, coupled with the elevated expression of Ifit1 in SHR
juveniles compared with SHR adults, leads to cluster of animals with modestly elevated
blood pressure and maximum expression of ifit1. This cluster of juvenile SHRs throws
the linear regression model and prevents an accurate regression line from being drawn.
With this in mind, an argument could be made for expanding upon this approach
with the use of non-linear regression. Here for simplicity a linear model was employed.
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However multiple biomarkers have been found to follow non-linear patterns in their
diagnostic potential. For example, a study in 2011 found levels of cerebrospinal fluid
β-Amyloid and Tau proteins to follow a biphasic relationship with development of
the Alzheimer’s disease.162 For this reason, an iterative approach towards regression
modelling may reveal a better “Goodness of Fit” for the model produced. However
before this approach is employed, efforts need to be made to ensure the Ifit1 transcript
is truly a suitable biomarker for hypertension and not simply due to a heterogeneous
SHR transcriptome.
4.5.3 Oaz1 as a reference gene
A literature review of the genes showing the lowest CV percentages revealed that
only Ornithine decarboxylase antizyme 1 (Oaz1) has been previously highlighted as a
reference gene from a range of sample preparations.163,164
For this reason, Oaz1 was selected for validation against the new cohort of cDNA
samples to confirm it was stable in its expression across both strains. Oaz1 performed
suitably within the juvenile cohorts, as no significant difference existed between the
strains given the equal quantity of RNA used for the analysis. This stability across the
individuals therefore allows for each sample to be normalised against its expression.
As Oaz1 was selected based only RNAseq data from juvenile rats, there was no
way of anticipating its expression profiles between the normotensive and hypertensive
animals at the 12 week adult age. From the qPCR (Figure 4.4), Oaz1 showed a
downward trend in the aged animals. This was not significant across ages within the
same strain, however was between the WKY and SHR at the adult age. For this reason,
oaz1 does not present a suitable reference gene for the adult comparison, preventing an
accurate profiling of ifit1 expression as the animals age. In order to find a reference
gene that does not display significant differences between the strains, at any given age,
additional transcripts highlighted by the CV analysis should be assessed at the adult age.
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An alternative to this, would be to carry out a high-throughput qPCR assay plate, such
as those outlined in section 3.5.4. Indeed many of these plates have been designed for
identifying suitable reference genes, and can be custom built to include the top reference
gene candidates produced by the CV analysis outlined here. However often these can
only analyse a single sample at a time, and once this is scaled to include multiple age
groups across both strains, the cost becomes prohibitively large, and comparable to
conducting RNAseq analysis on these groups.
4.5.4 Genetic spread of the SHR and WKY rats
The SHR is an inbred rat strain that was originally established from outbred Wistar
rats that displayed elevated BP.150 The normotensive control strain, the WKY, was
established from the same Wistar stock as the SHR and as a result is commonly used as
a control strain for the SHR for studies conducted around the world. Due to the global
usage of the WKY and SHR strains, the sources of animals vary between studies. This
translates to significant levels of variability in the results obtained and can be attributed,
in part, to the fact that the WKY breeding stock was distributed to breeders before
being fully inbred.165–167 Furthermore, the littermates used for producing the inbred
WKY from the Wistar rats were selected >10 years after the initiation of inbreeding
for the SHR.166 This further increases the heterogeneity between the strains, and has
caused many to question the validity of using the WKY as a control for the SHR.168
While some substrains of the SHR have been observed, the level of homogeneity
among SHRs is believed to be much greater than within WKYs. This is exemplified by
the near 100% incidence of hypertension within the SHR across the world.150,166 This
observation is further supported here via direct blood pressure measurements in a colony
of SHRs that were geographically remote from the animals used in section 2.4.2. A study
in 2013 set out to map these differences in the genetic architecture of the WKY and
SHR substrains from different sources.127 The team took 16 commonly used WKY and
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SHR substrains and used genome-wide SNP genotyping data to map levels of genetic
drift. They found a large genetic divergence within both of the strains and were able
to resolve the substrains through multidimensional scaling analysis (MDS), revealing
distinct clustering based on the supplier from which the substrain was obtained. Based
on the 9,407 SNPs covered, the team found a non-negligible genetic difference of 2.5%
between two of the WKY substrains tested. They propose these subtle differences to
be responsible for the significantly different phenotypes observed across behavioural
paradigms from WKYs obtained from different vendors.167
With respect to the Ifit1 blood expression profiles observed for both the Brazilian
and U.K. cohorts, a similar pattern of expression could be found. However, data from
these experiments can only shed light on relative fold changes between the strains and
can not be used to compare the cohorts themselves. These were isolated experiments,
making use of relative abundances produced by internal normalisation, before being
displayed as a ratio of expression between the strains. An interesting comparison could
be made between the different colonies if tissue was obtained at the same time, and
processed identically. However, this was not possible due to logistical difficulties when
conducting experiments across the world. One way to mitigate this drawback would be
to conduct an absolute assessment of transcript abundance, making use of a calibration
curve displaying known quantities of Ifit1 transcript. This way, it would be valid to
compare experiments that were conducted at different times or locations by plotting
the absolute abundances of Ifit1. Given the variability of genetic architecture outlined
above, an absolute metric of expression would show just how stable Ifit1 expression is
across several cohorts of SHRs that all robustly develop hypertension.
4.5.5 Concluding remarks
Here and despite the varied genetic architecture of these strains globally, a similar
expression profile of Ifit1 was observed within this geographically distinct cohort of
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animals. This further validates its suitability as a comparative biomarker between these
two strains.
Furthermore, this chapter was successful in clarifying an important assumption made
at the outset of this work. Previous work focused on 4-weeks being a prehypertensive age
within the SHR model of hypertension. Here direct blood pressure readings contradict
this assumption, showing a significant increase in blood pressure between the WKY and
SHR strains. This clarification is key, as it no longer allows for candidate biomarkers
to be seen as prognostic at this age. However it does strengthen the use of Ifit1 as a
generalised biomarker of hypertension as its profile remains elevated across these two
ages tested.
Regardless, Ifit1 needs to be taken forward from the classical WKY versus SHR
comparison and interrogated against additional animal models of hypertension. These
additional animal models all vary in the aspects of human hypertension they emulate,
potentially allowing a correlation between Ifit1 expression and the specific aetiology of
the disease each model represents. By profiling its expression in additional animal models
of hypertension, the transcript’s suitability as a diagnostic tool can be determined.
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5.1 Introduction
The profile differences observed in Ifit1 between the WKY and SHR strains are robust
and significant, however there is a possibility these relative differences flagged up by
qPCR and RNAseq could be attributable to the sole comparison of the WKY and
SHR transcriptomes, and therefore not useful for identifying a hypertensive strain from
amongst a population of other normotensive rat strains. In order to ascertain whether
these biomarker expression profiles were truly indicative of the SHR hypertensive strain,
a blood analysis across 3 additional rat strains was conducted. The 5 total strains
selected for the expression profiling were therefore; spontaneously hypertensive rat
(SHR), Wistar Kyoto (WKY), Wistar (WIS), Sprague-Dawley (SD) and Lister hooded
(LH).
The key to this selection process was to provide a spectrum of normotensive strains
that may act as controls to allow for hypertension specific transcripts to be identified.
For this reason, a range of genetically similar and distinct strains were selected. In
addition to the SHR and WKY strains previously focused on, the more genetically
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distinct Wistar colony was also used from which both strains were originally obtained.150
The Wistar rat is an outbred albino rat that represents the first breed developed
for use in biological and medical research. It was originally developed at the Wistar
Institute. Prior to this, laboratories used the common house mouse (Mus musculus) as
their primary model organism. More than 50% of all laboratory rat strains that are
used today are descended from the original colony, developed in 1906.169 The Wistar
strain is one of the most popular rats used for research today, and has been further
used to develop many common rat stocks such as the SHR and SD.
One of the more interesting strains added to this experiment is that of the SD. There
exists a wealth of literature describing ways in which to evoke hypertension in this strain,
be it surgically, pharmacologically or dietary.170–172 It is therefore an appealing model
to use for manipulating blood pressure levels using established methods and to study
how blood pressure correlates with biomarker expression. Not only does this shed light
on the correlation between blood pressure and biomarker expression, it also allows the
reconciliation between the aetiology of hypertension and how transcripts are influenced.
One of these methods is a chronic 3-day dehydration protocol. Previous studies have
shown chronic dehydration to produce a significant increase in mean arterial pressure,
from the second day of dehydration.173
An extension of this genetic diversity was given by the even more genetically distinct
outbred LH rat strain. This was a strain originally bred from the Wistar outbred rat
at the Lister Institute. Although commonly used in many experiments today the LH
presented a strain that has seen little involvement in hypertension research.
In order to reconcile the interface between environmentally induced hypertension
and genetically predisposed hypertension the borderline hypertensive rat (BHR) was
later added to this series of experiments. This is a rat strain bred in order to study how
a mixed genetic background can influence blood pressure. Lawler et al., bred female
SHRs with male normotensive WKY rats to produce a F1 generation offspring that
had a genetic predisposition toward elevated blood pressure. The strain only exhibits a
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slightly elevated blood pressure than WKY controls. However, when stressed or exposed
to a diet high in salt, the strain develop overt hypertension at levels comparable to
SHRs.174,175 For this reason, this model presents an opportunity to study the complex
relationship between the genome and environment in the aetiology of hypertension.
Therefore, here an investigation on the expression profiles of biomarkers in the blood for
stressed and unstressed animals at both pre- and fully hypertensive ages was conducted.
The stress paradigm used was one established by Šarenac et al., 2011 and consisted of
a 9-day tube restraint course. This study replicated the stress paradigm in 4 and 12wk
old animals.137
Another experimental method of inducing increased blood pressure is through the
use of chronic dehydration. Several studies have observed this biological response to
dehydration through the use of tail cuff or cannula based recording techniques of blood
pressure.176–178 A study in 2011 confirmed this by showing a 3-day dehydration protocol
to robustly increase mean arterial blood pressure in a cohort of rats. The team go on to
show the involvement of elevated sympathetic nerve activity acting upon its downstream
effectors to raise blood pressure to a level higher than in euhydrated control animals.16
Using this many different control strains, from a range of different colonies, should
allow for a better assessment of the suitability of the biomarker being tested. With
such a large dataset of RNAseq significant transcripts between the WKY and SHR
blood, any that fail to identify the SHR from the 4 control groups can be quickly and
easily omitted without further study. Furthermore, characterising how genes change
in response to an environmentally induced model of elevated blood pressure will help
elucidate their potential role in hypertension.
5.2 Aims
The aim of this section is to take forward the work previously carried out and confirm
the applicability of our previously identified biomarkers, in both genetically predisposed,
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control and environmentally induced models of elevated blood pressure by;
• Assess Ifit1 expression using multiple control strains
• Use previously validated paradigms to environmentally induce acute blood pres-
sure changes
• To use these previously characterised models of elevating blood pressure to act as
proxy for studying transcript expression
• To profile any correlations between paradigms of inducing blood pressure changes
and Ifit1 expression
• Establishing a BHR Restrained Vs Control Environmentally induced model of
hypertension
5.3 Materials and Methods
5.3.1 Multi-strain Blood Analysis
Rats from each strain (SHR, WKY, Wistar, SD and LH; n = 8) were ordered at either
11 weeks of age or equivalent body weight based on supplier growth curves. This number
of replicates per group was selected as a balance of sufficient power (as an increase from
the n=3 and n=6 RNAseq experiments that showed significance for the Ifit1) and a
reduction of the total number of animals required from the original qPCR experiments
that made use of an n=12 per group. They were then left to habituate for 1 week before
sacrifice via cranium strike and guillotine at 12wks. Trunk blood was taken and stored
along with 2ml of RNAlater at -80°C before processing and qPCR analysis consistent
with the above protocols. Brains were extracted and frozen on dry ice before storage at
-80°C.
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5.3.2 Sprague Dawley Dehydration
For the dehydration group, Adult (11wks) SDs were allowed to habituate for 1 week
before removing water from their cages for 3 days (72 hours; onset 15:00 day 1, end 15:00
day 3). All DH rats had access to food. These were then sacrificed, along with a control
group of experimentally näıve SDs (n=12/group), at 12wks & 3 days of age. Trunk
blood and whole brains were collected and stored at -80°C before tissue processing and
qPCR analysis consistent with the above protocols.
5.3.3 BHR Restrained Vs Control (4wks & 12wks)
Here a 9-day repeat restraint stress paradigm was implemented using the BHRs that
could be compared to their age-matched Wistar controls. In addition to the stressed
groups at both 4 & 12 weeks old, age matched control groups were set aside and received
no stress. Animals in groups of 7 were housed at 25°C and supplied with food ad
libitum. Juvenile and adult restraint group animals began the protocol 9 days prior
to their 4th or 12th week of age respectively. The restrained protocol was the same
as outlined in Šarenac et al 2011.163 No direct, and potentially confounding blood
pressure readings were taken, so this protocol was followed to enable the animals to
act as proxies of elevated blood pressure. Briefly, each day at 9:00am, animals were
habituated in the protocol room for 30mins before being placed for 60minutes in a clean
plexiglass restraint ( 3.8cm for juveniles, 5.5cm for adults) in the supine position.
After which period, the animals were weighed. At the same time, the control group
of animals were weighed daily. On the ninth and final day, animals were sacrificed
immediately after restraint. Trunk blood and whole brains were collected and stored at
-80°C before tissue processing and qPCR analysis consistent with the above protocols.
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Figure 5.1: Multistrain Analysis of Ifit1 blood expression in 12-week old; Lister hooded
(LH), Sprague-Dawley (SD), spontaneously hypertensive rat (SHR), Wistar Kyoto (WKY),
and Wistar (Wis) rats. Displayed here are 2−∆∆CT of Ifit1 normalised to β-Actin and WKY
expression. Statistical analysis made use of one-way analysis of variance (ANOVA) with
Tukey’s multiple test correction. (P-Value <0.05, *; <0.01, **; <0.001, ***; <0.0001, ****).
5.4 Results
5.4.1 Multi-strain Blood Analysis
Ifit1 expression analysis saw an interesting spread in blood expression across all of the
various strains tested (Figure 5.1). Following a one-way ANOVA, and similar to the
comparisons made in sections 2.4.2 and 4.4.1, Ifit1 saw a robust and significant increase
in the SHR as compared with the WKY (Figure 5.1; WKY vs SHR, +26.02 Fold,
P-Value<0.0001). This highly significant increase in abundance was conserved when
comparing the SHR with any of the other control normotensive strains (Figure 5.1;
LH vs SHR, +26.95 Fold, P-Value<0.0001; SD vs SHR, +22.27 Fold, P-Value<0.0001;
Wistar vs SHR, +22.87 Fold, P-Value<0.0001;).
Despite being consistently elevated in the SHR, Ifit1 displayed a range of expression
values within each of the multiple control strains tested. The LH blood saw by far the
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lowest levels of Ifit1 expression, averaging at around 10% the expression values of the
WKY. This was a tightly clustered grouping of expression, with little deviation from
the mean (Mean=0.11, STDev=0.045). The SD cohort saw a much greater mean and
spread due to 25% of the datapoints being greatly upregulated in expression to a level
comparable with SHR expression (Mean=4.79; STDev=8.87). Here all expression values
were normalised to WKY expression, as this had been the normotensive control for prior
comparisons. Therefore, this became arbitrarily normalised as 2−∆∆CT values around
1.0. The spread of the WKY blood Ifit1 expression was relatively low compared with
the other strains (Mean=1.04, STDev=0.33). Finally, Wistar Ifit1 expression showed
a similar spread to the SD sample group, with a slightly diffuse profile of expression
values, and a single outlier value on a scale comparable to those observed in the SHR
blood expression values (Mean=4.19, STDev=9.17).
5.4.2 Sprague Dawley Dehydration
Following a 3-day chronic dehydration protocol, Ifit1 expression levels were assessed
in the blood of SD rats and their euhydrated controls (Figure 5.2). Similarly to
within the cohort of SD rats used for the multistrain analysis (Figure 5.1), Ifit1 saw
a wide spread in expression values in the control euhydrated group. After 3-days of
chronic dehydration, the spread of Ifit1 was much tighter than in the euhydrated cohort.
Furthermore, an unpaired Student’s T-Test revealed a highly significant downregulation
in the dehydrated cohort as compared with the euhydrated controls (Figure 5.2; SD vs
SD DH, -0.34 Fold, P-Value<0.0001).
5.4.3 BHR Restrained Vs Control (4wks & 12wks)
Expanding upon the dehydration method of induced elevated BP, a 9-day repeat
restraint stress paradigm was initiated, based on Šarenac et al .137 Blood expression of
Ifit1 was assessed in both juvenile and adult rats (Figure 5.3). Statistical analyses took
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Figure 5.2: Assessment of Ifit1 expression levels in an environmentally induced model of
hypertension; using 12 week old Sprague-Dawley (SD) rats and 3-days chronic dehydration (SD
DH). Displayed here are 2−∆∆CT Ifit1 normalised to β-Actin and WKY expression. Statistical
analysis made use of Student’s T-Test. (P-Value<0.0001, ****).
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Figure 5.3: Restraint stress paradigm of induced hypertension, using genetically predisposed
borderline hypertensive rat (BHR) against their Wistar controls. Both juvenile (4-weeks) and
adult (12-weeks), were subjected to a 9-day repeat restraint stress paradigm or remained as
unrestrained controls. Displayed here are 2−∆∆CT of Ifit1 normalised to β-Actin and control
juvenile Wistar Ifit1 expression. Statistical analysis made use of three-way analysis of variance
(ANOVA) with Tukey’s multiple test correction. (P-Value <0.05, *; <0.01, **; <0.001, ***).
the form of a three-way ANOVA and showed no comparisons to reach below the 0.05
threshold of significance. Here the comparison of BHR control versus restrained in the
juvenile cohort had the lowest P-Value of 0.08.
5.5 Discussion
5.5.1 Multi-Strain Analysis
The Multiple control strains were key to allowing the assessment of the suitability of
candidate biomarkers. Using this method, a distinction could be drawn between a
hypertensive strain, whilst ensuring any expression profile differences were not traits of
the WKY control strain alone. As this body of work is looking for a biomarker that
sheds light on individual susceptibility towards hypertension, it is to be expected that
a successful biomarker would be tightly grouped amongst hypertensives (SHRs) and
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spread amongst the normotensive controls. With this in mind, a genetically diverse set
of control candidates were selected.
The genetic diversity required for this analysis has been confirmed and quantified
through a variety of high-throughput studies. A study in 2013 looked into the genetic
spread of 27 commonly used laboratory rat strains, including a variety of models
for hypertension, insulin resistance, diabetes, and their resprective control strains.179
Using next-generation illumina sequencing Atanur et al achieved between 10-20x read
coverage, after rigorous filtering criteria, for all 27 strains. The team used the Brown
Norway (BN/Mcwi) genome as a reference, and detected 9,665,340 single nucleotide
variants (SNV) and 3,502,117 short indels. With this information, the team were able
to calculate the distance between any pair of strains by dividing the number of differing
SNVs by the length of the rat genome. A distance matrix could then be drawn using
the Fitch-Margoliash method, with 1000 bootstraps. The resulting matrix was used
to construct a phylogenetic tree (Figure 5.4). This independent analysis of rat strain
heterogeneity illustrates the genetic diversity of the control strains selected here via the
emergence of distinct clusters.
As this continuation was primarily a way of troubleshooting the ifit1 gene as a marker
of hypertension, an additional and important consideration is the role ifit1 plays in the
immune response. Ifit proteins, or Interferon-Induced proteins with tetratricopeptide
repeats, are a major component of the protective host defences against viral infection
encoded by interferon-stimulated genes (ISGs). Ifit genes are normally expressed at
very low levels of silent all together and their expression can be triggered by many
stimuli, although these are mainly within the context of viral and bacterial infection.180
Therefore, it is important to work out whether the presence of elevated ifit1 coincides
or precedes hypertension, or whether it is simply an artefact of a colony infection. For
this reason, the decision was made to obtain animals from different colonies as well as
different strains.
An interesting observation to note, was the separation of expression values that
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Figure 5.4: Phylogenetic Tree of 28 Rat Strains taken from Atanur et al 2013.179 Over 9.6
million single nucleotide variants (SNV) were used to construct a phylogenetic tree with a scale
representing genetic distance. This was calculated by dividing the number of single nucleotide
variants (SNV) between a given pair of strains by the length of the reference genome (Brown
Norway; BN/Mcwi). This tree was constructed using the Fitch-Margoliash method with
1,000 bootstraps. This tree illustrates the genetic diversity of the strains selected for further
biomarker validation, amongst many more; Wistar Kyoto (WKY), spontaneously hypertensive
rat (SHR), Goto-Kakizaki (GK), Milan normotensive strain (MNS), Milan hypertensive strain
(MHS), Lewis (LEW), Wistar albino Glaxo (WAG), biobreeding diabetes prone (BBDP),
salt sensitive (SS), salt resistant (SR), Lyon normotensive (LN), Lyon low blood pressure
(LL), Lyon hypertensive (LH), Fischer 344 (F344), Sabra hypertension prone (SBH), Sabra
normotensive (SBN), Fawn hooded low blood pressure (FHL), Fawn hooded high blood
pressure (FHH), August & Copenhagen inbred (ACI), Long Evans (LE), Brown norway (BN).
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appeared to stratify between a lower level of expression, and a greatly elevated ex-
pression, in an almost binary manner. This was exemplified in both the SD and
Wistar groups, as both had outlier samples whose blood expression of Ifit1 was hugely
elevated to an abundance comparable with the SHR levels of Ifit1 expression. This
gave rise to several questions. Firstly, were these animals naturally occurring hyperten-
sives/prehypertensives within their cohort. The strains with abundant Ifit1 expressing
outliers were the Wistar and SDs. Both of which represent outbred strains with a
greater level of genetic variability than the SHR or WKY strains. Indeed, the SHR was
derived from Wistars exhibiting elevated BP.150 It is conceivable that a true biomarker
of hypertension, or a propensity towards hypertension, would show a natural variance
in an outbred population, as this would be in line with the normal distribution of
blood pressure. It was therefore hypothesised that individual biomarker expression
profiles that outlie the normal range within their strain, and match the profile seen
within the hypertensive strain, could be indicative of either pre- or fully hypertensive
phenotypes. However, the only way to deduce this for certain would be with the
addition of physiological BP data alongside blood transcript expression data, to see
if a correlation could be drawn between these outliers and an elevated BP. Secondly,
whether or not Ifit1 expression would provide a dynamic metric of blood pressure if
elevated blood pressure were induced. Previous assessment of Ifit1 has been conducted
in the genetically predisposed SHR strain, and not in an environmental model of in-
duced hypertension. In order to answer both of these questions, and in lieu of direct
blood pressure measurements, a well documented environmentally-induced model of
hypertension was introduced on a new cohort of SDs in the form of a 3-day dehydration
protocol.173,181
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5.5.2 Sprague Dawley Dehydration
Based on the 5-strain analysis experiments, whereby 4 out of 12 (25%) SD animals
displayed elevated ifit1 expression, one might expect 25% (n=4) of this new population
to exhibit elevated ifit1. The näıve SD population saw a tight clustering of ifit1
expression values, with the majority similar to the SD population from the Multi-Strain
Analysis (Figure 5.1). One of the rats showed a high expression of ifit1, comparable
to both the 2 outliers of the Multi-Strain SD population, and the hypertensive SHR
population. This was at a ratio lower than expected, as only one animal from a
total of 12 exhibited this elevated expression profile. Interestingly, these expression
profiles appear to again stratify between high and low expression, with none exhibiting
expression levels in-between, as if ifit1 expression is switched on or off.
Following the 3-day dehydration protocol, Ifit1 saw a counter-intuitive reduction
in abundance. In other words, an environmentally induced elevation of blood pressure
occurred alongside a significant reduction in Ifit1 expression. The reasons behind this
are difficult to deduce, as a literature review of ISGs and dehydration revealed very
little work had been conducted on this subject. Indeed, high-throughput transcriptome
analysis on male SDs from our own group has revealed a reduction in the total number
of transcripts detected following a 3-day dehydration protocol.182,183 However, these
studies were all conducted in central regions of the brain tasked with cardiovascular
and osmolarity control (supraoptic nucleus (SON); paraventricular nucleus (PVN);
and neurintermediate lobe (NIL)) and not within whole blood. This reduction in
abundance suggests Ifit1’s inability to act as a dynamic metric of blood pressure when
it is environmentally manipulated, however it does not belie its potential utility as a
biomarker of genetically predisposition towards hypertension. One way of confirming
this hypothesis further would be an analysis of its expression in the Dahl-Salt Sensitive
model of hypertension.
The Dahl-Salt sensitive model of hypertension represents a strain with a genetic
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predisposition towards hypertension. The strain can be split into two, based on their
responsiveness towards a high salt diet; Salt sensitive and Salt resistant rats. Both of
which steadily become hypertensive given a diet of standard rat chow. However, once
given a diet high in salt, the salt sensitive cohort will develop a severe and fatal form of
hypertension. As this model marries genetic predisposition (as seen in the SHR) with
environmentally induced hypertension (as seen in the SD dehydration study), it may
allow for the assessment of Ifit1 as a metric of the genome-environment aetiology of
hypertension.
5.5.3 BHR Restraint
As the Dahl-Salt sensitive model was not available here, this work could be furthered
in a similarly predisposed model by use of the borderline hypertensive rat (BHR). Due
to its close relation to the SHR model, the BHR could be used to assess ifit1 expression
in a similarly genetically predisposed strain, with only a modest elevated BP and in
BHRs subjected to an environmentally induced form of elevated blood pressure.
The first thing noted by this study, was the high level of variability in the juvenile
animals, regardless of strain or restraint. This high level of variation prevented any
statistically significant calls being made by the three-way ANOVA employed here.
Within the BHR group, the level of Ifit1 expression was more or less comparable to
that observed within the Wistar controls. This is unlike the hugely robust fold changes
observed within the SHR animals as compared with their normotensive controls. Indeed,
there does appear a slight increase in expression in the BHR animals as compared
with the Wistars, although this is not significant. A similar non-significant pattern is
observed between the adult cohorts.
Assuming an elevation of blood pressure, the application of restraint stress appears
to do little in modulating blood expression of Ifit1, regardless of the age group or strain
tested. The juvenile BHR control versus restraint comparison has the lowest P-Value
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(P-Value = 0.08), showing an almost significant reduction of expression.
Here the expression of Ifit1 was not significantly modulated in either control or
restraint-stress treated animals. This was despite a model of induced elevated blood
pressure within a genetically predisposed strain, that has been well documented to
show an elevated BP.137 Taken together with the results of the SD dehydration study,
this is perhaps indicative of Ifit1’s inability to serve as a biomarker of borderline or
environmentally induced hypertension. In order to confirm this conclusion, the Dahl
salt sensitive model would prove invaluable.
However, due to the genetic similarity between the BHR and SHR animals, it is
promising to note a relatively low expression value in the control BHR. As this suggests
the model destined to get hypertension (SHR) alone sees this over abundance of the
transcript, and not the model of borderline hypertension.
5.5.4 Concluding remarks
This chapter was broadly successful in further characterising the ability of Ifit1 to discern
between a hypertensive strain, and a cohort of normotensive controls. However, unlike
the WKY versus SHR comparison which could be easily resolved by the stratification
of highly or lowly expressed Ifit1, two of the control strains also saw elevated Ifit1
expression in the blood. While it was not possible to correlate elevated Ifit1 expression
with an induced form of elevated blood pressure, Ifit1 may still serve as a suitable
biomarker for assessing the distribution of blood pressure across outbred strains.
Since much of this work has been conducted via proxy animals following validated
methods of inducing hypertension, future work should make use of direct physiological
measurements in order to confirm a rise in blood pressure has truly taken place. By
using plotting blood pressure changes, along with monitoring expression levels of Ifit1,
a correlation can be drawn between the two. This way, Ifit1 suitability can be measured





The natural progression after biomarker validation was to identify the role of interferon-
induced protein with tetratricopeptide repeats 1 (Ifit1) within the body, and to ascertain
whether Ifit1 had an involvement in any current mechanistic models of hypertension.
Whilst a biomarker only needs to serve as a reliable and reproducable metric of
blood pressure, and therefore does not need to be directly involved in hypertension,
characterising the role of ifit1 in this disease may well reveal novel insights into its
onset.
The Ifit family of proteins includes four canonical members within humans (Ifit1, Ifit2,
Ifit3, and Ifit5), and is widely conserved in mammals, amphibians, and fish.184,185 Within
rats specifically there are 4 ifit proteins; Ifit1, Ifit1b, Ifit2, and Ifit3.186 Interestingly,
Ifit proteins cannot be found in lower order animals, such as the fruit fly (Drosophila
melanogaster), nematode (Caenorhabditis elegans), yeast (Saccharomyces cerevisiae) or
plants187,188 (Figures 6.2 and 6.1).
Generally Ifit family genes are less abundantly expressed whilst in the absence of
stimuli. However their expression rapidly increases during stimulation with IFN, viral
infection, or other pathogen associated molecular pattern (PAMP) recognition. Most
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Figure 6.1: Exon-intron structural differences in Ifit family proteins, as taken from Liu
et al 2013.189 The exons are indicated by black boxes, and the introns by grey lines. The
orientation of the open reading frames is indicated by arrowheads.
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Figure 6.2: Phylogeny of Ifit family proteins, as taken from Zhou et al 2013, and generated
by MEGA4.0186,190
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of the Ifit family of genes have two exons and contain between two or three interferon
stimulated response elements (ISRE) as part of their promoter regions.191 The presence
of ISREs within the promoter of Ifits serves to explain their low basal expression levels
and rapid IFN-dependent induction.192 These ISRE are crucial cis-acting response
elements that are recognised by IFN-Stimulated Gene Factor 3 (ISGF3), a factor that
is induced by IFNs and various other stimuli.193 The main inducers of the ifit genes
therefore centre around the interferons (IFNs) and include; type I IFNs (IFN-α/β),
type III IFNs (IFN-λ), and to a much weaker degree Type II IFNs (IFN-γ).194,195
The Ifit protein family are mostly described for their role in antiviral immunity.
While none of the ifit family of proteins have any known enzymatic activity, they can
inhibit replication of viruses by binding and modulating the functions of cellular and
viral proteins and RNAs. All Ifits commonly share a tetratricopeptide (TPR) domain
containing a 34 amino acid motif with the consensus sequence [WLF ]−X(2)− [LIM ]−
[GAS]−X(2)− [Y LF ]−X(8)− [ASE]−X(3)− [FY L]−X(2)− [ASL]−X(4)− [PKE].
This motif folds into a resulting helix-turn-helix structure giving rise to a series of
unique concave and convex surfaces that permit binding to a diverse range of ligands.
TPR domains themselves are conserved in all kingdoms of life, and are considered to
function as protein and peptide recognition sites. The discovery of Ifit’s ability to
bind RNA has served to broaden the known ligand spectrum of TPR motifs to include
nucleic acids.
Through these TPR domains, ifit family proteins can modulate protein interac-
tions.196 For example, both Ifit1 and Ifit2 are involved in a nonspecific antiviral effect
via their direct interaction with eukaryotic initiation factor 3 (eIF3) translation complex.
The eIF3 complex is essential for translation initiation for several reasons; recruitment
of mRNA, scanning of the mRNA for a start codon, and delivery of tRNA to the trans-
lation machinery.197 Through binding with the subunits of the eIF3 protein, Ifits can
block mRNA recruitment and tRNA delivery.198 This leads to around 60% suppression
of translation within the cell during protein synthesis which can indeed be detrimental
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to the host cell, however this also prevents host-dependent viral replication.199–201
As well as inhibiting endogenous aspects of the viral replication pathway, recent
evidence has shown the ability of Ifit family proteins to directly bind viral RNA.
Generally speaking, host cytoplasmic RNAs are single stranded and mRNAs and
rRNAs/tRNAs contain either a N-7-methylated guanosine or 5’-monophosphate cap,
bound by a 5’-to-5’ triphosphate bridge to the first base respectively. Certain higher
order eukaryotes see a further modification to the mRNA in the form of a methylation
of the first ribose.202,203 These modifications confer more than simply translational
regulation as their absence aids in the detection of foreign nucleic acids. Viruses in
contrast may form double-stranded RNA, with the potential addition of 5’-Triphosphate
modification during their life cycle. Viruses carrying this 5’-Triphosphate-RNA are
recognised and bound by Ifit1, before an Ifit complex (containing Ifit1, Ifit2, and Ifit3)
sequester the bound virus for destruction.184
While little has been published on Ifit1’s potential role in hypertension, there is
a great deal of potential for linking the two due to the well established link between
hypertension and IFN expression. When focusing on the innate arm of immunity in
hypertension, it has been established that angiotensin II infusions induce an increase
in IFN-γ in the spleen and kidney of hypertensive rats.204 Studies on IFN’s role in
inflammation may well provide the link between hypertension and ISGs such as the Ifit
family of proteins.
6.1.1 Coupling Expression to Cardiovascular Centres of the
Brain
As much of the work of this laboratory is centred around transcriptome analysis of
central regions of cardiovascular control there have been terabytes of next-generation
sequencing data generated, both published and unpublished. This presented a novel
opportunity to reprocess these experimental outputs using the most up to date analysis
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pipelines as optimised previously. The resulting datasets could be re-mined to assess
whether Ifit1 expression was altered centrally between these strains, as it was within the
blood. One of the most revealing experimental designs, was the comparison of WKY
versus SHR at 12 weeks of age. The experiment isolated and sequenced three brain
regions that are key in sympathetic and hormonal control of blood pressure, namely the;
paraventricular nucleus (PVN), nucleus tractus solitarii (NTS), and rostral ventrolateral
medulla (RVLM). Following a re-analysis by way of the optimised pipeline outline above,
Ifit1 showed a significant upregulation in the SHR versus the WKY for both the PVN
and RVLM (Table 6.1). While the fold change increase was relatively modest compared
with the changes observed within blood, the read counts were consistent resulting in a
relatively low P-Value. Due to the integrative nature of the PVN, as outlined in section
1.1.4, this region was selected for further validation to assess Ifit1 expression.
DESeq2
Region Gene Name WKY.AvgCount SHR.AvgCount FC P-Value
PVN Ifit1 23.73 67.88 1.63 2.77E-05
NTS Ifit1 21.92 73.18 1.96 NA
RVLM Ifit1 14.50 52.23 1.90 7.10E-05
Table 6.1: RNAseq generated counts for Ifit1 expression in cardiovascular centres of the
brain. Based on n=3 experiments conducted on WKY versus SHR at 12 weeks of age, on
cryostat isolated brain regions; paraventricular nucleus (PVN), nucleus tractus solitarii (NTS),
and rostral ventrolateral medulla (RVLM). N.B. the “NA” P-Values issued by DESeq2 are
returned due to a single sample with an extreme outlier (as detected by Cook’s distance).
6.1.2 fluorescence-activated cell sorting (FACS)
Up until now this work has focused on Ifit1 expression in whole blood samples. However
blood itself is comprised of several subpopulations of cell types, each with a different
role in physiology. In order to delve further into characterising the overabundance of
Ifit1 in the hypertensive (SHR) blood the specific subtype of blood cell responsible for
its upregulation needed resolving. Of the major blood cell types (i.e. erythrocytes,
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leukocytes, and thrombocytes), only leukocytes contain a nucleus (nucleated), and are
therefore the focus of this study on transcription. Leukocytes as a type can be further
split into several different subtypes, each with their own specific role in immunity.
With this in mind fluorescence-activated cell sorting (FACS) presented an ideal
technology for resolving whole blood into its individual constituents, enabling Ifit1
expression to be quantified across each subpopulation of leukocytes. Cell sorting takes
place based on the presence or absence of specific characteristics, in this case the
presence of fluorophores conjugated to antibodies that can bind cell surface protein
markers. A combination of excitation lasers and detectors enable the physical separation
of cells, depending on how the operator calibrates the machine to isolate cells based on
a combination of fluorophore emission (a process known as “Gating”).
The difficulty presented with this technology, is the optimisation of antibodies
to be used and the gating strategy to be employed. With this in mind a literature
review revealed a team had optimised and validated a FACS pipeline for rat blood. In
2016 a 9-colour FACS method to characterise major leukocyte populations in the rat
was carried out.205 Barnett-Vanes et al. were able to produce a FACS pipeline that
resulted in resolving the key blood leukocyte factions. The protocol made use of a
comprehensive gating strategy to resolve the major blood leukocyte populations present
in rats (Figure 6.3). In addition to this, the team went on to validate their approach
using a model of lipopolysaccharide (LPS)-induced pulmonary inflammation. The team
exposed Sprague-Dawley to LPS (1mg/mL), and collected several tissues including;
blood, broncho-alveolar lavage fluid (BALF) and lungs. After having carried out a
flow-cytometry separation, Enzyme-Linked Immunosorbent Assay (ELISA) was used on
BALF tissue to validate their approach. Here the pipeline outlined in Barnett-Vanes et
al. became a foundation for these experiments. It allowed for the resolution the various
cellular populations contained within whole blood for the characterisation of which blood
fraction was responsible for the robustly elevated Ifit1 expression in the SHR animals.
By identifying this fraction it may be possible to guide a future literature review to
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shed light on Ifit1 and its link towards an immune-based aetiology of hypertension.
6.2 Aims
In this chapter, and building upon the discovery of Ifit1 as a potential biomarker, a
further characterisation of its expression and involvement in genetically predisposed
hypertension will be conducted. This will be achieved via the following;
• Assess expression within a key cardiovascular centre in the brain
• Characterise the faction of blood responsible for the elevated expression of ifit1 in
the SHR
• Conducting a literature review to assess role in mechanistic model of hypertension
6.3 Materials and Methods
6.3.1 Tissue Collection - PVN Isolation
Rats (WKY adults, SHR adults [12 Weeks], WKY juvenile, and SHR juvenile [4 Weeks]
n=8 per group) were stunned by a blow to the head and then decapitated. A scalpel
was used to make a longitudinal incision (rostral-caudal) on the crest of the head, and
the scalp was pulled back to reveal the cranium. Two cuts were made, approaching
from the site of decapitation to either side of the hindbrain using scissors. This enabled
forceps to prise open the top of the cranium, allowing the brain to be gently liberated
with a flat spatula. Brains were instantly frozen using powdered dry ice and stored
at -80°C until needed. The brain was sectioned and mapped using a cryostat (Leica
Microsystems CM1900 Cryostat). Coronal sections of tissue were cut rostral-caudal at
60µm thickness and stained with Toluidine blue (0.1% wt/vol in 70% EtOH; Sigma
Aldrich) in order to map the hypothalamus (Paxinos and Watson Rat Atlas) (Figure
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Chapter 6. Characterisation of Ifit1
6.4). A micropunch at 1mm diameter (Fine Science Tools) was used to isolate PVN
samples in unstained sections and deposit them into a 1.5ml centrifuge tube ready for
RNA extraction.
Figure 6.4: Coronal section of Rat Brain illustrating atlas coordinates and Toluidine Blue
stain of the Paraventricular Nucleus (PVN). Here is a coronal section of the rat brain at
Bregma -1.8mm showing the location of PVN lateral to the third ventrical. The PVN has been
enlarged in the left side of the image to illustrate both a Toluidine Blue stain of the region
(Right), and a depiction of how the nuclei are separated (Left; dorsal parvocellular subdivision
(DP), magnocellular division (MN), medial parvocellular subdivision (MP), periventricular
parvocellular subdividion (P), ventral parvocellular subdivision (VP).)
6.3.2 RNA Extraction
Similarly to the blood RNA extraction protocol, all procedures for PVN RNA extraction
were conducted in an RNAse free environment ensured by good laboratory practice in
addition to liberal cleaning of equipment and workspaces with RNAseZap (Ambion).
Sample punches were homogenized in 1ml TRIzol reagent (Invitrogen), before centrifug-
ing at ∼ 12,000 x g for 12 minutes at 4°C. Supernatants from each sample were carefully
decanted into new tubes, leaving behind a pellet of cellular debris to be discarded.
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One volume of EtOH (100% v/v) was added directly to one volume of sample
homogenate in TRIzol reagent before vortexing to ensure thorough mixing. Then the
sample mixtures were added into Zymo-Spin IIC Columns (Zymo Research) placed
in collection tubes and centrifuged at ∼ 12,000 x g for 1 minute. Spin columns were
then transferred to new collection tubes and 400µl DirectZol RNA PreWash buffer
was added to the column. Samples were again centrifuged for 1 minute with the
flow through discarded. This step was repeated. Next, 700µl RNA Wash Buffer was
added to the columns and samples were centrifuged for 1 minute. Flow-through was
discarded and samples were centrifuged again for 2 minutes to ensure complete removal
of the wash buffer. Columns were then transferred to an RNase-free tube and 50µl of
DNase/RNase-free water was added to the spin column. Samples were centrifuged for 1
minute to elute the RNA. Final concentrations of RNA for biomarker validation were
confirmed using spectrophotometry (Nanodrop 2000c, Thermo Scientific).
6.3.3 cDNA Synthesis
All cDNA synthesis steps were carried out as outlined in section 2.3.4 with the Quantitect
RT Kit (Qiagen).
6.3.4 Quantitative PCR Analysis
qPCR Analysis of Ifit1 expression in PVN was carried out as outlined in section 2.3.13.
6.3.5 9-Colour Panel Antibody Validation
Creation of an Ifit1 expressing construct
Initially, RNA was pooled from the SHR juvenile blood samples in order to maximise
the levels of Ifit1 transcripts contained. A cDNA synthesis was carried out using the
Qiagen Quantitect kit, as outlined in section 2.3.4. However, the random hexamer
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primers supplied with the kit were swapped for an oligo d(T)20 primer in order to
capture full length mRNA transcripts containing a complementary Polyadenylated tail.
Once a population of cDNA was produced, PCR Primers were selected to amplify and
amend the Ifit1 transcript for eventual ligation and transfection (Table 6.2). The 3’
boundary of the primers were designed to be comparible in size to those used for ifit1
in table 2.4.
Ifit1 BamH1 (F) 5’ – CGCGGATCCGCCACCATGGGAGAGAATGCTGGTGGTGA







Table 6.2: Primers for PCA amplification of Ifit1 Gene. Also shown are the specific regions
incorporated for later digestion in addition to a Kozak Consensus Sequence for increased
transcription.
Using the oligo d(T)20 Primer synthesised cDNA as a template, a PCR reaction
master mix was made up to 50µl total (Table 6.3). The sample was then ran on a
thermocycler to amplify the Ifit1 transcript and add on the necessary cleavage sites
required for insertion into a vector (Table 6.4). The PCR product was next run on a 1%
Agarose gel to inspect whether it had been successful. A solution of 0.3g Agarose (Sigma
Aldrich) was dissolved in 30ml of Millipore water, heated in the microwave, along with
1µl of Ethidium Bromide (Sigma Aldrich). This was mixed thoroughly and allowed to
cool to approximately 50°C. This mixture was then poured into a small gel rig (Sigma
Aldrich) with a loading comb in place and allowed to polymerise. Once polymerised, the
gel rig was filled with 1x TAE buffer to cover the gel. 10µl of Quick-Load Purple 1Kb
DNA Ladder (New England Biolabs) was loaded into the first well and two mixtures
of 10µl PCR product, 2µl 6x Loading Dye (New England Biolabs) and 1µl Ethidium
Bromide (Sigma Aldrich) were added into the adjoining lanes. The gel was run at 125v
until the loading dye was approx. 80% through the gel. Images were taken using the
UV transilluminator (Azure Biosystems) to confirm whether a product was seen at all,
Page 161
Chapter 6. Characterisation of Ifit1
and which size the band corresponded to. A size band corresponding to the ifit1 gene
CDS (1466bp) was indicative of a successful PCR amplification (Figure 6.5).
Component Volume Final Concentration
5x Phusion HF Buffer 10µl 1x
Primers (Table 6.2) 0.2µ Each 200µM
10mM dNTPs 1µl 0.5µM
Nuclease-free Water 36µl
Phusion DNA Polymerase 0.5µl 1.0 units/50µl PCR
cDNA Template 2µl
Table 6.3: Reaction master mix for Phusion DNA PCR
Step Temp Time
Initial Denaturation 98°C 30 Seconds
Amplification (35 Cycles) 98°C 1 Minute
72°C 30 Seconds
Final Extension 72°C 5 Minutes
Hold 4°C ∞
Table 6.4: PCR Amplification Protocol
The two bands were carefully excised from the gel using and a scalpel blade and a
UV transilluminator to view the bands. Care was taken to remove as much agarose
gel as possible. The containing DNA was then isolated using the Gel Extraction kit
(Qiagen). The excised gel bands were weighed and 3 volumes of Buffer QC were added
to 1 volume of gel (100mg - 100µl). This solution was incubated at 50°C for 10 minutes
and vortexed every 2 minutes to ensure the agarose gel was full digested. As the
adsorption of DNA to the QIAquick membrane is only efficient at acidic conditions of
pH ≤ 7.5, the Buffer contains a pH indicator. A check of the solution’s colour confirmed
the pH to still be acidic, and so no action was required. The QIAquick spin column
was then placed in a 2mL collection tube, and the solution was loaded into the column
and centrifuged at ∼ 14,200 x g for 1 minute. Flow-through was discarded, before
500µl of Buffer QC was loaded directly onto the column and left for 5 minutes at room
temperature. The column was then centrifuged again for 1 minute at ∼ 14,200 x g.
Next, the column was washed with 75µl of Buffer PE and left for 3 minutes at room
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Figure 6.5: PCR Product of size matching that of Ifit1. Viewed on 1% Agarose Gel
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temperature before centrifuging for 1 minute. Flow-through was again discarded, and
the column was centrifuged once more for 1 minute to remove any residue. Finally,
the column was placed into a clean 1.5mL microcentrifuge tube. To elute the DNA,
30µl of Buffer EB (10mM Tris-Cl, pH 8.5) was pipetted directly onto the centre of the
membrane and left to stand for 1 minute. The sample was then centrifuged at ∼ 14,200
x g for 1 minute and DNA was eluted.
A tube of purified DNA and a pcDNA3.1(+) vector were incubated overnight at
37°C with a reaction buffer to produce the specific corresponding sticky ends required for
ligation of the insert into the vector (Table 6.5). The digestion products were reran on
a 1% agarose gel and excised, as outlined above, in order to purify the product. In order
to optimise the ligation procedure, a concentration calculation was conducted. A 1%
agarose gel was ran with Quick-Load Purple DNA Ladder (New England Biosciences)
at varying loading concentrations (2µl, 4µl, & 8µl). The insert was loaded next at
either 2µl or 4µl of volume (mixed with 3µl or 1µl of water respectively to maintain a
loading volume of 5µl in total). The vector was loaded at either 1µl or 2µl of volume
(made up to 5µl with water) in the next two loading wells. This gave the opportunity






Cut Buffer (10x) 5µl
Water 15µl
Table 6.5: PCR Digestion Mastermix
Using the concentrations inferred from the gel, a ligation molar ratio could be
calculated of insert to vector using the equation outlined in Figure 6.7. A final quantity
of 13.5ng was determined for a 1:1 ratio of Insert:Vector. Since the Promega website
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× ng of vector
Where; Insert length = 1466bp
V ector amount = 50ng, as defined by the T4 Ligase Protocol
V ectorLength = 5428
Figure 6.7: Equation for calculating Ligation Molar Ratio
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state ligations are tested at ratios from 1:1 to 3:1, and given the collective experience of
colleagues within the laboratory, a ratio of 3:1 (40.5ng of insert) was selected to ensure
an excess of insert without requiring more than 20µl of reaction volume as outlined in
Table 6.6. This reaction mixture was made up in a microcentrifuge tube on ice and
mixed gently by pipetting up and down. It was then incubated at room temperature
(21°C) for 15 minutes before being placed back on ice to chill the reaction mixture.
Component Volume for 20µl Reaction
T4 DNA Ligase Buffer (10x) 2µl
Vector DNA 50ng (2.5µl)
Insert DNA 40.5ng (10.8µl)
Nuclease free water to 20µl
T4 DNA Ligase 1µl
Table 6.6: Ligation Mastermix for T4 DNA Ligase
Bacterial Transformation
The mixture containing ligated and unligated DNA could then be transformed into
competent Escherichia coli (E. coli) DH5α cells (Thermofisher). 50µl of DH5α in
calcium chloride suspension were thawed on ice and mixed with 5µl of the ligated
plasmid. This mixture was incubated on ice for 50 minutes before being placed in a
42°C water bath for 45 seconds to heat shock the bacteria. This was then placed back
on ice for 2 minutes. 450µl of Super Optimal Broth with glucose (SOC) medium was
then added in order to dilute the calcium chloride, stabilising the cells. This was then
left in a shaking incubator for 1 hour at 37°C. 100µl of the cells were plated onto an
agar plate containing ampicillin and incubated at 37°C overnight. Using a pipette tip,
three colonies were isolated and grown overnight in a 37°C shaking incubator in 5ml of
Lysogeny Broth (LB) containing ampicillin. The resulting bacterial suspensions were
passed through a QIAprep® Spin Miniprep Kit (Qiagen) to isolate plasmid DNA. 1ml
of bacterial culture was pelleted by centrifugation at >6,800 x g for 3 minutes at room
temperature (15-25°C). The pellets were next resuspended in 250µl of Buffer P1 and
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transferred to a microcentrifuge tube. 250µl of Buffer P2 was then added and the
mixture was inverted thoroughly until the solution became clear. Once the solution
was clear, 350µl of Buffer N3 was added and the mixtures were immediately mixed
thoroughly before centrifuging for 10 minutes at 17,900 x g. The supernatant from the
previous step was decanted via a pipette to a QIAprep spin column and centrifuged for
30-60 seconds. The flow-through was discarded. via an additional centrifugation, 0.75ml
of Buffer PE was used to wash through the spin columns and again the flow-through
was discarded. The columns were centrifuged at the above speed for 1 minute in order
to remove residual wash buffer. Next, the columns were transferred to a clean 1.5ml
microcentrifuge tube and 50µl of Buffer EM (10mM Tris·Cl) was added to the centre
of the column. These were left to stand for 1 minute before centrifuging for 1 minute
to elute the plasmid DNA. A nanodrop spectrophotometer was used to quantify the
resulting plasmid DNA (Table 6.7).
Colony Conc (ng/µl) A260 A280 260:230 260:230
A 205.7 4.11 2.23 1.84 1.83
B 276.4 5.53 2.99 1.85 1.78
C 347.5 6.95 3.72 1.87 1.97
Table 6.7: Spectrophotometry output for Isolated Ifit1 constructs
As the pcDNA3.1(+) vector confers ampicillin resistance, growth of colonies on
the ampicillin containing agar only confirmed successful transformation of the plasmid.
These may contain the insert of interest, or may well be re-ligated vectors. In order to
confirm a successful ligation of the vector and insert, the plasmid DNA was initially
incubated with BamHI and XhoI and ran on a 1% agarose gel to assess the size of
bands produced from the digestion (Table 6.8, Figure 6.8). Three distinct bands are
apparent from the BamHI and XhoI digestion at; 5,500bp, 3,500bp and 1,400bp. The
whole pcDNA3.1(+) is 5428bp in size, which seems consistent with the strongest band
at 5,500bp. This band appears to be either undigested, or simply does not contain
the insert and so digestion only serves to linearise the plasmid as the BamHI and XhoI
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sites are only 56bp away from each other. The band at 1,500 appears to be the Ifit1 in-
sert itself, as the insert is 1466bp and directly flanked by BamHI and XhoI digestion sites.
Figure 6.8: BamHI & XhoI Digest on Plasmid Construct
For additional confirmation, 1500ng of each sample DNA was sent for Sanger Se-
quencing with primers corresponding to either side of the ligation sites (Table 6.9).
The results were curated and both ends of the sequencing were merged to give a final
sequence of the inserts. These were then ran through a BLAST search algorithm to
confirm the sequence identity with the NCBI Ifit1 Rattus norvegicus sequence. Each
of the inserts showed a high sequence identity with Ifit1 sequence entry and so were
deemed suitable for usage downstream (Appendix C).
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Cut Buffer (10x) 5
Water 3




Table 6.9: Sanger Sequencing of Plasmid Primer Sequences
Transfection into HEK293t Cell line
Six wells of a 24-well plate were seeded with carefully thawed Human Embryonic
Kidney Cells, expressing a mutant version of the SV40 large T antigen (HEK293T).
They were maintained in Dulbecco’s Modified Eagle Medium containing pH indicator,
with additional L-Glutamine (4mM), Streptomycin (1%), and Fetal Bovine Serum
(FBS, 10% Thermofisher). These were maintained with fresh medium and incubated at
37°C until they reached approximately 70% confluency. At this point, a lipofectamine
transfection could be carried out of either control plasmid (pcDNA3.1(+)) or the
plasmid construct containing rat Ifit1 (pcDNA3.1(+)·Ifit1) as per the manufacturer’s
instructions (Invitrogen).206 In two 1.5ml microcentrifuge tube, 4.5µl Lipofectamine
3000 Reagent was diluted in 150µl Opti-MEM Reduced Serum Medium and mixed
well. In two additional tubes, 150µl of Opti-MEM media was mixed with 1.5µg of
respective DNA (1.5µl pcDNA3.1(+), 3.78µl pcDNA3.1(+)·Ifit1). To both of these,
3µl of p3000 Reagent was added. Each of the tubes were combined with one of the
previously prepared Lipofectamine tubes and left to incubate at room temperature for 5
minutes. Serum containing media was decanted from each of the wells on the plate, and
replaced with Opti-MEM Reduced serum medium before dividing each lipofectamine
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mixture between three wells (3 x pcDNA3.1(+), 3 x pcDNA3.1(+)·Ifit1) and incubating
at 37°C. Cells were checked several times daily to prevent toxically high confluence from
occurring. After 2-days of expression, cells could be lysed to confirm protein expression.
Confirmation of Protein Expression
Transfected cells (HEK293T Control and HEK293T·Ifit1) were lysed on their respective
cell culture dishes using 150µl of lysis solution consisting of sodium dodecyl sulfate
(SDS), Tris·HCl and HEPES·NaOH. After the solution was applied to each of the plates,
a cell scraper (Sigma-Aldrich) was used to detach the cells from the plate and ensure
thorough lysis. Cell lysates were collected into a 1.5ml centrifuge tube, and passed
through a 5mL syringe with 25G needle to break up the cells further.
Protein concentrations of both lysates was measured using the Nanodrop 2000c
(Thermofisher). This was calculated by assessing A280 absorbance values with 1 Abs
being equal to 1mg/mL. Protein concentrations were relatively equal and therefore did
not warrant further dilutions to normalise between the two groups.
Next, 50µl of 4x loading buffer (Table 6.10) was added to each of the sample lysates
to make loading of the samples into their respective wells easier, as well as enabling
visualisation of the bands as they progress through the electrophoresis gel. Sample
lysates were next heated on a heat block to 95°C briefly to ensure any SDS had not
precipitated in the lysate mixes and the proteins were properly denatured prior to gel
separation.
A 10% electrophoresis gel was prepared (Table 6.10), with a 4% stacking gel
component. This was prepared along with 1L of running buffer.
Along with the HEK293T and HEK293T·Ifit1 sample lysates, lysates from two
other cell lines were included to assess endogenous expression of ifit1 for potential
involvement in further validation studies. These were the Att20 mouse pituitary cells
and the PC12 rat adrenal medulla cells and were available due to ongoing experiments
of colleagues within the laboratory. All four cell lysates were loaded at both 30µg and
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60µg concentrations, as well as 10µl of protein size ladder (Novex™ Sharp Pre-Stained
Protein Standard, Thermofisher).
The gel was run for approximately 45 minutes at 180v, until the size markers had
separated sufficiently to easily resolve the 50kDa marker. At this point a semi-dry
protein transfer was conducted using the Trans-Blot SD Semi-Dry Transfer Cell (Bio-
Rad). A transfer buffer was initially prepared (Table 6.10). A PVDF membrane
(Millipore) was first activated in 100% Methanol for 30 seconds before rinsing with
dH2O and submerging in transfer buffer to acclimatise prior to the transfer. Four sheets
of filter paper were used to sandwich the PVDF membrane and electrophoresis gel.
The stack was soaked in transfer buffer and ran at 20v for 110 minutes. The PVDF
membrane was soaked in Ponceau Red reagent (0.1% w/v Ponceau, 5% v/v Acetic acid)
for approximately 10 minutes then rinsed in dH2O to visualise the protein transfer was
successful. The membrane was destained with several washes in bovine serum albumin
(BSA) in phosphate buffered saline (PBS) (5% w/v) ready for antibody visualisation
(Figure 6.9).
Immunocytochemistry
A newly transfected population of cells (as outlined above) were grown on glass cover
slips (Thermanox - Nalge Nunc International, NY, USA). Growth media was aspirated
from them before being gently washed with 1mL of sterile PBS. This was carefully
removed, and 1mL 4% Paraformaldehyde (PFA) was added to fix the cells. This was
left on for 15 minutes at room temperature. Following fixation, cells were washed a
further two times with fresh PBS. Cells could then be blocked and permeabilised by
incubation for 10 minutes with permeabilisation buffer (2% Bovine Serum Albumin
(BSA), 0.1% Triton X-100). Primary Anti-Ifit1 (OTI3G8, Novus Biologicals) diluted
in PBS containing 5% BSA was dropped onto parafilm strips in a light-sealed box.
Coverslips could then be removed from the cell culture plates and inverted ontop of the
parafilm to enable an economical usage of primary antibody. Coverslips were light-sealed
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Buffer Constituents Quantity
2x Separation Buffer Tris Base 9.08g
SDS 0.2g
HCl/NaOH pH to 8.8
H2O Up to 100mL
2x Stacking Buffer Tris Base 3g
SDS 0.2g
HCl/NaOH pH to 6.8
H2O Up to 100mL




APS (10% in H2O) 100µL




APS (10% in H2O) 20µL
10x Running Buffer Tris Base 30.3g
Glycine 144g
SDS 10g
HCl/NaOH pH to 8.3
H2O Up to 1L
1x Transfer Buffer Tris Base 3g
Glycine 15g
Methanol 200mL
HCl/NaOH pH to 8.3
H2O Up to 1L






HCl/NaOH pH to 6.8
Table 6.10: Reagents used for Western Blot analysis of Ifit1 protein expression
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Figure 6.9: Antibody test on various cell lysates. Here Hek293t cells, either transfected with
Ifit1 or a control pcDNA3.1 construct, were lysed and ran on a Western Blot before being
incubated with the Anti-Ifit1 antibody. Also featured are cell lysates from Att20, and PC12
cells. Two clear bands can be seen just above the 55kDa size, a size consistent with the Ifit1
protein. There also appears to be a distinct band in both of the Att20 lysates at approximately
100kDa in size. This may be a product of ifit protein dimerisation, due to insufficient SDS
denaturation. Indeed the IFIT2 protein has been shown to dimerise in vivo.207 However the
evidence for IFIT1 dimerisation is less clear. Further characterisation of these bands would
be possible through extraction and interrogation using Mass Spectrometry techniques.
Page 173
Chapter 6. Characterisation of Ifit1
and left overnight at 4°C before being washed with PBS three times. Using the same
inverted incubation method coverslips were incubated with secondary antibodies diluted
in PBS with 5% BSA for 1 hour at room temperature in the dark. After this incubation
period DAPI was added and samples were left for a further 10 minutes. Following three
additional washes in BSA samples were imaged on a DMI6000B microscope (Figure
6.10; Leica - Wetzlar, Germany).
Figure 6.10: Antibody test on HEK293T cells containing either control transfection
(pcDNA3.1(+)) or Ifit1 transfection (pcDNA3.1(+)Ifit1). Cells were incubated with anti-Ifit1
antibody (1:50, 500ms exposure, red) and DAPI (1:1000, 1-20s exposure, blue) before being
imaged at 10x and 40x magnification. Here the ifit1 transfected cells show a clear signal in
the red channel whereas no signal can be seen in the control transfected cells.
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6.3.6 Fluorescence-activated cell sorting
Antibody Panel Viability
Once antibodies had been delivered, the first step was to assess their integrity was
not compromised during transit, and that their binding efficiency was suitable for my
intended downstream application. To do this, 2µl of each antibody was added to a glass
tube containing 1 drop of OneComp eBeads™ Compensation Beads (ThermoFisher
Scientific). Each drop of beads contains two populations; a positive population that
has reactivity with any rat, mouse or hamster antibody, and a negative population
that has no reactivity towards any antibodies. Firstly, a solution of unstained beads
was ran through the cytometer to show the FSC/SSC of 10,000 events. This allowed
a single-cell gate to be drawn across the relevant proportion of events prioritised for
antibody optimisation, preventing any cohered beads from passing through at the same
time and flagging a false positive/negative. Then each antibody containing tube was
ran individually through the FACS machine (BD Fortessa X20 analyser, BD Biosciences
- Franklin Lakes, NJ USA) with their corresponding excitation wavelength laser and
filter parameters set up to a measured total of 10,000 events (Table 6.11).
The resulting emission profiles showed a bimodal distribution for each antibody,
with a clear separation observed between the negative and positive peaks. Care was
taken to ensure each peak lay on a linear, and not logarithmic, measure apart. This
keeps the final measurements within the dynamic range of the antibodies, allowing
quantities to be measured more accurately than if binding was outside of the linear
range. This process also enables a pragmatic test as to whether there is any cause for
concern with the panel design by highlighting any potential crossover of emission bands.
Based on the antibody emissions from this optimisation, the software can mitigate this
by creating compensation parameters to better resolve peaks that show similar profiles.
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Chapter 6. Characterisation of Ifit1
Tissue Isolation
Following a week habituation period, 3 WKY and 3 SHRs at 12 weeks old were sacrificed
by a cranium strike stun and guillotine. Whole blood was collected into sodium citrate
containing tubes (BD Vacutainer) on ice to prevent coagulation and RNA degradation
respectively. To obtain the plasma layer, blood was transferred into 2mL microcentrifuge
tubes and spun at 1300 x g for 10 minutes at 4°C. The upper plasma layer was removed
and frozen at -80°C for further experiments. The next step was to perform a red
blood cell (RBC) lysis preparation to deplete the samples from erythrocytes that could
interfere with the dynamic range of the FACS experiment. This was carried out using
an ammonium chloride based Lysing Buffer (BD Biosciences) as per the manufacturer’s
recommended protocol. For every 200µl of whole blood, 2.0mL of lysing solution was
added. Tubes were gently vortexed immediately after adding the lysing solution, and
incubated at room temperature for 15 minutes in an area out of the light. Once samples
were no longer cloudy, they were centrifuged for 5 minutes at 200 x g. The supernatant
was carefully aspired without disturbing the pellet, and discarded. FACS buffer was
made up for diluting antibodies and consisted of 0.5% BSA (Sigma-Aldrich) in PBS
(Sigma-Aldrich). This solution was passed through Millipore filters in order to sterilise
it. The now RBC depleted pellet was resuspended in FACS buffer for flow cytometric
analysis.
In order to assess both the success of the RBC depletion, and calculate how many
leukocytes are present in the final FACS suspension, hemocytometry was conducted.
The population of leukocytes was obtained, suspended in FACS buffer and integrity
was verified, antibodies could be added to aid in identification and separation of the
various cellular factions present. This was initially done by taking a 100µl aliquot
of the undiluted RBC depleted FACS suspension and mixing with 100µl of Trypan
Blue Solution (0.4%, Sigma) for identification of non-viable cells that have ruptured.
A cover slip was placed on top of the Bright-Line™ hemocytometer (Sigma-Aldrich)
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and aligned so it rested balanced on the two spacing risers either side of the count
matrices. 50-100µl of the FACS suspension/Trypan Blue mix was pipetted onto both
of the counting matrices to create a drop of the stained suspension on each. Using a
light microscope at 100x magnification (Nikon Eclipse TS100) and a hand counter, I
was able to count cells within each of the five large 5x5 grids. Cells were excluded if
they were touching the upper or left boundaries of the matrix and care was taken to
discern between trypan blue stained cells (ruptured) and non-stained cells in the final
counts. Then using the below formula, a calculation of viable cells per mL was made
(Figure 6.11).
Cell V iability =
Number of Live Cells
Number of DeadCells
Measured Cell Density (Cells/mL) =
Average Cells per Square×Dilution Factor
V olume of a small square (mL)
Total V iable Cells = Cell Density (Cells/mL)× V olume (mL)× V iability
F inal V olume (mL) =
Total V iable Cells
Target Density (Cells/mL)
Figure 6.11: Calculations for Cell Abundance and Viability
Optimisation of Antibody Dilutions
Before carrying the final FACS sorting experiment, it was pertinent to optimise the
antibody dilutions so as to ensure sufficient antibody is present and to minimise non-
specific binding by excess probing. To do this, one of the samples obtained from the
SHR blood was selected for an antibody titration. A serial dilution of each antibody in
FACS buffer was first made with the recommended dilution being used as the starting
concentration. The dilutions tested are listed in Table 6.11.
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Between 200,000-500,000 cells used for each antibody dilution. Cells were pelleted
by spinning at 200g for 5mins and supernatant was removed, whilst being careful not
to dislodge the cell pellet. 25µl of Anti-CD32 antibody was added at a concentration of
1:50 to the cell pellet and mixed. This was done in order to block antibodies binding
non-specifically to the FcγII receptor. The solution was incubated for 10 minutes at
room temperature. Following this incubation, 25µl of each antibody dilution (in FACs
buffer) was added to each respective tube containing FcγII-blocked cells. These were
briefly mixed by vortexing before incubated on ice, and in the dark, for 30 minutes.
Cells were washed with 500µl of FACs buffer and vortexed before re-spinning to once
again pellet the cells. Supernatants were discarded carefully, and cells were resuspended
in 300µl of FACs buffer ready for cytometry assessment of antibody concentrations.
The suitability of each antibody dilution was mathematically assessed by use of the
stain index (Figure 6.12, Table 6.12). The highest stain index denotes the concentration
most able to discern between an antigen positive and negative population. For this
reason, efforts were made to pick dilutions that would give a suitably high stain index,
whilst ensuring an economical usage of the antibody. The antibody dilutions selected




Where; MFI = Mean Fluorescence Intensity
σ = Standard Deviation of Negative MFI
Figure 6.12: Equation to calculate the Stain Index for Fluorescently conjugated Antibodies
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Chapter 6. Characterisation of Ifit1
6.3.7 FACS Analysis on Permeabilised Cells
Validation of Biotinylated Anti-Ifit1 Antibody
In order to attempt a positive selection of Ifit1 expressing blood cells, and to ensure
it could be incorporated into the 9-panel FACS protocol, a biotinylated form of the
same anti-Ifit1 clone was employed. To validate its suitability in a FACS protocol, the
Control (pcDNA3.1) and Ifit1 (pcDNA3.1(+)·Ifit1) transfected cells were obtained via
the above protocol. Initially, FACS buffer (0.5% BSA in PBS), Fixation buffer (4%
PFA in PBS), and permeabilisation buffer (0.1% Triton X-100, 0.5% BSA in PBS) were
all made up using autoclaved PBS solution.
After 48 hours since transfection, cells were Trypsin-detached (0.25%, sterile-filtered,
BioReagent 2.5 g porcine trypsin and 0.2 g EDTA, Sigma-Aldrich) and pelleted at 180
x g for 3 minutes. These populations were washed with 1mL of sterile PBS and pelleted
again. This wash step was repeated. Cells were counted using a hematocytometer as
outlined above and resuspended at approx. 1x106 Cells/100µl PBS. At this point the
cells could be incubated with 1µl of Zombie dye per 100µl of cells for 15-30 minutes
at room temperature in the dark. They were then washed with 2mL of FACS Buffer
and resuspended to approx 3.24x106 Cells/mL in ice cold FACS buffer. The following
fixation method was adapted from Abcam’s FACS Protocol database and conducted in
the dark to preserve fluorescence of the Zombie Stain.208 Cells were pelleted at 100 x g
for 2 minutes before being resuspended in Fixation Buffer for 10-15 minutes. Cells were
then washed with 2mL of Permeabilisation Buffer for 15 minutes and centrifuged at
100 x g for 5 minutes. The supernatant was discarded and they were resuspended in
2mL of 1% BSA in PBS. The Ifit1 transfected cells were divided into 5 groups for the
assessing the following antibody dilutions; 1:50, 1:100 (Recommended), 1:200, 1:400,
1:800 (Figure 6.13). The control transfected cells were divided into 10 groups, as a
no-primary antibody control was to be used for each dilution. Primary biotinylated
anti-Ifit1 antibody was added to each of the populations at the above dilutions, apart
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Figure 6.13: FACS Validation of Dilutions for Biotinylated Anti-Ifit1 Antibody
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Figure 6.13: FACS Validation of Dilutions for Biotinylated Anti-Ifit1 Antibody
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Figure 6.13: FACS Validation of Dilutions for Biotinylated Anti-Ifit1 Antibody
from the no-primary controls. The groups were left to incubate for 1 hour at room
temperature. Samples were then washed with incubation buffer (1% BSA in PBS) and
centrifuged at 100 x g for 3 minutes to pellet. The supernatant was carefully aspirated
and discarded, and the wash step was repeated. Cell pellets were then resuspended in
100µl streptadvidin conjugated secondary, diluted 1:400 in 0.5% BSA containing PBS
(BV605 Streptavidin, BD Horizon). These were then left for 30 minutes incubating
at room temperature in the dark. Samples were washed twice in incubation buffer as
outlined above before being stored at 4°C in 0.5% BSA PBS with 1mM EDTA and
0.1% sodium azide ready for FACS analysis.
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6.4 Results
6.4.1 Ifit1 Expression in the PVN
Figure 6.14 shows the relative expression of Ifit1 in punched PVN sections between the
WKY and SHR, as both juvenile and adult ages. Similarly to within blood tissue, Ifit1
shows a marked increase in abundance in the SHR as compared with the WKY, across
both ages tested (Figure 6.14; juvenile WKY vs SHR, +10.1 fold, P-Value<0.0001;
adult WKY vs SHR, +15.5 fold, P-Value=0.0002).
6.4.2 FACS Analysis to Isolate Cell Types
Novel distribution of cell types across strains
The initial sorting protocol revealed novel differences in Leukocyte abundance between
the WKY and SHR bloods (Figure 6.15; Table 6.13).
Cells expressing CD3+ appeared subtly more abundant within the WKY blood
than within the SHR blood, however this was by a small degree and did not reach
significance (Figure 6.13; WKY vs SHR, -0.21 fold, P-Value=0.254).
The CD4+ marker was again subtly different within the WKY blood than in the
SHR blood, but this appears to be due to random spread (Figure 6.13; WKY vs SHR,
-0.14 fold, P-Value=0.451).
There was a significant downregulation of CD8+ cells in the SHR blood, with a fold
change of -0.36 (Figure 6.13; WKY vs SHR, -0.32 fold, P-Value=0.039).
B-Cell populations did not appear to vary between the two strains, and remained
relatively constant at around 16% of the total leukocyte population (Figure 6.13; WKY
vs SHR, +0.04 fold, P-Value=0.704).
Interestingly, total monocytes showed a trend towards increased abundance within
the SHR. Whilst this was not significant, the breakdown of all monocytes into CD43Hi/His48Lo
and CD43Lo/His48Hi subpopulations revealed the CD43Hi/His48Lo monocytes to be
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Ifit1 Expression - PVN
****
***
Figure 6.14: qPCR Relative Expression of Ifit1 in the PVN, displayed as 2−∆∆CT values.
Statistical analysis made use of a Student’s T-Test (P-Value <0.05, *; <0.01, **; <0.001, ***;
<0.0001, ****).
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significantly upregulated in the SHR (Figure 6.13; WKY vs SHR, Monocytes +0.61
fold, P-Value=0.053; CD43Hi/His48Lo +0.96 fold, P-Value=0.014; CD43Lo/His48Hi
+0.37, P-Value=0.287).
The FACS gating strategy for Neutrophils showed very little variation between the
two strains, with both having neutrophils accounting for approx. 18% of the total
leukocyte population (Figure 6.13; WKY vs SHR, -0.14 fold, P-Value=0.670).
Finally, the strongest change in abundance was observed with the NK Cells as
the WKY expressed negligible levels whereas NK Cells accounted for approx. 3% of




































































Figure 6.15: Differences in leukocyte populations across WKY and SHR strains. Statistical
analysis made use of a Student’s T-Test (P-Value <0.05, *; <0.01, **; <0.001, ***; <0.0001,
****).
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Chapter 6. Characterisation of Ifit1
Assessment of Ifit1 expression within the cell subtypes
Initial FACS isolation of cell populations for later qPCR analysis proved unsuccessful,
as RNA levels were barely detectable across the samples. Nucleic acid concentrations
ranged from 0 - 9ng/µl, with low accompanying 260:280 values. This was therefore
prohibitive for taking samples forward for qPCR analysis of Ifit1 expression. One of the
ways to further control this experiment would be to utilise the transfected HEK293t
cells as positive controls. This lack of useable RNA led to a change in approach towards
positive selection of Ifit1 containing cells by the FACS equipment.
6.4.3 FACS Analysis on Permeabilised Cells
FACS analysis was conducted on permeabilised leukocyte cells, incubated with the
biotinylated anti-Ifit1 antibody. When applying the gates as originally optimised in
section 6.3.7, very few cells showed a positive signal (Figure 6.16). This lack of positive
signal resulted in very few cells able to pass through the various other gates used for
determining leukocyte population (Figure C.1).
6.5 Discussion
6.5.1 Ifit1 Role in Hypertension
A growing body of evidence is suggesting the importance the innate immune system
plays in several inflammatory processes known to affect the cardiovascular system.
Innate immunity refers to the body’s first line of non-specific defense mechanisms
against pathogens. However, the innate immune system also plays an important part in
responding to endogenous damage. Increasing research is highlighting Ifit proteins in the
innate immune response, specifically the Ifit1 protein. In 2012, McDermott et al. used
several large-scale transcriptomic datasets from mouse and mouse macrophage studies
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Figure 6.16: fluorescence-activated cell sorting (FACS) output of BV605 Positive cells
(Stained with anti-Ifit1 antibodies), illustrating how few yielded a positive signal.
to identify a series of targets important in controlling innate immune responses.209
By comparing these datasets, the team were able to infer networks from statistical
associations between transcript expression profiles. From these networks, genes with a
high-betweenness centrality were deemed important “bottlenecks” of the innate immune
response. Across all the datasets analysed, they found only six conserved bottleneck
genes including; Ifi47, Axud1, Ppp1r15a, Tgtp, Ifit1, and Oasl2. They continued to
validate Ifit1 through qPCR analysis of expression in model of LPS-mediated TLR4
activation. Using Ifit1 siRNA expression of the predicted first-order network genes
was robustly reduced, suggesting Ifit1 exerts an important regulatory influence across
several downstream immune genes in this model of infection.
The method of inducing the innate immune response by way of LPS exposure is a
common one. However studies on LPS and blood pressure appear to yield mixed results.
Many studies into the acute effects of LPS observe a reduction in blood pressure as a
result of the infection, accompanied by a steady increase in heart rate to account for
the lower blood pressure.210 Another study into the time course effects of hemodynamic
responses to LPS noted a rapid reduction of blood pressure after a low dose of LPS
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(0.06mg/kg) was injected. Interestingly, the same team saw a significant increase
in blood pressure at doses between 20-40mg/kg.211 Chronic studies on LPS are less
revealing, as animals rapidly desensitise to the exposure of LPS and as a result blood
pressure remains unchanged for the duration of the study.212
It would certainly be of interest to manipulate this system in future, with LPS
exposure at a higher level to see the effect it has on blood pressure and whether it is
accompanied with a concomitant rise in Ifit1 expression occurs within the blood.
6.5.2 Ifit1 in the paraventricular nucleus (PVN)
Here a significant upregulation of Ifit1 expression was observed within the PVN. The
hypothalamic PVN has been heavily implicated in the relationship between innate
immunity and hypertension. Studies have shown increased levels of pro-inflammatory
cytokines (PICs) to play an important factor in the development of hypertension. Shi et
al. (2010) show the involvement of microglial cytokines in neurogenic hypertension by
administering either an anti-inflammatory antibiotic, or an adeno-associated virus for the
overexpression of the anti-inflammatory IL-10 alongside angiotensin II in the PVN. The
team measured a series of physiological metrics associated with a hypertensive disease
state including; mean arterial pressure, cardiac hypertrophy, and plasma norepinephrine
after chronic angiotensin II administration. They found a significant reduction in all
of these parameters after both of the treatments as compared with PBS or AAV-GFP
controls. The team further quantify a significant increase in activated microglia, as
defined by increase OX42 antibody binding, the neuroglial cells tasked with innate
immune responses to pathogens. Taken together these results highlight an important
role for microglia and pro-inflammatory cytokines in AngII induced hypertension within
the PVN (213). In addition to the immunological roles of these cytokines and their
receptors, a large body of evidence suggests a role for them as vital messengers in CNS
regions.214 Ifit1 specifically has been observed in the PVN regions of 6 human donors
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based on a search of the Allen Brain Atlas (2010 Allen Institute for Brain Science).
For this reason, coupled with its other important regulatory roles outlined above,
the PVN was a key region for investigating Ifit1 involvement in hypertension.
Indeed a case could be made for Ifit1 being a consequence of toll-like receptor 4
(TLR4) signal transduction within the PVN. One of the key aspects of innate immunity
is the recognition of pathogen associated molecular pattern (PAMP)s in order to
exact an immediate and coordinated attack on possible pathogens. Cells do this via
pathogen-recognition receptor families (PRRs), such as that of the toll-Like Receptors
(TLRs). The toll surface protein was initially discovered in Drosophila and characterised
for its developmental role in determining the dorsal-ventral axis in embryos.215 Toll
homologues in humans were described in the late 1990s, and became later renamed
as toll-Like Receptors (TLRs). At the time, there was no knowledge of the function
they play in human biology. However, today they are known for their major role of the
innate immune system, an attribute which can be exemplified by how evolutionarily
conserved they are between species.216 Most vertebrates have one ortholog for each of
the TLRs family, and sequencing experiments have revealed them in genomes as diverse
as; chickens (Gallus gallus), Japanese pufferfish (Takifugu rubripes), and the opossum
(Monodelphis domesticus).217 In total, 13 isoforms of TLRs have been identified in
mammalian cells, with each recognising a specific PAMP.218
Upon activation TLRs set off a diverse range biomolecular cascades. There are two
major downstream branches of TLR activation that are characterised by the receptor
adapter proteins they recruit; Myeloid Differentiation Primary Response Protein 88
(MyD88), and TIR-domain-containing Adapter Protein Inducing Interferon (TRIF).
The latter leads to IRF3 activation, inducing the transcription of a broad range of ISGs;
including Ifit family proteins.219,220 It is therefore plausible that Ifit1 upregulation
could be consequence of TLR4 activation, and therefore an indirect consequence of a
well documented mechanism of elevated blood pressure.
Several studies have noted the pharmacological blockade of TLR4, specifically within
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the PVN, to attenuate blood pressure in a genetic model of hypertension. A study in
2015 used a bilateral inhibition of TLR4 within the PVN of the SHR and measured the
blood pressure of the animals.218 Their study firstly revealed SHR rats to have a higher
level of TLR4 in their PVN compared with WKY rats. Furthermore blockade of the
TLR4 using a viral inhibitory peptide (VIPER) significantly lowered the blood pressure
in the SHR animals and attenuated the cardiac hypertrophy often observed within
SHRs. They found TLR4 inhibition to attenuate PICs (e.g. TNF-α), induced Nitric
Oxide Synthase (iNOS) and the activity of the NF-κβ as well as an increase to levels
of anti-inflammatory IL-10 within the PVN of hypertensive rats. Along with these
observations, the team found a significant reduction to circulating plasma Noradrenaline
in the SHRs, a circulating hormone responsible for the constriction of blood vessels to
increase blood pressure.221 As NF-κβ was seen to be significantly reduced, the team
suggest this attenuation to be attributable to a reduced inflammation, in turn leading
to disruption of a detrimental positive feedback cycle involved in the progression of
hypertension. Indeed recent studies have shown AngII induced hypertension to be
blocked by NF-κβ blockade in the PVN.222 The team continue to postulate the method
by which TLR4 blockade to attenuate blood pressure as being via ultimately inhibiting
sympathetic outflow. Noradrenaline is an indirect indicator of sympathetic activity, and
was significantly reduced in the SHRs treated with the TLR4 blockade. Additionally,
TNF-α and NF-κβ have both been implicated in cardiac remodeling in hypertension
and end organ damage respectively.223,224 Strengthening this hypothesis when taken
together with the team’s observations on cardiac hypertrophy.
A study in 2018 built upon these findings using the TAK-242 selective blocker of
TLR4 in the PVN of SD rats fed on a low (0.3%) or high-salt (8%) diet.225 The team
also noted elevated TLR4 expression in the PVN of the hypertensive rats, however
this time in an environmentally induced form of hypertension. This was alongside a
corresponding increase in reactive oxygen species and PICs. The team then used a
different experimental method to block TLR4 expression, and again noted a resulting
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reduction in blood pressure. Excessive reactive oxygen species have a well established
role in increasing sympathetic nerve excitability, ultimately leading to an elevated blood
pressure.226 These findings shed additional light on the method by which TLR4 activity
translates to elevated blood pressure. While these studies did not study the resulting
levels of Ifit1 expression in the PVN, they do implicate the innate immune system that
has been associated to “bottleneck” upon this protein. These studies highlight the need
for further analysis of ifit1’s central role in blood pressure regulation in the PVN and
suggest TLR4 activity in the PVN as having a potential involvement in ifit1 elevated
expression.
6.5.3 FACS Analysis to Isolate Cell Types
Here focus was given to resolving the leukocyte population responsible for the elevated
abundance of Ifit1 mRNA in the SHR blood. Whole blood contains several types of
blood cell that can be broadly grouped into; erythrocytes, leukocytes, and thrombocytes.
Of these, only leukocytes contain a nucleus and are therefore the subject of interest for
studying elevated transcription of a transcript. However in 2009 a revolutionary study,
that making use of microarray analysis, revealed the presence of over 1000 transcripts
in a population of erythrocytes.227 This observation has clear ramifications towards
studying the transcriptome of whole blood. While it should be noted that this study
has not since been repeated, focus needs to be given to anucleated cells such as the
erythrocytes and their progenitors (i.e. reticulocytes) when trying to deduce the source
of a transcript of interest. Probing this 2009 dataset did reveal many the Ifit family
of genes were detected by the microarray analysis. It may therefore be of use here to
include erythrocytes in downstream analyses as they could be the source of the robustly
elevated Ifit1 transcript.
Despite the high availability of rat bloods from other’s experiments, the decision was
made to prioritise optimisation of the above protocol in SHR blood alone. The primary
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reason for this was the well documented increase in total leukocytes in SHR blood when
compared to the WKY blood. A study from 1991 found an increase in leukocytes of
between 50-100% in young, mature, and old hypertensive rats compared with controls.228
The study further showed a 300% increase in activated granulocytes, detected by a
nitroblue tetrazolium reduction, in the SHR. These effects appeared consistent in rats
obtained from colonies in Massachusetts, Denmark and [West] Germany. Therefore
mitigating the various differences related to colony and seasonal variations in leukocyte
counts. For this reason, it seemed pertinent to optimise antibody dilutions for use in
the SHR, so as to prevent; lack of binding due to low concentration or signal saturation
due to over binding with a high concentration.
A series of interesting observations arose from the initial FACS analysis of SHR
and WKY blood cells. The relative abundances of specific leukocytes were significantly
different between the two strains, notably the CD43 High/His48 Low monocytes, and
the natural killer cells. These experiments were conducted with only 3 replicates,
however the variance seen was sufficiently low to produce significant differences between
the two cohorts. The observation of a differential abundance of leukocytes between
these strains is not a new one, as many studies have noted the elevated levels of total
leukocytes in the SHR as compared with the WKY.
NK Cells
Interestingly, the SHR blood saw a significant increase in NK cells as compared with
the WKY blood, where none were detected. Natural killer (NK) cells are non-B, non-T
lymphocytes with the ability for “natural” antigen-independent cytotoxic activity and
as such play a central role in the innate immune system.229 NK cells are responsible for
responding to abnormal or stressed tissue, and can activate or suppress inflammatory
responses via their interactions with T-Cells, Dendritic cells, and macrophages.230With
regards to hypertension, a mutual activation has been demonstrated between NK cells
and monocytes in an angiotensin II-induced model of hypertension.231 This connection
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between NK cells and hypertension was furthered through the observations on vascular
remodeling by Taherzadeh et al, who used a congenic strain bred from C57BL/6 and
BALB/c mice to show those sharing the same NK gene complex had a similar blood
pressure response to a chronic L-NAME-induced hypertension model. This study
highlights the potential role for NK cells in the sensitivity towards nitric oxide synthase
(NOS) inhibited forms of hypertension.
It has been shown in mice that angiotensin II induced inflammation and vascular
dysfunction are associated with an accumulation of natural killer (NK) T cells in
the aortic wall which, upon activation, rapidly release IFN-γ.231 This angiotensin II
caused effect is drastically reduced in Tbx21−/− a transcription factor that drives IFN
production. Due to this massive upregulation in NK cells, coupled with the regulation
of Ifit1 by IFNs, it appears quite probable they could be the source of the upregulated
Ifit1 in the SHR blood. Either directly as the source of Ifit1, or indirectly through the
upregulation of IFNs.
Monocytes
Monocytes also represent another rapid responder to areas of inflammatory response,
where upon activation differentiate to macrophages.232 Unlike NK cells, a great deal of
work has explored the relationship between macrophages and hypertension. Macrophages
are always present within the vessel walls and within the kidney in hypertensives.233
Via the detection of CD43 and His48, the total monocyte population appeared
higher in abundance in the SHR, however this trend did not reach statistical significance
(P=0.053). Based on the validation carried out in Barnett-Vanes et al. (2016), these
two cell surface markers are sufficient to differentiate between two monocyte subtypes;
classical, and non-classical.205 In rats, the CD43 hi and lo monocytes are considered
to be analogous to the mouse Ly6C Lo (non-classical) and Hi (classical) monocytes
respectively.234,235 Classical (CD43hi/His48lo) monocytes represent the most abundant
subtype, and are thought to represent newly released cells from the bone marrow.236
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The non-classical (CD43lo/His48hi) monocytes are lower in abundance at around
40% of the total circulating monocytes, until they expand in inflammatory states.236
This subtype is implicated as playing a role in patrolling the early immune response, tis-
sue repair, and neovascularisation, as well as an increased production of TNFα.237 They
have been dubbed the “sentinels” and “caretakers” of vascular tissue, due to their ability
to recognise and clear dying endothelial cells, maintaining vascular homeostasis.238,239
While this non-classical subtype seem to be primarily involved in a homeostatic caretak-
ing role they have also been seen to contribute to several autoimmune and inflammatory
diseases, such as; rheumatoid arthritis, multiple sclerosis, and aetherosclerosis.240
It was this non-classical subtype that saw a significant increase in abundance within
the SHR blood, an observation that has not previously been noted in this model of
hypertension. Indeed, this specific subtype has been implicated in human hypertension
in a 2018 study conducted by Loperena et al., who used a FACS gating strategy to
quantify monocyte populations in hypertensive and normotensives. The team observed
a progressive decline in classical monocyte populations, and a concomitant increase in
the percentage of non-classical monocytes as levels of hypertension increased.236
The resulting cell populations were sorted directly into trizol, in an attempt to
stabilise the cells and contained RNA as quickly as possible. Following a well established
RNA extraction protocol, as outlined previously, the RNA yield was prohibitively low
and prevented downstream qPCR analysis of Ifit1 expression levels. Due to time
constraints, the samples for this experiment were immediately frozen at -80°C in order
to stabilise them. After conducting a literature review to troubleshoot the protocol,
several groups had noted a significant drop in RNA recovery following the freezing of
the sample-trizol mix with some reporting as much as a 50% reduction in RNA yield.241
A further concern could be the presence of RNases in the vicinity of the FACS
machinery. It was not feasible to thoroughly prepare the instruments to reduce RNase
activity. However, some protocols suggest adding an RNase inhibitors to the FACS
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suspension in order to mitigate any RNA degradation.242 This approach presents a
simple modification to the protocol followed above, and may well yield higher quality
RNA for downstream analysis.
6.5.4 FACS Analysis on Permeabilised Cells
Due to the resulting RNA being of poor quality, qPCR could not shed light on the
relative abundances of Ifit1 expression within the different cell populations. The
experiment did however yield a novel insight into the relative abundances of leukocytes,
as outlined above. In order to overcome the poor RNA yield, a change in approach was
attempted. Rather than physically isolating the live cells before extracting RNA, cells
were permeabilised in order to allow antibodies to access the intracellular Ifit1. This
way, Ifit1 positive cells could be detected and cross-referenced with the signal profiles of
cell surface markers used to discern between leukocyte types. Furthermore, the act of
permeabilisation required the fixation of the cells; thereby killing them. This fixation
approach did not present as many concerns towards cell/transcript stability that were
present for the live-cell sorting approach.
This approach was unsuccessful in resolving Ifit1 containing cell populations, due
to the low levels of Ifit1 positive cells being detected. There could be many reasons
behind this, all centering on one of two possibilities; either the experimental approach
failed to detect the expressed Ifit1 protein, or Ifit1 protein is not expressed at levels
comparable to the transcript.
It must be noted, that here previous analysis has been conducted on transcript
levels of Ifit1 within the blood and PVN. A clear and robust increase in expression is
occurring between the strains being tested, however this expression may not result in
different levels of functional protein. A good review on the matter was conducted by
Vogel and Marcotte (2012), who showed a correlation between expression levels and
resulting proteins to be as little as 40%.243 There exist many processes of translational
Page 198
Chapter 6. Characterisation of Ifit1
control between transcript expression and function protein, all of which present a stage
at which a disparity can arise. mRNA stability, Protein stability, and the rate of mRNA
transcription versus protein translation all factor into the correlation observed.
Focusing biomarker discovery work on transcripts is a valid approach if they stably
and reliably act as a metric for physiological changes, as observed here. However, no
conclusions can be drawn on Ifit1’s specific role within hypertension without the use
of a reliable antibody that is robustly validated. Transcriptomic analysis therefore
presents a useful way to identify potential candidates for down-stream work at the level
of the protein.
6.5.5 In Silico Characterisation of Ifit1
Since the robust increase in ifit1 mRNA was present in the juvenile SHR at only 4 weeks,
and previous blood pressure measurements of the SHR suggest it to be hypertensive at
this age, it remains unclear whether Ifit1 is causative, resultant or neither with regards
to hypertension.
The high sequencing depth, coupled with the relatively large number of replicates,
enabled me to look towards the NGS reads to resolve and nucleotide specific changes
between the WKY and SHR Ifit1 mRNA in the blood. I was therefore able to characterise
the genetic differences that exist between the WKY and SHR ifit1 gene, and furthermore
whether these differences are responsive for the altered expression levels. With this
in mind, and using the BAMtools suite of bioinformatic tools, I was able to merge all
of the previously aligned BAM files from the juvenile WKY and SHR blood RNAseq
experiment (n=6). This resulted in two BAM files containing all of the reads, aligned
to the RN6 reference sequence, across all WKY samples and all SHR samples for a
straightforward downstream analysis. The WKY and SHR compiled BAM files where
sorted and indexed using the bamtools index command. Both the .bam aligned reads
and the .bam.bai indexes could be read into the Integrative Genome Viewer (Version
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2.4.4, Broad Institute California).244,245 As these were both aligned and indexed against
the same reference sequence (RN6), a simple search for “ifit1” localises the viewing
panel to the locus of ifit1 in the rat genome. Once all reads are visualised against the
ifit1 locus, a coverage histogram could be generated. Upon first assessment, and as
expected with the predicted upregulation observed in chapter 1, there is a consistently
higher number of RNAseq reads aligning to the gene from the SHR samples, than in
the WKY samples. What is interesting, with regards to the WKY sample reads, is the
relatively short span of ifit1 gene towards the 5’ that shows a high number of aligned
reads (reaching 1789 overlapping reads).
The IGV software also allows for single nucleotide polymorphism calling (SNP),
by comparing each read base against the reference genome. For the above coverage
histogram, an allele frequency threshold can be arbitrarily set to reveal the site having
that proportion of alleles called differently to the reference genome. Any loci whose
proportion of reads are above this threshold will highlight as red on the coverage
histogram (Table 6.14). The default threshold setting is left at 0.2, meaning over
20% of reads on that particular locus have to differ from the reference base for the
locus to highlight red. To increase stringency, and assess how prevalent any discovered
SNPs are within each strain, I iteratively increased this threshold to inspect the result-
ing coverage profiles. At a threshold of 1.0, meaning an differential base calling event
in every single read within the SHR population, 3 loci were highlighted as being different.
Locus Percentage of reads SNP Amino Acid Change Intron/Exon
Chr1:252,944,180 100% C → T S → L Exon
Chr1:252,944,345 87% C → T S → L Exon
Chr1:252,944,471 99% A → G N → S Exon
Chr1:252,944,488 100% A → G T → A Exon
Chr1:252,945,968 100% G → T R → I Exon
Table 6.14: Location of single nucleotide polymorphisms in SHR Ifit1 transcripts, as compared
against the RN6 reference genome
However, it must be noted that as there were no reads from the WKY samples
covering the above loci, it is not possible to assess whether these SNPs were truly part
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of a different genetic profile in the SHR. They may well be a part of a genetic profile
shared between the strains, yet different from the RN6 reference genome the bases are
being compared against. When this threshold was dropped to 0.87 (87% of reads), two
more loci were highlighted. What is interesting is that one of these aligns with the only
section of the ifit1 gene that saw a large number of reads within the WKY samples.
At Chr1:252,944,345, an exchange of Cytosine → Thymine was observed in the SHR
across those 87% of reads covering that locus. For the same site for the WKY reads,
no such SNP has taken place. This is therefore the only site where evidence exists to
suggest a SNP existing between the WKY and SHR at this site.
At this point it should be noted that the sequence-specific error profile of RNAseq
data is in no way 100% accurate. This is a major consideration when attempting de
novo assembly or indeed the SNP calling attempted here. The potential issues with
RNAseq inaccuracy are discussed earlier in greater length, however SNP calling is most
reliant on preventing substitution-type miscalls of bases. A comparison study in 2011
looked into the various different sequencing platforms and estimated miscall rates to be
≥0.1% of bases. This translates to a conservative 1 miscalled base in every 1000 bases
sequenced.245 While this number can be greater depending on platform used to sequence,
our laboratory uses a Phred cutoff score of >Q30, translating to 0.1% miscalls per base.
This threshold ensures the samples included in our analyses are at what is considered
to be the current benchmark of accuracy given the library preparation chemistry at
the time of sequencing. Illumina purports sequencing phred scores can often exceed
this score, however it is seldom reported in the literature. Another consideration with
base miscalls and phred score, is that this is calculated as an average of the entire read
length. This becomes a problem because the miscall error rate tends to increase along
the read length, as outlined in section 1.5.2 (Figure 1.6).246 For this reason, a read
with a Phred Q30 score could on the surface appear sufficient to pass the stringent
exclusion criteria for a given study. However, if this is an average of a read of Q40
between bases 1-100 and Q10 for the bases 101-150, the latter section of the read has
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a significantly large error rate of 1 miscall per 10 bases. This should therefore be a
consideration when evaluating RNAseq data, and a level of stringency should exist
that is sufficient to mitigate these error rates. Since these SNPs appear in >80% of
reads, coupled with a high read depth, for each loci it seems highly unlikely that these
could be miscalls. Probing the ENSEMBL database for Ifit1 reveals 25 SNPs have been
identified within the region. All 5 of the SNPs detected here have also been listed as
part of this database however none of which were linked with any publications discussing
their potential importance. Further assessment of these potentially different SNPs
could be achieved by PCR amplification of the ifit1 region, before Sanger sequencing to
reveal any differences in the ifit1 gene between the WKY and SHR strains. Due to the
implication of many disease states with SNPs, looking towards these polymorphisms
could prove an important direction to take for predicting disease susceptibility.
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7.0.1 Furthering the validation of Ifit1
This body of work has laid a strong foundation in furthering the discovery of novel
biomarkers of hypertension. Using an optimised approach towards RNAseq analysis,
a candidate list was produced of transcripts that were differentially expressed in the
blood between the WKY and SHR strains. From this list several candidates were
taken forward and validated using independent experimental approaches and additional
models of hypertension. However, one of the key questions remaining unanswered is
the specific aetiology of hypertension that Ifit1 expression is indicative of. It is clear
that Ifit1 is abundantly expressed in a genetic model of hypertension, unlike any of its
other protein family members. However when attempting to environmentally induce
hypertension Ifit1 saw a counterintuitive decline in expression. It follows that Ifit1
may simply be a metric for genetic predisposition, and not one of blood pressure in its
entirety. Here, only two genetic models of hypertension were assessed; the SHR and the
BHR. Both of which are so closely related that it is not possible to discern whether Ifit1
upregulation is a relfection of the SHR lineage or indeed a true biomarker of genetic
hypertension. Several genetically distinct models of hypertension exist, as shown in
figure 5.4. By examining the expression of Ifit1 in these strains, it should be possible
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to conclude whether or not Ifit1 is indeed a metric of hypertension or simply the SHR
strain itself. In order to further reconcile this uncertainty, efforts should be made to
obtain the Dahl-Salt sensitive and salt resistant strains for analysis. This model of
hypertension would allow for an assessment of the balance between environmentally
induced and genetically predisposed forms of elevated blood pressure. Another area to
explore would be the role of ifit1 in response to certain immune challenges. Due to its
well characterised involvement in the innate immune response, its elevated expression in
a human population may be indicative of certain immune challenges. It is therefore likely
that expression levels may need to be assessed in conjunction with other non-immune
responsive genes to ensure its expression is not resulting on infection. It would be
possible to mitigate this concern by looking solely are the genomic level for features
associated with hypertension, such as SNPs. There exists a wealth of literature studying
the correlations between polymorphisms and disease states. However genomic studies
will only show genetic predisposition towards hypertension, and not the contribution of
the many lifestyle factors established to lead to elevated blood pressure. It was therefore
the aim of this current body of work to attempt to look towards the transcriptome as a
way of reconciling this genome-environment interface.
Furthermore, due to the high-throughput nature of this study there exist many other
candidate biomarkers that may well be successfully taken through the various validation
strategies outlined here. Herein lies the novel benefit of RNAseq technologies; to guide
biological discovery in a manner free from bias. As more studies are produced, a greater
level of data mining can occur to elucidate important differences in gene expression,
allowing for an increasingly guided selection of candidate biomarkers to be made.
7.0.2 The Aetiology of Hypertension
This study set out with the aim of identifying novel prognostic biomarkers of hyperten-
sion. Although a biomarker only needs to present an objective measure of a disease
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state, it would be of interest to further characterise any mechanistic involvement in
hypertension, if at all. By exploring the biology of these biomarkers in the context of
blood pressure regulation it may enable us to shed light on how hypertension arises.
While results were inconclusive, preliminary work has been carried out to ascertain
Ifit1’s involvement in hypertension by characterising the leukocyte population responsible
for its expression. Future research should therefore build upon this to enable a source
to be identified such that a more guided literature review of leukocyte involvement in
hypertension be conducted.
7.0.3 Translating the findings to a human cohort
From these findings it is now of great interest to expand validation studies to assess how
suitable these biomarkers are for a metric of human hypertension. With this in mind,
the quality in organ donation (QUOD) initiative presented a novel opportunity to test
biomarkers in human tissues from patients with comprehensive medical histories noted.
The initiative was formed as part of the Nuffield Department of Surgical Sciences
with the aim of identifying pathways of injury and repair in donor organs, in the hopes of
mitigating any arising complications to organ recipients. It is well known that patients
of donated organs from these with high blood pressure exhibit a lower survival rate.247
This present study aims to see if novel changes taking place in the blood can help to
identify those that have a higher blood pressure. This would enable improved screening
of postmortem donors where it is no longer possible to measure blood pressure for
the biomarkers associated with chronically elevated blood pressure as identified here.
Furthermore, this study is also looking towards prognostic changes that occur before
the onset of high blood pressure. This would allow for treatment plans to be put in
place prior to blood pressure rising and putting strain on internal organs.
Due to the operating of the initiative, blood tissue was not available from donors.
However, as the spleen is heavily vascularised it will be used as a proxy measurement
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of blood transcripts. At the time of writing, ethical approval was granted for usage of
these tissues for biomarker validation. From an initial list of 364 potential male donors,
40 individual samples have been selected based on the clinical data provided in order
to conduct a pilot study. This was carried out by narrowing down the total potential
donor list to those with no history of smoking, or cardiovascular disease and binned
into those with documented hypertension and those with no history of hypertension.
From this narrowed list of potential candidates 20 patients were selected from either
the hypertensive or normotensive cohorts based on how comprehensive their medical
history was.
Tissues have since been received from the QUOD biobank and are currently stored
at -80°C ready for RNA extraction and quantification. Linear regression modelling
will then enable us to assess whether any correlations between expression and blood
pressure exist. This will allow the direct assessment of how suitable our biomarkers are
in a human population, and to further assess how well transcripts obtained post mortem
correlate with patient blood pressure pre-mortem. It therefore presents an interesting
avenue for furthering research into biomarkers of hypertension.
7.0.4 Concluding remarks
Given the significant health and financial impact of essential hypertension, coupled
with an ever increasing population, work towards a better diagnostic approach is of
huge importance. Only with continued study towards identifying the aetiology of
hypertension will it result in improved diagnostic assessment, ultimately leading to
a therapeutic design centred on prophylaxis rather than symptomatic management.
With this in mind, High-throughput ’omics’ approaches hold a great deal of promise in
providing a thorough characterisation of disease states. In diagnosing patients earlier in
the disease’s progression, sufficient preventative steps can be put in place to minimise




Percentage of Aligned Reads (%)
Reads Aligned Multiple Alignments Discordant Rate Concordant Rate
WKY1 66.7 0.4 62.8 23.2
WKY2 67.5 0.4 60.7 25.1
WKY3 63.3 0.7 59.5 24.5
SHR1 68.2 0.9 44.5 35.1
SHR2 68.1 1.2 41.3 37.3
SHR3 61.7 1.3 45.5 31.9
Mean All 65.92 0.85 52.38 29.52
WKY 65.83 0.57 61.00 24.27
SHR 66.00 1.13 43.77 34.77
Table A.1: Post-Trimming Alignment Rates for n=3 RNAseq Dataset
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Reference: Zheng Zhang, Scott Schwartz, Lukas Wagner, and
Webb Miller (2000), "A greedy algorithm for aligning DNA
sequences", J Comput Biol 2000; 7(1-2):203-14.
Reference for database indexing: Aleksandr Morgulis, George
Coulouris, Yan Raytselis, Thomas L. Madden, Richa Agarwala,
Alejandro A. Schaffer (2008), "Database Indexing for
Production MegaBLAST Searches", Bioinformatics 24:1757-1764.
Job Title: Ifit1A_MERGE
Query: None Query ID: lcl|Query_138329 Length: 1444
Rattus norvegicus interferon-induced protein with tetratricopeptide repeats 1 (Ifit1), mRNA
Sequence ID: NM_020096.1 Length: 2174
Number of Matches: 1
See 1 more title(s):
Rattus norvegicus mRNA for glucocorticoid-attenuated response gene 16 product (garg16 gene)
Sequence ID: AJ276893.1 Length: 2174
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Number of Matches:
Range 1: 86 to 1490
Score:2562 bits(1387), Expect:0.0,
Identities:1399/1405(99\%), Gaps:0/1405(0\%), Strand: Plus/Plus
Query 31 GCCACCATGGGAGAGAATGCTGGTGGTGACCAGGTCATGGAGAATCTGCTTCAGCTGAGA 90
|| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 86 GCAACCATGGGAGAGAATGCTGGTGGTGACCAGGTCATGGAGAATCTGCTTCAGCTGAGA 145
Query 91 TGTCACTTCACATGGGGCCTGCTCTTTGaaaaaaaTGACATACCTGATTTGGAAGTGAGG 150
|||||||||||||||||||||||||| |||||||||||||||||||||||||||||||||
Sbjct 146 TGTCACTTCACATGGGGCCTGCTCTTCGAAAAAAATGACATACCTGATTTGGAAGTGAGG 205
Query 151 ATCTCAGAGCAGGTCCAGTTCCTTGACATCAAGAACTCACTGGGGATGCACAACCTCCAG 210
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 206 ATCTCAGAGCAGGTCCAGTTCCTTGACATCAAGAACTCACTGGGGATGCACAACCTCCAG 265
Query 211 GCCTACGTGAGACACCTGAAAGGTGAGCAGGAGGAAGCCCTGCAGAGCTTGAAAGAGGCT 270
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 266 GCCTACGTGAGACACCTGAAAGGTGAGCAGGAGGAAGCCCTGCAGAGCTTGAAAGAGGCT 325
Query 271 GAAGCCTTGATTGAGGGAGAGCAGTTGGGCAAGAGAAGCCTGGTGACCTGGGGCAACTGT 330
||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 326 GAAGCCTTGATCGAGGGAGAGCAGTTGGGCAAGAGAAGCCTGGTGACCTGGGGCAACTGT 385
Query 331 GCCTGGGTGCATTACCACAGGGGCAGCTTGGCAGAAGCCCAGATCTACCTGGACAAGGTG 390
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 386 GCCTGGGTGCATTACCACAGGGGCAGCTTGGCAGAAGCCCAGATCTACCTGGACAAGGTG 445
Query 391 GAGAATGTTTGCAGGGAGTTCTCAAGTCCCTTCCGCTACAGGATGGAGTGTGCTGAGATA 450
||||||||||||||||| ||||||||||||||||||||||||||||||||||||||||||
Sbjct 446 GAGAATGTTTGCAGGGAATTCTCAAGTCCCTTCCGCTACAGGATGGAGTGTGCTGAGATA 505
Query 451 GACTGTGAGGAAGGCTGGGCCTTGCTGAAGTGTGGAGGAAGTAACTATATGCGAGCCATG 510
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 506 GACTGTGAGGAAGGCTGGGCCTTGCTGAAGTGTGGAGGAAGTAACTATATGCGAGCCATG 565
Query 511 GCCTGCTTTGCAAAGGCTCTGCAGGTGGACCCAGAAAACCCTGAGTACAATGCTGGCTAT 570
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 566 GCCTGCTTTGCAAAGGCTCTGCAGGTGGACCCAGAAAACCCTGAGTACAATGCTGGCTAT 625
Query 571 GCAGTTGTGGCCTATCGCCAAGATTTCGATGACAACCATGTTTCTCTAGAACCTCTAAGG 630
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 626 GCAGTTGTGGCCTATCGCCAAGATTTCGATGACAACCATGTTTCTCTAGAACCTCTAAGG 685
Query 631 AAGGCTGTCAGGTTAAATCCAGAAGATCCACACCTTAAAGTTCTCCTTGCTCTAAAGCTT 690
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 686 AAGGCTGTCAGGTTAAATCCAGAAGATCCACACCTTAAAGTTCTCCTTGCTCTAAAGCTT 745
Query 691 CAGGATTTAGGGGAACAAGATGAAGCAGAAACACACATTGAAGAAGCCCTCAGCAGCACA 750
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 746 CAGGATTTAGGGGAACAAGATGAAGCAGAAACACACATTGAAGAAGCCCTCAGCAGCACA 805
Query 751 TCTTGCCAAAGCTATGTCTTTCGCTACGCAGCCAAGTATTTCCGCCGGAAAGGTGACATA 810
||||||||||||||||||||||||||||||||||| ||||||||||||||||||||||||
Sbjct 806 TCTTGCCAAAGCTATGTCTTTCGCTACGCAGCCAAATATTTCCGCCGGAAAGGTGACATA 865
Query 811 AACGAAGCTCTTCATCTTCTACACAGGGCCTTGCAGACGTCACCTTCCTCTGGCTACCTA 870
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 866 AACGAAGCTCTTCATCTTCTACACAGGGCCTTGCAGACGTCACCTTCCTCTGGCTACCTA 925
Query 871 CATTACCAAAAAGGGCTCTGTTACAAGCAACAGATGATCCAACTGAAGACATCTGGAAAC 930
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 926 CATTACCAAAAAGGGCTCTGTTACAAGCAACAGATGATCCAACTGAAGACATCTGGAAAC 985
Query 931 AGGCAGGCCAGAAGGCAGGAGAATATACAGGAATTGGCACATCAGGCCATTTGTGAATTT 990
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 986 AGGCAGGCCAGAAGGCAGGAGAATATACAGGAATTGGCACATCAGGCCATTTGTGAATTT 1045
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Query 991 CAAGAGACTTTGAATCTGAGGCCCACATTTGAGATGGCTTACGTTTGCATGGCTGAAATG 1050
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 1046 CAAGAGACTTTGAATCTGAGGCCCACATTTGAGATGGCTTACGTTTGCATGGCTGAAATG 1105
Query 1051 CAGGCAGAAATTGGCCAATATGAAGAAGCAGAGGGAAATTTCCAGGAGGCCCTGAACCTC 1110
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 1106 CAGGCAGAAATTGGCCAATATGAAGAAGCAGAGGGAAATTTCCAGGAGGCCCTGAACCTC 1165
Query 1111 AACAACCTTGTAGCCCACATAGAGCAGGATATTCATTTCCGCTACGGCCGTTTCCAACAA 1170
|||||||||||||||||||||||||||||||||||||||||||||||||||| |||||||
Sbjct 1166 AACAACCTTGTAGCCCACATAGAGCAGGATATTCATTTCCGCTACGGCCGTTCCCAACAA 1225
Query 1171 TTTCATAAGAAGTCAGAAGACAAGGCAATCACTCACTACTTAAAAGGTCTAAAACTAGAA 1230
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 1226 TTTCATAAGAAGTCAGAAGACAAGGCAATCACTCACTACTTAAAAGGTCTAAAACTAGAA 1285
Query 1231 GAGAAGTCCTTTGCCTGGAGGAAACTACTCACAGCTTTGGAGAAAGTGGCTGAAAGACGT 1290
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 1286 GAGAAGTCCTTTGCCTGGAGGAAACTACTCACAGCTTTGGAGAAAGTGGCTGAAAGACGT 1345
Query 1291 GTTCGCCAGAATGTCCGGCTTGTGGAGAGCACCAGCCTTCTTGGACTGGTCTTCAAACTG 1350
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 1346 GTTCGCCAGAATGTCCGGCTTGTGGAGAGCACCAGCCTTCTTGGACTGGTCTTCAAACTG 1405
Query 1351 AAAGGGCAGGAGATGAAGGCCCTGCTTTACTATGAGAAGGCCCTGAGGCTCTCTGGGGAA 1410
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 1406 AAAGGGCAGGAGATGAAGGCCCTGCTTTACTATGAGAAGGCCCTGAGGCTCTCTGGGGAA 1465
Query 1411 ATGAACCCTGCATTTTGAATGCAGC 1435
|||||||||||||||||||||||||
























Query: None Query ID: lcl|Query_241007 Length: 1444
Rattus norvegicus interferon-induced protein with tetratricopeptide repeats 1 (Ifit1), mRNA
Sequence ID: NM_020096.1 Length: 2174
Number of Matches: 1
See 1 more title(s):
Rattus norvegicus mRNA for glucocorticoid-attenuated response gene 16 product (garg16 gene)
Sequence ID: AJ276893.1 Length: 2174
Number of Matches:
Range 1: 86 to 1490
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Score:2562 bits(1387), Expect:0.0,
Identities:1399/1405(99\%), Gaps:0/1405(0\%), Strand: Plus/Plus
Query 31 GCCACCATGGGAGAGAATGCTGGTGGTGACCAGGTCATGGAGAATCTGCTTCAGCTGAGA 90
|| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 86 GCAACCATGGGAGAGAATGCTGGTGGTGACCAGGTCATGGAGAATCTGCTTCAGCTGAGA 145
Query 91 TGTCACTTCACATGGGGCCTGCTCTTTGaaaaaaaTGACATACCTGATTTGGAAGTGAGG 150
|||||||||||||||||||||||||| |||||||||||||||||||||||||||||||||
Sbjct 146 TGTCACTTCACATGGGGCCTGCTCTTCGAAAAAAATGACATACCTGATTTGGAAGTGAGG 205
Query 151 ATCTCAGAGCAGGTCCAGTTCCTTGACATCAAGAACTCACTGGGGATGCACAACCTCCAG 210
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 206 ATCTCAGAGCAGGTCCAGTTCCTTGACATCAAGAACTCACTGGGGATGCACAACCTCCAG 265
Query 211 GCCTACGTGAGACACCTGAAAGGTGAGCAGGAGGAAGCCCTGCAGAGCTTGAAAGAGGCT 270
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 266 GCCTACGTGAGACACCTGAAAGGTGAGCAGGAGGAAGCCCTGCAGAGCTTGAAAGAGGCT 325
Query 271 GAAGCCTTGATTGAGGGAGAGCAGTTGGGCAAGAGAAGCCTGGTGACCTGGGGCAACTGT 330
||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 326 GAAGCCTTGATCGAGGGAGAGCAGTTGGGCAAGAGAAGCCTGGTGACCTGGGGCAACTGT 385
Query 331 GCCTGGGTGCATTACCACAGGGGCAGCTTGGCAGAAGCCCAGATCTACCTGGACAAGGTG 390
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 386 GCCTGGGTGCATTACCACAGGGGCAGCTTGGCAGAAGCCCAGATCTACCTGGACAAGGTG 445
Query 391 GAGAATGTTTGCAGGGAGTTCTCAAGTCCCTTCCGCTACAGGATGGAGTGTGCTGAGATA 450
||||||||||||||||| ||||||||||||||||||||||||||||||||||||||||||
Sbjct 446 GAGAATGTTTGCAGGGAATTCTCAAGTCCCTTCCGCTACAGGATGGAGTGTGCTGAGATA 505
Query 451 GACTGTGAGGAAGGCTGGGCCTTGCTGAAGTGTGGAGGAAGTAACTATATGCGAGCCATG 510
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 506 GACTGTGAGGAAGGCTGGGCCTTGCTGAAGTGTGGAGGAAGTAACTATATGCGAGCCATG 565
Query 511 GCCTGCTTTGCAAAGGCTCTGCAGGTGGACCCAGAAAACCCTGAGTACAATGCTGGCTAT 570
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 566 GCCTGCTTTGCAAAGGCTCTGCAGGTGGACCCAGAAAACCCTGAGTACAATGCTGGCTAT 625
Query 571 GCAGTTGTGGCCTATCGCCAAGATTTCGATGACAACCATGTTTCTCTAGAACCTCTAAGG 630
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 626 GCAGTTGTGGCCTATCGCCAAGATTTCGATGACAACCATGTTTCTCTAGAACCTCTAAGG 685
Query 631 AAGGCTGTCAGGTTAAATCCAGAAGATCCACACCTTAAAGTTCTCCTTGCTCTAAAGCTT 690
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 686 AAGGCTGTCAGGTTAAATCCAGAAGATCCACACCTTAAAGTTCTCCTTGCTCTAAAGCTT 745
Query 691 CAGGATTTAGGGGAACAAGATGAAGCAGAAACACACATTGAAGAAGCCCTCAGCAGCACA 750
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 746 CAGGATTTAGGGGAACAAGATGAAGCAGAAACACACATTGAAGAAGCCCTCAGCAGCACA 805
Query 751 TCTTGCCAAAGCTATGTCTTTCGCTACGCAGCCAAGTATTTCCGCCGGAAAGGTGACATA 810
||||||||||||||||||||||||||||||||||| ||||||||||||||||||||||||
Sbjct 806 TCTTGCCAAAGCTATGTCTTTCGCTACGCAGCCAAATATTTCCGCCGGAAAGGTGACATA 865
Query 811 AACGAAGCTCTTCATCTTCTACACAGGGCCTTGCAGACGTCACCTTCCTCTGGCTACCTA 870
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 866 AACGAAGCTCTTCATCTTCTACACAGGGCCTTGCAGACGTCACCTTCCTCTGGCTACCTA 925
Query 871 CATTACCAAAAAGGGCTCTGTTACAAGCAACAGATGATCCAACTGAAGACATCTGGAAAC 930
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 926 CATTACCAAAAAGGGCTCTGTTACAAGCAACAGATGATCCAACTGAAGACATCTGGAAAC 985
Query 931 AGGCAGGCCAGAAGGCAGGAGAATATACAGGAATTGGCACATCAGGCCATTTGTGAATTT 990
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 986 AGGCAGGCCAGAAGGCAGGAGAATATACAGGAATTGGCACATCAGGCCATTTGTGAATTT 1045
Query 991 CAAGAGACTTTGAATCTGAGGCCCACATTTGAGATGGCTTACGTTTGCATGGCTGAAATG 1050
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||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 1046 CAAGAGACTTTGAATCTGAGGCCCACATTTGAGATGGCTTACGTTTGCATGGCTGAAATG 1105
Query 1051 CAGGCAGAAATTGGCCAATATGAAGAAGCAGAGGGAAATTTCCAGGAGGCCCTGAACCTC 1110
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 1106 CAGGCAGAAATTGGCCAATATGAAGAAGCAGAGGGAAATTTCCAGGAGGCCCTGAACCTC 1165
Query 1111 AACAACCTTGTAGCCCACATAGAGCAGGATATTCATTTCCGCTACGGCCGTTTCCAACAA 1170
|||||||||||||||||||||||||||||||||||||||||||||||||||| |||||||
Sbjct 1166 AACAACCTTGTAGCCCACATAGAGCAGGATATTCATTTCCGCTACGGCCGTTCCCAACAA 1225
Query 1171 TTTCATAAGAAGTCAGAAGACAAGGCAATCACTCACTACTTAAAAGGTCTAAAACTAGAA 1230
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 1226 TTTCATAAGAAGTCAGAAGACAAGGCAATCACTCACTACTTAAAAGGTCTAAAACTAGAA 1285
Query 1231 GAGAAGTCCTTTGCCTGGAGGAAACTACTCACAGCTTTGGAGAAAGTGGCTGAAAGACGT 1290
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 1286 GAGAAGTCCTTTGCCTGGAGGAAACTACTCACAGCTTTGGAGAAAGTGGCTGAAAGACGT 1345
Query 1291 GTTCGCCAGAATGTCCGGCTTGTGGAGAGCACCAGCCTTCTTGGACTGGTCTTCAAACTG 1350
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 1346 GTTCGCCAGAATGTCCGGCTTGTGGAGAGCACCAGCCTTCTTGGACTGGTCTTCAAACTG 1405
Query 1351 AAAGGGCAGGAGATGAAGGCCCTGCTTTACTATGAGAAGGCCCTGAGGCTCTCTGGGGAA 1410
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 1406 AAAGGGCAGGAGATGAAGGCCCTGCTTTACTATGAGAAGGCCCTGAGGCTCTCTGGGGAA 1465
Query 1411 ATGAACCCTGCATTTTGAATGCAGC 1435
|||||||||||||||||||||||||


























Sequences producing significant alignments: (Bits) Value ident
NM_020096.1 Rattus norvegicus interferon-induced protein with ... 2562 0.0 100\%
ALIGNMENTS
>NM_020096.1 Rattus norvegicus interferon-induced protein with tetratricopeptide
repeats 1 (Ifit1), mRNA
AJ276893.1 Rattus norvegicus mRNA for glucocorticoid-attenuated response
gene 16 product (garg16 gene)
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Length=2174
Score = 2562 bits (1387), Expect = 0.0
Identities = 1399/1405 (99\%), Gaps = 0/1405 (0\%)
Strand=Plus/Plus
Query 31 GCCACCATGGGAGAGAATGCTGGTGGTGACCAGGTCATGGAGAATCTGCTTCAGCTGAGA 90
|| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 86 GCAACCATGGGAGAGAATGCTGGTGGTGACCAGGTCATGGAGAATCTGCTTCAGCTGAGA 145
Query 91 TGTCACTTCACATGGGGCCTGCTCTTTGaaaaaaaTGACATACCTGATTTGGAAGTGAGG 150
|||||||||||||||||||||||||| |||||||||||||||||||||||||||||||||
Sbjct 146 TGTCACTTCACATGGGGCCTGCTCTTCGAAAAAAATGACATACCTGATTTGGAAGTGAGG 205
Query 151 ATCTCAGAGCAGGTCCAGTTCCTTGACATCAAGAACTCACTGGGGATGCACAACCTCCAG 210
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 206 ATCTCAGAGCAGGTCCAGTTCCTTGACATCAAGAACTCACTGGGGATGCACAACCTCCAG 265
Query 211 GCCTACGTGAGACACCTGAAAGGTGAGCAGGAGGAAGCCCTGCAGAGCTTGAAAGAGGCT 270
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 266 GCCTACGTGAGACACCTGAAAGGTGAGCAGGAGGAAGCCCTGCAGAGCTTGAAAGAGGCT 325
Query 271 GAAGCCTTGATTGAGGGAGAGCAGTTGGGCAAGAGAAGCCTGGTGACCTGGGGCAACTGT 330
||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 326 GAAGCCTTGATCGAGGGAGAGCAGTTGGGCAAGAGAAGCCTGGTGACCTGGGGCAACTGT 385
Query 331 GCCTGGGTGCATTACCACAGGGGCAGCTTGGCAGAAGCCCAGATCTACCTGGACAAGGTG 390
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 386 GCCTGGGTGCATTACCACAGGGGCAGCTTGGCAGAAGCCCAGATCTACCTGGACAAGGTG 445
Query 391 GAGAATGTTTGCAGGGAGTTCTCAAGTCCCTTCCGCTACAGGATGGAGTGTGCTGAGATA 450
||||||||||||||||| ||||||||||||||||||||||||||||||||||||||||||
Sbjct 446 GAGAATGTTTGCAGGGAATTCTCAAGTCCCTTCCGCTACAGGATGGAGTGTGCTGAGATA 505
Query 451 GACTGTGAGGAAGGCTGGGCCTTGCTGAAGTGTGGAGGAAGTAACTATATGCGAGCCATG 510
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 506 GACTGTGAGGAAGGCTGGGCCTTGCTGAAGTGTGGAGGAAGTAACTATATGCGAGCCATG 565
Query 511 GCCTGCTTTGCAAAGGCTCTGCAGGTGGACCCAGAAAACCCTGAGTACAATGCTGGCTAT 570
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 566 GCCTGCTTTGCAAAGGCTCTGCAGGTGGACCCAGAAAACCCTGAGTACAATGCTGGCTAT 625
Query 571 GCAGTTGTGGCCTATCGCCAAGATTTCGATGACAACCATGTTTCTCTAGAACCTCTAAGG 630
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 626 GCAGTTGTGGCCTATCGCCAAGATTTCGATGACAACCATGTTTCTCTAGAACCTCTAAGG 685
Query 631 AAGGCTGTCAGGTTAAATCCAGAAGATCCACACCTTAAAGTTCTCCTTGCTCTAAAGCTT 690
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 686 AAGGCTGTCAGGTTAAATCCAGAAGATCCACACCTTAAAGTTCTCCTTGCTCTAAAGCTT 745
Query 691 CAGGATTTAGGGGAACAAGATGAAGCAGAAACACACATTGAAGAAGCCCTCAGCAGCACA 750
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 746 CAGGATTTAGGGGAACAAGATGAAGCAGAAACACACATTGAAGAAGCCCTCAGCAGCACA 805
Query 751 TCTTGCCAAAGCTATGTCTTTCGCTACGCAGCCAAGTATTTCCGCCGGAAAGGTGACATA 810
||||||||||||||||||||||||||||||||||| ||||||||||||||||||||||||
Sbjct 806 TCTTGCCAAAGCTATGTCTTTCGCTACGCAGCCAAATATTTCCGCCGGAAAGGTGACATA 865
Query 811 AACGAAGCTCTTCATCTTCTACACAGGGCCTTGCAGACGTCACCTTCCTCTGGCTACCTA 870
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 866 AACGAAGCTCTTCATCTTCTACACAGGGCCTTGCAGACGTCACCTTCCTCTGGCTACCTA 925
Query 871 CATTACCAAAAAGGGCTCTGTTACAAGCAACAGATGATCCAACTGAAGACATCTGGAAAC 930
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 926 CATTACCAAAAAGGGCTCTGTTACAAGCAACAGATGATCCAACTGAAGACATCTGGAAAC 985
Query 931 AGGCAGGCCAGAAGGCAGGAGAATATACAGGAATTGGCACATCAGGCCATTTGTGAATTT 990
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 986 AGGCAGGCCAGAAGGCAGGAGAATATACAGGAATTGGCACATCAGGCCATTTGTGAATTT 1045
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Query 991 CAAGAGACTTTGAATCTGAGGCCCACATTTGAGATGGCTTACGTTTGCATGGCTGAAATG 1050
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 1046 CAAGAGACTTTGAATCTGAGGCCCACATTTGAGATGGCTTACGTTTGCATGGCTGAAATG 1105
Query 1051 CAGGCAGAAATTGGCCAATATGAAGAAGCAGAGGGAAATTTCCAGGAGGCCCTGAACCTC 1110
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 1106 CAGGCAGAAATTGGCCAATATGAAGAAGCAGAGGGAAATTTCCAGGAGGCCCTGAACCTC 1165
Query 1111 AACAACCTTGTAGCCCACATAGAGCAGGATATTCATTTCCGCTACGGCCGTTTCCAACAA 1170
|||||||||||||||||||||||||||||||||||||||||||||||||||| |||||||
Sbjct 1166 AACAACCTTGTAGCCCACATAGAGCAGGATATTCATTTCCGCTACGGCCGTTCCCAACAA 1225
Query 1171 TTTCATAAGAAGTCAGAAGACAAGGCAATCACTCACTACTTAAAAGGTCTAAAACTAGAA 1230
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 1226 TTTCATAAGAAGTCAGAAGACAAGGCAATCACTCACTACTTAAAAGGTCTAAAACTAGAA 1285
Query 1231 GAGAAGTCCTTTGCCTGGAGGAAACTACTCACAGCTTTGGAGAAAGTGGCTGAAAGACGT 1290
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 1286 GAGAAGTCCTTTGCCTGGAGGAAACTACTCACAGCTTTGGAGAAAGTGGCTGAAAGACGT 1345
Query 1291 GTTCGCCAGAATGTCCGGCTTGTGGAGAGCACCAGCCTTCTTGGACTGGTCTTCAAACTG 1350
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 1346 GTTCGCCAGAATGTCCGGCTTGTGGAGAGCACCAGCCTTCTTGGACTGGTCTTCAAACTG 1405
Query 1351 AAAGGGCAGGAGATGAAGGCCCTGCTTTACTATGAGAAGGCCCTGAGGCTCTCTGGGGAA 1410
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 1406 AAAGGGCAGGAGATGAAGGCCCTGCTTTACTATGAGAAGGCCCTGAGGCTCTCTGGGGAA 1465
Query 1411 ATGAACCCTGCATTTTGAATGCAGC 1435
|||||||||||||||||||||||||
Sbjct 1466 ATGAACCCTGCATTTTGAATGCAGC 1490
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Figure C.1: Example of fluorescence-activated cell sorting (FACS) gating strategy used to
isolate Ifit1 expressing cells in SHR blood, following strategy outlined by Barnett-Vanes et
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New Findings What is the topic of this review?
We describe roles of crucial signalling molecules in the paraventricular nucleus of the
hypothalamus and highlight recent data suggesting sex-specific changes in the expression
of crucial signalling molecules and their receptors, which may underlie sex differences in both
cardiovascular and metabolic function. What advances does it highlight?
This review highlights the integrative capacity of the paraventricular nucleus in mediating
cardiovascular and metabolic effects by integrating information from multiple signalling
molecules. It also proposes that these signalling molecules have sex-specific differential gene
expression, indicating the importance of considering these differences in our ongoing search
to understand the female–male differences in the regulation of crucial autonomic systems.
Many traditional cardiovascular hormones have been implicated in metabolic function.
Conversely, many hormones traditionally involved in metabolic regulation have an effect on
cardiovascular function. Many of these signalling molecules exert such effects through specific
actions in the paraventricular nucleus, an integrative autonomic control centre located in the
hypothalamus. Here, we focus on four cardiovascular/metabolic peptide hormones that signal
within the paraventricular nucleus, namely angiotensin II, orexin, adiponectin and nesfatin-1.
Each of these hormones has specific electrophysiological effects on paraventricular nucleus
neurons that can be related to its physiological actions. In addition, we introduce preliminary
transcriptomic data indicating that the genes for some of these hormones and their receptors
have sex-specific differential expression.
(Received 6 June 2017; accepted after revision 20 July 2017; first published online 1 August 2017)
Corresponding author A. V. Ferguson: Department of Biomedical and Molecular Sciences, Botterell Hall, Queen’s
University, Kingston, Ontario, Canada K7L 3N6. Email: avf@queensu.ca
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Introduction
The hypothalamic paraventricular nucleus (PVN) is
widely known to be a crucial autonomic control centre that
plays essential roles in energy homeostasis, fluid balance
and cardiovascular regulation, through neuroendocrine
and autonomic functions (Swanson & Sawchenko, 1983).
Within the PVN exist three subpopulations of neurons,
the magnocellular (MNC) neurosecretory, parvocellular
pre-autonomic (PA) and parvocellular neuroendocrine
(NE) neurons (Swanson & Sawchenko, 1983). The
MNC neurons project to the posterior pituitary, where
they release vasopressin and oxytocin (OT) into the
general circulation. In addition to their neurohypophysial
projection, axons of OT-secreting MNC neurons send
collaterals to several forebrain regions, including the
central amygdala and nucleus accumbens (Knobloch et al.
2012). The PA neurons project to autonomic centres in
the medulla and spinal cord, including the nucleus tractus
solitarii (NTS; Kannan & Yamashita, 1985), to influence
autonomic control. Finally, NE neurons project to the
median eminence, where they secrete hypophysiotrophic
hormones, including corticotrophin-releasing hormone
(CRH) and thyrotrophin-releasing hormone.
The PVN receives afferent projections from additional
hypothalamic regions, including the lateral hypothalamus
and arcuate nucleus (Swanson & Sawchenko, 1983).
Inputs are also received from extrahypothalamic sites,
including the subfornical organ (Swanson & Sawchenko,
1983), one of the sensory circumventricular organs. The
PVN integrates information provided by a vast number
of signalling molecules, many of which are circulating
hormones that also act as neuropeptides within the
CNS (Table 1) and could be thought of collectively
as the alphabet for communication in this crucial
autonomic control centre. In this review, we highlight
four cardiovascular/metabolic peptides that signal within
the PVN and present preliminary data indicating that the
genes for some of these molecules and their receptors are
differentially expressed in males and females.
Angiotensin II
Angiotensin II (Ang II), a crucial component of the
renin–angiotensin system (RAS) and potent vasocons-
trictor, is perhaps the most studied peptide hormone
involved in cardiovascular regulation. As it is unlikely
that Ang II can freely cross the blood–brain barrier,
circulating Ang II must signal in the brain through the
sensory circumventricular organs. Indeed, a subfornical
organ–PVN pathway has been well characterized, with
neuronal projections from the subfornical organ to the
PVN using Ang II as a neurotransmitter (Li & Ferguson,
1993). The Ang II type 1 (AT1) receptor is expressed
predominantly in NE neurons, specifically in those
Table 1. Signalling molecules in the paraventricular nucleus:
ABCs of integrated autonomic control?
❖ Adiponectin ❖ Kisspeptin
❖ Adrenomedullin ❖ Leptin
❖ Adropin ❖ Macrophage migration
❖ Angiotensin inhibitory factor
❖ Atrial natriuretic peptide ❖ Melanocyte-stimulating
❖ Apelin hormone
❖ Brain-derived ❖ Nesfatin
neurotrophic factor ❖ Neuronostatin
❖ Bone morphogenetic ❖ Nitric oxide
protein ❖ Neuropeptide W
❖ Corticotrophin-releasing ❖ Neuropeptide Y
hormone ❖ Orexin
❖ Endothelin ❖ Oxytocin
❖ Estradiol ❖ Pituitary adenylate
❖ Gastrin-releasing peptide cyclase-activating polypeptide
❖ Ghrelin ❖ Phoenixin
❖ Glucocorticoids ❖ Prokineticin 2
❖ Glucagon-like peptide 1 ❖ Relaxin
❖ Hydrogen sulfide ❖ Substance P
❖ Insulin ❖ Vasopressin
❖ Interleukin
Note that references supporting roles for each of these peptides
in the paraventricular nucleus can be found through PubMed
search for paraventricular nucleus and the relevant peptide.
They have not been included here given Journal limitations on
the number of references.
that express CRH and thyrotrophin-releasing hormone
(de Kloet et al. 2017). Unsurprisingly, optogenetic
stimulation of these neurons results in activation of
their respective axes, the hypothalamic–pituitary–adrenal
and hypothalamic–pituitary–thyroid (HPT) axes (de
Kloet et al. 2017). Systemic administration of the AT1
blocker, losartan, which can cross the blood–brain barrier,
abrogates the Ang II-induced hypertensive effects of
activation of the subfornical organ–PVN pathway (Li et al.
1993).
Angiotensin II has excitatory electrophysiological
effects on PVN neurons from all three subpopulations
(Fig. 1A and B). In NE neurons, Ang II directly depolarizes
these cells by specifically modulating both a non-selective
cationic current and a K+ current (Latchford & Ferguson,
2005). Angiotensin II has indirect depolarizing effects
on MNC neurons mediated via glutamate interneurons
(Latchford & Ferguson, 2004) and direct excitatory effects
on PA neurons that project to the rostral ventrolateral
medulla (Cato & Toney, 2005). With these heterogeneous
excitatory effects of Ang II, it is not surprising that this
peptide influences more than cardiovascular function.
Angiotensin II, along with the other components of the
RAS, has also been implicated in energy homeostasis.
Similar to its effects on blood pressure, losartan has also
been shown to attenuate body weight gain in obese and
C© 2017 The Authors. Experimental Physiology C© 2017 The Physiological Society
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diet-resistant rats fed a high-fat diet (Smith et al. 2014).
Paraventricular nucleus AT1a knockout mice fed a high-fat
diet have increased adiposity attributable to both increased
energy consumption and decreased energy expenditure
(de Kloet et al. 2013). These mice also exhibit decreased
blood pressure and hypothalamic mRNA expression of
CRH and OT (de Kloet et al. 2013). Electrophysiologically,
this AT1a deletion eliminates the responsiveness of PVN
parvocellular neurons to bath-applied Ang II (de Kloet
et al. 2013). These results suggest that Ang II signals in
the PVN via AT1a receptors in parvocellular neurons to
regulate energy balance and to mediate part of its effect on
blood pressure.
Preliminary transcriptome data from our laboratory
have revealed sex-specific differences between some of
the genes for components of the RAS. The gene for the
precursor of Ang II, Agt, displays the greatest difference
in expression, being 1.3-fold higher in males versus
females (Fig. 1C). Although the Ang II receptor, AT1,
is not differentially expressed (Fig. 1C), the increased
expression of AGT may lead to increased levels of Ang II
and a subsequent increase in blood pressure. As the RAS is
also implicated in energy homeostasis, these sex-specific
differences might also contribute to their effects on obesity.
Orexin
Orexins/hypocretins (OX-A and OX-B or hypocretin 1
and hypocretin 2, respectively), as their name suggest,
are potent orexigenic peptides derived from a common
precursor and are almost exclusively expressed in the
lateral hypothalamic area (Sakurai et al. 1998). There are
two OX receptors, OX1R and OX2R, both of which bind
each OX isoform (Sakurai et al. 1998). OX-A has a higher
affinity for the OX1R than OX-B, whereas both isoforms
have equal affinity for the OX2R (Sakurai et al. 1998).
Lateral hypothalamic neurons, including those that are























































Figure 1. Angiotensin II (Ang II) influences the excitability of neurons in the paraventricular nucleus
(PVN)
A, representative current-clamp recordings from three separate PVN neurons exhibiting depolarizations
in response to increasing concentrations of bath-applied Ang II (0.01, 0.1 and 1,0 µM, top to bottom).
Angiotensin II application is represented by the horizontal grey bars. B, mean ± SEM change in resting
membrane potential (RMP) elicited by bath application of 10−8, 10−7, 10−6 and 10−5 M Ang II. Data
were fitted to a sigmoid concentration–response function, and the corresponding curve of best fit was
overlaid. C, preliminary transcriptome data comparing the expression level of angiotensin-related genes
in male versus female rats. Abbreviations: Ace2, angiotensin-converting enzyme 2; Agt, angiotensinogen;
and Agtr1a, angiotensin II type 1a receptor.
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1998). Additionally, OX receptors are expressed in PVN
neurons (Backberg et al. 2002), thus implicating this
nucleus in OX-mediated signalling. Indeed, researchers
in our laboratory have demonstrated indirect and direct
depolarizing effects of OX on MNC and parvocellular
PVN neurons, respectively (Fig. 2A and B; Follwell &
Ferguson, 2002).
In addition to their effects on food intake, both OX-A
and OX-B have hypertensive effects when administered
centrally (Shirasaka et al. 1999). In male obese Zucker
rats, microinjection of OX-A into the PVN increases
blood pressure and renal sympathetic nerve activity,
presumably through upregulation of OX1R in PVN PA
neurons projecting to the spinal cord (Zhou et al. 2015).
These results suggest that OX signalling in the PVN
contributes to obesity-related hypertension. In addition,
immobilization stress-induced ACTH stimulation is
blocked by pretreatment with an OX1R antagonist,
which also abolishes the OX-A-induced increase in
blood pressure (Samson et al. 2007). These findings
suggest that OX-A acts in the PVN to activate the
hypothalamic–pituitary–adrenal axis.
Based on our transcriptome data, only one of the orexin
receptors, OX2R, exhibits a sex-specific difference, with
greater expression in females than males, whereas the
expression of OX1R is similar in both sexes (Fig. 2C). These
data are in agreement with a study that looked at nicotine
exposure in piglets and observed an increase in OX2R
in the PVN of female animals after nicotine treatment
(Hunt et al. 2013). These differences may have important
implications for the effects of OX in each sex when we
consider that the OX isoforms have varying affinities for
each OX receptor.
Adiponectin
The adipokine adiponectin (ADP) is involved in glucose
and lipid homeostasis. Similar to Ang II, circulating
ADP can signal within the brain as a neuropeptide.




















































Figure 2. Orexin (OX) influences the excitability of neurons in the PVN
A, representative current-clamp recordings from three separate PVN neurons showing that bath
application of OX-A (500 nM, top; 100 nM, middle) or OX-B (100 nM, bottom) results in depolarization of
the membrane potential. The time of OX application is indicated by the horizontal red bars. B, mean ±
SEM change in membrane potential elicited by bath application of 1, 10, 50, 100 and 500 nM OX-A. Data
were fitted to a sigmoid concentration–response function, and the corresponding curve of best fit was
overlaid. C, preliminary transcriptomic data comparing the expression level of the orexin receptor genes
in male versus female rats. Abbreviations: ORX1R, orexin receptor type 1; and ORX2R, orexin receptor
type 2.
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and AdipoR2 (Yamauchi et al. 2003), both of which are
expressed in PVN neurons (Hoyda et al. 2007). AdipoR
knockout mice exhibit differential effects on energy
metabolism. AdipoR1−/− mice have increased adiposity
along with decreased glucose tolerance and energy
expenditure, whereas AdipoR2−/− mice are resistant to
high-fat diet-induced obesity and have improved glucose
tolerance (Bjursell et al. 2007). Likewise, ADP has
differential electrophysiological effects on MNC neurons
that appear to be correlated with AdipoR expression,
suggesting that neurons expressing both AdipoRs
hyperpolarize, whereas those that express only AdipoR2
depolarize (Fig. 3A; Hoyda et al. 2007). In addition to
receptor profiles, researchers in our laboratory have
also characterized ADP responses to the molecular
phenotype of PVN neurons; MNC neurons that express
OT hyperpolarize in response to ADP (Hoyda et al. 2007).
Intriguingly, this peptide depolarizes PA OT neurons
(Hoyda et al. 2009a), indicating that ADP has opposite
effects on functionally distinct OT-expressing PVN
neurons.
We have shown a direct depolarizing effect of ADP
on NE CRH neurons in the PVN (Fig. 3B), leading
to subsequent release of ACTH (Hoyda et al. 2009a).
Similar direct depolarizing effects of ADP were found
to occur in NTS neurons that express neuropeptide Y,
further implicating ADP in feeding behaviour (Hoyda
et al. 2009b). Additionally, direct injection of ADP
into the NTS decreases blood pressure (Hoyda et al.
2009b), and nanoinjection of neuropeptide Y into the
PVN induces a similar pressor response (Cassaglia et al.
2014). As the parvocellular region of the PVN receives
afferent projections from the NTS (Kannan & Yamashita,
1985), these results provide an indirect mechanism of
ADP-mediated CRH secretion via the NTS. The reciprocal
connections between the PVN and the NTS, and the
actions of ADP on both nuclei, suggest a dual effect of this
peptide on both feeding behaviour and cardiovascular
function.
Although ADP itself does not display a sex-specific
difference in expression, one of its receptors does. The gene
for AdipoR1 has increased expression in females compared
with males (Fig. 3C). As ADP signalling depends on the
AdipoR expression profile, this differential gene expression
might cause differences in the effects of ADP in males
versus females, at least at the cellular level.
Nesfatin-1
Nesfatin-1 is an anorexigenic peptide derived from
the precursor, nucleobindin2 (NUCB2; Oh et al.
2006). NUCB2 is expressed in multiple hypothalamic
nuclei, including the lateral hypothalamic area, the
























Figure 3. Adiponectin (ADP) influences the excitability of neurons in the PVN
A, representative current-clamp recordings from two separate magnocellular PVN neurons showing
that bath application of 10 nM adiponectin (horizontal blue bars) caused a depolarization (top),
whereas the second PVN neuron (bottom) exhibited a hyperpolarization. B, representative current-clamp
recording from a corticotrophin-releasing hormone PVN neuron showing that bath application of 10 nM
adiponectin (horizontal blue bar) caused a depolarization. C, preliminary transcriptomic data comparing
the expression level of the adiponectin receptor genes in male versus female rats. Abbreviations: Adipor1,
adiponectin receptor 1; and Adipor2, adiponectin receptor 2.
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(Oh et al. 2006). During starvation, the concentration
of nesfatin-1 is reduced in the PVN, while remaining
unchanged in the other hypothalamic nuclei (Oh et al.
2006). Paraventricular nucleus-specific NUCB2 mRNA
knockdown in mice increases food intake, leading to
subsequent obesity (Nakata et al. 2016). Additionally,
central pretreatment with an OT receptor antagonist
blocks the inhibitory effect of nesfatin-1 on food
intake (Yosten & Samson, 2010), implicating OT in
nesfatin-1-mediated feeding behaviour. Clearly, the PVN
is involved in mediating the feeding effects of nesfatin-1.
In addition to its role in food intake, nesfatin-1 has
also been implicated in cardiovascular function, as central
administration has been shown to increase blood pressure
in rats (Yosten & Samson, 2009). This nesfatin-1-induced
pressor effect occurs through the central melanocortin
pathway (Yosten & Samson, 2009), the same pathway
used by this peptide for its effect on food intake
(Oh et al. 2006). Additionally, pretreatment with an
OT receptor antagonist abrogates both the anorexigenic
and the hypertensive effects of nesfatin-1 (Yosten &
Samson, 2010), again implicating OT, and thus the
PVN, in mediating these nesfatin-1 effects. Nesfatin-1
has non-specific electrophysiological effects in the PVN,
causing both depolarizations and hyperpolarizations in
PVN neurons from all three subpopulations (Price et al.
2008). Single-cell RT-PCR experiments revealed that
these heterogeneous effects are not dependent on the
molecular phenotype of these neurons, because both
effects occur in PVN neurons that express OT, vasopressin,
CRH or thyrotrophin-releasing hormone (Price et al.
2008). Additional studies are required to relate the
electrophysiological effects of nesfatin-1 in the PVN to
a specific physiological action of the peptide; however,
it is clear that this nucleus is involved in regulating
the cardiovascular and metabolic effects of nesfatin-1.
Although the receptor for nesfatin-1 remains elusive,
transcriptome data on the precursor gene for nesfatin-1,
Nucb2, show a similar expression in the PVN of both
females and males.
Conclusion
Many signalling molecules that have traditionally been
thought to influence only one major system in fact
influence multiple systems. These effects, unsurprisingly,
are often mediated at least in part by the PVN. We have
highlighted four hormones that signal through the PVN
and influence both cardiovascular and metabolic function.
To study the electrophysiological effects of these hormones
within the brain, many studies, including the numerous
ones from our laboratory, often obtain data exclusively
from male animals, in order to avoid the influence of
the female oestrous cycle. However, the preliminary data
presented in this review suggest sex-specific differences in
gene expression that should be taken into consideration
when performing experiments relating to these hormones
or their receptors, especially if they involve both male and
female animals. Future research should aim at elucidating
potential mechanisms underlying these differences and
determine whether these differences result in observable
effects at the physiological level.
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a b s t r a c t
Elderly people exhibit a diminished capacity to cope with osmotic challenges such as dehydration. We
have undertaken a detailed molecular analysis of arginine vasopressin (AVP) biosynthetic processes in
the supraoptic nucleus (SON) of the hypothalamus and secretory activity in the posterior pituitary of
adult (3 months) and aged (18 months) rats, to provide a comprehensive analysis of age-associated
changes to the AVP system. By matrix-assisted laser desorption/ionization time-of-flight mass spec-
trometry analysis, we identified differences in pituitary peptides, including AVP, in adult and aged rats
under both basal and dehydrated states. In the SON, increased Avp gene transcription, coincided with
reduced Avp promoter methylation in aged rats. Based on transcriptome data, we have previously
characterized a number of novel dehydration-induced regulatory factors involved in the response of the
SON to osmotic cues. We found that some of these increase in expression with age, while dehydration-
induced expression of these genes in the SON was attenuated in aged rats. In summary, we show that
aging alters the rat AVP system at the genome, transcriptome, and peptidome levels. These alterations
however did not affect circulating levels of AVP in basal or dehydrated states.
 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
As we age, disorders of body salt and water composition become
more commonplace. Cases of hyponatremia/hypernatremia are
muchmore prevalent in the elderly, where they have been linked to
increased incidences of falls, fractures, and osteoporosis, thus
contributing to increased hospital admissions and morbidity and
mortality (Cowen et al., 2013). To promote healthy living well into
old age, it is thus necessary to determine why such imbalances
occur. Age-associated changes to both peripheral and central
mechanisms that control salt and water homeostasis are deemed
responsible. There is a progressive age-related decline in renal
function, with less urine concentrating capacities in the elderly
compared with younger subjects (Ishunina and Swaab, 2002). Such
impaired capacity to conserve body water, together with reports of
reduced thirst and inadequate fluid intake after periods of fluid
deprivation, makes the elderly more susceptible to dehydration
(Mack et al., 1994; Phillips et al., 1993). Inappropriate release of the
antidiuretic hormone arginine vasopressin (AVP) into the systemic
circulation has been highlighted as one of the causes of irregular
water homeostasis in aging (Swaab and Bao, 2011).
AVP is synthesized in magnocellular neurons of the supraoptic
nucleus (SON) and paraventricular nucleus (PVN) of the hypothal-
amus. A change in plasma osmolality is detected by osmosensitive
neurons in circumventricular organs of the brain that provide direct
inputs to shape the firing of AVP magnocellular neurons that are
osmosensitive themselves and to coordinate AVP synthesis and
secretion from the posterior (neural) lobe of the pituitary gland
(Mecawi Ade et al., 2015; Nissen et al., 1994; Zhang and Bourque,
* Corresponding author at: University of Bristol, Dorothy Hodgkin Building,
Whitson Street, Bristol, BS1 3NY, England. Tel.: þ44 (0) 117 3313 071; fax: þ44 (0)
117 3313 035.
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2003). Once released, following incidences such as rise in plasma
osmolality or decrease in blood volume (Kondo et al., 2004), AVP
promotes sodium and water reabsorption by the kidney (Ares et al.,
2011; Breyer and Ando, 1994). When placed under stress, the
capabilities of the AVP system have been shown to decrease with
age (Frolkis et al., 1999; Keck et al., 2000; Sladek et al., 1981).
The AVP system has been interrogated on multiple levels, from
synthesis to secretion, in aged subjects with differing results. For
example, basal circulating AVP levels have been found to decrease,
to remain unchanged, and to increase with age in humans, as well
as rodents (Frolkis et al., 1999). These discrepancies have been
attributed to genetic, age, and strain differences. Although there are
many disputations, 1 area of agreement is that, while in many brain
areas neuronal activity decreases with age (Burke and Barnes,
2006), paradoxically AVP neurons become more active (Palin
et al., 2009; Terwel et al., 1992). This hyperactivity is thought to
be a compensatory mechanism for decreased responsiveness to
AVP in the kidney due to decreased receptor abundance in aged
subjects (reviewed by Ishunina and Swaab, 2002), although this
theory has been questioned (Preisser et al., 2004) and is not intui-
tive with the profound difference in circulating AVP described in
aging models. The AVP magnocellular neurons undergo numerous
morphological changes as they age including increased size of
perikarya, nucleoli, and Golgi apparatus in humans and rodents
(Ishunina and Swaab, 2002), analogous to morphological changes
in these neurons with dehydration (Hatton and Walters, 1973).
Increased AVP neuron size in states of dehydration is recognized as
a necessary measure to meet cellular demands for increased tran-
scription and protein synthesis under hypertonic stimulationwhere
circulating levels of AVP are robustly increased (Zhang et al., 2001).
It has been suggested that such hyperactivity of AVP neuronsmay in
itself lead to electrolyte disorders in the elderly (Swaab and Bao,
2011), but the relationship between the activity of AVP neurons
and circulating levels of AVP is poorly understood.
Transcriptional changes have been identified in AVP neurons
with aging. A study by Palin et al. (Palin et al., 2009) showed
increased expression of immediate early gene c-Fos, a commonly
used marker of neuronal activity, in the rat SON, consistent with
hyperactivation of the AVP neurons. In contrast to increased activity
under basal conditions, reports have described an attenuation of
the evoked AVP secretion in response to osmotic stress with aging
in rodents (Sladek and Olschowka, 1994; Swenson et al., 1997). This
has led some to suggest that deficits in mechanisms controlling
transcription, mRNA stability, or translation in the aging SON
magnocellular neurons may be responsible (Lucassen et al., 1997).
Moreover, we recently showed that dehydration initiates the for-
mation of new methylation marks on the rat Avp promoter
(Greenwood et al., 2016a), suggesting that altered methylation
patterns could lie beneath these transcriptional changes in aging
AVP neurons.
Few studies have sought to combine information on the physi-
ological aspects of aging with analyses of the molecular changes
occurring in the hypothalamus. The reasons why old AVP neurons
have elevated basal activity, or why they can fail to adequately
respond under stress, is not well understood. In particular, the
molecular basis for these changes in relation to circulating levels of
AVP has received little attention. We reasoned that aging-
associated deficits in the AVP system may be due to a combina-
tion of changes at the genome, transcriptome, and peptidome
levels, and that these changes might be responsible for distur-
bances in osmotic stability. In this study, we have interrogated the
physiological aspects of aging, performedmetabolicmeasurements,
and analyzed peptide levels in plasma and pituitary, correlating the
results with molecular events occurring within the hypothalamus
of aged rats. Furthermore, we have used our extensive knowledge of
the transcriptome of the adult rat SON in euhydrated and dehy-
drated states to uncover novel changes surrounding altered Avp
transcription in aging.
2. Materials and methods
2.1. Animals
All experiments were performed under a Home Office UK
licence held under, and in strict accordance with, the provisions of
the UK Animals (Scientific Procedures) Act (1986); they had also
been approved by the University of Bristol Animal Welfare and
Ethical Review Board. We choose to use male Wistar Han rats from
the international genetic standardization program (IGS) in our ag-
ing study (Charles River, France). The carefully managed breeding
program for these animals helps to manage genetic drift, so col-
onies bred in different locations around the world are not signifi-
cantly divergent from each other giving a level continuity in aging
studies performed in laboratories worldwide. The Charles River
Han Wistar rats have been extensively studied at 2 years of age
when these rats are reaching the end of their natural life spans.
Incidences of neoplastic and non-neoplastic lesions were high in
tissues including the kidney and pituitary gland at this age.
Furthermore, rats surviving to this age varied from 30% to 80%
across 20 control studies (www.criver.com). Therefore, in this aging
study, we opted for rats of 18 months of age to minimize patho-
physiological effects and thus allow investigation of the aging
process in healthy animals. All adult rats used in this study were
free of pituitary tumors; however, 6 of 50 aged animals were
removed from this study because of tumors on the pituitary gland.
On arrival, rats were 2 weeks younger than the desired ages,
3 months (adult) and 18months (aged), to enable sufficient time for
acclimatization before experimentation. Rats were housed at a
constant temperature of 22 C and a relative humidity of 50%e60%
(v/v) under a 14:10-hour light/dark cycle (lights on at 0500) with
food and water ad libitum for 2 weeks. To induce hyperosmotic
stress, both adult and aged rats were randomly assigned to 2
groups: control (free access to drinking water) and dehydrated
(removal of drinking water for 3 days). All rats were humanely
killed by striking of the cranium (stunning) and then immediately
decapitated with a small-animal guillotine (Harvard Apparatus,
Holliston, MA). Trunk blood was collected in heparin-coated tubes.
Brains were rapidly removed from the cranium and immediately
frozen by covering with powdered dry ice (within 3 minutes of
stunning). The pituitary gland was removed from the base of the
skull within 2 minutes after decapitation. The neurointermediate
lobe (NIL) was carefully separated from the anterior pituitary using
a scalpel blade and then either placed into 1.5-mL tubes containing
500 mL of 0.1 M of HCl or 0.2-mL tubes containing 150 mL of 15 mg/
mL of 2, 5-dihydroxybenzoic acid (DHBA) solution. Frozen brains
and NIL in HCl solution were stored at 80 C, whereas NILs in
DHBA solution were stored at 4 C. Animal experiments were per-
formed between 9 AM and 2 PM.
2.2. Metabolic measures in adult and aged rats
For metabolic measurements, animals were individually housed
in metabolic cages (Techniplast, Italy) to allow precise daily mea-
sures of fluid and food intake and urine output. A plastic gnawing
disc was suspended from the lid of the cage to provide environ-
mental enrichment throughout the study. Animals were first
acclimatized to metabolic cages for 48 hours. Measures of food
hoppers, water bottles, and urine collection tubes were performed
for 3 consecutive days, by weight. Extrarenal secretion of fluid was
calculated by subtracting water intake from urine output. Plasma
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and urine osmolalities were measured by freezing point depression
using a Roebling micro-osmometer (Camlab).
2.3. Vasopressin measures
The NIL of the pituitary was sonicated for 15 seconds in 0.1 M of
HCl and incubated at 85 C for 20 minutes. Cellular debris was
removed by centrifugation at 3000  g for 30 minutes at 4 C. Pi-
tuitary AVP content was determined using an AVP8-Vasopressin
ELISA (ADI-900-017A; Enzo) kit. The supernatant was diluted
(1:10,000) with assay buffer, and ELISA was performed following
the manufacturer’s protocol. The signal was detected on an iMark
microplate absorbance reader (Bio-Rad). For radioimmunoassay,
trunk blood was centrifuged at 1600  g for 15 minutes at 4 C.
Extractions were performed from 1 mL of plasma. Two sample
volumes of ice-cold acetone were added, and samples were vor-
texed for 1 minute. Protein precipitates were removed by centri-
fugation at 2500  g, 4 C, for 25 minutes. The supernatant was
transferred to a new tube and mixed with 2 mL of cold petroleum
ether by vortexing for 1 minute. The tubes were left to stand for
1 minute at room temperature before discarding the upper phase.
The lower phase solution was lyophilized using a freeze dryer
(Benchtop Pro; Biopharma). AVP concentration was determined by
a specific radioimmunoassay (Husain et al., 1973).
2.4. Peptide analysis of the NIL
Peptides were measured directly in individual NIL extracts by
mass spectrometry (MS) (Romanova et al., 2014; Romanova and
Sweedler, 2015).
2.4.1. Extraction of peptides
NIL samples were incubated in 15 mg/mL of DHBA solution for
48 hours as described by Romanova et al. (2008). The samples were
grouped as follows: adult control (n ¼ 14), adult 3-day dehydrated
(n¼ 16), aged control (n¼ 11), and aged 3-day dehydrated (n¼ 13).
2.4.2. Measurement of the NIL peptide profiles by MALDI-TOF MS
For MALDI-TOF MS measurements, 0.7 mL of the NIL extraction
solution was spotted on a stainless steel MALDI target in triplicates
and cocrystallized with 0.7 mL of a freshly prepared concentrated
DHBA matrix (50 mg/mL, 50% (v/v) acetone). Positive ion mass
spectra of each spotted sample were acquired automatically at
1-KHz laser frequency, and constant power optimized for the
sample type in the 600e6000 m/z region using an ultrafleXtreme
mass spectrometer (Bruker Daltonics) operated in reflectron mode
via the AutoXecute protocol. Acquisition parameters included laser
fuzzy control logic, random laser walk over the entire sample area,
250 laser shots per raster step, maximum of 5000 shots per sample
in 250-shot increments, and dynamic termination of spectrum
acquisition when the signal intensity reached 30,000 counts for 3
peaks, regardless of the number of fired laser shots. Peak evaluation
was set to a signal intensity per shot of 20 or above, minimal res-
olution of 10,000, signal-to-noise ratio (S/N) ¼ 3, maximum 300
peaks per spectrum, and centroid peak detection algorithm; 50
failed spectrum judgments were required before acquisition mov-
ing to the next sample. External quadratic calibration was adjusted
automatically for every 5  5 sample spot square.
2.4.3. Principal component analysis of the peptide profiles
Statistical analysis of raw MALDI MS data was performed using
ClinProTools 2.2 software (Bruker Daltonics). All spectra were
normalized to total ion count upon loading into ClinProTools and
level scaled. Spectra were processed for convex hull baseline
correction within 800e5500 m/z, smoothed with 0.1 Da  2 cycles
of the Savitzky-Golay method and a data reduction factor of 2, null
spectra exclusionwas enabled, and spectra grouping applied. Other
criteria included automatic peaks selection on the total average
group spectrum by intensity, S/N ¼ 5 cut off, 1% relative threshold
base peak on average group spectrum, unlimited picking. Manual
peak editing for the integration area after automatic peak picking
was done on the mean spectrum representative of each sample
group to include entire isotopic clusters of highly resolved peaks.
Peptide profiles of the mean spectra were compared by principal
component analysis (PCA) followed by the Anderson-Darling
normality test and Student’s unpaired t-test for normal distributed
data. Data not showing normal distributions (pAnderson-Darling 
0.05) were evaluated by Kruskal-Wallis tests, respectively (Kruskal
and Wallis, 1952; Stephens, 1974; Wilcoxon, 1945). To decrease the
number of false positives while computing individual peak statis-
tics on the complex spectra, the Benjamini-Hochberg procedure
incorporated into ClinProTools was automatically applied for
p-value adjustment during analysis (Dudoit and Shaffer, 2003).
Unsupervised clustering of spectrawas performed on PCA-modified
data using Euclidean distance, average distance methods, and a
Minkowski exponent of 1.5. The following peptide profile differ-
ences were investigated: (1) between control aged and adult rats;
(2) between dehydrated aged and adult rats; and (3) between
control and dehydrated rats of either age.
2.5. Dual DNA and RNA extraction from SON punch samples
SON samples (12 unilateral punches) were collected from 12
coronal slices using a 0.35-mm sample corer (Fine Scientific Tools)
using the optic chiasm as a reference. Total RNA and genomic DNA
were extracted from each sample as previously described
(Greenwood et al., 2016a).
2.6. Complementary DNA synthesis and quantitative PCR
For cDNA synthesis, 40 ng of total RNA was reverse transcribed
using the QuantiTect reverse transcription (RT) kit (Qiagen).
Primers for rat genes used in this study: Avp (50-TGCCTGCT
ACTTCCAGAACTGC-30 and 50-AGGGGAGACACTGTCTCAGCTC-30),
heteronuclear Avp (hnAvp) (50-GAGGCAAGAGGGCCACATC-30 and
50-CTCTCCTAGCCCATGACCCTT-30), ras-related dexamethasone
induced 1 (Rasd1) (50-CCCTCAGCGTTGTGCCTACT-30 and 50-AAAGA
GCGCACGGAACATCT-30), caprin familymember 2 (Caprin2) (50-CAG
GGTTAAGTGCAAGCGAT-30 and 50-CTGGTGGTTGACTGGTTGAG-30),
c-Fos (50-AGCATGGGCTCCCCTGTCA-30 and 50-GAGACCAGAGTGGG
CTGCA-30), cAMP responsive element binding protein 3 like 1
(Creb3l1) (50-GCCAACAGGACCCTGCTCCA-30 and 50-AGTGCCAGT
CTGTGTGGCCG-30), gonadotropin inducible ovarian transcription
factor 1 (Giot1) (50-GACACTTCCGGTCCGTCATAG-30 and 50-GCCTCA
CTCAAGCACCCAGT-30), DNA methyltransferase 1 (Dnmt1) (50-AACC
ACTCAGCATTCCCGTA-30 and 50-TGCTGGTACTTCAGGTCAGG-30),
Dnmt3a (50-AAGACCCCTGGAACTGCTAC-30 and 50-TGGCGAAGAAC
ATCTGGAGT-30), mature oxytocin (Ot) (50-TGCCCCAGTCTTGCT
TGCT-30 and 50-TCCAGGTCTAGCGCAGCCC-30), heteronuclear Ot
(hnOt) (50-TGAGCAGGAGGGGGCCTAGC-30 and 50-TGCAAGAGAAA
TGGGTCAGTGGC-30), proprotein convertase subtilisin/kexin type 1
inhibitor (proSAAS) (50-GAGCTGCTGAGGTACTTGCT-30 and 50-ACC
CAAATCCTGGTCCACAG-30), heteronuclear proSAAS (hnproSAAS)
(50-GAAGTGACGACCGAGGTGTA-30 and 50-GCAGTATTGTAGGGCGT
TCG-30), tet methylcytosine dioxygenase 1 (Tet1) (50-TGACCCACTCT
TACCAGACC-30 and 50-GATGGGCCATTGCTTGATGT-30), Tet2 (50-TCG
GAGGAGAAGAGTCAGGA-30 and 50-TAGGGCTTGCATTTTCCATC-30),
Tet3 (50-ATGGCATGAAACCACCCAAC-30 and 50-ACTTGATCTTCC
CCTCCAGC-30), and ribosomal protein L19 (Rpl19) (50-GCGTCT
GCAGCCATGAGTA-30 and 50-TGGCATTGGCGATTTCGTTG-30) were
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synthesized by Eurofins MWG Operon. QuantiTect Primer Assays
for solute carrier family 12, member 1 (Slc12a1) were purchased
from Qiagen. The optimization and validation of primers were
performed using standard Applied Biosystems protocols. The cDNA
from RT reaction was diluted 1:4 with H2O and used as a template
for subsequent polymerase chain reactions (PCRs), which were
carried out in duplicate using SYBR green (Roche) on an Applied
Biosystems StepOnePlus Real-Time PCR system. For relative quan-
tification of gene expression, the 2DDCT method was used (Livak
and Schmittgen, 2001). The internal control gene used for these
analyses was the housekeeping gene Rpl19.
2.7. Poly(A) tailelength assay
The poly(A) tail length of the AvpmRNAwas examined using the
USB poly(A) TaileLength Assay Kit (Affymetrix). RNA extracted from
SON (50 ng) was used as the starting material. Guanosine and
inosine residues were added to the 30 ends of poly(A)-containing
RNAs using the poly(A) polymerase enzyme. After incubation at
37 C for 1 hour, stop solution was added and the tailed-RNAs were
converted to cDNA by RT using the newly added G/I tails as priming
sites. PCR amplification products were generated by using 2 primer
sets: set 1, gene-specific forward and reverse primer set for Avp
(forward 50-CGAGTGTCGAGAGGGTTTTT-30, reverse 50-TTTATTTTC
CATGCTGTAGG-30), and set 2, Avp geneespecific forward primer
and a universal reverse primer provided in the kit. PCR reactions
were performed using 2 mL of the undiluted RT sample. PCRs were
performed using the following cycling conditions: 94 C for 2 mi-
nutes followed by 40 cycles of 94 C for 10 seconds, 60 C for
45 seconds, and 72 C for 5 minutes. The PCR products were
separated on 2.5% (w/v) agarose/TAE gel. The PCR products were
visualized on ethidium bromideestained gels using a Syngene
G:BOX imaging system.
2.8. Bisulfite conversion and sequencing
Genomic DNA from SON punches (25 ng) was bisulfite converted
using an EZ DNA Methylation-Gold kit (Zymo Research). The
amplification and sequencing steps were performed as previously
described (Greenwood et al., 2016a).
3. Results
3.1. Physiological assessment of adult and aged rats
We singly housed adult and aged rats in metabolic cages to
assess their ingestive behaviors. As expected, the average weight of
aged rats was significantly higher than that of adult rats (Fig. 1A).
Despite their larger size, aged rats consumed significantly less food
(Fig. 1B) and water (Fig. 1C) over consecutive 24-hour periods
compared to adult rats. The lower water intake in aged rats was not
accompanied by a significant decrease in urine output compared to
adult rats (Fig. 1D) but reflected a decrease in extrarenal water loss
compared to their younger counterparts (Fig. 1E). Urine osmolality
was not affected by age (Fig. 1F).
3.2. The AVP system in adult and aged rats
To test how fluid homeostatic systems respond to osmotic
stress, rats were deprived of water for 3 days. A decrease in weight
from the starting body weight was observed for both adult and
aged rats (Fig. 2A). This period of dehydration increased plasma
osmolality by similar degrees in both aged and adult rats (Fig. 2B).
However, a higher basal plasma osmolality was observed in aged
rats, a difference that was preserved in response to 3 days of
dehydration, suggestive of different osmolality set points in adult
and aged rats. We investigated the expression of Avp mRNA and
hnAvp RNA, a surrogate measure of Avp transcription (Herman
et al., 1991), in the SON of control and dehydrated adult and
aged rats using qRT-PCR (Fig. 2C and D). The abundance of Avp
mRNA under basal conditions was not influenced by age (Fig. 2C),
while increased hnAvp expression in aged animals indicated
increased transcription of the Avp gene compared to adult rats
(Fig. 2D). In contrast, the osmotic stimulus of dehydration
increased hnAvp levels above adult basal measures for both adult
and aged rats; however, this response was only significant in adult
rats. The AVP content in the pituitary was investigated by AVP
ELISA (Fig. 2E). There was a decrease in NIL AVP content in rats
subjected to dehydration for both age groups. AVP NIL content was
unchanged by age. Interestingly, the expected decline of AVP
content with dehydration was marginally attenuated in aged rats,
Fig. 1. Comparison of metabolic parameters in adult and aged rats. Physiological parametersd(A) body weight, (B) food intake, (C) water intake, (D) urine output, (E) extrarenal
water secretion, and (F) urine osmolalitydwere recorded in adult (3-month old) and aged (18-month old) male rats (n ¼ 6) housed in metabolic cages. **, p < 0.01; ***, p < 0.001 by
the 2-way analysis of variance with Bonferroni post hoc test.
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with higher AVP levels detected in aged dehydrated compared to
adult dehydrated rats. However, there was no significant effect of
age on basal or osmotically induced plasma AVP levels when
comparing adult and aged rats (Fig. 2F).
3.3. Peptide analysis of the NIL in control and dehydrated states
3.3.1. Effect of dehydration on NIL peptide profiles in adult rats
The abundance of peptides in the NIL provides a good measure
for assessing changes in peptide synthesis/secretion. To study
effects of aging on peptide profiles in the NIL, we used MS-based
peptide measurements (Romanova et al., 2013; Romanova and
Sweedler, 2015) to characterize and quantify the neuropeptide
changes of the NIL. In adult rats, control and dehydrated profiles
were easily classified by PCA according to principal component 1
(PC1) (w60% of variance; Fig. 3A). Loading plots indicated that
peptides contributing to this difference matched the masses of AVP
and its sodiated ion, the sodiated ion of oxytocin (OT), acetylated
alpha-MSH, di-acetylated alpha-MSH, a portion of the ACTH
domain, and other proopiomelanocortin (POMC)-derived peptides
(Fig. 3B). The level of AVP and OT decreased with dehydration,
whereas alpha-MSH and proSAAS levels increased (Fig. 3C).
Fig. 2. Effect of aging on the rat AVP system. Adult and aged male rats were subjected to dehydration for 3 days and AVP measures were performed. (A) Body weights were recorded
before and after dehydration (n ¼ 11e14). (B) Plasma osmolality was measured (n ¼ 19e23) by freezing point depression. The effect of aging on Avp expression was examined at the
transcriptional level in control and dehydrated adult and aged rats. (C, D) The RNA expression level of Avp (both heteronuclear [hnAvp] and mature form) was examined by qRT-PCR
(n ¼ 6). AVP measures were performed on NILs and plasma extracts. (E) AVP content in NILs was measured by ELISA (n ¼ 9e10). (F) Plasma AVP level was determined by
radioimmunoassay (n ¼ 9). *, p < 0.05; ***, p < 0.001 by the 2-way analysis of variance with Bonferroni post hoc test. #, p < 0.05 by unpaired t-test. Abbreviations: AVP, arginine
vasopressin; DH, dehydrated; NIL, neurointermediate lobe.
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Fig. 3. Peptide analysis in aged rats. Adult and aged male rats were subjected to dehydration for 3 days, and NIL peptide measures were performed by MALDI-TOF MS. (AeE) Signal
intensity of peptides in NILs was measured by MALDI-TOF MS in individual tissue extracts from adult and aged rats in basal and dehydrated states (n ¼ 11e16). (A) Control and
dehydrated peptide profiles are easily classified by PCA according to PC1 (w60% of variance) in adult rats; PCA plot is shown for the first 3 PCs. (B) Loading plot indicates that a small
subset of peptides contributes to differences between control and dehydrated adult rats, among which are masses matching AVP, acetylated alpha-MSH, and di-acetylated alpha-
MSH. (C) The AVP and OT signal decreases significantly, while the alpha-MSH signals and proSAAS (221-237) increase significantly with dehydration in adult rats. (D, E) The effect of
age on peptide signals in the NIL. (D) The OT signals decreased, while the signals of POMC-derived peptides increased in aged compared to adult rats. (E) Peptide signals in the NIL of
adult and aged rats subjected to 3 days of dehydration. The AVP-copeptin signal increased, whereas the proSAAS signal decreased with age. (F) Peptides uniquely altered as a
function or aging or by just dehydration. (G) Relative RNA expression of proSAAS and OT in the SON of adult and aged rats. *p < 0.05 by unpaired t-test or peptide names beginning
with * by Kruskal-Wallis tests. Abbreviations: AVP, arginine vasopressin; DH, dehydrated; NIL, neurointermediate lobe; PCA, principal component analysis; POMC,
proopiomelanocortin.
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3.3.2. Comparison of the NIL peptide profiles between aged and
adult rats
A comparison was performed for adult and aged rats. In PCA, 10
PCs were required to explain 93% of variance in the data set, with
most sample segregation achieved along PC1 accounting for about
30% of variance. Spectra from aged animals showed more broad
distribution within the 3D space constructed of the first 3 PCs. In
this data set, a total of 78 peaks passed the criteria for statistics
selection, of which 22 (w30%) were detected at statistically
different intensities (p  0.05) between compared age groups (see
Supplementary Tables 1 and 2). Some of the peaks can be matched
to POMC by peptide mass fingerprinting or other previously
reported neuropeptides expressed in pituitary including OT
(Fig. 3D). Relative to adult rats, the aged rats exhibited significant
decrease in the sodiated ion and potassiumated ion of OT and
increases in the intensity of peptides matching themasses of alpha-
MSH, acetylated alpha-MSH, di-acetylated alpha-MSH, and 5 other
POMC-derived peptides.
3.3.3. Effect of aging on NIL peptide profiles in dehydrated rats
A comparison was performed for NILs of adult and aged dehy-
drated rats. In PCA, 13 PCs were required to explain 95% of variance
in the data set. Both adult and aged rats showed a range of profiles
that could not be reliably classified by PCA and unsupervised
clustering. Four of 13 adult rats and 2 out of 16 aged rats were
particularly different. A total of 121 peaks were selected for statis-
tics, of which 20 (w16%) were detected at statistically different
intensities (p  0.05) between compared age groups (see
Supplementary Tables 3 and 4). Similar to the control groups, aged
animals had higher levels of peptides matching by mass to the
POMC prohormone as well as proSAAS and AVP-copeptin (Fig. 3E).
3.3.4. Effect of dehydration on NIL peptide profiles in aged rats
With the set of 24 aged rats (11 control and 13 dehydrated), no
significant changes in NIL profiles were seen with dehydration, and
no clear segregation was observed on a PCA plot.
3.3.5. Peptide changes specific to age or dehydration
A number of peptides profiles in the NIL were altered only as a
function of aging (Fig. 3F). In addition, a separate cohort of peptides
was found to only differ between adult and aged rats in dehydra-
tion. (Fig. 3F). These included OT (aging) and proSAAS (dehydration)
whose precursor proteins are known to be synthesized in magno-
cellular neurons in the SON (Murphy et al., 2012). Using qRT-PCR,
we show that expression of these genes in the SON is not altered
by age or dehydration (Fig. 3G).
3.4. Changes in Avp promoter methylation as a consequence of
aging
To see if changes in methylation could account for Avp gene
transcriptional differences in the SON with age, we looked at the
expression of genes known to regulate methylation status of DNA,
namely the Dnmt and Tet families, in the SON (Fig. 4A). We found
decreased Dnmt1 and Tet1 in the SON of aged compared to adult
rats, whereas expression of the closely related genes Dnmt3a and
Tet2/3 remained unchanged with age. In the dehydrated state,
Dnmt1 increased and Tet1 decreased in adult rat SON samples,
whereas no changes in these genes were observed with dehydra-
tion and aging. To analyze gene-specific methylation changes, we
chose to examine the methylation profile of the Avp promoter
within the SON by sequence analysis of bisulfite-converted DNA.
Using primers spanning the proximal Avp promoter (325
to 24 bp), we investigated the methylation status of a cluster of 7
cytosine-phosphate-guanine (CpG) sites (Fig. 4B). Analyses of the
methylation pattern of CpGs in single clones from individual control
and dehydrated animals with aging are depicted in Fig. 4C. Analysis
of the overall methylation of the Avp promoter for the SON revealed
decreased methylation in aged compared to adult animals by the 2-
way analysis of variance (p < 0.002), whereas methylation levels
increased in response to dehydration in aged rats (Fig. 4D). In
comparison, overall methylation was not significantly altered by
dehydration in the SON of adults.
We next compared the methylation profiles of individual CpGs
(Fig. 4E). Of the 7 CpGs analyzed, only CpG2 was significantly
influenced by age, with lower methylation compared to adult
controls. In aged rats, dehydration increased methylation of CpGs 1,
3e5, and 7 compared to aged controls. By contrast, only CpG4
showed increased methylation in dehydrated adult rats compared
to adult controls. Of note, the methylation of individual CpGs was
found to be similar in dehydrated adult and aged rats.
3.5. Aging changes gene expression in the SON and alters the effect
of dehydration
We have used transcriptomics to catalog all of the genes
expressed in the adult male SON and to identify genes that are
differentially regulated by dehydration (Hindmarch et al., 2006).
The challenge now is to place these genes into physiologically
relevant pathways; thus, in pursuit of this aim, our functional in-
vestigations have revealed novel genes involved in AVP elaboration
[Creb3l1 (Greenwood et al., 2014, 2015a,b); Slc12a1 (Konopacka
et al., 2015b); Caprin2 (Konopacka et al., 2015a); Giot1 (Qiu et al.,
2007); and Rasd1 (Greenwood et al., 2016b)]. We have now asked
if the expression of these genes is altered with aging, under both
euhydrated and dehydrated conditions (Fig. 5). We used qRT-PCR to
reveal age-related increases in mRNA expression of transcription
factors c-Fos (a general marker of neuronal activation), Creb3l1,
Giot1, and RNA-binding protein Caprin2 under basal conditions,
while levels of the small G-protein Rasd1 and the Na-K-2Cl
cotransporter Slc12a1 were unchanged. The expression of all of
these genes was increased by dehydration in both adult and aged
animals. In aged rats, dehydration induced smaller rises in the
expression of all analyzed genes, reaching statistical significance
compared to adult dehydrated rats, with 1 notable exception,
Caprin2.
3.6. Post-transcriptional modification to Avp mRNA in aging
A known feature of the Avp mRNA is that the unusually long 30
poly(A) tail further increases in length in response to osmotic stress
(Carter andMurphy,1991). Here, we have used poly(A) tail assays to
determine the length of the Avp mRNA poly(A) tail in adult and
aged rats in the basal condition and in response to dehydration
(Fig. 6A). The length of the Avp poly(A) tail was found to be sus-
ceptible to change with aging. In aged rats, the poly(A) tail was
longer than that in adult control rats (Fig. 6B), perhaps suggesting
altered transcript stability with age. The Avp poly(A) tail length
increased more in adult rats in dehydration, but overall poly(A) tail
lengths ended up being the same size in both dehydrated groups
reflecting the smaller starting point in adult rats.
4. Discussion
With increased life expectancy, maintaining health and well-
being into old age is becoming a priority, making the push toward
understanding our aging homeostatic systems ever more pertinent.
A decline of appetite accompanied by a reduction in daily fluid
intake, as we observed in the rat, is common behavioral charac-
teristics observed in the elderly (Kmiec, 2006; Phillips et al., 1993),
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Fig. 4. Epigenetic changes in Avp gene promoter in aging. Methylation status of the Avp promoter in the SON of control and dehydrated adult and aged male rats. (A) Relative mRNA
expression of Dnmt1, Dnmt3a, Tet1, Tet2, and Tet3 was determined by qRT-PCR. (B) Diagram showing 7 CpG sites on the Avp promoter that were examined by colony-based PCR. (C)
Representative tile diagrams showing the methylation status of 7 CpG sites for individual clones of the Avp promoter extracted from the SON. (D) Percentage of global methylation
on this region of the Avp promoter in control and dehydrated adult and aged rats. (E) Percentage methylation of individual CpG sites on the Avp promoter in control and dehydrated
adult and aged rats. *, p < 0.05; **, p < 0.01; ***, p < 0.001 by the 2-way analysis of variance with Tukey’s post hoc test. #, p < 0.05 by unpaired t-test. Abbreviation: SON, supraoptic
nucleus.
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suggesting that our rat model is of particular value to study meta-
bolic changes related to aging. Comparisons of basal and dehy-
drated urine osmolalities in both age groups suggested that urine
concentrating capacity and thus renal function are not impaired in
our model at this age. Furthermore, AVP circulating levels were
comparable in adult and aged rats in the basal state and in response
to dehydration, suggesting no changes in hypothalamo-
neurohypophysial system (HNS) responsiveness to osmotic and
volume stimuli. Hence, the circulating levels of AVP and the renal
response to it are adequate to concentrate urine in these aging rats.
Chronic dehydration depletes AVP stores in the posterior pitui-
tary to meet necessary circulatory demands for AVP to facilitate
increased water uptake by the kidney (Antunes-Rodrigues et al.,
2014). The large stores of AVP in the posterior pituitary were
depleted by comparable amounts in both age groups by dehydra-
tion. However, when compared to adult rats, aged rats had higher
levels of pituitary AVP as a consequence of dehydration.We propose
that increased basal AVPpituitary is responsible for this difference as
opposed to ineffective stimulation of AVP secretion. This concept is
consistentwith the comparable increases in circulating levels of AVP
after dehydration. Therefore, the ability to store and secrete
adequate quantities of AVP in response to 3 days of dehydrationwas
not compromised in these Han Wistar rats at this age. Taken
together, these data show that changes to AVP secretion cannot
account for the observed metabolic changes in aged compared to
adult rats. The altered fluid intake and plasma electrolytes may
represent changes to other systems coordinating salt and water
balance. For example, the renin-angiotensin-aldosterone and atrial
natriuretic peptide systems are known to be altered in rats and
humans as a function of aging (El-Sharkawyet al., 2014; Pollacket al.,
1997; Silver et al.,1993). However, any involvement of these systems
in this particular aging model remains to be investigated.
A higher set-point for basal plasma osmolality in our aged
model, one of the reported characteristics of aging in humans and
rodents (McLean et al., 1992; Terwel et al., 1992), provides one
possible explanation for AVP neuron hyperactivation in the basal
state. A small rise in plasma osmolality of approximately 1% is
normally sufficient to activate Avp transcription in magnocellular
neurons of the SON and PVN, and these transcriptional events are
well known to occur together with increased AVP secretion from
the posterior pituitary in adult rats (Arima et al., 1999). The
higher plasma osmolality in aged rats, being approximately 1%
above adult rats, was indeed associated with increased tran-
scription but not with increased secretion of AVP. In contrast,
3 days of dehydration, a well-characterized model for activating
Avp transcription in the SON (Greenwood et al., 2014), increased
AVP secretion but not Avp transcription in the aged group. This is
despite a rise in plasma osmolality of greater than 2% by this
osmotic stimulus.
The synthesis and secretion of AVP are normally twinned to
maintain neurohypophysial homeostasis because AVP stores in the
pituitary become depleted and need to be replenished with newly
synthesized AVP (Murphy and Carter, 1990). Any delay in replen-
ishing pituitary AVP stores to prestimulus levels might leave the
system at greater risk from further hyperosmotic insults. The
elderly living at care homes have been shown to have lower daily
intakes of fluid than those living at home. Furthermore, elderly
peoplewith cognitive impairments such as dementia often forget to
drink. These behavioral characteristics, coupled with reduced thirst
perception in elderly people, greatly increase their risk of dehy-
dration (El-Sharkawy et al., 2014). In elderly patients admitted to
hospitals, hypernatremia has been associated with an increased
mortality rate (Snyder et al., 1987). In addition, clinical studies of
care home patients who develop acute illness and require hospital
treatment reported that approximately 30% became markedly
hypernatremic in hospitals (Cowen et al., 2013). The uncoupling of
plasma osmolality and Avp transcription did not alter AVP secretion
here in healthy aging rats but may become important in
Fig. 5. Effect of aging on the expression of osmotically induced genes. Relative mRNA expression of genes involved in hyperosmotic stress in the SON of the hypothalamus in control
and 3-day dehydrated adult and aged rats. *, p < 0.05; **, p < 0.01; and ***, p < 0.001 by the 2-way analysis of variance with Bonferroni post hoc test. #, p < 0.05 by unpaired t-test.
Abbreviations: DH, dehydrated; SON, supraoptic nucleus.
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Fig. 6. Effect of aging on transcriptional and post-transcriptional Avp gene expression. The effect of aging on Avp poly(A) tail length in the SON in control and dehydrated adult and
aged rats. (A) Diagram of poly(A) tail assay design for the rat Avp gene. (B) poly(A) tail length of the Avp mRNAwas examined using a PCR-based poly(A) tail assay. Abbreviations: Ad,
adult; Ag, aged; DH, dehydrated; RT, reverse transcription; SON, supraoptic nucleus.
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pathophysiological conditions if the rate of Avp transcription ever
fails to meet secretory demands.
We next investigated if the observed uncoupling of
synthesis and secretion was unique to AVP in the aging HNS. We
revealed a cohort of peptides, in particular, POMC-derived peptides,
N-terminal truncated form of copeptin, proSAAS, and OT in addition
to AVP, which were susceptible to changes with age and also
dehydration. POMC has been shown to be expressed in the pituitary
intermediate lobe, with its expression altered by osmotic stimula-
tion and changes in blood pressure (Felder and Garland,1989; Pardy
et al., 1990). In rats supplied with a drinking diet of 2% NaCl, POMC
mRNA expression was shown to decrease in the intermediate lobe
of the pituitary (Pardy et al., 1990). In relation to blood pressure,
spontaneously hypertensive (SHR) rats have lower POMC expres-
sion in the intermediate lobe compared toWistar Kyoto (WKY) rats.
Lowering blood pressure in SHR rats with antihypertensive agents
normalizes POMC expression in the intermediate lobe to that in the
WKY rat (Felder and Garland, 1989). We show here age-related
increases in an array of POMC-derived peptides in the NIL under
basal and dehydrated conditions. How, or if, these POMC peptides
contribute to age-related changes to physiology is currently not
known.
Copeptin and AVP are derived from the same common precursor
molecule. Copeptin is the C-terminal part of pro-AVP that is cleaved
during processing and released with AVP into the circulation. The
functions of copeptin are not known, but due to its higher stability
in plasma, it is commonly used as surrogate measure for circulating
levels of AVP (Christ-Crain and Fenske, 2016). Here, we have iden-
tified an N-terminal truncated form of copeptin in the NIL and
further show that the abundance of this peptide increases in the
dehydrated rat as a function of aging. This peptide has previously
been identified in a peptidomic study of the rat SON (Bora et al.,
2008). Therefore, increased abundance of this peptide in the NIL
might suggest increased processing of pro-AVP in aging magno-
cellular neurons in response to dehydration. In support of this
concept, a study using microdialysis probes to measure release
patterns of AVP in the PVN and SON in the aging male Wistar rat
showed an age-associated increase in AVP release in the PVN,
though not in the SON (Keck et al., 2000).
ProSAAS and OT are known to be expressed in magnocellular
neurons of the hypothalamus and the posterior lobe of the pituitary
gland (Bora et al., 2008; Gouraud et al., 2007). The propeptide
precursor ProSAAS is processed into a number of smaller peptides
in the brain and pituitary including big SAAS, little SAAS, PEN, big
LEN, and little LEN (Mzhavia et al., 2001). Here, we identify age-
associated alterations in truncated forms of little SAAS (ProSAAS
42-57) and PEN (ProSAAS 221-237) in the dehydrated NIL. Inter-
estingly, dehydration for 3 days also increases ProSAAS expression
in the SON while decreasing ProSAAS expression in the NIL, sug-
gesting that the ProSAAS peptide might be secreted (Gouraud et al.,
2007), although this remains to be determined. The previous pep-
tidomic study performed on rat SON samples also identified this
cleavage of ProSAAS (42-57) and multiple PEN peptides in mag-
nocellular neurons. One possibility for the involvement of ProSAAS
in the regulation AVP is through its interactions with proprotein
convertase 1. Pro-AVP is processed by proprotein convertase 1, and
ProSAAS inhibits the activity of this convertase (Murphy et al.,
2012). Therefore, changes in ProSAAS expression in aging might
alter the processing and thus the availability of AVP.
OT is probably best known for its role in female reproduction but
also functions as a natriuretic hormone that reduces sodium
appetite and increases sodium excretion at the kidney (Verbalis
et al., 1991). Circulating levels of OT increase in response to stim-
ulation by osmotic stress, and this depletes pituitary stores of this
peptide consistent with this study (Silverman et al., 1990). Our data
suggest that OT stores are depleted in the NIL as a consequence of
aging, in agreement with earlier studies of the aging HNS
(Silverman et al., 1990; Zbuzek et al., 1988). Because OT and
ProSAAS are synthesized in magnocellular neurons of the hypo-
thalamus, such as AVP, we have also investigated their transcript
abundance in the SON to assess this phenomena of uncoupling
observed for AVP. We report no age-related effects on OT or Pro-
SAAS transcription in the SON, although our data indicate altered
peptide levels in the pituitary.
We have made significant steps to understanding the mecha-
nism regulating AVP in the adult rat and have applied our under-
standing to the Avp transcriptional changes in this aging model.
Based on our recent study where we described altered methylation
patterns of the Avp promoter with dehydration, we hypothesized
that altered methylation marks in the Avp promoter could be
responsible. Cellular aging is closely associated with a decrease in
expression of Dnmt1, an enzyme that stabilizes methylation marks
on DNA (Casillas et al., 2003), as we observed here in the SON. This
is thought to be 1 reason for hypomethylation of DNA sequences in
rodents as well as humans and is consistent with hypomethylation
of the Avp promoter in the aged rat SON.We also found lower levels
of Tet1 expression in the aged rat and adult SON following
dehydration. Tet1, by hydroxylation of 5hmc, has been shown to
promote active demethylation of DNA in the rodent brain (Guo
et al., 2011).
The decrease in Avp promoter methylation in aged rats may
perhaps explain the increased Avp transcription in the aging SON.
Many studies have shown that lower levels of promotermethylation
correlatewith increased gene transcription.We previously reported
increased Avp transcription in hypothalamic 4B cells following
demethylation by 5-aza-20-deoxycytidine treatment, consistent
with this hypothesis (Greenwood et al., 2016a). Individual CpG sites
were largely unaffected byage, apart fromCpG2,which resides close
to a cAMP responsive element, which underwent hypomethylation
with age. Methylation at cAMP response element sites has been
shown to inhibit cAMP response element binding protein (CREB)e
mediated transcription (Elliott et al., 2010; Zhang et al., 2005), so
hypomethylation of this site may serve to enhance Avp promoter
activation by CREB (Iwasaki et al., 1997). Interestingly, methylation
signatures on this segment of the Avp promoter remained largely
unchanged by dehydration in adult rats, differing from our findings
in the SpragueDawley rat (Greenwood et al., 2016a).We suggest this
is due to strain differences. Nonetheless, dehydration induced the
hypermethylation of CpG3, 4, and 7 in aged rats, as observed in adult
Sprague Dawley rats, thus adding strength to the argument for a
relationship between the methylation status of specific Avp pro-
moter CpGs and Avp gene transcription.
To further aid our understanding of AVP neuron activity in aging,
we looked at the expression of genes known to be robustly induced
by osmotic stimuli, and whose functions have been the subject of
interrogation by us in relation to AVP biosynthesis in the SON, and
the overall regulation of fluid balance in the rat (Greenwood et al.,
2014, 2016b; Konopacka et al., 2015a,b; Qiu et al., 2007). We
recently identified Creb3l1 as a putative transcription factor regu-
lating the expression of the Avp gene (Greenwood et al., 2014).
Therefore, in the basal condition, increased Avp transcription can
perhaps be explained by the upregulation of Creb3l1 expression,
and conversely, the attenuated Creb3l1 induction in aged dehy-
drated rats following osmotic stimulation may explain the reduced
capacity to elevate Avp. The altered expression of genes regulating
transcriptional events (c-Fos, Creb3l1, and Giot1) in basal and
dehydrated states implies dramatic changes in the SON tran-
scriptome with aging. These genes are all activated by cAMP
pathways (Greenwood et al., 2015a; Qiu et al., 2007), suggesting
that altered cAMP signaling may determine altered transcriptional
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responses in the aged SON. The source of these altered signaling
responses is not known but may be a consequence of either altered
inputs from the circumventricular organs due to changes in plasma
osmolality (McKinley et al., 2004) or changes within the magno-
cellular neurons themselves.
It is interesting to note that basal Rasd1 and Slc12a1 expression
levels were not influenced by age implying activation of these genes
by separate signaling pathways not affected by age. Rasd1 is a
member of the Ras family of small G-proteins, which is expressed in
AVP magnocellular neurons of the PVN and SON, where increased
circulating glucocorticoids and/or raised plasma osmolality induce
its expression (Greenwood et al., 2016b). Interestingly, plasma
corticosterone levels increase in aging rodents as a result of
hyperactivity of the hypothalamo-pituitary-adrenal axis
(Goncharova, 2013). At the same time, there is an age-associated
decrease in the sensitivity of the hypothalamus, along with other
Fig. 7. Modeling of molecular events in the SON in aging and dehydrated rats. (A) How aging may alter Avp expression in the SON compared to younger counterparts. (B) Proposed
differential regulation of Avp expression in the SON as a function of both aging and dehydration. Abbreviation: SON, supraoptic nucleus.
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brain nuclei, to glucocorticoids (Goncharova, 2013), which may
account for the blunted increase in Rasd1 expression in dehydrated
aged animals, despite changes to corticosterone levels. By lentiviral
vectoremediated overexpression of Rasd1 in the SON, we recently
showed that Rasd1 inhibits osmotically induced Avp transcription
in this nucleus (Greenwood et al., 2016b). The aged dehydrated rats
appear to have lost this dehydration-induced inhibitory input on
Avp transcription in the aging SON.
The expression of Slc12a1 in magnocellular neurons of the SON
and PVN is also known to be induced by chronic and acute osmotic
stimulation (Konopacka et al., 2015b). We recently showed that
lentiviral-mediated knockdown of Slc12a1 in these hypothalamic
nuclei altered fluid homeostasis by increasing fluid intake and urine
output during salt loading. Furthermore, the loop diuretics bume-
tanide and furosemide were found to inhibit gamma-aminobutyric
acid-mediated excitation of AVP neurons and AVP release, respec-
tively. Therefore, an altered abundance of Slc12a1 might be ex-
pected to alter neuronal activity in aging AVP neurons.
The Avp mRNA is subject to post-transcriptional modification in
the form of an increase in the length of the poly(A) tail, as seen in
the SON in response to osmotic challenges (Carter and Murphy,
1991) and as we show here by age. An increased poly(A) tail
length is thought to reduce the degradation and increase the
stability of many transcripts (Zeevi et al., 1982) andmay be involved
in the control of translation (Palatnik et al., 1984). We recently
showed that the RNA-binding protein Caprin2 binds to the Avp
mRNA and, in doing so, mediates an increase in the length of the
poly(A) tail (Konopacka et al., 2015a). It is interesting to note that
the expression of Caprin2 in the aging SON increases in parallel
with the Avp mRNA poly(A) tail length. The increase in Avp mRNA
poly(A) tail length in response to dehydration was not affected by
age, as previously reported (Sladek and Olschowka, 1994), which
was further corroborated by there being no difference in Caprin2
expression in dehydrated adult and aged rats. A previous Northern
blot study on Fischer 344 rat SON samples reported no change in
Avp poly(A) tail length with age (Sladek and Olschowka, 1994). We
suggest that this discrepancy could be due either to strain differ-
ences or to the different methodological approaches used.
4.1. Conclusions
In summary, we have performed a comprehensive analysis of
the AVP system in aging HanWistar rats. There were no age-related
changes to AVP circulating levels in basal or dehydrated states,
suggesting that the functioning of the HNS in body water homeo-
stasis is intact in healthy rats at this age. In stark contrast, we
describe in the magnocellular neurons of the SON a plethora of
molecular changes known to alter Avp expression. These include
methylation changes to the Avp promoter and altered expression of
genes involved in transcriptional and post-transcriptional regula-
tion of the Avp gene (Fig. 7). We currently do not understand the
origin of these changes or why they are a necessary part of normal
aging in the rat. The current rat model was perfectly capable of
coping with 3 days of dehydration by secreting adequate quantities
of AVP. However, this may not be true for pathophysiological con-
ditions commonly encountered in the aging process. The stimulus
secretion uncoupling of Avp transcription as seen here in normal
aging could increase the likelihood of fluid and electrolyte disorders
in critically ill elderly patients. Not being able to adequately correct
or respond to fluid and electrolyte disturbances such as a rise
plasma osmolality would certainly lead to hypernatremia, a con-
dition that is regularly observed in elderly patients admitted to
hospitals (El-Sharkawy et al., 2014). Further studies are necessary to
address whether Avp transcription can be a rate-limiting step in the
aging HNS. The identification by MS of additional peptides that are
also influenced by age in the NIL gives further scope for exploring
other peptidergic systems in the aging hypothalamus, in the
context of healthy aging. Understanding how aging alters these
hormonal systems may help to improve treatment regimens and
perhaps improve the clinical outcomes for elderly patients.
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João R Breda, Adilson C Pires, Nadir Tassi, and Luiz Carlos de Abreu. Cardiac
baroreflex is already blunted in eight weeks old spontaneously hypertensive rats.
International archives of medicine, 3:2, jan 2010.
156 M C Andresen, S Kuraoka, and A M Brown. Baroreceptor function and changes in
strain sensitivity in normotensive and spontaneously hypertensive rats. Circulation
research, 47(6):821–828, dec 1980.
157 Ryuji Nagai, Shinya Nagata, Fumiyo Fukuya, Jitsuo Higaki, Hiromi Rakugi, and
Toshio Ogihara. Changes in autonomic activity and baroreflex sensitivity with the
hypertension process and age in rats. Clinical and Experimental Pharmacology and
Physiology, 30(5-6):419–425, 2003.
158 Sean D Stocker and Martin S Muntzel. Recording sympathetic nerve activity chroni-
cally in rats: surgery techniques, assessment of nerve activity, and quantification.




159 Christopher R Pryce and Joram Feldon. Long-term neurobehavioural impact of the
postnatal environment in rats: manipulations, effects and mediating mechanisms.
Neuroscience & Biobehavioral Reviews, 27(1):57–71, 2003.
160 Seymour Levine, David M Huchton, Sandra G Wiener, and Patricia Rosenfeld. Time
course of the effect of maternal deprivation on the hypothalamic-pituitary-adrenal
axis in the infant rat. Developmental Psychobiology, 24(8):547–558, 1991.
161 G J Mangos, S W Turner, T B Fraser, and J A Whitworth. The role of corticosterone
in corticotrophin (ACTH)-induced hypertension in the rat. Journal of hypertension,
18(12):1849–1855, dec 2000.
162 Jonathan H Williams, Gordon K Wilcock, Jeffrey Seeburger, Aimee Dallob, Omar
Laterza, William Potter, and A David Smith. Non-linear relationships of cerebrospinal
fluid biomarker levels with cognitive function: an observational study. Alzheimer’s
Research & Therapy, 3(1):5, 2011.
163 Mi Jeong Kwon, Ensel Oh, Seungmook Lee, Mi Ra Roh, Si Eun Kim, Yangsoon Lee,
Yoon-La Choi, Yong-Ho In, Taesung Park, Sang Seok Koh, and Young Kee Shin.
Identification of Novel Reference Genes Using Multiplatform Expression Data and
Their Validation for Quantitative Gene Expression Analysis. PLOS ONE, 4(7):1–15,
2009.
164 Hendrik J M de Jonge, Rudolf S N Fehrmann, Eveline S J M de Bont, Robert
M W Hofstra, Frans Gerbens, Willem A Kamps, Elisabeth G E de Vries, Ate G J
van der Zee, Gerard J te Meerman, and Arja ter Elst. Evidence based selection of
housekeeping genes. PloS one, 2(9):e898, sep 2007.
165 T W Kurtz, M Montano, L Chan, and P Kabra. Molecular evidence of genetic
heterogeneity in Wistar-Kyoto rats: implications for research with the spontaneously
hypertensive rat. Hypertension (Dallas, Tex. : 1979), 13(2):188–192, feb 1989.
166 W J Louis and L G Howes. Genealogy of the spontaneously hypertensive rat and
Wistar-Kyoto rat strains: implications for studies of inherited hypertension. Journal
of cardiovascular pharmacology, 16 Suppl 7:S1–5, 1990.
167 W P Pare and J Kluczynski. Differences in the stress response of Wistar-Kyoto
(WKY) rats from different vendors. Physiology & behavior, 62(3):643–648, sep 1997.
168 E St Lezin, L Simonet, M Pravenec, and T W Kurtz. Hypertensive strains and
normotensive ’control’ strains. How closely are they related? Hypertension (Dallas,
Tex. : 1979), 19(5):419–424, may 1992.
169 Bonnie Tocher Clause. The Wistar Institute Archives: Rats (Not Mice) and History.
Mendel Newsletter, 1998.
170 Gerard D’Angelo, Jennifer S Pollock, and David M Pollock. Endogenous endothelin
attenuates the pressor response to acute environmental stress via the ETA receptor.




171 B T Alexander, K L Cockrell, A N Rinewalt, J N Herrington, and J P Granger.
Enhanced renal expression of preproendothelin mRNA during chronic angiotensin II
hypertension. American journal of physiology. Regulatory, integrative and comparative
physiology, 280(5):R1388–92, may 2001.
172 Mohamed A Bayorh, Agaba A Ganafa, Robin R Socci, Danita Eatman, Natalia
Silvestrov, and Imad K Abukhalaf. Effect of losartan on oxidative stress-induced
hypertension in Sprague-Dawley rats. American journal of hypertension, 16(5 Pt
1):387–392, may 2003.
173 Debora S A Colombari, Eduardo Colombari, Andre H Freiria-Oliveira, Vagner R
Antunes, Song T Yao, Charles Hindmarch, Alastair V Ferguson, Mark Fry, David
Murphy, and Julian F R Paton. Switching control of sympathetic activity from
forebrain to hindbrain in chronic dehydration. The Journal of physiology, 589(Pt
18):4457–4471, sep 2011.
174 B J Sanders and J E Lawler. The borderline hypertensive rat (BHR) as a model
for environmentally-induced hypertension: a review and update. Neuroscience and
biobehavioral reviews, 16(2):207–217, 1992.
175 J E Lawler, B J Sanders, R H Cox, and E F O’Connor. Baroreflex function in
chronically stressed borderline hypertensive rats. Physiology & behavior, 49(3):539–
542, mar 1991.
176 M Burnier, J Biollaz, D B Brunner, and H R Brunner. Blood pressure maintenance
in awake dehydrated rats: renin, vasopressin, and sympathetic activity. American
Journal of Physiology-Heart and Circulatory Physiology, 245(2):H203–H209, 1983.
177 R L Woods and C I Johnston. Contribution of vasopressin to the maintenance of
blood pressure during dehydration. The American journal of physiology, 245(5 Pt
1):F615–21, nov 1983.
178 S M Gardiner and T Bennett. Interactions between neural mechanisms, the renin-
angiotensin system and vasopressin in the maintenance of blood pressure during
water deprivation: studies in Long Evans and Brattleboro rats. Clinical science
(London, England : 1979), 68(6):647–657, jun 1985.
179 Santosh S Atanur, Ana Garcia Diaz, Klio Maratou, Allison Sarkis, Maxime Rotival,
Laurence Game, Michael R Tschannen, Pamela J Kaisaki, Georg W Otto, Man
Chun John Ma, Thomas M Keane, Oliver Hummel, Kathrin Saar, Wei Chen, Victor
Guryev, Kathirvel Gopalakrishnan, Michael R Garrett, Bina Joe, Lorena Citterio,
Giuseppe Bianchi, Martin McBride, Anna Dominiczak, David J Adams, Tadao
Serikawa, Paul Flicek, Edwin Cuppen, Norbert Hubner, Enrico Petretto, Dominique
Gauguier, Anne Kwitek, Howard Jacob, and Timothy J Aitman. Genome sequencing
reveals loci under artificial selection that underlie disease phenotypes in the laboratory
rat. Cell, 154(3):691–703, aug 2013.
180 Volker Fensterl and Ganes C Sen. Interferon-induced Ifit proteins: their role in viral
pathogenesis. Journal of virology, 89(5):2462–2468, mar 2015.
Page 262
Bibliography
181 V R Antunes, S T Yao, A E Pickering, D Murphy, and J F R Paton. A spinal
vasopressinergic mechanism mediates hyperosmolality-induced sympathoexcitation.
The Journal of physiology, 576(Pt 2):569–583, oct 2006.
182 Jing Qiu, Song Yao, Charles Hindmarch, Vagner Antunes, Julian Paton, and David
Murphy. Transcription factor expression in the hypothalamo-neurohypophyseal
system of the dehydrated rat: upregulation of gonadotrophin inducible transcription
factor 1 mRNA is mediated by cAMP-dependent protein kinase A. The Journal of
neuroscience : the official journal of the Society for Neuroscience, 27(9):2196–2203,
feb 2007.
183 Georgina G J Hazell, Charles C Hindmarch, George R Pope, James A Roper,
Stafford L Lightman, David Murphy, Anne-Marie O’Carroll, and Stephen J Lolait. G
protein-coupled receptors in the hypothalamic paraventricular and supraoptic nuclei–
serpentine gateways to neuroendocrine homeostasis. Frontiers in neuroendocrinology,
33(1):45–66, jan 2012.
184 Andreas Pichlmair, Caroline Lassnig, Carol-Ann Eberle, Maria W Gorna, Christoph L
Baumann, Thomas R Burkard, Tilmann Burckstummer, Adrijana Stefanovic, Sigurd
Krieger, Keiryn L Bennett, Thomas Rulicke, Friedemann Weber, Jacques Colinge,
Mathias Muller, and Giulio Superti-Furga. IFIT1 is an antiviral protein that
recognizes 5’-triphosphate RNA. Nature immunology, 12(7):624–630, jun 2011.
185 Michael S Diamond and Michael Farzan. The broad-spectrum antiviral functions of
IFIT and IFITM proteins. Nature reviews. Immunology, 13(1):46–57, jan 2013.
186 Xiang Zhou, Jennifer J Michal, Lifan Zhang, Bo Ding, Joan K Lunney, Bang Liu,
and Zhihua Jiang. Interferon induced IFIT family genes in host antiviral defense.
International journal of biological sciences, 9(2):200–208, 2013.
187 J Chebath, G Merlin, R Metz, P Benech, and M Revel. Interferon-induced 56,000
Mr protein and its mRNA in human cells: molecular cloning and partial sequence of
the cDNA. Nucleic acids research, 11(5):1213–1226, mar 1983.
188 J Kusari and G C Sen. Transcriptional analyses of interferon-inducible mRNAs.
Molecular and cellular biology, 7(1):528–531, jan 1987.
189 Ying Liu, Yi-Bing Zhang, Ting-Kai Liu, and Jian-Fang Gui. Lineage-Specific
Expansion of IFIT Gene Family: An Insight into Coevolution with IFN Gene Family.
PLOS ONE, 8(6):1–14, 2013.
190 Koichiro Tamura, Joel Dudley, Masatoshi Nei, and Sudhir Kumar. MEGA4: Molecu-
lar Evolutionary Genetics Analysis (MEGA) software version 4.0. Molecular biology
and evolution, 24(8):1596–1599, aug 2007.
191 Volker Fensterl and Ganes C Sen. The ISG56/IFIT1 gene family. Journal of
interferon & cytokine research : the official journal of the International Society for
Interferon and Cytokine Research, 31(1):71–78, jan 2011.
Page 263
Bibliography
192 Saumendra N Sarkar and Ganes C Sen. Novel functions of proteins encoded by viral
stress-inducible genes. Pharmacology & therapeutics, 103(3):245–259, sep 2004.
193 S J Gobin, A Peijnenburg, V Keijsers, and P J van den Elsen. Site alpha is crucial for
two routes of IFN gamma-induced MHC class I transactivation: the ISRE-mediated
route and a novel pathway involving CIITA. Immunity, 6(5):601–611, may 1997.
194 S D Der, A Zhou, B R Williams, and R H Silverman. Identification of genes
differentially regulated by interferon alpha, beta, or gamma using oligonucleotide
arrays. Proceedings of the National Academy of Sciences of the United States of
America, 95(26):15623–15628, dec 1998.
195 A Kohli, X Zhang, J Yang, R S Russell, R P Donnelly, F Sheikh, A Sherman,
H Young, T Imamichi, R A Lempicki, H Masur, and S Kottilil. Distinct and
overlapping genomic profiles and antiviral effects of Interferon-λ and -α on HCV-
infected and noninfected hepatoma cells. Journal of viral hepatitis, 19(12):843–853,
dec 2012.
196 Luca D D’Andrea and Lynne Regan. TPR proteins: the versatile helix. Trends in
biochemical sciences, 28(12):655–662, dec 2003.
197 William C Merrick. Cap-dependent and cap-independent translation in eukaryotic
systems. Gene, 332:1–11, may 2004.
198 Daniel J Hui, C Ramana Bhasker, William C Merrick, and Ganes C Sen. Viral
stress-inducible protein p56 inhibits translation by blocking the interaction of eIF3
with the ternary complex eIF2.GTP.Met-tRNAi. The Journal of biological chemistry,
278(41):39477–39482, oct 2003.
199 Daniel J Hui, Fulvia Terenzi, William C Merrick, and Ganes C Sen. Mouse p56
blocks a distinct function of eukaryotic initiation factor 3 in translation initiation.
The Journal of biological chemistry, 280(5):3433–3440, feb 2005.
200 Fulvia Terenzi, Daniel J Hui, William C Merrick, and Ganes C Sen. Distinct
induction patterns and functions of two closely related interferon-inducible human
genes, ISG54 and ISG56. The Journal of biological chemistry, 281(45):34064–34071,
nov 2006.
201 J Guo, D J Hui, W C Merrick, and G C Sen. A new pathway of translational regulation
mediated by eukaryotic initiation factor 3. The EMBO journal, 19(24):6891–6899,
dec 2000.
202 Ivan Topisirovic, Yuri V Svitkin, Nahum Sonenberg, and Aaron J Shatkin. Cap
and cap-binding proteins in the control of gene expression. Wiley interdisciplinary
reviews. RNA, 2(2):277–298, 2011.
203 Fatima Gebauer and Matthias W Hentze. Molecular mechanisms of translational
control. Nature reviews. Molecular cell biology, 5(10):827–835, oct 2004.
Page 264
Bibliography
204 Jing Shao, Masaomi Nangaku, Toshio Miyata, Reiko Inagi, Koei Yamada, Kiyoshi
Kurokawa, and Toshiro Fujita. Imbalance of T-cell subsets in angiotensin II-infused
hypertensive rats with kidney injury. Hypertension (Dallas, Tex. : 1979), 42(1):31–38,
jul 2003.
205 Ashton Barnett-Vanes, Anna Sharrock, Mark A Birrell, and Sara Rankin. A Single
9-Colour Flow Cytometric Method to Characterise Major Leukocyte Populations in
the Rat: Validation in a Model of LPS-Induced Pulmonary Inflammation. PloS one,
11(1):e0142520, 2016.
206 Invitrogen. Lipofectamine 3000 Reagent Protocol.
207 Zhenlin Yang, Huanhuan Liang, Qian Zhou, Ying Li, Haiwei Chen, Wen Ye, Danying
Chen, Joy Fleming, Hongbing Shu, and Yingfang Liu. Crystal structure of ISG54
reveals a novel RNA binding structure and potential functional mechanisms. Cell
research, 22(9):1328–1338, sep 2012.
208 Abcam. Flow cytometry intracellular staining protocol.
209 Jason E McDermott, Keri B Vartanian, Hugh Mitchell, Susan L Stevens, Antonio
Sanfilippo, and Mary P Stenzel-Poore. Identification and validation of Ifit1 as an
important innate immune bottleneck. PloS one, 7(6):e36465, 2012.
210 Minghua Fan, Xiaobing Li, Xiaolin Gao, Lihua Dong, Gang Xin, Liqun Chen,
Jianqing Qiu, and Yongping Xu. LPS Induces Preeclampsia-Like Phenotype in Rats
and HTR8/SVneo Cells Dysfunction Through TLR4/p38 MAPK Pathway. Frontiers
in physiology, 10:1030, 2019.
211 Fernanda Brognara, Jaci Airton Castania, Daniel Penteado Martins Dias, Alexandre
Kanashiro, and Helio Cesar Salgado. Time Course of Hemodynamic Responses to
Different Doses of Lipopolysaccharide in Unanesthetized Male Rats. Frontiers in
physiology, 10:771, 2019.
212 Wilbur Y W Lew, Evelyn Bayna, Erminia Dalle Molle, Nancy D Dalton, N Chin
Lai, Valmik Bhargava, Vincent Mendiola, Paul Clopton, and Tong Tang. Recurrent
exposure to subclinical lipopolysaccharide increases mortality and induces cardiac
fibrosis in mice. PloS one, 8(4):e61057, 2013.
213 Peng Shi, Carlos Diez-Freire, Joo Yun Jun, Yanfei Qi, Michael J Katovich, Qiuhong
Li, Srinivas Sriramula, Joseph Francis, Colin Sumners, and Mohan K Raizada. Brain
microglial cytokines in neurogenic hypertension. Hypertension (Dallas, Tex. : 1979),
56(2):297–303, aug 2010.
214 A H de Haas, H R J van Weering, E K de Jong, H W G M Boddeke, and K P H
Biber. Neuronal chemokines: versatile messengers in central nervous system cell
interaction. Molecular neurobiology, 36(2):137–151, oct 2007.
215 NICHOLAS J GAY and FIONNA J KEITH. Drosophila Toll and IL-1 receptor.
Nature, 351:355, may 1991.
Page 265
Bibliography
216 Luke A J O’Neill, Douglas Golenbock, and Andrew G Bowie. The history of Toll-like
receptors - redefining innate immunity., jun 2013.
217 Jared C Roach, Gustavo Glusman, Lee Rowen, Amardeep Kaur, Maureen K Purcell,
Kelly D Smith, Leroy E Hood, and Alan Aderem. The evolution of vertebrate
Toll-like receptors. Proceedings of the National Academy of Sciences of the United
States of America, 102(27):9577 LP – 9582, jul 2005.
218 Rahul B Dange, Deepmala Agarwal, Ryoichi Teruyama, and Joseph Francis. Toll-like
receptor 4 inhibition within the paraventricular nucleus attenuates blood pressure
and inflammatory response in a genetic model of hypertension. Journal of Neuroin-
flammation, 12(1):31, 2015.
219 Robert F Schwabe, Ekihiro Seki, and David A Brenner. Toll-Like Receptor Signaling
in the Liver. Gastroenterology, 130(6):1886–1900, 2006.
220 Ekihiro Seki and David A Brenner. Toll-like receptors and adaptor molecules in liver
disease: Update. Hepatology, 48(1):322–335, 2008.
221 Dmitry A Chistiakov, Kenneth W Ashwell, Alexander N Orekhov, and Yuri V
Bobryshev. Innervation of the arterial wall and its modification in atherosclerosis.
Autonomic neuroscience : basic & clinical, 193:7–11, dec 2015.
222 Jeffrey P Cardinale, Srinivas Sriramula, Nithya Mariappan, Deepmala Agarwal,
and Joseph Francis. Angiotensin II-induced hypertension is modulated by nuclear
factor-kappaBin the paraventricular nucleus. Hypertension (Dallas, Tex. : 1979),
59(1):113–121, jan 2012.
223 Yun-Ching Fu, Ching-Shiang Chi, Sui-Chu Yin, Betau Hwang, Yung-Tsung Chiu,
and Shih-Lan Hsu. Norepinephrine induces apoptosis in neonatal rat cardiomy-
ocytes through a reactive oxygen species-TNF alpha-caspase signaling pathway.
Cardiovascular research, 62(3):558–567, jun 2004.
224 Manveen K Gupta, T V Neelakantan, Mishra Sanghamitra, Rakesh K Tyagi, Amit
Dinda, Subir Maulik, Chinmay K Mukhopadhyay, and Shyamal K Goswami. An
assessment of the role of reactive oxygen species and redox signaling in norepinephrine-
induced apoptosis and hypertrophy of H9c2 cardiac myoblasts. Antioxidants & redox
signaling, 8(5-6):1081–1093, 2006.
225 Mo-Lin Wang, Xiao-Jing Yu, Xiao-Guang Li, De-Zhi Pang, Qing Su, Roland Osei
Saahene, Hong-Bao Li, Xu-Ying Mao, Kai-Li Liu, Li-Yan Fu, Ying Li, Guo-Qing
Zhu, and Yu-Ming Kang. Blockade of TLR4 Within the Paraventricular Nucleus
Attenuates Blood Pressure by Regulating ROS and Inflammatory Cytokines in
Prehypertensive Rats. American Journal of Hypertension, 31(9):1013–1023, 2018.
226 Qing Su, Jin-Jun Liu, Wei Cui, Xiao-Lian Shi, Jing Guo, Hong-Bao Li, Chan-Juan
Huo, Yu-Wang Miao, Meng Zhang, Qing Yang, and Yu-Ming Kang. Alpha lipoic acid
supplementation attenuates reactive oxygen species in hypothalamic paraventricular
Page 266
Bibliography
nucleus and sympathoexcitation in high salt-induced hypertension. Toxicology letters,
241:152–158, jan 2016.
227 Sveta Kabanova, Petra Kleinbongard, Jens Volkmer, Birgit Andree, Malte Kelm, and
Thomas W Jax. Gene expression analysis of human red blood cells. International
journal of medical sciences, 6(4):156–159, 2009.
228 G W Schmid-Schonbein, D Seiffge, F A DeLano, K Shen, and B W Zweifach.
Leukocyte counts and activation in spontaneously hypertensive and normotensive
rats. Hypertension (Dallas, Tex. : 1979), 17(3):323–330, mar 1991.
229 Eric Vivier, Serge A van de Pavert, Max D Cooper, and Gabrielle T Belz. The
evolution of innate lymphoid cells. Nature immunology, 17(7):790–794, jun 2016.
230 Eric Vivier, Elena Tomasello, Myriam Baratin, Thierry Walzer, and Sophie Ugolini.
Functions of natural killer cells. Nature immunology, 9(5):503–510, may 2008.
231 Sabine Kossmann, Melanie Schwenk, Michael Hausding, Susanne H Karbach, Maria I
Schmidgen, Moritz Brandt, Maike Knorr, Hanhan Hu, Swenja Kroller-Schon, Tanja
Schonfelder, Stephan Grabbe, Matthias Oelze, Andreas Daiber, Thomas Munzel,
Christian Becker, and Philip Wenzel. Angiotensin II-induced vascular dysfunction
depends on interferon-gamma-driven immune cell recruitment and mutual activation
of monocytes and NK-cells. Arteriosclerosis, thrombosis, and vascular biology,
33(6):1313–1319, jun 2013.
232 Florent Ginhoux and Steffen Jung. Monocytes and macrophages: developmental
pathways and tissue homeostasis. Nature reviews. Immunology, 14(6):392–404, jun
2014.
233 Bernardo Rodriguez-Iturbe, Hector Pons, and Richard J Johnson. Role of the
Immune System in Hypertension. Physiological reviews, 97(3):1127–1164, jul 2017.
234 Dalit Strauss-Ayali, Sean M Conrad, and David M Mosser. Monocyte subpopulations
and their differentiation patterns during infection. Journal of leukocyte biology,
82(2):244–252, aug 2007.
235 Cord Sunderkotter, Tatjana Nikolic, Marilyn J Dillon, Nico Van Rooijen, Martin
Stehling, Douglas A Drevets, and Pieter J M Leenen. Subpopulations of mouse
blood monocytes differ in maturation stage and inflammatory response. Journal of
immunology (Baltimore, Md. : 1950), 172(7):4410–4417, apr 2004.
236 Roxana Loperena, Justin P Van Beusecum, Hana A Itani, Noah Engel, Fanny
Laroumanie, Liang Xiao, Fernando Elijovich, Cheryl L Laffer, Juan S Gnecco,
Jonathan Noonan, Pasquale Maffia, Barbara Jasiewicz-Honkisz, Marta Czesnikiewicz-
Guzik, Tomasz Mikolajczyk, Tomasz Sliwa, Sergey Dikalov, Cornelia M Weyand,
Tomasz J Guzik, and David G Harrison. Hypertension and increased endothelial
mechanical stretch promote monocyte differentiation and activation: roles of STAT3,




237 Kai-Uwe Belge, Farshid Dayyani, Alexia Horelt, Maciej Siedlar, Marion Franken-
berger, Bernhard Frankenberger, Terje Espevik, and Loms Ziegler-Heitbrock. The
proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF. Jour-
nal of immunology (Baltimore, Md. : 1950), 168(7):3536–3542, apr 2002.
238 Leo M Carlin, Efstathios G Stamatiades, Cedric Auffray, Richard N Hanna, Leanne
Glover, Gema Vizcay-Barrena, Catherine C Hedrick, H Terence Cook, Sandra
Diebold, and Frederic Geissmann. Nr4a1-dependent Ly6C(low) monocytes monitor
endothelial cells and orchestrate their disposal. Cell, 153(2):362–375, apr 2013.
239 Amado Quintar, Sara McArdle, Dennis Wolf, Alex Marki, Erik Ehinger, Melanie
Vassallo, Jacqueline Miller, Zbigniew Mikulski, Klaus Ley, and Konrad Buscher.
Endothelial Protective Monocyte Patrolling in Large Arteries Intensified by Western
Diet and Atherosclerosis. Circulation research, 120(11):1789–1799, may 2017.
240 Prakash Babu Narasimhan, Paola Marcovecchio, Anouk A J Hamers, and Cather-
ine C Hedrick. Nonclassical Monocytes in Health and Disease. Annual review of
immunology, 37:439–456, apr 2019.
241 Cell Analysis Facility. Cell Sorting for RNA Isolation.
242 M T Barrett, J Glogovac, L J Prevo, B J Reid, P Porter, and P S Rabinovitch.
High-quality RNA and DNA from flow cytometrically sorted human epithelial cells
and tissues. BioTechniques, 32(4):888–890,892,894,896, apr 2002.
243 Christine Vogel and Edward M Marcotte. Insights into the regulation of protein
abundance from proteomic and transcriptomic analyses. Nature reviews. Genetics,
13(4):227–232, mar 2012.
244 Helga Thorvaldsdottir, James T Robinson, and Jill P Mesirov. Integrative Ge-
nomics Viewer (IGV): high-performance genomics data visualization and exploration.
Briefings in bioinformatics, 14(2):178–192, mar 2013.
245 Travis C Glenn. Field guide to next-generation DNA sequencers. Molecular ecology
resources, 11(5):759–769, sep 2011.
246 Jay Shendure and Hanlee Ji. Next-generation DNA sequencing. Nature biotechnology,
26(10):1135–1145, oct 2008.
247 Zhenhua Hu, Shengmin Mei, Jie Xiang, Jie Zhou, Zhiwei Li, Lin Zhou, Sheng
Yan, Weilin Wang, and Shusen Zheng. Survival rates after liver transplantation
using hypertensive donor grafts: an analysis of the Scientific Registry of Transplant
Recipients database. Journal of hepato-biliary-pancreatic sciences, 24(8):441–448,
aug 2017.
Page 268
